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 ABSTRACT 
 
The aim of this thesis is to help the RM industry avoid misguidedly investing in technologies that are 
unlikely to be cost-effective and reimbursed by healthcare providers. Health economics provides the 
tools to demonstrate value for money. These tools are typically used by healthcare providers to drive 
demand side decisions. However, they can be used by manufacturers to inform the supply side. I 
propose a simple approach, termed the headroom method. This ‘back of the envelope’ calculation is 
based on estimates of effectiveness of the proposed treatment towards the upper end of the plausible 
range. The method can be used either to inform an intuitive decision to continue or abandon 
development, or as a screening test to decide if more elaborate models are justified. One problem I 
encountered was the development of technologies without clearly defining the clinical problem. In 
particular, the marginal gain in benefit over alternative treatments is frequently overlooked. A large part 
of this thesis is therefore concerned with the clinical epidemiology of the conditions at which treatment 
is targeted. In this way, it was found, for example, the headroom for health gain from new treatment for 
inguinal hernia was much smaller than that for incisional hernias.  
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 GLOSSARY 
Unless otherwise stated, all definitions have been identified using the following online medical 
dictionaries:  http://www.mondofacto.com/dictionary/, 
http://www.nlm.nih.gov/medlineplus/mplusdictionary.html,  
http://medical-dictionary.thefreedictionary.com. 
Allogenic Genetically different, although from the same species 
Allograft A graft of tissue obtained from a donor genetically different from, although 
of the same species as the recipient 
Anastomose To unite by openings 
Anastomosis* The surgical connection of separate or severed tubular hollow organs to 
form a continuous channel, as between two parts of the intestine 
Angiogenesis The process of vascularisation of a tissue involving the development of 
new capillary blood vessels 
Antimesenteric The part of the intestine that lies opposite the mesenteric attachment 
Arthroplasty The surgical repair of a joint 
Atrophy A decrease in the size of a cell, tissue, organ or part 
Autograft Tissue for transplantation that is taken from the patient 
Autologous Belonging to the same organism 
Avascular Without blood or lymphatic vessels 
Bacteriuria The presence of bacteria in the urine with or without consequent urinary 
tract infection  
Bilharziasis A parasite infection by a trematode worm acquired from infested water 
(also known as, schistosomiasis). The species, which live in man, can 
produce liver, bladder, and gastrointestinal problems. The species which 
cannot live in man cause swimmer's itch 
Bioreactor A container in which living organisms carry out a biological reaction 
Botulinum toxin Neurotoxin produced by certain strains of Clostridium botulinum 
Buccal mucosa Mucous membrane lining the inner cheek 
Cancellous Bone Adult bone consisting of mineralised regularly ordered parallel collagen 
fibres and found in the end of long bones 
Cardinal Numbers that express an amount. Denotes quantity but not order 
Cell therapy The transplantation of human or animal cells to replace or repair damaged 
tissue and/or cells 
Cells Minute protoplasmic masses that make up organised tissue. Consist of a 
nucleus surrounded by a protoplasm containing various organelles. Cells 
are the fundamental, structural, and functional units of living organisms 
Chondrocyte Differentiated cell responsible for cartilage formation 
Colon This structure has 6 major divisions: caecum, ascending colon, transverse 
colon, descending colon, sigmoid colon, and rectum. The total length is 
approximately 5 feet in the adult and it is responsible for forming, storing, 
and expelling waste matter. Also called the large intestine 
Colostomy A surgical procedure used to create an opening for urine and faeces to be 
released from the body 
Condyle A rounded articular surface at the extremity of a bone 
Cortical Bone The superficial thin layer of compact bone 
                                                     
*
 Definition taken from dictionary.com, http://dictionary.reference.com/  
 Crepitation A dry, crackling sound or sensation, such as that produced by the grating 
of the ends of a fractured bone 
Cystectomy* Excision of a cyst or bladder, usually the urinary bladder 
Cystoplasty Any reconstructive operation on the urinary bladder 
Decalcification A loss of calcium from bone, causes weakening 
Dehiscence The parting of the sutured lips of a surgical wound resulting from infection 
Dermis connective tissue underlying the epithelium of the skin 
Detrusor A muscle that has the action of expelling a substance 
Devitalised Devoid of life 
Diabetes Mellitus A condition in which the pancreas no longer produces enough insulin, or 
cells stop responding to the insulin that is produced, so that glucose in the 
blood cannot be absorbed into the cells of the body. Symptoms include 
frequent urination, lethargy, excessive thirst, and hunger. Treatment 
includes changes in diet, oral medications, and in some cases, daily 
injections of insulin. 
Diaphysis The shaft of a long bone 
Diverticulum A small sac-like structure that sometimes forms in the walls of the 
intestines, diverticula can trap particles of food (e.g. small seeds and 
undigested grains) and become very inflamed and painful (a condition 
called diverticulitis) 
Enteric Relating to the small intestine 
Enterocolitis Inflammation of the small intestine and colon 
Enterocutaneous Pertaining to or communicating with the intestine and the skin, or surface of 
the body 
Epispadias A congenital defect resulting in the urethral opening on the dorsum of the 
penis 
Epithelialised To become covered with epithelial tissue 
Epithelium The cellular covering of internal and external body surfaces, including the 
lining of vessels and small cavities. It consists of cells joined by small 
amounts of cementing substances and is classified according to the 
number of layers and the shape of the cells 
Extraperitoneal Outside of the peritoneal cavity 
Fascia The flat layers of fibrous tissue that separate different layers of tissue 
Fistula A permanent abnormal passageway between two organs in the body or 
between an organ and the exterior of the body 
Fournier's Gangrene A type of necrotizing infection (gangrene) usually affecting the male 
genitals 
Gangrene The necrosis and subsequent decay of body tissues, usually the result of a 
critically insufficient blood supply. Caused by infection or thrombosis and 
sometimes injury and subsequent bacteria contamination.  
Gastroesophageal Relating to the stomach and the oesophagus 
Gene therapy The insertion of genetically altered genes into cells to replace defective 
genes 
Growth factors Proteins made by cells that cat on other cells to stimulate or inhibit their 
function. Growth factors are essential to the normal cell cycle, and are thus 
vital elements in the life of animals from conception to death.  
Haematoma A localised collection of blood, usually clotted, in an organ, space or tissue, 
due to a break in the wall of a blood vessel 
Health economics The branch of economics concerned with issues related to scarcity in the 
allocation of health and health care. 
                                                     
*
 Definition taken from dictionary.com, http://dictionary.reference.com/  
 Hernia Hernia is a general term used to describe a bulge or protrusion of an organ 
through the structure or muscle that usually contains it 
Hernioplasty see herniorrhaphy 
Herniorrhaphy The surgical repair of a hernia. This surgery can be done under local or 
general anaesthesia. May be performed using a conventional incision or 
using a laparoscope 
Herniotomy A cutting for the cure or relief of hernia 
Homeostasis Stability of the internal environment of an organism 
Horizon Scanning* The systematic examination of potential threats, opportunities and likely 
future developments, including (but not restricted to) those at the margins 
of current thinking and planning 
Hyaline Clear, transparent and granular free 
Hydroxyapatite A calcium phosphate complex and the primary mineral component of bone 
Hyperchloraemic 
acidosis 
A rare, sometimes familial, disorder of the renal tubule characterised by the 
inability to excrete urine of normal acidity 
Hypertrophy Enlargement or overgrowth of an organ due to an increase in size of its 
constituent cells 
Hypospadias A congenital defect in which the urethra opens on the ventral (bottom) 
surface of the penis rather than on the glans 
Ileal conduit An isolated segment of ileum serving as a replacement for another tubular 
organ; specifically, the use as a urinary conduit into which ureters can be 
implanted following total cystectomy or loss of normal bladder function  
Ileocystoplasty Surgical reconstruction of the bladder involving the use of an isolated 
intestinal segment to augment bladder capacity 
Ileostomy Surgical creation of an opening into the ileum, with a stoma on the 
abdominal wall 
Ileus A partial or complete non-mechanical blockage of the small and/or large 
intestine 
Ileum The last portion of the small intestine that communicates with the large 
intestine 
Immunodeficiency A group of disorders in which part of the immune system is missing or 
defective, therefore, the body's ability to fight infections is impaired. As a 
result, the person with an immunodeficiency disorder will have frequent 
infections that are generally more severe and last longer than usual. 
Immunogenicity Being able to evoke an immune response in an organism 
In vitro In an artificial environment outside the living organism 
In vivo Within a living organism 
Incarcerated hernia A hernia so occluded that it cannot be returned by manipulation; it may or 
may not be strangulated 
Incisional hernia A hernia through an old abdominal incision 
Infertility The failure of a couple to conceive a pregnancy after trying to do so for at 
least one full year  
Inguinal hernia Hernia located in the groin 
Interstitial Relating to or situated in the small, narrow spaces between tissues or parts 
of an organ 
Interstitial cystitis A chronic inflammatory condition of the bladder, cause is unknown, but 
occurs more commonly in females. Symptoms include difficulty urinating, 
pain on urination, urinary urgency and increased frequency of urination 
Intraperitoneal Within the peritoneal cavity, the area that contains the abdominal organs 
                                                     
*
 Definition taken from office of science and technology, 
http://www.foresight.gov.uk/HORIZON_SCANNING_CENTRE/FANclub/Index.html  
 Laparotomy A surgical incision into the peritoneal cavity, usually performed under 
general or regional anaesthesia 
Malabsorption Impaired intestinal absorption of nutrients 
Malnutrition Malnutrition is the condition that develops when the body does not get the 
right amount of the vitamins, minerals, and other nutrients it needs to 
maintain healthy tissues and organ function 
Meatus A natural passage or canal; as, the external auditory meatus 
Mesenchymal Cells Derived from mesodermal layers and develop into tissue, muscle or blood  
Mesenteric A membranous fold attaching various organs to the body wall 
Mesentery The membranes, which connect the intestines and their appendages with 
the dorsal wall of the abdominal cavity.  
Metaphysis A conical section of bone between the epiphysis and diaphysis of long 
bones 
Metaplasia The change in the type of adult cells in a tissue to a form which is not 
normal for that tissue 
Multiple sclerosis A neurodegenerative disease characterised by the gradual accumulation of 
focal plaques of demyelination, onset is usually in 3rd or 4th decade with 
intermittent progression over an extended period. Cause uncertain 
Myelodysplasia Abnormal or defective formation of the bone marrow cells. Also known as 
myelodysplastic syndromes (MDS, formerly known as "preleukemia")  
Myelomeningocele A congenital defect in which the neural arches fail to close, so exposing the 
contents of the spinal canal, usually occurring in the lower back of the 
spine. Also known as Spina Bifida Cystica 
Myocutaneous Vascularised autologous tissue, composed of, or supplying both muscles 
and skin 
Necrosis Cell death caused by the degenerative action of enzymes 
Omphalocele A congenital hernia in which a small portion of the foetal abdominal 
contents, covered by a membrane sac, protrudes into the base of the 
umbilical cord 
Opportunity cost* The cost of the benefits forgone from not using the resources on the next 
best alternative 
Ordinal Numbers that express position in a series or place in an ordered sequence 
Ossification The formation of bone 
Osteoarthritis Non-inflammatory degenerative joint disease accompanied by pain and 
stiffness 
Osteoblasts Bone cells that build new bone tissue 
Osteocalcin Polypeptide found in extracellular matrix of bone 
Osteochondritis 
Dissecans 
A type of osteochondritis in which articular cartilage and associated bone 
becomes partially or totally detached from the joint loose bodies 
Osteoclasts Bone cells that break down and remove bone tissue 
Osteoconduction Provision of a scaffold for the growth of new bone 
Osteocytes Bone cells that maintain bone tissue 
Osteogenesis Growth of new bone 
Osteoinduction Acceleration of new bone formation by chemical means 
Osteopontin A bone specific protein that links cells and hydroxyapatite of mineralised 
matrix. Found only in calcified bone, probably produced by osteoblasts 
Ostomy A surgical procedure creating an opening in the body for the discharge of 
body wastes 
Osteomyelitis Inflammation of bone, which may remain localised or may spread through 
the bone to involve the marrow, cortex, cancellous tissue and periosteum 
Pancreatitis Inflammation of the pancreas 
                                                     
*
 Definition taken from (Drummond et al., 2005) 
 Paraesthesia An abnormal sensation, as burning, prickling, formication, etc 
Parenteral Taken into the body or administered in a manner other than through the 
digestive tract, as by intravenous or intramuscular injection 
Parotid Parotid gland, one of the salivary glands situated just in front of or below 
the ear. It is the largest of the salivary glands in man, and its duct opens 
into the interior of the mouth opposite the second molar of the upper jaw 
Pericardium A double membranous sac, which envelops and protects the heart. The 
layer in contact with the heart is referred to as the visceral layer; the outer 
layer in contact with surrounding organs is the parietal pericardium. In 
between the two layers is the pericardial space. 
Perineum The area between the opening of the vagina and the anus in a woman, or 
the area between the scrotum and the anus in a man 
Periosteum The membrane of fibrous connective tissue which closely invests all bones 
except at the articular surfaces 
Peristomal Pertaining to the area of skin surrounding a stoma in the abdominal wall 
Peritoneal dialysis The removal of soluble substances and water from the body by transfer 
across the peritoneum, utilizing a solution which is intermittently introduced 
into and removed from the peritoneal cavity 
Peritonitis Inflammation of the peritoneum 
PEST analysis* Analysis of the external macro-environment that affects all firms. P.E.S.T is 
an acronym for Political, Economic, Social, and Technological 
Pharmacoeconomics The scientific discipline that compares the value of one pharmaceutical 
drug or drug therapy to another. A sub-discipline of health economics 
Porosity Condition of having pores or open spaces 
Prophylactically Acting to defend against or prevent something, especially disease; 
protective 
Prostatism A symptom complex resulting from compression or obstruction of the 
urethra, due most commonly to nodular hyperplasia of the prostate 
Pseudoarthrosis A pathologic entity characterised by deossification of a weight-bearing long 
bone 
Pyelonephritis Inflammation of the kidney and its pelvis, beginning in the interstitium and 
rapidly extending to involve the tubules, glomeruli and blood vessels, due 
to bacterial infection 
Radiopacity The property of obstructing the passage of radiant energy, such as x-rays, 
the representative areas appearing light or white on the exposed film 
Regenerative 
medicine† 
Replaces or regenerates human cells, tissues or organs, to restore or 
establish normal function 
Resection Surgical removal of all or part of an organ, tissue, or structure 
Revascularisation The restoration of blood supply to a part or organ 
Scaffold A support, either natural or artificial, that maintains tissue contour. 
Schistosomiasis Disease caused by trematode worms of the genus Schistosoma, the adults 
of which live in the urinary or mesenteric blood vessels. See Bilharziasis 
Seroma A mass or swelling caused by the localized accumulation of serum within a 
tissue or organ 
Serum Blood plasma with the blood clotting proteins removed. It is prepared by 
removing blood from the subject, allowing blood to form a blood clot, and 
then using a centrifuge to remove the red blood cells and the blood clot 
Small Bowel 
Obstruction 
An obstruction of the small intestine that prevents the free passage of 
material; sometimes caused by postoperative adhesions 
                                                     
*
 Definition taken from dictionary.com, http://dictionary.reference.com/  
†
 Definition taken from Mason and Dunhill (Mason et al., 2008)  
 Sphincter A ring like band of muscle fibres that constricts a passage or closes a 
natural orifice, also called musculus sphincter 
Spicules A needle like structure or part 
Spondylosyndesis Spinal fusion surgery 
Steatorrhea Presence of excess fat in stools, caused by disease of the pancreas or 
intestine, and characterized by chronic diarrhoea and weight loss 
Stem cells Relatively undifferentiated cells of the same lineage (family type) that retain 
the ability to divide and cycle throughout postnatal life to provide cells that 
can become specialised and take the place of those that die or are lost 
Stoma A mouth like opening, particularly an incised opening which is kept open for 
drainage or other purposes 
Strangulated hernia So tightly constricted as to compromise the blood supply of the hernial sac, 
leading to gangrene of the sac and its contents 
Strictures A narrowing, especially of a tube or canal, due to scar tissue or tumour 
Submucosa A layer of tissue beneath a mucous membrane 
SWOT analysis* A strategic planning tool used to evaluate the Strengths, Weaknesses, 
Opportunities, and Threats involved in a project or in a business venture. It 
involves specifying the objective of the business venture or project and 
identifying the internal and external factors that are favourable and 
unfavourable to achieving that objective 
Syngenic Genetically identical individuals 
Tachyphylaxis The rapidly decreasing response to a drug or physiologically active agent 
after administration of a few doses 
Tissue engineering† Tissue engineering is the use of a combination of cells, engineering and 
materials methods, and suitable biochemical and physio-chemical factors 
to improve or replace biological functions 
Trigone A smooth triangular area on the inner surface of the bladder, limited by the 
apertures of the ureters and urethra 
Tubercular Of, pertaining to or resembling tubercles or nodules 
Tuberculosis An infection caused by a species of Mycobacterium, remains a major 
worldwide health problem.  
Urease An enzyme that breaks urea down into carbon dioxide and ammonia, its 
typically used to measure urea concentrations 
Ureters The tubes that carry urine from each kidney to the bladder 
Urethroplasty An operation for the repair of an injury or a defect in the walls of the urethra 
Urinary obstruction Urethral or ureteral obstruction often caused by lodgement of a urinary 
calculus in the narrow lumen.  
Urogenital Pertaining to the urinary and genital apparatus, genitourinary 
Urothelium A layer of transitional epithelium in the wall of the bladder, ureter, and renal 
pelvis 
Vascular pedicle The tissues containing arteries and veins of an organ  
Viscera The soft internal organs of the body, especially those contained within the 
abdominal and thoracic cavities 
Xenogenic Originating outside of the organism, or from a foreign substance that has 
been introduced into the organism 
Xenograft A tissue graft  transplanted from one species to another (e.g. pig to human) 
 
                                                     
*
 Definition taken from dictionary.com, http://dictionary.reference.com/  
†
 Definition taken from dictionary.com, http://dictionary.reference.com/  
 LIST OF ABBREVIATIONS 
 
ACI Autologous Chondrocyte Implantation 
ACS Abdominal Compartment Syndrome 
ATS Advanced Tissue Sciences 
BMPs Bone Morphogenic Proteins 
CBA Cost-Benefit Analysis 
CCI Characterised Chondrocyte Implantation 
CEA Cost-Effectiveness Analysis 
CMA Cost-Minimisation Analysis 
CTS Clinical Trial Simulation 
CUA Cost-Utility Analysis 
DBM Demineralised Bone Matrix 
DDD Degenerative Disc Disease 
EBHC Evidence-Based Healthcare 
ERG Evidence Review Group 
GNP Gross National Product 
HADM Human Acellular Dermal Matrix 
HES Hospital Episode Statistics  
HTA Health Technology Assessment 
ICER Incremental Cost Effectiveness Ratio 
ICRS International Cartilage Repair Society 
IDET Intradiscal Electrothermal Therapy 
IVD Intervertebral Disc Degeneration 
KOOS Knee Injury and Osteoarthritis Outcome Score 
MACI Matrix-Induced Chondrocyte Implantation 
MSCs Mesenchymal Stem Cells 
NICE National Institute for Health and 
Clinical Excellence (UK) 
NHS National Health Service (UK) 
OA Osteoarthritis 
QALY Quality Adjusted Life Years 
HRQL Health-related quality of life 
R&D Research and Development 
RCTs Randomised Control Trials 
RM Regenerative Medicine 
SG Standard Gamble 
SIS Small Intestinal Submucosa 
SMEs Small and Medium enterprises 
TAR Technology Assessment Report 
TE Tissue Engineering 
TKR Total Knee Replacement 
TTO Time Trade-Off 
VAS Visual Analogue Scale 
VOI Value of Information 
WHO World Health Organisation 
WTP Willingness-to-Pay 
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PREFACE 
 
This work was supported by the EPSRC REMEDI Grand Challenge (EP/C534247/1) and the EU FP-6 
STEPS (FP6-500465) projects. The aim of this thesis is to help the regenerative medicine RM industry 
reduce the risk of investing in a new technology that once developed is unlikely to be reimbursed by 
the healthcare providers. The objectives of this thesis are:   
i. To assess whether headroom method can be used, before the development process begins, 
to understand the scale of the market and clinical opportunity 
ii. To develop a novel method using health economic principles that can be used early in 
healthcare technology development and that is simple enough to be used by Small and 
Medium enterprises (SME’s) 
iii. To demonstrate to the RM industry how this method can be used to assess the economic 
potential of their products at early stage product development 
 
This thesis argues for the integration of the headroom method, which uses health economic principles, 
within healthcare technology development. Health economics provides the tools necessary to 
demonstrate value for money. These tools are typically used by healthcare providers to drive demand 
side decisions i.e. to select or reject treatment for reimbursement. However, these same tools can also 
be used by healthcare technology manufacturers and investors, to inform supply side decisions i.e. to 
determine whether the expected returns will outweigh the expected costs. The RM industry provides a 
good example to demonstrate the value of supply side analysis. Despite a rapid proliferation of start up 
companies in the 1990’s very few RM products have been able to make the transition from laboratory 
bench to patient bedside. The failed attempts had been largely due to insufficient marginal 
effectiveness delivered for marginal costs incurred. In addition, the RM industry is heavily comprised of 
SME’s all of which require large external investment to continue product development. Demonstrating 
value for money during the early stages of product development can be compelling evidence to attract 
further investment. However, conducting cost-effectiveness analysis when a product is yet to be 
developed is an extremely uncertain undertaking.  
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In order to conduct a cost-effectiveness analysis the question must be clearly defined. The proposed 
technology must be compared with the best existing treatment. I found that the industry had often not 
carried out this step and so a substantial part of my thesis has been concerned with defining the 
natural history and effectiveness of existing treatments with which a new proposed method will have to 
compete. Once this step is complete, the cost-effectiveness modelling can be carried out. There is an 
immediate difference here between traditional cost-effectiveness modelling versus the supply side 
modelling that I was doing. Supply side modelling involves estimating the effectiveness of a 
technology that does not yet exist, let alone one that has undergone head-to-head assessment. Two 
approaches were possible: i) full economic modelling across a Bayesian prior estimate and ii) 
modelling against the most optimistic plausible assumptions of effectiveness. I have called the latter 
the headroom method. The idea here is that if a technology is unlikely to be cost-effective under 
optimistic assumptions then the investment is unlikely to be repaid. Essentially a model is created at 
the optimistic end of a potential sensitivity analysis.  
 
The thesis begins with a general introduction to the RM industry and health economics before going 
on to discuss the role of health economics within the RM industry. Chapter 2 reviews the current 
literature on the use of health economics during early stage product development within the wider 
healthcare industry. This chapter aims to identify the reasons for conducting early economic evaluation 
as well as the current tools and methods suggested for conducting early economic evaluation. Chapter 
3 describes the research methodology used in this thesis. Chapter 4 describes the headroom method, 
and explains the key principles necessary to understand this method. In Chapters 5 through to 8, I 
illustrate the use of health economics at the supply side using real examples from the nascent industry 
of RM. In chapter 9, I describe the problems faced by SMEs associated with eliciting utilities and 
propose a new approach. Finally, in chapter 10 I will discuss the limitations of the headroom method 
and the implications of this work. I will close this thesis by means of a summary of this work and 
explanation of how it fits in the context of the current literature. I will review the unresolved issues and 
summarise the next steps for this work.  
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 CHAPTER 1 GENERAL INTRODUCTION 
 
1.1 The Regenerative Medicine Industry 
1.1.1 What is Regenerative Medicine and Tissue Engineering? 
Many definitions of RM exist. The world tissue-engineering centre defines RM as “an emerging 
multidisciplinary field of research and technology development focused on the repair, replacement or 
regeneration of cells, tissues, or organs, which has the potential to revolutionise medicine by changing 
the methods of health care treatment and improving health-related quality of life” (WTEC, 2002). More 
recently, Greenwood and colleagues offered a lengthier more detailed explanation: “Regenerative 
medicine is an emerging interdisciplinary field of research and clinical applications focused on the 
repair, replacement, or regeneration of cells, tissues or organs to restore impaired function resulting 
from any cause, including congenital defects, disease, trauma and aging. It uses a combination of 
several technological approaches that moves it beyond traditional transplantation and replacement 
therapies. These approaches may include, but are not limited to, the use of soluble molecules, gene 
therapy, stem cell transplantation, tissue engineering, and the reprogramming of cell and tissue types” 
(Greenwood et al., 2006). In 2008, Mason and Dunnill offered a simpler, shorter explanation for 
regenerative medicine: “Regenerative medicine replaces or regenerates human cells, tissues or 
organs, to restore or establish normal function” (Mason et al, 2008). This was based on Greenwood 
and colleagues earlier definition but with the exclusion of ‘repair’, a word Mason and Dunnill felt did not 
encompass the full potential of RM, which is to return a patient to full health. They also excluded 
specific techniques, which they feel are likely to change over time and make the definition longer and 
more confusing.  
 
Currently, RM approaches include tissue engineering (TE) (the use of cells, engineering and materials 
methods, and biochemical factors to improve or replace biological functions), cell therapy (the 
transplantation of human or animal cells to replace or repair damaged tissue and/or cells), and gene 
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therapy (the insertion of genetically altered genes into cells to replace defective genes). This thesis 
focuses primarily on the TE approach to RM. TE is defined, by the world tissue-engineering centre, as 
“the application of principles and methods of engineering and life sciences toward fundamental 
understanding of structure-function relationships in normal and pathological mammalian tissues, and 
the development of biological substitutes to restore, maintain, or improve tissue function” (WTEC, 
2002). However, the European commission has defined TE in narrower terms as “the regeneration of 
biological tissue through the use of cells, with the aid of supporting structures and/or biomolecules” 
(Bock A.K et al., 2003).  
 
Essentially, it is generally agreed that RM is a new multidisciplinary field of medicine with the potential 
to cause a step change in the delivery of healthcare and the main purpose of RM is to replace missing 
tissue and buttress the body’s natural healing ability. A RM or TE product comprises of one or more of 
the following: growth factors (proteins made by the cells that act on other cells to stimulate or inhibit 
their function), cells (the fundamental, structural, and functional units of living organisms), or scaffolds 
(a support, either natural or artificial, that maintains tissue contour). Using growth factors 
independently is impractical because they will diffuse rapidly from the injected site and be 
enzymatically digested or deactivated. Likewise, cells delivered to a defect site may require some form 
of support to aid their growth and proliferation. Scaffolds alone will not usually work well unless the 
defect has the inherent potential to regenerate anyway (Tabata, 2005). However, the use of cells 
and/or growth factors can improve the performance of scaffolds. Therefore, practically speaking, these 
products are made up in one of the following three ways:  
1. Scaffold and cells 
2. Scaffold and growth factor 
3. Scaffold, cells, and growth factors  
 
A crucial technical aspect of these products is whether they are developed in vitro (in an artificial 
environment outside the living organism) or in vivo (within the living organism). In vitro tissue 
engineering occurs when the tissue, made in an artificial environment - usually a bioreactor (a 
container in which living organisms carry out a biological reaction), is implanted directly into the defect, 
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e.g. a tissue-engineered bladder is made outside the body and designed to replace the original 
bladder (see chapter 4). In vivo tissue engineering involves the implantation of a scaffold impregnated 
with growth factors and/or cells into the defect, e.g. bone morphogenic proteins impregnated on a 
collagen sponge for implantation into bony defects (see chapter 6). Finally, any cells used in these 
products may be autologous (belonging to the same organism), allogenic (being genetically different 
although belonging to the same species) or xenogenic (belonging to a different species). An allogenic 
or xenogenic cell is genetically and immunologically incompatible, and unlike an autologous cell can 
cause an immunological response in the patient. In addition to the manufacturing differences between 
in vitro an in vivo products there are also differences in costs. In vitro production incurs unavoidable 
costs compared to in vivo production stemming from the necessarily rigorous quality control as a well 
as from the logistics of co-ordinating laboratory and clinical activities. 
 
1.1.2 The History of the Industry 
Introduction 
The field of TE has been developing since the early 1970s (although the term ‘tissue engineering’ was 
yet to be introduced) when the first attempts were made to generate cartilage, using chondrocytes 
seeded onto spicules (a needle-like structure) of bone and implanted into (immuno-suppressed) nude 
mice. Although unsuccessful it was concluded that with the advent of innovative biocompatible 
materials it would be possible to generate new tissue by seeding viable cells onto appropriately 
configured scaffolds (Vacanti, 2006). Over the coming decades research continued in this new 
discipline; by the mid-1980s, designs for an appropriate scaffold for cell delivery were emerging, and 
by the mid-1990s the TE field began to expand with a rapid proliferation of start-up companies 
(Vacanti, 2006). The worldwide investment in the industry between 1990 and 2000 rose to an 
estimated $3.5 billion (£2.1 billion, €2.4 billion)* (Lysaght et al., 2001), although 90% of funding was 
from the private sector.  
 
 
                                                     
*
 Currency conversion conducted using www.xe.com. Correct as of 04/11/10 
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Where it all went wrong 
Organogenesis and Advanced Tissue Sciences (ATS) were the first companies to bring mass-
produced TE skin products to market for the management of diabetic foot ulcers and venous leg 
ulcers. Their investors were promised a multi-billion dollar market for their product, based on the costs 
to treat chronic wounds at the time. However, this turned out to be a gross overestimation of the 
market for artificially engineered skin. Sales were poor and failed to cover operating costs; the two 
companies filed for bankruptcy in 2001 (Lysaght et al., 2004). The early failure of Organogenesis and 
ATS had a negative impact on interest and activity in the TE industry. Between 2000 and 2002 activity 
fell by 50% and the capital value of publicly traded TE corporations dropped by 90% (Lysaght et al, 
2004). TE firms ran out of money and investors became increasingly reluctant to give more. 
 
The demise of Organogenesis and ATS has been attributed to a poor business model. In reality, these 
artificial skin products were only appropriate for the small proportion of wounds that fell into the 
category between small, easy-to-heal wounds, and large, difficult to heal, gangrenous wounds. There 
was insufficient demand from clinicians for a high-tech solution for the treatment of wounds in this 
intermediate category and this quickly became a classic case of a technology looking for its application 
(Bouchie, 2002). The industry blames regulatory bodies for slow product and reimbursement approval. 
However, the lack of clinical and economic evidence supporting the cost-effectiveness of these 
products combined with the high production, maintenance, and transportation costs, limited demand 
and made regulators wary. In contrast, current more traditional therapies, such as collagen dressings 
and gels, had no restrictions placed upon them (Bouchie, 2002).  
 
Despite many advances in the field of TE and RM, and although some products have made it to 
market, TE has had less of an impact in clinical practice than the enthusiasts predicted (Williams et al., 
2005). The business side of the industry did not maintain the expectations of the scientists. The 
industry has had difficulty making the transition from development stage to commercial production 
(Lysaght et al, 2004;Mansbridge, 2006), due largely, I believe, to the insufficient marginal 
effectiveness delivered for the cost incurred. As with many new industries, the eventual success 
stories will be built on the foundations of numerous commercial failures.  
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A Brighter Future? 
Investment in the industry is once again growing, with increasing interest from public investment, 
although the majority of investment remains private (Kemp, 2006). There are signs that the industry 
has learnt the lessons from the past. It has been observed that for the industry to achieve success it 
needs to marry a biologics operating model (which costs a lot to run) with a device-type business 
model (which typically yields small margins) (Kemp, 2006), and accept that potential applications must 
first be identified and the technology developed to meet the need.  
 
Despite increases in investment many hurdles still face the industry, not only in the science, but also in 
the commercialisation of these products (Kemp, 2006). A recent report (Rowley et al., 2009) 
discusses, in depth, the barriers to commercialisation and utilisation of RM in the UK as viewed by 54 
individuals from academic, industry, and clinical communities.  
 
The barriers to commercialisation are viewed as: 
− Regulation - a historically uncertain environment, which needs rapid clarification 
− Collaboration – between sectors (academics, industry and clinicians) to share language and 
skills  
− Funding - particularly in translational research,  
− Knowledge – more needed at basic science level. 
 
The barriers to utilisation are viewed as: 
− Collaboration with clinicians - invention is no good without adoption,  
− Evidence – an evidence base is demanded by clinicians, and increasingly by organisations 
that ration health care such as the National Institute for  Health and Clinical Excellence (NICE)  
in England and Wales*,  
− Reimbursement – currently, RM is expensive compared with current treatments, and the silo 
budgets (compartmentalised budgets) within the National Health Service (NHS) makes 
                                                     
*
 an independent organisation responsible for providing national guidance on promoting good health in 
England and Wales and preventing and treating ill health, further information at: www.nice.org.uk 
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economic arguments difficult when costs are incurred in one area while savings are realised in 
another 
− Organisational structure – the NHS is a poor adopter of innovation, and many perceive the 
bureaucratic nature of the NHS as prohibitive 
− Clinical fit - product design as well as distribution and storage.  
 
It is the reimbursement challenge, which is addressed by this thesis. The aim is to help the RM 
industry reduce the risk of investing in a new technology that, once developed, is unlikely to be 
reimbursed by the healthcare providers.  
 
1.2 Health Economics  
1.2.1 What is Health Economics? 
Health economics manages the scarcity of resources. It provides the tools necessary to assess the 
most efficient (best value for money) use of available resources in the allocation of health and health 
care. Economic evaluation is “the comparative analysis of alternative courses of action in terms of both 
their costs and consequences” (Drummond et al, 2005). Crucially it is concerned with the value of the 
opportunity cost – the cost of the benefits forgone from not using the resources on the next best 
alternative. It tries to identify where more benefit can be produced at the same cost, or a lower cost 
can be achieved for the same benefit. There are different types of economic evaluation. Most measure 
costs in a similar way but differ considerably in the way they measure consequences. A summary of 
each type is described below (Drummond et al, 2005). 
 
• Cost-minimisation analysis (CMA): The consequences of two or more treatments are equivalent, 
so the difference between them reduces to a comparison of costs. 
• Cost-effectiveness analysis (CEA): Consequences are common to both interventions but achieved 
to different degrees and measured in natural life units such as life years gained. 
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• Cost-utility analysis (CUA): a particular kind of CEA whose consequences are not common to both 
interventions. To make comparisons, treatments are compared by converting the outcomes to a 
common scale – a utility scale. Quality adjusted life years (QALYs) are such a scale. 
• Cost-benefit analysis (CBA): Consequences not necessarily common to both interventions but 
instead of utility as a common scale all outcomes are measured in monetary units.  
 
1.2.2 The Changing Face of Health Care Purchasing 
Healthcare markets are increasingly competitive. CEA has become an important component of health 
technology assessments (HTA). Health services are using HTA to a greater extent to guide purchasing 
and reimbursement decisions. Assessments of whether a intervention is worthwhile have to be made 
by reference to an external standard (e.g. a specific budget constraint or a threshold cost-
effectiveness ratio) (Drummond et al, 2005;Morris et al., 2007). In the UK, HTA reports are reviewed 
by NICE, who assess the evidence of clinical and cost-effectiveness of a particular technology, and 
gives recommendations to the NHS about whether and in what circumstances the technology should 
be used.  
 
I will elaborate on the approach used by NICE to make reimbursement decisions, but first I will discuss 
a number of health economic concepts, which are appropriate and necessary to understanding the 
subsequent chapters of this thesis. 
 
1.2.3 Health Utilities 
Modern utility theory was first presented by von Neumann and Morgenstern in 1944 (von Neumann et 
al., 1944). This theory describes how individuals should make decisions in the face of uncertainty if 
they wish to act in a way that is defined as rational (Torrance, 1997). A health utility is a broader 
measure of health benefit. A utility is a cardinal value (measured from 0, death, to 1, perfect health) 
that represents the strength of an individual’s preference for specific outcomes, under conditions of 
uncertainty (Petrou, 2001). A health utility is a preference for a specific health state or treatment. If 
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there is a greater preference for a particular health outcome there is also greater utility for that health 
outcome (Drummond et al, 2005).  
 
Utility analysis, employed when conducting a CUA, is viewed as a particularly useful technique as it 
provides a generic outcome measure for comparison of costs and outcomes in different programmes 
(Drummond et al, 2005). This generic outcome is usually expressed as a quality adjusted life year 
(QALY). 
 
Quality adjusted life years (QALYs) 
Incremental health benefit is expressed in QALYs. A concept first introduced during 1968 by Herbert 
Klarman and colleagues (Drummond et al, 2005). A QALY allows comparisons to be made between 
illnesses and treatments. It provides a comparison of the relative value of one health state over 
another, which in turn can guide the setting of priorities to allow efficient distribution of healthcare 
resources for the general population (Hirskyj, 2007).  A QALY is a measure that takes into account 
both the quantity of life and the health-related quality of life (HRQL) generated by healthcare. Quantity 
is expressed in years, in terms of survival or remaining life expectancy. Quality is measured by health 
utilities (a utility-based HRQL score).  
 
Utilities can be used to calculate QALYs, unlike health-related quality of life scores, which directly 
measure the impact of a disease or treatment on people’s ability to function in life and which cannot be 
used to calculate QALYs. QALYs, like utilities, are measured from 0, death, to 1, perfect health. One 
year of perfect health is worth 1 i.e. 1 QALY is equal to 1 year of perfect health. 
 
Total incremental QALY (∆QALY) for a new technology is calculated as in equation 1.1 - a function of 
the improvement in health utility (∆utility) between the new technology and the current gold standard 
treatment, and duration of improvement, when the new technology is compared to the current gold 
standard.  
Equation 1.1: ∆QALY = ∆Utility x duration of time (years) with that health state 
33 
It should be noted that the concept of QALYs has been controversial since its conception. There is a 
great deal of debate in the literature surrounding the potential limitations of QALYS. The criticisms (to 
name a few) relate to difficulties in accommodating chronic disease, where HRQL is a major issue and 
survival less so; the high dependence on age and the inadequate weight attached to emotional and 
mental health problems (Phillips et al., 2003). Several alternatives to QALYs have been suggested 
such as healthy-life years (HYEs) and Disability adjusted life years (DALYs), but currently no 
alternative solves all the challenges (Drummond et al, 2005;Prieto et al., 2003). These methods are 
not used within the context of this work so are not explained here. However, a useful summary can be 
found in the book ‘Economic Evaluation of Health Care Programmes’ by Drummond et al (Drummond 
et al, 2005).     
 
1.2.4 Measuring Preferences  
There are different types of economic evaluation (described in section 1.2.1, page 30). It is cost-utility 
analysis (CUA), where benefit is measured using QALYs, that is advocated by NICE (NICE, 2008). As 
described, a QALY takes account of both the quantity, expressed in years, and the quality, measured 
by health utilities, of life generated by healthcare. It is usually straightforward estimating the duration of 
time in a particular health state, what is more difficult is estimating the utility-based HRQL associated 
with that health state.  
 
There are three approaches to identifying a health utility: 
i. Personal judgement (uncommon); 
ii. Literature or in the database of utilities  held by TUFTS (Tufts Medical Centre, 2009); 
iii. Formal methods, using a primary survey  
 
If a utility score is not given in the literature, it is necessary to elicit the utility directly from patients 
using formal methods. There are three key stages involved in measuring utilities using formal 
methods: 
i. Define a set of health states of interest (e.g. side-effects of current treatment); 
ii. Identify individuals to obtain utilities from (e.g. patients, clinicians, general public); 
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iii. Total across the individuals to determine average values for each health state 
 
A number of formal methods exist for measuring preferences and eliciting utilities. Firstly, there are 
direct methods, those elicited from the general population by mapping preferences directly onto a 
utility scale via means of a rating scale or a trade off (standard gamble or time trade-off). The most 
common of which are the rating scale, time trade-off (TTO) and standard gamble (SG) (Drummond et 
al, 2005). Secondly, there are indirect methods. Elicited from patients using the treatment, these 
methods involve the mapping of preferences indirectly onto a utility scale via means of preference-
based multi-attribute health status questionnaires such as EuroQoL (EQ-5D – www.EuroQoL.org) or 
SF-36 (www.sf-36.org/.). Finally, a method exists to estimate utility in monetary terms. This method is 
termed the contingent valuation method or willingness to pay (WTP). Individuals are asked to state a 
maximum WTP value to ensure welfare gain occurs.   
 
i. Direct Methods 
Rating Scale 
This is the simplest of the direct methods. Subjects are first asked to rank health outcomes in order of 
preference, from most preferred to least preferred. Second they are asked to place the outcomes on a 
scale such that the spaces between placements corresponds to the differences in preferences 
perceived by the subject; i.e. outcomes almost equally desirable would be placed close together whilst 
those perceived as very different would be further apart (Drummond et al, 2005). There are many 
variations to the rating scale but the scale of numbers usually spans from 0 to 100. A common type of 
the rating scale is the visual analogue scale, which consists of a line often 10cm in length, with clearly 
defined end-points, and with or without other marks along the line. Although this may be the simplest 
method it is also the least favourable method as it is associated with a number of biases (Drummond 
et al, 2005).  The most important biases are the end-of-scale bias in which subjects tend to shy away 
from using the ends of eh scale, and the context bias in which subjects tend to space out the 
outcomes over the scale regardless of how good or bad states are (Drummond et al, 2005). 
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Standard Gamble 
Standard gamble (SG) is a classical method of measuring cardinal preferences based on a choice 
between the certainty of one outcome and a gamble with two possible outcomes. Subjects are offered 
two alternatives. Alternative 1 is a health state with certainty (H1), and alternative 2 is a gamble that 
has two possible outcomes, either the patient is returned to full health (H2) with probability P, or has a 
risk of dying (H3 = 1-P). The probability is varied until the subject is indifferent between the two 
alternatives, at which point, the preference score of H1= P (assuming the time in that health states (H1) 
is 1.o years)  (Drummond et al, 2005;Morris et al, 2007). 
 
Time Trade-Off 
Time Trade-off (TTO) is a simpler alternative to standard gamble. Here, the subject is offered two 
alternatives: a) health outcome i for time t (life expectancy of an individual with chronic condition, e.g. 
10 years) followed by death; b) healthy for time x < t followed by death. Time x is varied until subject is 
indifferent between the two alternatives at which point the required preference score for health 
outcome i is given as Hi = x/t. The TTO values are converted into HRQL-based utility scores (U) using 
the following equation: 
Equation 1.2: U = x/t 
However, this method along with all direct measures can be time consuming and complex to 
administer.  
 
ii. Indirect Methods 
These are less time consuming and easier to administer alternative to direct measures. These 
questionnaires stratify data into a number of different dimensions. The questionnaire responses are 
converted to utilities by means of a tariff. These tariffs are available as a result of previous exercises in 
which various possible health states have been calibrated by means of a trade-off (for EQ-5D) or 
standard gamble (for SF-36) from a sample of the general population (Arnold et al., 2009). The 
rationale behind this is that the values are supposed to reflect the preferences of local taxpayers and 
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potential receivers of healthcare. The four most widely used indirect approaches are EQ-5D, Short 
Form-6D (SF-6D), Health Utilities Index (HUI), and the quality of well being scale (QWB).  
 
EQ-5D 
Devised by the EuroQoL group (EuroQol Group, 2008), a consortium in Western Europe, the EQ-5D is 
a health preference questionnaire, which addresses five attributes: mobility, self-care, usual activity, 
pain/discomfort, and anxiety/depression. Each attribute has three levels: no problem, some problems, 
and major problems. Therefore, this system results in 243 possible health states. The scoring function 
of the EQ-5D was devised by measuring the preferences of 3000 members of the UK adult population 
using TTO (described above). Further details on the EQ-5D can be found at: www.EuroQoL.org. 
 
SF-6D 
This is a utility instrument based on the HRQL questionnaire, the Short Form 36 (SF-36). The SF-6D 
was developed to convert the SF-36 into utilities and QALYs. It assesses six attributes: physical 
function, role limitations, social functioning, pain, mental health, and vitality (Brazier et al., 2002) and 
each attribute has four to six levels, resulting in a possible 18000 possible health states. To use this 
system, first the SF-36 questionnaire must be completed, then using the SF-6D scoring table the 
results can be translated into utilities (Drummond et al, 2005). 
  
HUI 
The Health Utility Index (HUI) consists of two systems, HUI2 and HUI3. HUI2 measures six attributes: 
sensation, mobility, emotion, cognition, self-care, pain, and fertility (can be deleted if not relevant). 
Each attribute has three to five levels (Torrance et al., 1996). HUI3 measures eight attributes: vision, 
hearing, speech, ambulation, dexterity, emotion, cognition, and pain. Each attribute is measured by 
either five or six levels (Furlong et al., 2001). In both cases, the scoring formula is based on standard 
gamble utilities measured on the general public (Drummond et al, 2005). More information can be 
found at www.healthutilities.com.    
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QWB 
The Quality Well Being (QWB) scale classifies patients according to four attributes: mobility, physical 
activity, social activity, and symptom-problem complex (Drummond et al, 2005). The scoring function 
is based on category scaling measurements previously taken on a random sample of the general 
public in San Diego, California. The disadvantage of the QWB system compared to the other indirect 
methods discussed above is that it is time consuming to administer (Drummond et al, 2005).  
 
iii. Contingent Valuation 
The final method I will discuss is known as contingent valuation or Willingness-to-Pay (WTP). The 
contingent valuation method is a survey based approach for eliciting consumer’s monetary valuations 
for programme benefits for use in cost-benefit analysis (CBA) (Diener et al., 1998) (see section 1.2.1, 
page 30). CBA is based on the principles of welfare economic theory, which is defined as the 
‘systematic analysis of the social desirability of any set of arrangements, the state of the world or 
allocation of resources, solely in terms of the utility obtained by individuals’ (Morris et al, 2007). Rather 
than measuring health utilities on a cardinal scale from 0 to 1, this approach estimates utility in 
monetary terms, therefore directly estimating the welfare gains/losses. Individuals are asked to state a 
maximum WTP or WTA (willingness-to-accept) value to ensure that the welfare gain occurs or to 
tolerate the welfare loss (depending on whether a programme is being introduced or removed) 
(Drummond et al, 2005). 
 
There are a number of practical difficulties involved in measuring willingness-to-pay. The most 
important issue in order to obtain a precise and unbiased estimate of WTP is making sure the 
respondents understand the market scenarios presented to them and find them plausible and 
meaningful (Morris et al, 2007). There are two general formats a question can take: closed ended or 
open-ended. Closed ended questions are formed of three formats: payment scales, bidding games or 
discrete choice (‘take-it-or-leave-it’). In the payment scale method the respondents are given a range 
of choices and asked to put a tick next to the amounts they are sure they would pay, a cross next to 
the amounts they are sure they would not pay and a circle around the maximum they would pay. The 
disadvantage is that respondents are given cues on the size of the WTP that is considered sensible 
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(Drummond et al, 2005;Morris et al, 2007). Bidding games can only really be conducted in an 
interview, respondents are given a price and asked if they would be willing to pay that price or not. The 
price is then raised or lowered, depending on the previous answer, this continues until the respondent 
can no longer choose. However this method leads to starting point bias (Drummond et al, 2005;Morris 
et al, 2007). In discrete choice format respondents are given a single value that they must choose to 
accept or reject. Different values are presented to different people in a sample and WTP values are 
estimated from the average responses (Drummond et al, 2005;Morris et al, 2007). Open-ended 
formats can be more difficult for respondents to understand, however, there is currently no consensus 
on which elicitation method should be used and all have associated biases.  
 
iv. Practical Issues 
Given the lack of a gold standard for utility elicitation, the person eliciting the utilities is required to 
decide between direct or indirect methods. On the grounds of efficiency, the indirect methods are 
preferable as they are far simpler to administer. However, it is well known that different methods of 
utility estimation yield systematically different values (Drummond et al, 2005;Hirskyj, 2007).  
 
Arnold and colleagues (Arnold et al, 2009) compared direct and indirect methods for eliciting utility and 
found that the two methods yield different results. Direct methods produce significantly higher utility 
values compared to indirect methods across a wide range of diseases. Arnold and colleagues (Arnold 
et al, 2009) offer potential explanations for the observed differences. Firstly, indirect methods impose 
constraints; respondents are forced to encapsulate their potentially complex condition within just a few 
categories. In addition, the questionnaires do not allow respondents to report, for example, potentially 
positive aspects of their situations, which would give higher values of utility. Secondly, it is likely that 
the respondents who contribute trade off values for the tariffs used in indirect methods are 
systematically different from the patients that participate in direct methods. The general population 
used to obtain tariffs for indirect methods are spread across a wider age range than patient 
populations typically used in direct estimation.  
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It is important to note, however, that the utility score you get depends on how you do the measuring 
(Drummond et al, 2005;Hirskyj, 2007). Two key aspects can affect the outcome, firstly, how the 
question is framed, specifically whether the outcomes are certain or uncertain, and secondly, how the 
subject is asked to respond, specifically whether the subject is asked to perform a scaling task based 
on introspection or to make a choice (Drummond et al, 2005).  
 
There is also debate in the literature regarding whose preferences should be measured; clinicians or  
healthcare professionals who are the caregivers and are knowledgeable about health states; patients 
who experience the impact of the disease and treatment; or the general public who may not have 
experienced the health state but who do represent public opinion (Hirskyj, 2007;Petrou, 2001). Some 
people think that utilities should be derived from patients because they really know what the condition 
is like. Whereas others think the citizen’s perspective is more important. However, regardless of this 
debate, it is agreed that respondents should be representative of the relevant population required.  
 
v. Conventional practice 
The NICE guidance on methods of technology appraisal (NICE, 2008) state that as far as possible, for 
the valid analysis of clinical effectiveness, the principal outcome(s) will be clinically relevant; that is, 
they measure health benefits and adverse effects that are important to patients and/or their carers. 
The clinical outcome measures would usually be expected to have an impact on survival or HRQL and 
should be expressed in terms of QALYs for the evaluation of cost effectiveness. NICE states that the 
EQ-5D is the preferred method of measuring HRQL. As described earlier, different methods of 
measuring preferences produce different results, which cannot easily be compared. However, they 
acknowledge that access to EQ-5D data is not always possible. In these circumstances, they advise 
estimating EQ-5D utilities by mapping EQ-5D data from other HRQL measures. I have done this in 
chapter 5. Alternatively, direct methods can be used if this is seen as the most appropriate and EQ-5D 
utilities are not available, in which case the TTO approach is advocated. To maintain consistency with 
the methods of the EQ-5D it is specified that the TTO approach uses full health as the upper anchor 
(NICE, 2008). 
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1.2.5 Incremental cost effectiveness ratio (ICER) 
CUA aims to quantify the incremental cost effectiveness ratio (ICER). This is the extra cost per unit of 
benefit when comparing one treatment, technology, or program against another. This is most 
commonly done on a cost per QALY basis i.e. using cost-utility analysis. The comparator should 
always be the current gold standard treatment for a specific condition, as only an improvement on this 
performance will support the reimbursement of a new technology.  
 
An ICER is calculated as in equation 1.3, using the incremental cost (change in cost from treatment A 
to treatment B (∆C)) and the incremental effectiveness (change in effectiveness from treatment A to 
treatment B (∆E)), resulting in a cost per additional unit of benefit. ∆E can be measured in different 
terms; in the UK, this is most frequently the QALY (discussed further below). ∆QALY becomes the 
measure of the change in effectiveness between the two treatment options thus, ICER = ∆C / ∆QALY. 
This gives a cost per additional unit of effectiveness, or an incremental cost per QALY. Estimates of 
cost per QALY can help to determine whether or not an intervention provides good value for money. 
The ICER determines whether an increase in cost is justified by a sufficient increase in effectiveness 
and reimbursement decisions are based on a threshold level for an ICER. This is done using the cost 
effectiveness plane. 
Equation 1.3: ICER = ∆Cost / ∆Effectiveness 
 
1.2.6 The cost effectiveness plane  
New technologies can be represented graphically according to their cost and effectiveness on a cost-
effectiveness plane (figure 3.2). The origin represents zero additional costs and zero additional effects, 
respectively. The region above the horizontal axes represents higher costs and the region to the right 
of the vertical axes indicates increased effects (Morris et al, 2007). This plane shows those 
interventions, which are cost-effective, i.e. which are eligible for reimbursement by the healthcare 
system, and those that are not.  
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Figure 1.1: Cost effectiveness plane illustrating reimbursable region 
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In figure 3.2, a straight line passes through the origin, where cost is equal to benefit. The gradient of 
this line is dependent on the threshold limit of the ICER. This is the maximum cost a healthcare 
provider will pay for 1 QALY. It is also referred to as the maximum willingness to pay (WTP) threshold 
i.e. the maximum WTP for 1 QALY. This will vary from country to country. The line divides the plane 
into cost-effective (right half) and non-cost-effective (left half) sections. The ICER for the new 
technology can be plotted onto the plane. Depending on the position, the new technology may be 
accepted or rejected for reimbursement by the healthcare provider (Black, 1990). As stated in section 
1.2.2 (page 31), assessment of cost-effectiveness needs to be compared to an external standard.  
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1.2.7 Decision Making in the UK 
As described earlier, NICE is the body in the UK, which assesses HTA reports - the evidence of 
clinical and cost effectiveness of new technologies - and makes recommendations about whether and 
in what circumstances the technology should be used. NICE has to make decisions across different 
technologies and disease areas. It is therefore crucial that all analyses of clinical and cost-
effectiveness adopt a consistent approach. NICE has defined a ‘reference case’ (table 1.1) that 
specifies the methods considered appropriate. The methods of HTA and appraisal by NICE are 
summarised in the ‘Guide to the methods of technology appraisals’ (NICE, 2008). 
 
In summary, the judgements on cost-effectiveness made by NICE are influenced by the following 
factors: 
• The strength of the supporting clinical-effectiveness evidence 
• The robustness and appropriateness of the structure of the economic models, in particular, 
whether the model reflects the decision problem at hand and the uncertainties around the 
assumptions on which the model is based 
• The plausibility of the inputs into, and the assumptions made, in the economic models 
• The preferred modelling approach is one that accounts for all of the economic evidence submitted 
• The range and plausibility of the ICERs generated by the models reviewed 
• The likelihood of decision error and its consequences 
 
NICE decides if a technology is cost-effective based on a threshold range (NICE, 2008). Technologies 
with an ICER below £20,000 ($33,000, €23,000)* per QALY gained are recommended for 
reimbursement. Technologies with an ICER between £20,000 and £30,000 ($49,000, €34,000)* per 
QALY gained need other factors to be present to favour acceptance of the technology and 
technologies with an ICER above £30,000 per QALY gained need strong additional arguments 
favouring treatment.  
 
                                                     
*
 Currency conversion conducted using www.xe.com. Correct as of 04/11/10 
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Table 1.1 NICE Reference Case for estimating clinical and cost-effectiveness 
Element of HTA Reference case Position statement  
Defining the decision 
problem 
The scope developed 
by NICE 
Estimating clinical and cost effectiveness should begin with a clear 
statement of the decision problem. This will require a definition and 
justification of the technologies being compared and the relevant 
patient group(s) to be treated. These characteristics should be 
consistent with the Institute’s scope for the appraisal. 
Comparator Therapies routinely 
used in the NHS, 
including 
technologies 
regarded as current 
best practice 
Perspective on costs NHS and PSS The perspective on outcomes should be all direct health effects, 
whether for patients or, when relevant, other people (principally 
carers). The perspective adopted on costs should be that of the 
NHS and PSS. Technologies for which a substantial proportion of 
the costs (or cost savings) are expected to be incurred outside of 
the NHS and PSS, or which are associated with significant non-
resource effects other than health, should be identified during the 
scoping stage of an appraisal. In these exceptional circumstances, 
information on costs to other government bodies, when these are 
not reflected in HRQL measures, may be reported separately from 
the reference-case analysis. The intention to include such data will 
normally be agreed with the DoH before finalisation of the remit. 
Perspective on 
outcomes 
All health effects 
Type of economic 
evaluation 
Cost-effectiveness 
analysis 
Cost-effectiveness (specifically cost–utility) analysis is the preferred 
form of economic evaluation. This seeks to establish whether 
differences in costs between options can be justified in terms of 
changes in health effects. Health effects should be expressed in 
terms of QALYs. 
Synthesis of 
evidence on 
outcomes 
Based on a 
systematic review 
The objective of the analysis of clinical effectiveness is the 
production of an unbiased estimate of the mean clinical 
effectiveness of the technologies being compared. The analysis of 
clinical effectiveness should be based on data from all relevant 
studies of the best available quality and should consider the range 
of typical patients, normal clinical circumstances, clinically relevant 
outcomes, comparison with relevant comparators, and measures of 
both relative and absolute effectiveness with appropriate measures 
of uncertainty. 
Measure of health 
effects 
QALYs For cost-effectiveness analysis, the value of health effects should 
be expressed in terms of QALYs for the appropriate time horizon. 
The measurement of changes in HRQL should be reported directly 
from patients and the value of changes in patients’ HRQL (that is, 
utilities) should be based on public preferences using a choice-
based method. The EQ-5D is the preferred measure of HRQL in 
adults. The methods to elicit EQ-5D utility values should be fully 
described. When EQ-5D data are not available or are inappropriate 
for the condition or effects of treatment, the valuation methods 
should be fully described and comparable to those used for the EQ-
5D. Data collected using condition-specific, preference-based 
measures may be presented in separate analyses. The use of utility 
estimates from published literature must be supported by evidence 
that demonstrates that they have been identified and selected 
systematically. 
Source of data for 
measure of HRQL 
Reported directly by 
patients and/or 
carers 
Source of preference 
data for valuation of 
changes in HRQL 
Representative 
sample of the public 
Discount rate An annual rate of 
3.5% on both costs 
and health effects 
Cost-effectiveness results should reflect the present value of the 
stream of costs and benefits accruing over the time horizon of the 
analysis. An annual discount rate of 3.5% should be used for both 
costs and benefits. When results are potentially sensitive to the 
discount rate used, consideration should be given to sensitivity 
analyses that use differential rates for costs and outcomes and/or 
that vary the rate between 0% and 6%. 
Equity weighting An additional QALY 
always has the same 
weight   
An additional QALY should receive the same weight regardless of 
any other characteristics of the people receiving the health benefit. 
Source: (NICE, 2008) 
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1.2.8 Uncertainty in Economic Evaluations  
In addition to the reference case, it is also necessary for the HTA report to provide evidence of the 
uncertainty and limitations associated with the clinical and cost effectiveness evidence. Uncertainty 
may arise from missing data, imprecise estimates, or methodological controversy. Consideration of 
any uncertainties and consideration of the possible consequences of an uncertain decision for the 
NHS, is essential prior to any recommendations on the use of the technology (NICE, 2008).  
 
Uncertainty in economic evaluation can exist around a number of areas: 
1. Structural uncertainty – when constructing a model there is potential for selection bias in the 
inputs to the model, for example, the representation of different pathways of care.  
2. The choice of data sources to inform key parameters, i.e. the sources of estimates for costs 
and benefits.  
3. The precision of the key parameters, i.e. the uncertainty associated with the mean parameter 
values.  
 
To appreciate the uncertainties and limitations of the economic evaluation the evidence and rationale 
of any assumptions made in the model, along with the data sources used, must be clearly documented 
(NICE, 2008). It is recommended that mean values are reported along with the distribution around the 
mean and sensitivity analysis is used to reflect the implications of any uncertainties around parameter 
estimates (NICE, 2008). 
 
Sensitivity analysis is a way of exploring uncertainty in the results of economic evaluations. Sensitivity 
analysis examines the effect on the result of using different assumptions around the parameter 
estimates. There are different types of sensitivity analysis, these are summarised below. 
1. Univariate analysis - one way simple sensitivity analysis – each parameter is varied 
individually to isolate the consequences of each parameter 
2. Scenario analysis – Multi-way simple sensitivity analysis  - two or more parameters are varied 
at the same time and overall effect on the results is evaluated 
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3. Threshold sensitivity analysis – the critical value of parameters above or below which 
conditions of the study will change are identified 
4. Probabilistic sensitivity analysis – probability distributions are assigned to the uncertain 
parameters and are incorporated into evaluation models based on decision analytical 
techniques (for example, Monte Carlo simulation). NICE recommend this method as the 
preferred approach when it is necessary to provide distributions around the mean. 
 
1.2.9 Limitations of economic evaluation 
In some circumstances, the identity of the recipient group, (for example, the elderly) may be an 
important factor in assessing the social desirability of a service or programme. Although it has been 
suggested whether differential weights be attached to the value of outcomes accruing to special 
recipient groups, this is not normal procedure. Rather, an equitable distribution of costs and 
consequences across social groups is viewed as a competing dimension upon which decisions are 
made. Finally it is important to remember that an evaluation of any sort is itself a costly activity i.e. it is 
worth considering whether economic evaluations should be subject to economic evaluations 
(Drummond et al, 2005). 
 
1.3 Using Health Economics at the Supply Side 
The aim of this thesis is to help the RM industry reduce the risk of investing in a new technology that 
once developed is unlikely to be reimbursed by the healthcare providers. As I have already stated the 
RM industry has had difficulties translating RM products from laboratory bench to patient bedside and 
the failed attempts have been largely due to insufficient marginal effectiveness delivered for marginal 
costs incurred.  
 
The adoption of new technologies is determined (at least in part) by its cost-effectiveness. CEA is 
typically conducted from the demand side i.e. after the product has been developed, using parameter 
estimates made available from direct studies. At this stage if the product is deemed not to be cost-
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effective and thus not appropriate for reimbursement it can lead to commercial failure, as was seen 
with the first TE products that reached the market.  
 
This thesis is inspired by the idea that health economics could reduce the risk of commercial failure by 
helping to inform investment decisions and indicate which products have the greatest potential. By 
conducting CEA at the supply side i.e. early stage development, when effectiveness is unknown,  at 
key stages throughout product development, predictions about the probability of the product being 
sufficiently affordable can be established and could prove significant in persuading third party payers, 
patients and investors of its value (Archer et al., 2005;Williams et al, 2005). However, unlike 
conventional CEA, in the case of a technology yet to be developed, or in early stages of development, 
the very nature of the product is uncertain and no effectiveness studies have been conducted. I 
propose a simple approach, which I term the headroom method, to the challenge of conducting supply 
side analysis. The headroom method is designed to help healthcare manufacturers avoid misguidedly 
investing in those technologies that are very unlikely to be cost-effective. The headroom method is 
described in further detail in chapter 3 (page 65). 
 
This thesis concerns the application of health economics in decision making at the supply side and 
hence builds on the premise that there is a need for such an approach. The underlying idea is that 
adoption of new technologies is determined (at least in part) by its cost-effectiveness and 
manufacturers and investors would be well advised to take a view on how their projects are likely to be 
assessed in the procurement of healthcare. Clearly, this only applies as far as health economics really 
does enter the frame when such procurement decisions are made. This differs around the world but I 
discern a trend of increased use of explicit cost effective models to inform health procurement 
decisions while recognising that this methodology is perhaps most influential in England and Wales, 
through the operations of NICE. However, I also discern a growing tendency to follow this pathway in 
many other jurisdictions. Likewise, there is an increasing tendency for journals to publish CEA (see 
chapter 2, section 2.5.1, page 51) and they presumably do this because or in response to growing 
recognition throughout the world, of the concept of opportunity cost and hence the need to inform 
decisions through health economics.  
47 
The Headroom Method in this thesis has been applied using reimbursement thresholds applicable to a 
UK setting. These values were selected as the UK, through NICE, has been more transparent than 
most other countries in clarifying the range where the threshold limit lies. However, any threshold 
value deemed to be appropriate by the manufacturer and investor can be applied. Although, it should 
be noted that the value of applying these methods at the supply side is dependent on the planned 
technologies being aimed at the third party (an organisation other than the patient (first party) or 
healthcare provider (second party)).  
 
In the next chapter I review the literature to ascertain the purpose of conducting early economic 
evaluation and, what, if any, methodologies exist for conducting health economic analysis at the 
supply side before going on to outline my own approach to the problem of conducting CEA when 
effectiveness is unknown.  
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 CHAPTER 2 HEALTH ECONOMICS AT THE DEVELOPMENT 
STAGE: A LITERATURE REVIEW 
 
2.1 Introduction 
Health economic evaluation, the assessment of healthcare technologies based on costs and 
effectiveness, has rapidly grown in popularity since the 1990’s (Shemer et al., 2005). This has been 
driven by a worldwide increase in the demand for healthcare coupled with limited healthcare resources 
in relation to supply. As cost-effectiveness of a new technology demonstrates value for money, 
economic evaluation plays an increasing role in reimbursement decisions.  
 
Investing in healthcare innovation is risky business with the potential for large gains but also 
substantial losses. The financial viability of the innovative activities is dependent not only on scientific 
and medical progress, but is also critically reliant on the costs and returns of new drug development. 
With high R&D costs, good choices make the difference between success and failure so it is worth 
spending resources, time, and effort in establishing a reasonable way of choosing successful projects 
(Senn, 1996). In essence, health economics can not only help inform on the future economic viability 
of the product but can also help rationalise product development decisions (DiMasi et al., 2001). 
 
2.2 Objectives 
In this chapter, I examine the literature to identify the following:  
i. The origins of economic evaluation of healthcare technologies; 
ii. The purpose of early economic evaluation in the healthcare industry;  
iii. The methodologies proposed to conduct early economic evaluation of new healthcare 
technologies.  
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I did not expect to identify literature relating to early economic evaluation within the RM industry, as 
this is a new healthcare industry. Instead, I included literature relating to early economic evaluation in 
the more mature pharmaceutical or medical device industries. Finally, I discussed whether the reasons 
and methodologies identified relate to the RM industry.  
 
2.3 Search Strategy 
I conducted a review of the literature using the search strategy shown in table 2.1. I identified literature 
through a search of the electronic database PubMed (www.ncbi.nlm.nih.gov/pubmed/), Google 
Scholar, and the Cochrane Library. All papers found in the search were assessed on their abstract 
content, and where there appeared to be relevant information, the full paper was scrutinised and 
relevant references sourced. Any articles not available online were sourced through the University of 
Birmingham’s libraries or the British library, when necessary. My search uncovered a recent review 
article by Hartz and colleagues (Hartz et al., 2008), which reviews the contribution of economic 
evaluation to decision making in early phases of product development. I have used this as a basis for 
my review, updating Hartz’s review where applicable. 
 
Table 2.1: Search Strings  
Search Term Yield 
1 Economic evaluation AND new technolog* AND Invest* 75 
2 Investing AND new technolog* 20 
3 Economic evaluation AND emerging Medical Technolog* 5 
4 Economic evaluation AND investing in medical technology 3 
5 Emerging Medical Technolog* AND cost effectiveness analysis 3 
6 Economic evaluation AND product development 491 
7 Economic evaluation AND early product development 36 
8 health economics AND product development 849 
9 health economics AND early product development 53 
10 regenerative medicine AND economic evaluation 16 
11 regenerative medicine AND cost effectiveness analysis 8 
12 tissue engineering AND cost effectiveness analysis 15 
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2.4 Summary of Findings  
Health technology assessment (HTA) has been around since the 1970’s but has rapidly grown in 
popularity over the last two decades due to concerns about unproven technologies, rising costs of new 
technologies and a rise in consumer expectations and demands. These drivers have put healthcare 
purchasers under increasing pressure to provide value for money over alternative clinical practice. As 
a result, the healthcare industry now considers cost-effectiveness as the fourth hurdle to market, after 
safety, efficacy, and quality (Shemer et al, 2005).  
 
Traditionally, new technologies have been evaluated at the demand side, as a one off exercise by 
decision makers to decide whether to purchase the technology. As the health service decision makers 
think this way, the manufacturers have started to respond by looking at the technologies in the same 
way and providing the necessary evidence required by the decision makers, which, if in favour of cost-
effectiveness can be also be used as a marketing tool. The demand side has driven the supply side. 
The timely application of economic evaluation in the product development process can provide the 
manufacturer with a vast amount of useful information, not just on the future economic viability of the 
new product (Pietzsch et al., 2008;Shemer et al, 2005). A search of the literature identifies six potential 
benefits of early economic evaluation, along with five methodologies for conducting such an 
evaluation. However, the manufacturers may not have the resources to conduct such complex health 
economic modelling. Based on the findings of this review I found that there is a need for a simple 
approach to the problem of conducting CEA, when the availability of clinical and economic data is 
limited, for use by SME’s.  
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2.5 Main Results 
2.5.1 Health Technology Assessment at the Demand Side 
Background 
The term HTA was first used in the US in 1967, and in 1972 the congressional office of technology 
assessment was established (Banta, 2003). At this time, the definition of technology assessment was 
“a comprehensive form of policy research that examines the short- and long- term social 
consequences of the application or use of technology” (Banta, 2003). Also in 1972, a landmark in the 
development of HTA came in the form of a book published by Cochrane (Banta, 2003), “Effectiveness 
and Efficiency: random reflections on health services”” (Cochrane, 1972), this became a milestone in 
the effectiveness revolution. Cochrane identified the scarcity of evidence of effectiveness in health 
care and strongly advocated the randomised control trial (RCT) as the solution (Stevens et al., 2003). 
In 1992, the first Cochrane centre opened in the UK with the aim of developing a database of evidence 
on which to base decisions. Since then the collaboration has grown to include 15 centres in 12 
countries (Banta, 2003). The Cochrane collaboration has had a big impact in the development of 
evidence-based health care (EBHC) – the process of linking evidence to healthcare practice, with the 
aim of improving quality and effectiveness of patient care. 
 
The healthcare field has become one of the principal applications of CEA and the number of studies 
conducted continues to increase. This was illustrated by Eisenburg (Eisenberg, 1992). Using only the 
search terms “drug “ and “economics”, he found that in 1970 there were 68 published cost-
effectiveness studies but by 1990 this had grown to 687 (Pausjenssen et al., 1998). Since the 1990’s, 
the growth in cost-effectiveness studies has been ever more rapid. Using the PubMed database I 
conducted the same search as Eisenburg and found that in 2009 there were 40776 published studies 
(however, using PubMed, I found that there were 219 published articles in 1970 and 4067 in 1990) 
(figure 2.1). This simple search demonstrates the rapid growth of CEA in the last two decades as well 
as its importance today in the assessment of healthcare technologies. 
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Figure 2.1: A graph to demonstrate the increase in the number of cost-effectiveness studies 
over the last four decades  
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Number of published articles found when using only the search terms “drug” and “economics”. 
 
The Case for HTA 
HTA works to influence health policy. It is closely linked to EBHC and CEA. It can be defined as the 
provision, to healthcare decision makers, of high quality research information on the cost, 
effectiveness and broader impact of health technologies, where health technologies are all 
interventions offered to patients (Stevens et al, 2003). Similarly to EBHC and CEA, HTA has also 
grown in popularity over the last two decades and three main forces have driven these developments 
(Stevens et al, 2003):  
1. Concern about  the adoption of unproven technologies – many interventions were seen to be 
under-researched and not based on robust science 
2. Concern about cost-containment  - there are increasing numbers of new technologies and the 
unit costs of these new technologies are much higher than those they replace 
3. Inexorable rise in consumer expectations and demand 
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HTA in Practice 
Currently, new technologies are evaluated at the demand side, as a one off exercise by decision 
makers who decide whether to purchase the technology. Traditionally, market access for 
manufacturers was ensured once the product passed three regulatory hurdles – safety, efficacy, and 
quality. However, the three drivers discussed above have put health care purchasers and budget 
holders under extreme pressure to provide value for money over alternative clinical practice  (Paul et 
al., 2001).   
 
Many countries have now established national technology assessment centres that use HTA to make 
purchasing and reimbursement decisions. In the UK, this agency is NICE. The NHS HTA programme 
provides the scientific information on clinical and cost-effectiveness that NICE requires to determine 
whether technologies should be encouraged into, or discouraged from, routine clinical practice. 
Although not the first – Australia and Canada were the pioneers of this process - NICE is one of  the 
most influential of all healthcare technology assessment agencies around the world, and in contrast to 
other agencies NICE are much more open in their review process (Paul et al, 2001).  
 
HTA (and CEA) will continue to be important as the need to contain costs and reduce unjustified 
variations in clinical practice and health service provision mean future decision makers need more, not 
less, high quality information on treatment impact (Stevens et al, 2003). Next, I investigate the growing 
interest in early HTA.  
 
2.5.2 Health Technology Assessment at the Supply Side 
As discussed previously, currently, the HTA process is applied at the demand side, to existing 
technologies i.e. licensed technologies. However, evaluating new technologies earlier in the 
development cycle has started to attract attention (Hartz et al, 2008). Manufacturers have started to 
look at their technologies in the same way as the decision makers in order to make better investment 
decisions. Since the final commercial success of a proposed product will be largely determined by a 
cost-effectiveness analysis, it is sensible to conduct such an analysis at the outset. The dilemma when 
it comes to the assessment of innovative medical technologies in the early stages is that the available 
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evidence of clinical and cost-effectiveness is still lacking or only available to a very limited extent. A full 
assessment can only be undertaken when enough relevant data is available, but at that point of time, 
the technology is often already in a stage that can no longer be considered experimental or emerging 
(Hartz et al., 2009). Pietzsch and colleagues provide a useful summary of the similarities and 
differences of a classical HTA, conducted after a technology has been developed, versus an early 
HTA, conducted during technology development (table 2.2).  
 
Table 2.2: Similarities and differences between classical HTA and early HTA 
 
 
Classical HTA Early HTA 
Aim Assess safety, effectiveness and 
cost-effectiveness profiles of a new 
technology 
Assess (likely) safety, 
effectiveness and cost-
effectiveness profiles of a new 
technology 
Decision Support Decision-support for regulators, 
payers, and patients, about 
market clearance, payment, and 
usage of a technology 
Decision-support for 
manufacturers and investors 
about design and management of 
a technology, as well as regulatory 
and reimbursement strategy 
Available Evidence Usually evidence from clinical 
studies performed with the new 
technology 
Evidence from early bench and 
animal testing, and from previous 
generations of the technology 
Influence on technology 
performance 
Limited or no influence on clinical 
performance of a new technology 
Potentially significant influence on 
(future) clinical performance of a 
new technology 
Adapted from Pietzsch et al, 2008 
 
 
i. Early Economic Evaluation 
Introduction 
In 1997, Sculpher (Sculpher et al., 1997) advocated that economic evaluation should not be a one off 
activity during late phase development but should begin with an early developmental stage and 
progress through development as the innovation matures and moves into routine clinical practice. This 
was later corroborated by Langley (Langley, 2004) who advocated that health economic activities 
should be linked directly to each phase of technology development.  
 
Early economic evaluation can be defined by the limited availability of clinical and economic data 
(Vallejo-Torres et al., 2008). Sculpher (Sculpher et al, 1997) proposes it should take place once the 
basic science has been investigated. It should focus on the systemic review of costs and effectiveness 
55 
of the current practice, which the new technology seeks to replace. An estimate of the likely range of 
the differences in cost and effectiveness between innovation and cost of practice can be calculated. 
The aim of early economic evaluation is to assess the extent to which current practice is less than 
effective and estimate an ‘effectiveness gap’. If the existing practice is highly effective, there is limited 
scope for the new technology to be cost effective, unless it can offer a clear cost advantage. If the 
current practice is ineffective for a large proportion of patients, or if it is associated with significant side 
effects, there will be potential for the innovation to represent good value for money, even if it is more 
costly.  
 
Langley (Langley, 2004) refers to early economic evaluation as “the foundation health economic 
assessment”. He suggests this should involve defining the disease state, providing an epidemiological 
profile, reviewing the health economics literature, undertaking a preliminary treatment pattern analysis 
to identify principal pathways, providing pooled clinical analysis of comparator therapies to identify 
end-points, evaluating treatment guidelines, undertaking preliminary assessment of treatment costs, 
pricing options, and developing a preliminary business opportunity. 
 
The Case for Early Economic Evaluation 
1. Strategic Research and Development (R&D) Decision Making 
Most healthcare technology R&D is a long, costly, and risky undertaking. The cost of development 
increases as a technology progresses through development phases. In the pharmaceutical industry, it 
is common for a number of drugs to be in development at any one time. Many will be unsuccessful, 
but the few that may be successful must pay for the rest (Senn, 1996).  Therefore, it is important to 
determine early in the product development whether the expected returns on their successful products 
will outweigh their expected R&D costs. The pharmaceutical industry has also reported that early 
economic evaluations can be used to guide the selection of promising compounds and identify 
potentially safe and effective doses and dosing regimens (DiMasi et al, 2001;Miller et al., 2005). 
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2. Pre-clinical preliminary market assessment 
This assessment includes the investigation of disease state, target population and epidemiological 
factors as well as associated costs and current treatments to picture disease impact (Hartz et al, 
2008). Costs and effectiveness of available therapies have to be assessed, the less effective the 
current treatments are, the higher the potential for a new therapy to be cost-effective (Sculpher et al, 
1997). This can be achieved through a review of the literature. The results of this assessment provide 
a benchmark for the minimum performance required and a forecast of market potential that can be 
used in a business opportunity assessment (Hartz et al, 2008;Langley, 2004). 
 
3. Go/no-go decisions, identification of potentially successful projects 
As previously discussed, the pharmaceutical industry often receives their profits from a small number 
of products, and it depends on these blockbusters to subsidise the unsuccessful products. Data from 
phase I and phase II clinical trials can be fed into the business opportunity assessment and serve as a 
basis for R&D priority setting and “go/no-go decisions” (Hartz et al, 2008;Langley, 2004). This will help 
to determine whether development should continue into the more expensive phase III trials 
(Drummond, 1994). It is important to identify successful and unsuccessful projects as early as 
possible; the later a drug fails the more expensive that failure becomes. DiMasi (DiMasi, 2002) 
reported that 8% reductions in costs can be achieved if the decision to abandon is shifted from phase 
II to phase I and more if the decision to terminate is shifted from phase III to phase II or I.  
 
The Methods for Early Economic Evaluation 
1. Simple Deterministic Economic Modelling 
Based on the work by Sculpher and Langley (described above), this type of modelling serves three 
functions, firstly, to synthesise the available clinical and economic evidence, secondly, to provide a 
useful framework to analyse various scenarios, and thirdly, as an interface to external decision makers 
(Hartz et al, 2008). However, this early modelling has its drawbacks, primarily the scarcity and 
uncertainty of data. Here, data is sought from the literature, expert opinion, or early clinical evidence. 
However, this data is often from studies with small sample sizes, short follow-up times, and 
unrepresentative participants and study settings, which do not reflect routine practice. 
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An example of this method has been demonstrated by Craven and Colleagues (Craven et al., 2009), 
who have devised a simple Excel spreadsheet tool based on a basic decision tree model. This tool is 
designed as a decision aid for estimating the cost-effectiveness of specific medical device innovations 
in the early stages of product development, and for use by the non-expert health economist. The tool 
is provided in a spreadsheet package consisting of instructions, data input sheet, interactive decision 
tree, cost-effectiveness plane chart and financials (a breakeven analysis sheet, which includes selling 
price, predicted market share, unit manufacturing cost and non-recoverable expense). The user enters 
data onto the data input sheet. Each parameter requires a value as well as a range of minimum and 
maximum possible values, which automatically populate the decision tree and produce a resulting 
ICER. The tool can also assist with sensitivity analysis on the ICER. The authors provide three 
example applications of this tool but acknowledge that further work is required, noting the difficultly 
between balancing the generalisability of the decision tree and the need to keep the model simple.  
 
2. Probabilistic Economic Modelling 
Bayesian methods can be defined as the explicit quantitative use of external evidence in the design, 
monitoring, analysis, interpretation, and reporting of HTA (Spiegelhalter et al., 2000). These methods 
are based on Bayes’ theorem of:  
i. A prior distribution or belief about the value of a quantity of interest (for example, a treatment 
effect) based on evidence not derived from the study under analysis, with;  
ii. A summary of the information concerning the same quantity available from the data collected 
in the study (known as the likelihood), to yield;  
iii. An updated or posterior distribution of the quantity of interest (Spiegelhalter et al, 2000). 
 
Bayesian methods allow for existing evidence, knowledge or beliefs about a parameter, formally 
expressed as a probability distribution, to be updated by new information as it becomes available from 
further studies, making explicit and quantitative use of all information available at that point (Vallejo-
Torres et al, 2008). These methods directly address the question of how new evidence should change 
what we currently believe (Spiegelhalter et al, 2000). As the Bayesian framework provides an updated 
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knowledge valuable to decision makers it has been recommended for use in R&D, in particular to help 
inform phase II trial design and to support go/no-go decisions (Hartz et al, 2008).  
 
More recently, Vallejo-Torres and colleagues (Vallejo-Torres et al, 2008) have argued for a 
commercial application of a Bayesian approach for medical devices. Medical devices, unlike 
pharmaceuticals, are fast changing technologies with short life cycles. The authors recommend that a 
Bayesian approach could support medical device development in three ways: 
i. By allowing the estimation of potential cost-effectiveness to be part of the investment 
decision process and to avoid investing in a technology that could never be cost-effective;  
ii. By supporting companies to prioritise between several competing possibly cost-effective 
concepts or prototypes;   
iii. By identifying from early stages of development, those parameters that have the largest 
influence on the likely cost-effectiveness of the product to direct scarce research resources.  
 
Vallejo-Torres and colleagues (Vallejo-Torres et al, 2008) suggest that Bayesian methods are used, 
following initial early economic evaluation (similar to that described earlier by Sculpher and Langley), 
as a means of combining new, but limited data with the beliefs previously identified. This allows for 
expert opinion based on extensive experience to influence the estimated outcome, which is of interest 
when the only available evidence is from small and uncontrolled trials (Vallejo-Torres et al, 2008).  
However, the cost in terms of time and resources of collecting this extra information is typically high, 
and companies will need to decide whether they should fund this additional research to reduce 
uncertainty. 
 
Early Economic Evaluation in Practice 
In 2001, DiMasi and colleagues (DiMasi et al, 2001) conducted a study to assess the emerging role of 
pharmacoeconomics in R&D decision making. Almost half (42%) of the thirty-one pharmaceutical 
companies questioned indicated that it is company policy to subject all products to pharmacoeconomic 
evaluation at some point during the development process (although, this also indicates that almost half 
have no policy to conduct economic evaluation on their products at any stage of development). 
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However, DiMasi found that over the past decade, pharmacoeconomic staff sizes had grown rapidly 
and this was expected to increase further as reimbursement approval becomes more dependent on 
such evidence. DiMasi and colleagues concluded that those companies that recognise the strategic 
value of pharmacoeconomic analysis and effectively integrate pharmacoeconomics into R&D decision-
making processes would acquire important competitive advantages over those who do not.  
 
This study was conducted back in 2001 and could now be assumed out-of-date. It would be interesting 
to see how things have changed in pharmaceutical companies. I expect that as pharmaceutical 
companies have grown, so have the health economics teams and as a result I would expect that 
economic evaluation per se, including early economic evaluation plays a larger role in R&D of new 
drugs. In addition, the size of many pharmaceutical companies would suggest that they have the 
resources to tap into the ever-expanding health economist consultancies.  
 
However, the same cannot be said for the medical device industry. Recently, Vallejo-Torres (Vallejo 
2008) and colleagues have reported that conducting health economic evaluations is not a core activity 
of most medical device companies, especially, not the smaller ones, such an evaluation, if undertaken 
is usually done as a one-off exercise at the late stage of development of new technologies. Most 
medical device companies operate some form of staged decision making development process that is 
regularly reviewed as the route to commercialisation is complicated by regulatory and reimbursement 
approval requirements (Vallejo-Torres et al, 2008). This has been supported recently by Craven and 
Colleagues (Craven et al, 2009) who conducted 12 detailed industry interviews as part of a wider 
programme of research (EPSRC MATCH programme) and found that few medical device companies, 
and no SME’s, had used heath economics during product development. 
 
ii. Modelling to Inform Clinical Trials 
Introduction 
As discussed in the previous section, early economic evaluation has a role in informing early strategic 
decisions, in selecting potentially successful products and assessing the potential market. This 
analysis is conducted during the pre-clinical stages of technology development i.e. before the 
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technology reaches humans. The next stage of development is the clinical trial. Economic evaluation 
can also be used to inform the development of future trial design and improve R&D resource allocation 
(Hartz et al, 2008). 
 
The Case for Informing Clinical Trials 
Economic evaluation can be used in clinical trial study design, particularly from phase II onwards 
(Hartz et al, 2008). Economic modelling in early stages can identify parameters such as choice of 
comparator, outcome parameters, endpoints, and health-related quality of life measures, to which 
cost-effectiveness is particularly sensitive. These crucial parameters can then be prioritised to ensure 
that appropriate data are collected for late-stage cost-effectiveness studies (Annemans et al., 
2000;Chilcott et al., 2003;DiMasi et al, 2001;Sculpher et al, 1997). 
 
The Methods used to Inform Clinical Trials 
1. Value of Information (VOI) analysis 
Founded on statistical decision theory, the underlying principal of VoI is to determine the value of 
obtaining additional information to support a decision. It can also provide insights into the variables in 
the model for which additional information would be most valuable (Hartz et al, 2008;Vallejo-Torres et 
al, 2008). VoI is based on the idea that information is valuable because it reduces costs of uncertainty 
surrounding a decision  (Vallejo-Torres et al, 2008). VoI can be combined and updated with the 
Bayesian methodology to help identify the decision problems where the cost of uncertainty are 
highest, so that additionally gained information will be most valuable which can support R&D 
prioritisation decisions (Hartz et al, 2008).  
 
Whether or not a company should fund additional research to reduce uncertainty relating to the 
reimbursement decision can be informed by means of VoI analysis, but this needs to be adapted to 
inform the value of that further information to the company, rather than the standard value to society of 
reducing uncertainty (Vallejo-Torres et al, 2008).  
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2. Clinical Trial Simulation (CTS) 
Computer simulation of clinical trials uses mathematical synthesis to integrate simultaneously models 
of pharmacokinetic and pharmacodynamic drug action, disease progression, placebo effects, and 
patient variability (Hartz et al, 2008). The main objective is to increase drug development efficiency by 
improving trial protocols, maximising the probability to meet trial targets and enhancing quality of data 
gained. Different assumptions about parameters and intended trial design can be tested to detect 
weaknesses and limitations. CTS can help prevent trial failures and uninformative or unnecessary 
studies and can supply information otherwise unavailable for economic evaluation (Hartz et al, 2008). 
 
How often are these methods used in practice? 
There is a great deal of literature on VoI and this methodology has been demonstrated in an early 
assessment of second generation left ventricular assist devices (Girling et al., 2007) and in two UK 
pilot studies to establish the feasibility and requirements of using VoI analysis in health policy 
decisions (Claxton et al., 2004;Claxton et al., 2006). However, it is yet to be adopted by the healthcare 
purchasers. 
 
iii. Modelling to Determine Price 
Introduction 
Price determination with regard to the assessment of future reimbursement and pricing schemes can 
help manufacturers and investors decide whether to continue with investment. It is assumed that a 
company will only develop a new medical technology if it has evidence that it will provide returns that 
are greater than the investment required to develop that technology and bring it to the market (Brown 
et al., 2007). The price that can be commanded and the volumes sold determine the returns that will 
be made on the initial investment (Brown et al, 2007). Pricing of a new technology should start early in 
development and is necessary for two reasons: firstly, to understand the customers value perceptions 
and secondly, to ensure a product yields a sufficient return on investment (Hartz et al, 2008). 
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The case for Early determination of Price 
1. Assessment of Future Reimbursement 
An economic evaluation can help manufacturers gain reimbursement (Drummond, 1994). Some 
suggest this is of most importance as third party payers have replaced the solo physician as the major 
purchaser in the healthcare market and they demand proof of value for money, to which the 
manufacturers must respond (Pausjenssen et al, 1998). However, an assessment of future 
reimbursement can also be used as a marketing tool for physicians and patients (Drummond, 1994). 
 
2. Price Determination 
The price of a new technology must match its clinical value to avoid an unfavourable reimbursement 
scenario (Hartz et al, 2008). An economic model can also help find suitable price ranges for products 
(Drummond, 1994). A preliminary evaluation of the cost-effectiveness in key market segments at 
different pricing scenarios, patient populations, and indications can be modelled, which can help 
identify gaps in the evidence needed for reimbursement (Hartz et al, 2008). It can also determine 
which clinical profile has to be attained for a given price to make a product cost-effective, or for given 
clinical and economic outcomes, to calculate the cost-effectiveness under different pricing scenarios 
(Hartz et al, 2008).  
 
How often are these methods used in practice? 
Current published articles on price determination are few and simplistic. Later in chapter 6, I discuss 
further, how supply side analysis can be used to determine future pricing strategies. Recently, a more 
sophisticated model on pricing has been produced by my colleague Alan Girling (Girling et al., 2010) . 
 
2.6 Discussion and Conclusion 
2.6.1 Industry Differences 
The literature reviewed here is from the pharmaceutical and medical device industries. However, the 
market structure of these industries differs, and different still is the RM industry.  
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Medical device innovation is characterised more often by small, incremental steps than by large, 
technological leaps. The innovation process is sensitive to a variety of forces, including the availability 
of funds, the reactions of users and regulators, as well as market trends (Littell, 1994). Three-quarters 
of the medical device industry is comprised of SMEs and venture capital funding is critical for 
continued R&D innovation of smaller start-up companies (Littell, 1994). These small firms do not 
possess the resources or expertise to manage the uncertainty and resistance associated with 
innovation (Littell, 1994). This is a stark contrast to the large companies that make up the 
pharmaceutical industry, which have the resources to employ pharmacoeconomic teams. However, 
the time to market of a medical device can be as short as 18-24 months – very different to the 15-20 
years of a pharmaceutical product. 
 
A RM technology is more likely to be like a pharmaceutical product than a medical device product in 
terms of time to market. However, the RM industry is more comparable with the medical device 
industry in that it is comprised almost entirely of SMEs. SMEs have small staff numbers, therefore are 
unlikely to have designated health economists. In addition, they have limited funds, particular during 
early development stages, so have no capacity to employ healthcare consultants. It is necessary for 
SMEs to attract investment for further R&D but this is increasingly difficult if the company cannot 
provide evidence that their product is a sound investment. 
 
Littell (Littell, 1994) wrote about the challenges for innovation in the medical device industry 16 years 
ago, however, this has relevance to the current state of the RM industry. The RM industry is 
comprised of SMEs and reliant on investment from venture capitalists but unlike the medical device 
industry, has the added challenges from the regulatory bodies, which is likely to add to the already 
high production costs of RM technologies. Biotech firms have already found that the costs of 
manufacturer for biologics are higher than for generic drugs. Like RM, these too are mainly 
developmental stage companies, most are not profitable, and the variance of such financial statistics is 
greater than for the pharmaceutical industry (Grabowski et al., 2006). If RM companies do not begin to 
conduct early economic evaluation, as the pharmaceutical industry has done, then those that manage 
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to reach market could find their product is not reimbursable, but many will find they are unable to 
attract further investment to pursue product development altogether. 
 
2.6.2 Limitations with the Methodologies 
Problems with early economic data stem from the fact that they cover only a relatively short period of 
time and are likely to be different in real-world practice, so that the conclusions drawn cannot be taken 
as “hard facts” (Hartz et al, 2009). This uncertainty has to be accounted for in the decision (Hartz et al, 
2009) and there are various methods which can reduce this uncertainty. However, Bayesian methods 
are a controversial topic as they may involve the explicit use of subjective judgements in what is 
conventionally supposed to be a rigorous scientific exercise (Spiegelhalter et al, 2000). The main 
disadvantage of Bayesian methods and VoI analysis is that these approaches are complex to apply for 
those with no prior knowledge. The pilot studies have shown that it is not just the manufacturers that 
are unfamiliar with these methods but also the decision makers who are reluctant to base their 
decisions on such evidence (Hartz et al, 2008). 
 
2.6.3 Conclusion 
To date, it appears that across the worldwide healthcare industry, as a whole, most economic 
evaluations are conducted on products already launched. However, the interest in conducting early 
CEA is growing and gradually more CEA are being conducted prior to registration for marketing 
approval. As we have seen, if applied timely in the product development process, economic evaluation 
can provide the manufacturer with useful information on the future economic viability of the new 
product (Pietzsch et al, 2008;Shemer et al, 2005). The integration of health economics into the various 
stages of product development is essential to identifying, achieving, and maintaining an acceptable 
return on investment. Bringing in health economics at the last minute to try to achieve reimbursement 
is a recipe for disaster (Langley, 2004). 
 
However, it is all very well stating that the RM industry should start conducting economic evaluations 
but how does a SME conduct such analysis when they have no pharmacoeconomics department. I 
foresee two options; firstly, they could employ the services of a consultancy firm to conduct such 
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economic evaluations, but with limited resources, this may not be possible; secondly, they conduct a 
crude economic evaluation themselves, to give insight to potential market and demonstrate in early 
stage product development whether such a venture is worth pursuing.  
 
The following chapter describes my approach to the problem of conducting cost-effectiveness analysis 
at the supply side. Similar to the early economic modelling methodology described above, I will 
describe an approach that was published by myself and colleagues which has been termed the 
headroom method (Cosh et al., 2007). The headroom method is intended to help the healthcare 
industries reduce the risk of investing in a technology that, once developed, is unlikely to be cost-
effective, and reimbursed by the healthcare providers. As an alternative to a full cost-effectiveness 
analysis, at least in the first instance, the headroom method estimates the maximum cost that a 
technology can be brought to market and still be considered cost-effective. This is a necessary step to 
attracting further investment and this approach is designed to be simple enough to be targeted for use 
by SMEs within the RM industry so, at least in the first instance, early economic analysis can be 
conducted without employing an expensive consultant. As development progresses and the company 
grows a consultant could be used to conduct the more complex further economic modelling as 
described in this chapter, or investment could be sought to employ a health economist. 
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 CHAPTER 3 METHODOLOGY 
 
3.1 Introduction 
In a finite resource healthcare system, the cost-effectiveness of a technology can be compelling 
evidence for its adoption. It makes sense for a company developing a new technology to assess its 
potential cost effectiveness as early as possible in the development cycle, particularly when the new 
technology is likely to be high in cost, such as a RM technology.  
 
Chapter 2 showed that cost-effectiveness is an important hurdle for a new healthcare technology to 
reach the market. Early economic evaluation has been advocated in the pharmaceutical industry for 
the last 10 years. The potential benefits of early economic evaluation were highlighted in chapter 2, 
and although the literature was in the context of the pharmaceutical or medical device industries, these 
remain applicable to the RM industry. It makes sense to select potentially successful candidates as 
early as possible and a number of tools have been investigated for this purpose. Unfortunately, many 
of these tools require extensive knowledge of health economics and modelling. Thus, I believe there is 
a gap for a method directed towards manufacturers to guide them through the process of conducting 
their own very early-stage cost-effectiveness analysis.  
 
In this chapter, I describe the headroom method  (Cosh et al, 2007), an approach to the problem of 
conducting health economic analysis at the supply side, under circumstances where effectiveness is 
uncertain or even unknown. I then describe the research methodology used in the thesis to apply the 
headroom method to real examples from the nascent RM industry, all of which are under active 
consideration for development. 
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3.2 The Headroom Method 
3.2.1 The Origins of the Headroom Method 
The Headroom Method arose from work on the use of economics to inform supply side decisions. The 
Headroom Method had an intellectual and practical provenance. From the practical point of view, the 
task prescribed by the sponsors of this research (EPSRC REMEDI Grand Challenge (EP/C534247/1) 
and the EU FP-6 STEPS (FP6-500465)) was to develop a suite of methods to assist manufacturers 
and investors to assess the health economic value of proposed healthcare technology developments. 
From the intellectual point of view, the task proposed the challenge of performing a CEA in the 
absence of effectiveness parameter values. 
 
The formal approach to this challenge would be to construct a Bayesian prior and determine a 
distribution of cost effectiveness values over this prior in a standard manner. However, from a practical 
point of view, such an exercise represents a considerable undertaking and given the likely vague prior 
probability estimates, is bound to yield commensurately vague posteriors. Furthermore, a full 
implementation of such a model would have to take account of decision gates in the development 
pathway and hence calculation of option values. Thus, a pragmatic solution is required both to justify 
such an elaborated decision analytic model and to provide a methodology for industrial decision 
makers who are either unwilling or unable to commission a fully specified CEA.  
 
It was discerned that both the practical and intellectual problem could be addressed by reversing the 
question that usually motivates a CEA, thus instead of asking the question;  
“What are the probabilities that a new proposed treatment will achieve different levels of cost 
effectiveness?” 
We ask instead the question;  
“How cost effective would the technology have to be to represent value for money in the health 
service?” 
To put this another way, the approach consists of establishing the cost effectiveness gap, or the 
“headroom”, within which the technology could prove cost-effective. This methodology recognises that 
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the limiting case is defined by the epidemiology of the condition, most notably the effectiveness of the 
current best treatment and an optimistic assumption concerning the effectiveness of the new 
technology.  
 
Specifying the above properties of effectiveness of existing treatments and the upper plausible limit of 
the effectiveness of the new treatment is not entirely straightforward. This thesis is concerned with this 
problem. Crucial to the understanding of the headroom method, however, is that this is a rapid method 
to provide insight that would otherwise not exist. Such insights include the possibility that there is no 
point proceeding further and that even a full CEA would not represent good use of resources. The 
method acts as some mitigation against the risk that new technology might be developed based on its 
technical merits rather than the human need it can address.  
 
The headroom method is akin to a “back of the envelope” calculation and the counterfactual against 
which it should be judged is not a fully elaborated CEA over Bayesian prior probabilities but rather 
intuitive or ad hoc decisions that characterises the supply side of much of the device industry (Hartz et 
al, 2008).    
 
3.2.2 The Headroom Method as a Framework for Investment Decisions 
The headroom method, as previously described, is an approach to help industry avoid misguidedly 
investing in technologies that are unlikely to be cost-effective and reimbursed by the healthcare 
providers. It consists of a series of processes that should be conducted before substantial investments 
are made.  
 
The headroom method is based on the principles of cost-effectiveness analysis and is conducted 
towards the upper end of the sensitivity analysis with particular reference to the effectiveness of the 
technology. In other words, it simply looks at the potential of a clinically defined market and can be 
used to estimate the maximum potential cost of the new treatment (including development costs and 
factoring in any health service savings). If this cost is too low i.e. if the incremental cost of the product 
could not realistically be held below this level, then investment funds should be channelled elsewhere. 
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Of course, the reverse is not true; the new technology might still fail despite adequate headroom. For 
example, it might turn out to be less effective or more expensive than hoped or better alternatives may 
emerge while the technology is being developed. The headroom method is designed to reduce the risk 
of embarking on an investment that is doomed from the outset. 
 
This method fits into a broader decision framework, illustrated in Figure 3.1, which illuminates a 
situation that may otherwise be hard to fathom. In the remainder of this chapter, I discuss the steps of 
the decision-making framework in further detail and focus on the health economic concepts necessary 
to understand the key stages of the headroom method – stages 2 and 3 – defining the clinical problem 
and the headroom analysis itself. 
 
I have produced a user guide of this methodology to enable SMEs to conduct this preliminary 
assessment themselves. This guide is shown in appendix 1 and is available for download from 
(http://www.haps.bham.ac.uk/publichealth/methodology/hes/). 
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Figure 3.1: Framework for investment decisions for new technologies  
 
* discussed elsewhere (Vallejo-Torres et al, 2008) 
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effects 
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3.2.3 Strategic Considerations 
An organisation needs to begin by addressing strategic fit issues and asking questions such as:  
− Does this technology fit with our skills and strategy?  
− Who are our competitors?  
− How will our decision influence competitor behaviour?  
− What changes to the regulations are in the pipeline?  
− Are similar/competing technologies about to be launched?  
 
Management tools, such as PEST (political, economic, social, technology) and SWOT (strength, 
weaknesses, opportunities, threats) analysis, exist for structuring and defining a business problem 
situation. This process may do no more than formalise existing knowledge. It will however provide 
rigour to the decision and exclude obviously futile schemes. At the very least, it reduces the risk of 
accidentally omitting important considerations from the deliberations.  
 
With respect to regenerative medicine, however, there is an additional important question: 
− “What changes to the regulations are in the pipeline?” 
 
If the problem is not ruled out by strategic considerations, then the investigation should move to the 
next stage with a study of the clinical problem and an analysis of how the technology may help. 
 
3.2.4 Clinical Problem Definition 
In some circumstances, the decision to invest in a technology can be made without recourse to any 
formal method of evaluation. If an unmet clinical need can be identified and resolved, such as curing a 
common, chronic disease at low cost, then the decision makes itself. In 1895, when Roentgen’s wife 
was persuaded to interpose her hand between his x-ray source and a photographic plate, he did not 
need a health economist to tell him he was onto a winner. These blockbuster discoveries come along 
only seldom. The cost effectiveness of most proposed new technologies is much more difficult to 
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predict. In such cases, it is important not to be carried away by enthusiasm for the technology per se 
or to over estimate the size of the potential market. 
 
There is always a limit on how cost effective a new technology may be. The epidemiology and clinical 
features of the condition in question limit the potential benefit. All the conditions where a new 
technology may have an application should be examined in turn, at least to the point where it is clear 
there is a material clinical problem to be solved. It is important to be as specific as possible about the 
clinical problem. A clearly defined clinical need based on a clear understanding of the strengths and 
weaknesses of current treatment is crucial to the uptake of any new technology. It is essential to 
complete this prior to conducting the headroom analysis. This defines the effectiveness gap – the 
room for improvement in effectiveness between the current best treatment and that which the new 
technology might plausibly achieve. This issue was addressed in chapter 2. It was reported that a 
preliminary assessment of the market could be beneficial for forecasting market potential and 
providing a benchmark of minimum performance. In fact, in 1997, Sculpher (Sculpher et al, 1997) 
referred to the aim of early economic evaluation as the identification of the effectiveness gap.  
 
This point may sound obvious but, in my experience, investors and even inventors typically have a 
very vague, even naïve, understanding of the clinical problem. Enthusiastic supporters of a new 
technology may fall into the trap of superficial epidemiological analysis, leading to an overestimation of 
market size and value. Table 3.1 below outlines the questions that will help establish a clear definition 
of the clinical problem. The majority of this information can be sought through a systematic search of 
the literature (further details can be found in section 3.3.1 at the end of this chapter, page 81). 
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Table 3.1: Defining the clinical problem  
Questions Definition 
What is the 
technology? 
Give a precise description of new technology being considered, 
including a description of any uncertainties. For example, in the 
field of regenerative medicine it is uncertain whether a tissue-
engineered bladder will become re-innervated with nerves. 
What is the 
disease/condition? 
Give a precise description of disease and natural history. This 
includes analysis of disease sub-groups where the new 
technology may be more or less applicable. For example, there 
may be a greater need for tissue-engineered bone for fracture 
nonunion repair than for spinal fusion surgery to treat degenerative 
disc disease. 
What is the 
prevalence and 
incidence of the 
disease/condition? 
This information can be obtained through a literature search of 
published studies. Hospital episode statistics 
(www.hesonline.nhs.uk/) can be a useful source of data on 
incidence. This data will need to be broken down by relevant sub-
groups, since the effectiveness gap may vary widely by sub-group, 
as it does, for example in hernia repair. 
What are the 
current treatments? 
The current gold standard is the comparator for the new 
technology. However, new developments must also be reviewed 
as this may change the shape of the market. For example, the 
availability of bone morphogenic proteins is replacing the need for 
complicated bone scaffolds, especially those populated by living 
cells in vitro.  
What is the 
effectiveness of 
current treatments? 
The effectiveness, including any side effects and complications of 
the current gold standard treatment must be clearly described. Any 
side effects or complications, which could potentially be avoided 
by the new treatment, must be identified. For example, a tissue-
engineered solution to repair complex hernias would avoid 
adhesions and infections, which result from current treatment. 
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3.2.5  Headroom Analysis 
The headroom method simply looks at the potential of a clinically defined market. Instead of asking the 
conventional cost-effectiveness analysis question: 
“How cost-effective will the technology be?” 
I ask,    
“Would it be cost-effective if it works as well as one would hope?” 
 
In other words, optimistic assumptions are made about the incremental effectiveness of the proposed 
treatment over the best alternative. I then ask: 
“At what cost would this new technology be cost-effective?” 
 
The headroom method involves two key aspects: 
1. Establish the ‘headroom’ in effectiveness – the effectiveness gap. This is the room for 
improvement in effectiveness between the current and the new treatment. This is essential but 
not always straightforward. The comparator should always be the current gold standard 
treatment for a specific condition, as only an improvement on this performance will support the 
reimbursement of a new technology. The current gold standard treatment should have been 
identified during stage 2 - defining the clinical problem. 
 
2. Calculate the headroom - the maximum incremental cost (maximum additional cost compared 
to the current best treatment) of the new technology which could still be considered cost 
effective. This is based on optimistic but plausible estimates of effectiveness of the technology 
being assessed.  
 
Estimating the effectiveness gap 
The headroom is based on optimistic but plausible estimates of effectiveness of the technology being 
assessed. Of course, a developer will always have optimistic hopes for their product, but rather than 
blind faith, this method aims to concentrate the mind on a realistic upper limit. The degree of formality 
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used in eliciting these values is a matter for the decision maker(s) and dependent on the information 
and expertise available.  
 
Having defined the clinical problem and its epidemiology (as described in stage 2) the simplest 
situation is to assume the outcome of the prospective treatment will be as good as the current 
treatment, and that there is no difference in mortality. In this case, the utility of the new treatment is 
assumed the same as the current treatment and only the period of time during which the utility values 
of the two treatments differ need be considered.  
 
In other circumstances, when current treatment is suboptimal, an “effectiveness gap” (Sculpher et al, 
1997), can be estimated. That is, for those conditions with treatments, which are ineffective for large 
proportions of patients, or have significant side effects, the maximum potential increase in 
effectiveness over current treatment may be used as the optimistic assumption. Here I calculate the 
effectiveness gap by subtracting the utility value associated with the current treatment from a utility 
value of 1 (perfect health). Since the true effectiveness of our new technology is unknown, the most 
optimistic scenario for the new treatment is assumed.  
 
There are two steps required to calculate the effectiveness gap (max∆QALY):  
1. Establish health utility associated with current best treatment - At one extreme, they [the 
decision makers] may simply use personal judgement (uncommon). Alternatively health utilities 
can be identified in the literature or in the database of utilities  held by TUFTS (Tufts Medical 
Centre, 2009). If not, the utility values will have to be established by conducting a primary 
survey using formal methods. Health utilities are described in further detail in section 1.2.3 
(page 31). 
 
2. Estimate duration of improvement - Once the improvement in health utility has been 
established the next step is to identify the maximum potential duration of the clinical benefit 
expected from the new treatment. If there is no difference in life expectancy, it is necessary only 
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to consider the period of time during which the health utility values differ. If there is likely to be a 
difference in life expectancy then this must be included in the calculation.  
 
Using equation 1.1 (page 32) the max∆QALY can be calculated, which in turn can be used to calculate 
the maximum potential headroom associated with the proposed new treatment (see next section). 
 
Calculating the Headroom 
Quantifying the benefit of a treatment is an inherently uncertain process; even when the product is 
finalised, effects will vary from one population to another and there are limits to the precision with 
which effectiveness can be measured. These problems are much greater for a treatment that does not 
yet exist. At this stage, there are no head-to-head comparisons of the technology against an 
alternative and so effectiveness estimates rely on conjecture. 
 
As previously discussed, there is always a prior limit to how cost effective a new technology may be – 
the epidemiology and clinical features of the condition in question limit the potential benefit. The 
headroom calculation is based on the most optimistic assumptions in the plausible range. If the new 
technology does not show cost-effectiveness under the most optimistic scenario then it would not 
show cost-effectiveness under less optimistic assumptions, such as reduced effectiveness or lower 
threshold. 
 
The headroom is the maximum incremental cost for which the technology would still be considered 
cost-effective; this is calculated by rearranging equation 1.3 (page 40) into equation 3.1 below. You 
may notice that in this equation, ‘ICER’ is substituted by ‘WTP threshold’ this is for appropriateness. 
 
Equation 3.1: max ∆Cost = WTP threshold x max ∆QALY 
 
Where, max∆cost is the headroom – the maximum additional cost of new treatment over the 
comparator (current gold standard) for the new treatment to be deemed cost-effective. It is important to 
note that max∆Cost is the net difference in cost [to the health service] of the proposed new technology. 
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It includes any net savings or costs to the health service along with the costs of the product itself; WTP 
threshold is the maximum threshold for the incremental cost effectiveness ratio. As the headroom 
method is based on optimistic assumptions, I assume the most optimistic WTP threshold for the UK 
NHS of £30,000 ($49,000, €34,000). Equation 3.1 can also be expressed as max ∆Cost = £30,000 x 
max ∆QALY; max∆QALY is the effectiveness gap - the maximum additional benefit that could be 
obtained from the new treatment, this must be estimated before I calculate the headroom (see next 
section).  
 
If there is little or no chance that the technology could be marketed at a price that would keep the 
headroom (max∆Cost) below the cost effectiveness threshold, then the technology should not attract 
further investment. Since the ICER is calculated at the most optimistic end of the probability 
distribution for effectiveness, the headroom method is a CEA at the optimistic end of a conventional 
sensitivity analysis.  
 
However, it is important to revisit economic analysis with new information regarding the likely 
effectiveness of the technology as it becomes available. A headroom analysis is primarily useful as a 
barrier to misguidedly investing in those technologies, which are unlikely to be cost effective. As 
research progresses, estimates of costs and effectiveness can be updated, the headroom recalculated 
or further economic analysis conducted. Continual economic assessment at various stages of the 
development cycle will enable more accurate predictions of a product’s cost-effectiveness and hence 
of its market potential (Archer et al, 2005;Williams et al, 2005).  
 
3.2.6 Return on Investment 
For those technologies that appear to have headroom, continuing development and investment would 
appear to be justified. However, a viable new business requires substantial volumes to repay the 
return on investment. At this stage, our interest is focussed on whether or not this technology has the 
potential to succeed once it has been brought to market. Return on investment may be affected by the 
rarity of a condition or because it occurs, only in economies unable to support high cost remedies. 
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Although future development costs will contribute to the decision to continue or abandon, these will 
largely be based on factors internal to the organisation rather than the technology itself and, as such, 
are not discussed here.  
 
The revenue that can be generated is a function of headroom, the likely cost, and volumes, 
represented by equation 3.2.  
 
Equation 3.2: R = (max∆ Cost - C’) x V 
 
Here, R = revenue, ∆ Cost = Headroom, C’ = expected cost of production and V = cases per year. The 
expected profit however, must be discounted over a time horizon chosen to reflect the company 
strategy. 
 
3.2.7 Further Economic Evaluation: Bayesian Probability Distributions 
The steps outlined in this chapter may show that a technology could be profitable. It is a necessary but 
not sufficient basis on which to proceed. Two further possibilities exist.  
 
1. The investor can make an intuitive decision to invest based on the outcome of the headroom 
method.  
2. The investor can perform more formal value of investment analysis (Bayesian probability 
distributions, see below for more details).  
 
This latter option was discussed earlier in section 2.5.2, page 53 and involves testing a more ‘realistic’ 
prior probability than that taken from the most optimistic end of the plausible range. In the case of 
bladder cancer, for example, it would not be assumed that the RM solution would work as well as 
hoped in all cases – some may undergo contracture, or leak and hence require further surgery, for 
example. In that case, the calculation of ‘headroom’ can be repeated over a range of probability 
estimates for effectiveness and a threshold determined where the technology would not be cost-
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effective at its likely cost. To put another way, the probability that the technology would come into 
routine use would be derived. Next, ‘expected’ effectiveness contingent on this scenario would be 
calculated. The expected ‘headroom’ under the assumption is then calculated along with the 
consequent revenue streams in a ‘Value of Investment’ decision.  
 
This methodology has been illustrated elsewhere (Girling, 2007) using left ventricular assist devices 
(LVADs), particularly second-generation LVADs used as a destination therapy in end stage heart 
failure. Early cost-effectiveness assessments, based on first-generation devices, were not 
encouraging. A Bayesian model was used to assess the future cost-effectiveness of second-
generation LVAD therapy. Here, it was clear that the cost-effectiveness of the therapy depends on 
substantial improvements in survival being achieved. However, the lack of RCTs meant there was 
great uncertainty surrounding the survival benefits of second-generation LVAD therapy. A way forward 
was found by exploring the expert opinions of those best able to assess the likely effectiveness of the 
current generation of devices; in this case cardiac specialists with experience of this form of treatment. 
This assessment was done by eliciting Bayesian prior distributions for the survival parameters (using 
the elicitation procedure described by Garthwatie (Garthwaite et al., 2005)). The priors were used in 
two ways: first to estimate the probability that second-generation LVADs will turn out to be cost-
effective when their full benefits are known, and second in a Bayesian value-of-information analysis to 
address the secondary question of whether further trials in this area should be conducted. The results 
found that second-generation LVAD therapy is unlikely to be cost-effective at current UK QALY 
valuations of around £30,000 ($49,000, €34,000) if the device costs as much as the £60,000 ($97,000, 
€68,000) previously reported. Nevertheless, the figures were not inconsistent with an ultimately 
favourable assessment of second-generation LVAD therapy if the cost of the device were to fall in the 
future. Therefore, assuming a plausible device-cost of around £40,000, a future trial would represent 
value for money in a UK setting. Value of information is used here as a form of sensitivity analysis to 
explore the decision-value of parameter uncertainties in a cost-effectiveness model. 
 
From my perspective, there are two main differences between a Bayesian exercise (supply side 
analysis) and the HTA (demand side analysis): 
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i. The decision the model is designed to inform is not a dichotomous decision. In standard HTA 
the decision is dichotomised: to adopt or not to adopt the technology. However, at the design 
stage the decision is three way: develop, abandon, or develop to the next decision gate.  
ii. Often there is no direct evidence of effectiveness. The effectiveness parameter must 
therefore be captured by expert opinion through a Bayesian prior. This Bayesian prior can 
then be used in Value of Investment analysis, as for Value of Information. 
 
The use of further economic evaluation and Bayesian probability distributions goes beyond the scope 
of this thesis, but I feel it is worth mentioning that there are subsequent steps, as outlined in the 
framework (figure 3.1, page 70), that can be followed in order to build up a more comprehensive 
picture regarding the probability of reimbursement. The headroom method is designed to be the first 
step from which a crude estimate of likely cost-effectiveness can be obtained. It is the investor’s 
decision whether to continue to conduct economic analysis with more formal models. This work is 
currently ongoing under the EPSRC MATCH (multidisciplinary assessment of technology centre for 
health) programme led in Birmingham by Richard Lilford and Alan Girling. 
 
3.3 Research Methodology 
In the following chapters, I demonstrate the headroom method with real examples from the nascent 
industry of RM. The technologies I discuss have passed the strategic consideration stage and are all 
under active consideration for development.  
 
In chapter 4, I will investigate the potential for a TE technology for use in the repair of urethral 
strictures and bladder resection following cancer. In chapter 5, I will investigate the application with the 
greatest potential for a TE solution for the repair of abdominal wall defects. In chapter 6, I demonstrate 
supply side analysis using an example based on a RM alternative to bone for use in bony defects. 
Finally, in chapter 7, I conduct supply side analysis on RM treatments for articular cartilage defects of 
the knee.  
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The selection of the clinical applications to evaluate in this thesis was two-fold. Firstly, the research 
teams (EPSRC REMEDI GRAND Challenge (EP/C534247/1) and EU FP6 STEPS (FP6-500465)) had 
particular applications for which they sought an economic perspective. For example, bone defects 
were an interest in both the REMEDI and STEPS projects. Secondly, requests were received from 
SMEs, who had an interest in a particular area, for example, cartilage defects. In most cases there 
were overlapping academic and commercial interest. 
 
3.3.1 Literature Searches 
My first task for each application was to define the clinical problem. This distinguishes conditions with 
small headroom for improvement from those where headroom is larger. For each application, I review 
the clinical epidemiology of the potential conditions where a RM solution may be considered and 
document the strengths and weaknesses of the current treatment options. This is essential risk 
assessment for anyone considering investing their time or money in a particular RM method.  
 
The majority of this information can be sought through a systematic search of the literature. I begin by 
obtaining basic clinical and epidemiological information from textbooks. Then I attempt to seek a 
recent systematic review of the topic. Where no review was available, a search of primary literature is 
performed. I identify literature through the search of electronic databases, including PubMed 
(www.ncbi.nlm.nih.gov/pubmed/), Google Scholar (http://scholar.google.co.uk/), and the Cochrane 
Library (http://www.cochrane.org/). All papers found in the search are assessed on their abstract 
content, and where there appeared to be relevant information, the full paper and its references are 
scrutinised. Any articles not available online are sourced through the University of Birmingham’s 
libraries or the British library, when necessary. In addition, I conducted a search of NICE guidance 
(http://www.nice.org.uk/guidance/index.jsp) to obtain information on cost and effectiveness of current 
treatment and to identify whether there are any other potential treatments for the clinical condition in 
question.  
 
My second task is to identify the most propitious applications for a RM technology and compare 
clinical effectiveness (with special emphasis on HRQoL and utility) and costs of current treatment. 
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Clinical effectiveness is ascertained from the review of the literature. Costs are ascertained, where 
available, from the literature, the Department of Health national schedule of reference costs 
(Department of Health, 2006b;Department of Health, 2007) and National tariff (Department of Health, 
2006a). All cost data is given in pounds sterling, US dollars, and Euros (currency conversions were 
conducted on 04/11/10 using www.xe.com). Finally, I conduct cost-effectiveness analysis and apply 
the headroom method.  
 
3.3.2 Measuring Preferences 
Having defined the clinical problem, the next step is to calculate the ‘headroom’ for improvement in 
effectiveness (the effectiveness gap) between the current best treatment and that which the new 
technology might plausibly achieve. In the headroom method, effectiveness is measured in terms of 
QALYs, as advocated by NICE (NICE, 2008). As previously described (section 1.2.3, page 31), a 
QALY takes account of both the quantity and quality of life years that might be gained through a new 
technology.  
 
Estimating the duration of time spent in a particular health state is usually straightforward. However 
estimating the utility based-HRQL of the health state is more difficult. A health utility can be identified 
in the literature or in the database of utilities held by TUFTS (Tufts Medical Centre, 2009) as in 
chapters 6 and 7. However, when these sources are exhausted it is necessary to elicit utilities by 
means of primary studies, as in chapters 4 and 5. A number of formal methods have been developed 
for this purpose and these are described in chapter 1 (section 1.2.4, page 33).  
 
In the case of urogenital defects (chapter 4) and abdominal wall defects (chapter 5), I elicited the utility 
values were elicited using formal methods, as there were no utility values reported in the literature. For 
the purposes of this thesis, I decided to use direct methods, where practically and logistically possible, 
to elicit the required utility values (based on the findings from Arnold & colleagues (Arnold et al, 
2009)). Time trade-off (TTO) was the direct method selected (advocated by NICE (NICE, 2008)), in 
conjunction with the WTP approach. I designed a questionnaire based on the TTO and WTP 
approaches. For the TTO question, each interviewee was asked what amount of time they would be 
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willing to sacrifice, from 10 years of remaining life, to avoid the negative side effects of the condition 
described to them. In WTP, participants were asked how much they would be willing to pay for a 
treatment that would relieve them of the described health state. Combining the response from both 
WTP and TTO questions allowed me to calculate each individual’s WTP per QALY. 
 
Next, it was necessary for me to decide whom to ask. Ideally, with regard to this thesis, I would have 
preferred to elicit the utility values directly from patients. However, due to logistic, time and ethical 
constraints this was not possible. Instead, I used a proxy for the patients, for example, general 
population, and clinicians. I asked the proxy what they personally would trade to avoid a health state 
that has been described to them. It has been reported that there is a risk of discrepancy between the 
HRQL estimates from patients and the general population (Ubel et al., 2003) and this might 
exaggerate the impact of disease on the HRQL, as patients tend to rate their health states higher than 
the general population, leading to a lower estimate of these benefits of health care than would have 
been estimated by a proxy.  
 
In chapter 4 and 5, I used three questionnaires, two of the three questionnaires were completed by 
clinicians of relevant speciality to the condition in question, and the final one was completed by a 
sample of the general public. Further details describing how these questionnaires were completed, are 
included in the relevant corresponding chapters.  
 
3.3.3 Clinical Engagement 
A considerable proportion of this thesis is concerned with defining the clinical problem. Although, as 
previously described, this information was primarily sought from the literature, it was necessary and 
appropriate to expand on this by seeking expert opinion. Expert opinion was sought from clinicians 
specialising in an area relevant to the clinical application under consideration. Clinicians were found 
through Professor Lilford’s existing local network of clinicians, via recommendation from members of 
the EPSRC REMEDI and EU-FP6 STEPS projects, or through attendance at conferences. Clinicians 
were used to seek additional information, or clarification of the clinical problem, used to help describe 
the health state when writing the questionnaires, and, as described, to elicit utility values by 
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completing the questionnaires. Clinicians were engaged through email, teleconference, face-to-face 
meetings, and conferences. In addition, at the invitation of an orthopaedic surgeon with whom I had 
been in contact, I also had the opportunity of observing a spinal fusion operation. 
 
3.3.4 Industry Engagement 
Another necessary part of defining the clinical problem is engaging with the RM industry to ensure the 
information on the current state-of-the-art in RM technology is up-to-date. There were a number of 
industry partners (mostly SMEs) involved in both of the projects, which sponsored this work. In some 
cases, the industry partners were a substantial member of the consortium and were influential in 
steering, which clinical applications were to be assessed. For example, for the abdominal wall defects 
work I worked closely with the French TE firm, Sofradim - an industrial partner for the EU-FP6 STEPS 
project. In addition to these industry partners, I also established several other industry links, external to 
the projects, although contact was made through networks established in the projects. The industry 
partners were engaged through face-to-face meetings, teleconference, and conferences/meetings.  
 
In the following four chapters, the headroom method is demonstrated using real examples from the 
nascent industry of RM; urogenital defects, abdominal wall defects, bone, and cartilage. 
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 CHAPTER 4 COST EFFECTIVENESS ANALYSIS AT THE 
DEVELOPMENT PHASE OF TISSUE ENGINEERED 
BLADDER AND URETHRA 
 
4.1 Introduction 
In this chapter, I evaluate TE products designed for use in the field of urogenital medicine. Firstly, I 
consider a TE bladder, inspired by Atala’s work (Atala et al., 2006) and research at the French firm, 
Sofradim. Secondly, I consider a relatively simple application to bridge urethral gaps using a TE 
solution. The aim of this chapter is to investigate whether a TE solution to bladder and urethra defects 
may provide a higher patient HRQL and whether this approach may be cost-effective. 
 
The bladder and urethra are components of the urinary system (illustrations of the structures of the 
bladder and urethra are shown in figure 4.1). The bladder, also known as the urinary bladder, is a 
hollow muscular organ that serves to collect urine excreted by the kidneys prior to disposal by 
urination, a result of bladder contraction. A number of conditions can cause damage to the bladder, 
resulting in decreased bladder capacity. Currently, bladder capacity is increased via a bladder 
cystoplasty. This operation increases bladder capacity by directly increasing the volume of the bladder 
through the stitching of a section of detubularised ileum (small intestine) into the bladder. A TE 
solution aims to replace the use of ileum in this procedure.  
 
The urethra is the tube that conveys urine from the bladder to be discharged from the body. Medical 
problems associated with the urethra result from birth defects or physical damage later in life. Defects 
of the urethra are currently repaired via an urethroplasty, an operation to repair the urethra wall using 
tissue grafts and genital flaps to restore function. A TE solution aims to replace the use of tissue grafts 
in this procedure.  
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Figure 4.1: Structure of a bladder and urethra in males and females 
 
 
 
 
Copyright of Maurizio De Angelis, www.mdaillustration.com  
Source: http://www.mdaillustration.com/charts.html 
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4.2 Methods 
4.2.1 Overview 
The clinical conditions where TE urethral tissue could have potential are identified and the strengths 
and weaknesses of the current best treatment documented. The extent to which it was plausible that a 
TE solution may offset the problems associated with the current treatment, without introducing new 
hazards was ascertained. This enables the identification of the precise clinical problem that a TE 
solution is supposed to solve before applying the headroom method. 
 
4.2.2 Defining the Clinical Problem 
A former colleague from within my Public Health team∗ conducted the initial literature review in 2006. I 
conducted subsequent searches to update the review where applicable in 2009. Literature was 
sourced using the search strings shown in appendix 3 and the search strategy outlined in section 3.3.1 
(page 81). Additional online articles were sourced, when necessary, from e-Medicine 
(http://emedicine.medscape.com/), the world health organisation (WHO) website 
(http://www.who.int/en/), and Urology Today (http://www.urotoday.com/). The literature was 
supplemented by discussions with tissue engineers from Sofradim and FAB (two European TE 
companies known to us through the European Union Framework Package 6 STEPS (a systems 
approach to tissue engineering) project), and Tengion (an American company seeking to exploit Atala 
and colleagues breakthrough research) (Atala et al., 1993;Atala et al, 2006;Oberpenning et al., 1999)).   
 
Analysis of the clinical problem revealed two potential indications for TE urogenital tissue: cystoplasty 
for bladder carcinoma and urethroplasty for urethral strictures. The duration and severity of the clinical 
effects were documented along with the costs of the current treatment. As previously described in 
chapter 3, to conduct the headroom analysis it is necessary to obtain a utility-based HRQL score 
associated with the clinical effects of the current treatment. Following a comprehensive literature 
                                                     
∗
 The project grants, which subsequently funded my PhD, commenced before the start of my PhD and 
a former research associate conducted this work prior to the start of my PhD.  
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search, no existing utility-based HRQL scores associated with a cystoplasty or urethroplasty 
procedure were found so a questionnaire was devised to elicit the utility scores associated with each. 
The methods are described below. 
 
Eliciting Health Utility 
The utilities were elicited using TTO and WTP methods (section 3.3, page 80). In TTO, each 
interviewee was asked what amount of time they would sacrifice from a 10-year life expectancy, to 
avoid the negative side effects of the procedure in question, and have perfect health for the remainder 
of their life. The TTO values were converted into utility scores using equation 4.1. 
 
Equation 4.1: HRQL = TTO ÷ t 
 
In WTP, each participant was asked how much they would pay for a treatment that would relieve them 
of the described health state rather than them having to endure it for six months. Combining these 
responses with those from the TTO question made it possible to calculate each individual’s WTP per 
QALY.  
 
The questionnaire design, data collection, and data entry were all conducted by a former colleague 
Guy Freeman, assisted by two medical students doing work experience. More details on the 
questionnaire design are described in appendix 2 and a copy of the questionnaires is provided in 
appendix 4. 
 
It was not possible to obtain the health utility directly from patients due to insufficient time to get ethics 
approval and the logistics and time required to arrange face-to-face interviews. In addition, due to time 
and cost constraints, it was not possible to obtain a fully randomised sample of a national or 
international population. Instead, the utility scores for cystoplasty and urethroplasty were elicited from 
a sample of urologists and the general public, respectively. The urethroplasty questionnaire was 
completed by a sample of the general public, selected, at random, from within the public health 
building at the University of Birmingham (unknown to those collecting the data) and from Birmingham 
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city centre (outside Birmingham Central Library and New Street Station). The cystoplasty 
questionnaire was completed by a sample of specialist urologists. Sixteen urologists from within the 
Birmingham and Black Country area were identified by using the NHS website to identify hospitals and 
the individual hospital websites to identify the urologists. The reason for the geographical restriction 
was that face-to-face interviews were planned. However, this became difficult to organise, clinicians 
were not willing to give up their time, or their availability was very limited. This would have delayed the 
completion of the analysis. Instead, it was decided that a questionnaire would be emailed to each 
urologist and those who did not respond within two weeks were followed up by a phone call.  
 
I conducted data analysis using Excel. The key results (those necessary to complete the headroom 
analysis) are presented in the relevant sections within this chapter and the supplementary results are 
presented following the corresponding questionnaire in appendix 4. The supplementary analysis 
includes the analysis of potential covariates such as, familiarity with buccal mucosa donations, 
familiarity with the time-trade off method and cost-benefit method, and the location where the interview 
took place.  
 
4.2.3 Cost-Effectiveness Analysis 
Using the data collected by Guy Freeman, I calculated a utility-based HRQL score associated with the 
clinical effects of cystoplasty and urethroplasty. Using these utility scores, I populated equation 4.2 
and calculated the headroom - the maximum cost for which a TE solution for cystoplasty and 
urethroplasty would be considered cost effective. 
 
Equation 4.2: max∆Cost = max∆QALY x willingness-to-pay threshold 
 
Where, ∆Cost is the maximum headroom, ∆QALY is the maximum change in benefit measured in 
QALYs and willingness-to-pay threshold is the reimbursement threshold of £30,000 ($49,000, 
€34,000).  
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4.3 Treatment 
4.3.1 Current Treatment 
Bladder Cystoplasty 
When bladder capacity or function has been substantially reduced current surgical intervention is by 
means of a cystoplasty procedure. Complete bladder excision (radial cystectomy) is usually 
accompanied by urinary diversion, a procedure necessary to maintain the flow of urine via a reroute 
from the normal pathway through an opening in the abdominal wall. Substitution cystoplasty entails the 
creation of a new reservoir from bowel segments (ileum or colon), and has been advocated following 
radial cystectomy, provided the urethral sphincter (ring of muscle) and its innervation can be 
preserved. In such cases the urethras are implanted directly into the bladder substitute and voiding is 
achieved by the application of abdominal pressure (Venn et al., 2000). Currently, the vast majority of 
instances of substitution cystoplasty follow a radical cystectomy for invasive cancer (Venn et al., 
1998). 
 
Partial excision (partial cystectomy) of the bladder, where the trigone (a triangular region of the internal 
bladder sensitive to expansion of the bladder, (figure 4.1)) is spared, is usually accompanied by 
augmentation cystoplasty (operation to increase size of bladder). Augmentation cystoplasty involves 
material being stitched into the bladder, with the conventional patch being a section of detubularised 
ileum (small intestine) on a vascular pedicle (a tissue containing arteries and veins) (Duel et al., 
1998;Greenwell et al., 2001). This procedure is often termed an ileocystoplasty and is illustrated in 
figure 4.2.  
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Figure 4.2: Cystoplasty procedure 
 
 
1: The segment of ileum chosen for augmentation is isolated on an adequate mesentery (membrane 
which connects intestine with the dorsal wall of the abdominal cavity) and re-establishes intestinal 
continuity. Close the ends of the segment with suture, and open the antimesenteric surface (the part of 
the intestine that lies opposite the mesenteric attachment). 2: Fold the segment of ileum and sew it 
upon itself. This detubularises the segment, reduces enteric (intestine) contractions, and maximizes 
the volume that the segment contributes to urinary storage. 3: Anastomose (communicate or connect) 
the augmenting segment to the prepared bladder. Perform a wide-mouthed anastomosis (surgical 
connection of two normally separate hollow organs) to ensure that the augmentation is spherical. If 
this is not carried out properly, the augmenting segment can exist only as a poorly draining 
diverticulum (sac-like structure) that is prone to complications. 
Image reprinted with permission from eMedicine.com, 2009.  
Available at:  http://emedicine.medscape.com/article/443916-overview 
 
 
Urethroplasty 
Urethral surgery is required for strictures (narrowing of urethra) and other urethral abnormalities such 
as epispadias (congenital defect resulting in urethral opening on the upper side of the penis) and 
hypospadias (congenital defect resulting in urethral opening on the bottom of the penis).  
 
In a substitution urethroplasty, a section of the urethra is surgically opened or removed, and the 
urethra is repaired with a tissue graft or flap. Historically, skin graft has been the most widely used 
substitute for urethroplasty, but since the early 1990’s this has being largely superseded by buccal 
mucosa, the tissue making up the inner lining of the cheek (Bhargava et al., 2004). The impression 
that buccal mucosa is becoming the gold standard as a urethra substitute was gleaned from the 
literature and confirmed following discussion with urologists. Buccal Mucosa, like urethral tissue, is a 
 1. 2. 3. 
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mucous membrane, with similar physical and immunologic properties (Fichtner et al., 2004). It has 
high elasticity (Barbagli et al., 2003), compatibility with a wet environment, and is non-hair bearing 
(Bhargava et al, 2004). However, the use of buccal mucosa has disadvantages relating to the donor 
site. 
 
4.3.2 State of the Art in Tissue Engineering 
TE solutions for bladder and urethra are aimed at improving the quality rather than the quantity of life. 
They offer an alternative to the use of bowel for cystoplasty following partial or (more rarely) radial 
cystectomy and to the use of skin grafts for urethroplasty. 
 
TE material should be “amenable to surgical manipulation and reconfiguration, able to distend at low 
pressure with no spontaneous pressure generation, of low malignant potential, have no role in 
absorption or secretion of urinary constituents and should not produce mucus” (Duel et al, 
1998;Greenwell et al, 2001). In addition, the need for functional innervation should be added to this 
list.  
 
TE grafts can be one of two types in vivo or in vitro (Schultheiss et al., 2000). In vivo grafts are based 
on a natural but acellular matrix, which harnesses the bladder’s natural regenerative abilities by 
providing a structural platform for cells to migrate and proliferate, resulting in the ingrowth of smooth 
muscle tissue and mucosa (Shokeir, 2002). Urogenital grafts need to replicate bladder or urethral 
elasticity. Current acellular matrices include porcine SIS (Pig Small Intestine Submucosa) and BAMA 
(Bladder Acellular Matrix Allograft). These acellular grafts have been investigated in a variety of 
mammalian models (Kropp et al., 1995;Kropp et al., 1996;Nuininga et al., 2004;Piechota et al., 
1998a;Piechota et al., 1998b;Probst et al., 1997;Probst et al., 2000;Sutherland et al., 1996;Vaught et 
al., 1996) where the graft was found to acquire microscopic and macroscopic properties of bladder 
vestibule.  Unfortunately, not all the cited studies agree on the ability of the graft to acquire normal 
function and innervation. 
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The in vitro approach creates an entirely artificial bladder or urethra graft and uses both urothelial and 
smooth muscle cell types in a scaffold. Bladder grafts using this approach have been cited in a 
number of animal models (Atala et al, 1993;Oberpenning et al, 1999;Wang et al., 2006) demonstrating 
successful formation of tissue-specific architecture comparable with natural bladder (Atala et al, 
1993;Oberpenning et al, 1999;Wang et al, 2006) as well as increased bladder capacity (Oberpenning 
et al, 1999). The implantation of TE bladders into dogs (Oberpenning et al, 1999) has demonstrated 
that the bladder did become innervated and was able to void normally, but this possibility remains 
untested in humans. Atala et al (Atala et al, 2006)  reported that seven patients with upper motor 
neurone bladder lesions treated with a TE bladder had improved symptoms with fewer infections, 
reduced immunogenic reaction and no electrolyte disturbance. However, the patients were not able to 
void spontaneously, which the authors ascribe to the underlying neurological condition. However, TE 
regeneration of the complicated trigone area of the bladder is not currently on the horizon and thus 
remains but a distant hope.  
 
Both acellular and cellular grafts are promising solutions to the problem of finding the ideal urogenital 
tissue replacement. However, the question remains whether the advantages of cellular grafts would be 
enough to offset the significantly higher costs incurred by using an in vitro option. The acellular 
approach, if successful, may provide the economic “off the shelf” solution. Although, the resultant 
bladders following an in vivo approach are smaller than those obtained by in vitro approach. TE 
approaches for bladder cancer follow excision of substantial amounts of normal bladder tissue. Since 
a procedure is needed to make good large defects, it could be assumed that in vitro techniques would 
be necessary. In the case of urethra, however, a smaller defect has to be bridged and here both in 
vivo and in vitro solutions for this application are considered.  
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4.4 Potential Indications for a TE solution 
Four types of indication for a urogenital TE intervention were discerned following the literature review. 
These were:  
i. Dysfunctional bladder (e.g. neurological disease and detrusor instability)  
ii. Small contracted bladders (e.g. bilharziasis)  
iii. Bladder carcinoma   
iv. Urethral strictures  
 
The first three are potential indications for bladder augmentation and the last for urethroplasty. Now I 
consider the above four indications in turn to define the potential value for TE.  
 
4.4.1 Dysfunctional Bladders 
The dysfunctional bladder reduces the functional capacity of the bladder and can create a strong urge 
to urinate. It can be diagnosed as either idiopathic detrusor instability (spontaneous and uninhibited 
contraction of the detrusor muscle during bladder filling) or neuropathic bladder dysfunction 
(malfunctioning urinary bladder due to neurologic dysfunction), depending on whether or not a known 
underlying neurological condition is present. Detrusor instability has a number of synonyms and 
closely related conditions, including overactive bladder, urge incontinence, detrusor hyperreflexia, 
irritable bladder, spasmodic bladder, and unstable bladder. Detrusor instability is the more common 
condition with a prevalence rate of 17% among Europeans aged 40 and over (Milsom et al., 2001). 
This condition is controlled by drug or behaviour therapy, where this fails bladder augmentation can be 
used. The operation deactivates the “unstable” muscle by cutting through the detrusor close to the 
urethral meatus (Ivil et al., 2002). Cystoplasty then restores capacity to the now-stabilised bladder.  
 
Neurological conditions (such as Myelodysplasia (myelodysplastic syndromes (MDS), 
Myelomeningocele (Spina bifida), or multiple sclerosis (MS)) often affect bladder function causing 
either incontinence or inability to void (Jamison et al., 2004;Mingin et al., 2003). This is the case in 
95% of ambulatory Spina bifida sufferers (Mingin et al, 2003) and 80% of MS patients (Henze, 2005); 
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amounting to 211,000 and 65,000 patients in the USA and UK, respectively. A surgical intervention for 
neurogenic bladder is only considered if the patient does not respond to any form of medical therapy 
and if bladder symptoms are extremely incapacitating. This is the case in less than 10% of 
Myelodysplasia sufferers (Mingin et al, 2003). 
 
The niche for a TE solution for dysfunctional bladders is likely to be very small, for the following three 
reasons: 
1. Many patients with intractable over-activity are either unsuitable or unwilling to undergo a major 
operative procedure involving incision into “normal” bladder tissue for a functional lesion that is 
not life-threatening (Harper et al., 2004). If the bladder is not excised, lesions may re-grow with 
recurrent symptoms. Furthermore, if re-innervation occurs in TE bladder then symptoms are 
likely to recur even if bladder is excised.  
2. Patients with idiopathic detrusor instability have been documented to respond poorly to surgical 
interventions (see section 4.5, page 100).  
3. The advent of a new intervention, botulinum toxin (or botox), is likely to further curtail the role of 
adventurous surgical solutions, both for detrusor instability and for neurological lesions. 
Botulinum toxin targets the neuromuscular junction of the detrusor where it interferes with 
synaptic function. As a result, the detrusor enters a state of flaccid paralysis and bladder 
overactivity is significantly reduced. Treatment can then be carried out via minimally invasive 
surgery. The majority of studies into this treatment were in an outpatient setting and reported 
good results with no tachyphylaxis (decrease in response to drugs) (Harper et al., 
2003;Radziszewski et al., 2002;Reitz et al., 2004;Schurch et al., 2000). 
 
4.4.2 Small Contracted and Inflammatory Bladders 
The two most common conditions that lead to small contracted bladders indicating cystoplasty are 
bilharziasis and tuberculosis. Bilharziasis (or schistosomiasis) is a parasitic condition that is commonly 
found in the tropics and sub-tropics. The responsible species, Schistoma haematobium, is endemic in 
54 countries in Africa and the Middle East, and the WHO reports that 18 million sufferers endure the 
consequent bladder wall pathology (WHO, 2006). This presents a huge potential market, but 
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unfortunately not a viable one, with most countries where the condition is endemic having low GNP 
per capita (figure 4.3). 
 
Tuberculosis has a total incidence of 439,000 in Europe and more than 8,810,000 worldwide. Recent 
resurgences in incidence are mainly attributed to opportunistic infections accompanying AIDS. 
Treatment for the tubercular bladder is by augmentation cystoplasty; indeed, the technique of 
augmentation cystoplasty was popularised in the context of tubercular contracted bladders 
(Couvelaire, 1951). However, the incidence of augmentation cystoplasty for tubercular contracted 
bladder is now very low and has been cited in single figures worldwide; therefore, it is sceptical that 
there would be any substantial market for this indication. 
 
Interstitial cystitis (Hunner’s ulcer) is the chronic non-septic inflammation of the bladder wall. Some 
believe it to be common (Curhan et al., 1999), but the urologists consulted believe it to be rare, being 
frequently suspected but seldom confirmed. It is generally treated conservatively, but in very rare 
instances may constitute an indication for cystoplasty (Venn et al, 2000). 
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Figure 4.3: Map of Bilharzias and per capita GNP 
 
 
These diagrams illustrate that the potential market for augmentation cystoplasty is not a viable one. By 
comparing the two diagrams, it can be seen that the areas with highest levels of Bilharzias correspond 
to the areas with the lowest GNP per capita i.e. some of the world’s poorest nations. The top diagram 
shows the distribution of Schistosomiasis (Bilharzias). Source: Centers for Disease Control and 
Prevention - http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/schistosomiasis.aspx. The bottom 
diagram shows the distribution of GNP per capita. Adapted by permission from Macmillian Publishers 
Ltd : Nature (Sachs et al., 2002), copyright 2002.  
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4.4.3 Bladder Carcinoma 
Over 10,000 and 50,000 cases of bladder cancer are registered each year in the UK and the USA 
respectively (North American Association of Central Cancer Registries, 2006;Office for National 
Statistics, 2005). Incidence increases rapidly after the 6th decade of life and the mean age at diagnosis 
is 70 years in men and 73 years in women (Office for National Statistics, 2005).  
 
Bladder cancer can be either invasive or superficial. Surgery is used for invasive cancers and usually 
(90-94%) takes the form of radical cystectomy, with removal of the trigone (Hollenbeck et al., 2005).  
However, partial cystectomy can be a treatment option where the tumour is “primary, solitary and 
amenable to removal with 2cm surgical margins” (Rivera et al., 2000). Partial cystectomy is a less 
complex operation and has been used for 3% to 19% of patients with five-year overall survival rates 
reported to range from 35% to 80%, (Brannan et al., 1978;Faysal et al., 1979;Hayter et al., 
2000;Jardin et al., 1984;Merrell et al., 1979;Ojeda et al., 1983;Utz et al., 1973). Partial cystectomy is 
however less widely applicable as cancer recurrence rates can be as high as 80% in poorly selected 
patients (Hollenbeck et al, 2005).  
 
The bladder is a particularly difficult organ to treat for cancer. The high rate of cancer recurrence 
following treatment is not only confined to the organ itself. For instance, the incidence of a subsequent 
upper urinary tract tumour after a diagnosis of superficial bladder cancer has been reported to range 
from 2% to 26%. This is in addition to the high recurrence rate in the actual bladder itself. In light of 
this, the current therapeutic gold standard in bladder treatment is the radical cystectomy (Palou et al., 
2005).  
 
A successful TE bladder has an obvious potential application in patients who have been treated by 
cystectomy. The size of the potential market depends on whether the procedure is used only in the 
minority of cases undergoing trigone-sparing surgery (partial cystectomy) or whether the more 
exacting nerve-sparing operation catches on. Indeed, the latter may become more widely used if a TE 
solution replaces the need for complex bowel surgery.  
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4.4.4 Urethral Strictures 
A urethral stricture is an abnormal narrowing of the urethra which adversely affects the passage of 
urine (illustrated in figure 4.4 below). Urethral strictures have a number of causative factors including 
scar tissue from previous surgery, the passage of kidney stones, physical injury to pelvic area and 
sexually transmitted diseases. It may also be caused by external pressure from an enlarging tumor 
near the urethra, although this is rare. They are most common in men as the female urethra is much 
shorter in length. In the western world, incidence rates increase from 1 in 10,000 at the age of 25 to 1 
in 1,000 at the age of 65 (Wood et al., 2006). 
 
Circumstances can arise, if the stricture is long or the first intervention is unsuccessful, where the 
surgeon is not able to perform a satisfactory operation by means of the existing urethral tissue alone 
and a substitution urethroplasty is required. This is required only in a small percentage of cases of 
stricture. There were 3,142 finished consultant episodes in English hospitals in 2005-06 (HES Online, 
2007). On a purely “per head of population” basis, this would imply around 18,800 cases in the USA. 
 
 Figure 4.4:  Schematic diagram of urethral strictures 
 
 
Source: http://www.patient.co.uk/health/Urethral-Stricture.htm. Image reprinted with permission from 
Patient UK, copyright 2009, EMIS & PiP. 
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4.4.5 Conclusion 
The analysis of the clinical problem suggests the potential market for a TE solution for dysfunctional 
bladder and small contracted or inflamed bladders is probably far too small. Therefore, at this stage 
there are two remaining potential indications for TE urogenital tissue, which show promise: 
i. Bladder carcinoma  
ii. Urethral stricture  
 
The following section looks at the state of the art of TE that could be applied in these situations as a 
precursor for a ‘headroom’ cost-effectiveness analysis. Before making such an analysis I need to 
document the disadvantages of current treatment, which TE methods may overcome. 
 
4.5 Clinical Effectiveness 
Bladder Augmentation Cystoplasty using Bowel for Bladder Carcinoma 
The majority of complications that occur following a cystoplasty are due at least in part to the use of 
bowel in regenerating the bladder and are the primary focus of this section. A TE solution would avoid 
such complications, and would not affect the complications due to the bladder surgery itself and as 
such are not considered here. 
 
Short-term complications 
The most notable short-term complication arising from the use of bowel is adhesive small bowel 
obstruction, which is estimated to occur in 3% to 6% of patients (Greenwell et al, 2001) although this 
complication has been reported to occur in up to 10% of patients (Gough, 2001).   
 
Long-term Complications 
The majority of the side effects associated with this procedure are long-term complications. There are 
a number of complications, which can arise and these are summarised below.  
• Bowel disturbance - Terminal ileum resection may lead to bile acid malabsorption (diarrhoea), fat 
malabsorption (with consequent steatorrhea (excess fat in faeces) and reduced absorption of 
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vitamin B12. Diarrhoea has been reported to occur in up to 25% of patients, although whether 
this is a direct consequence of the bowel surgery or some associated disturbance of bowel 
function is unclear (Greenwell et al, 2001). 
• Metabolic disturbance - The absorptive characteristics of the bowel when in contact with urine can 
lead to a series of metabolic reactions. Active reabsorption of ammonia, ammonium chloride, 
sodium, water and hydrogen ions and the increased loss of bicarbonate and potassium into 
urine can lead to hyperchloraemic acidosis (inability to excrete urine of normal acidity). This is 
easy to treat and seldom troublesome, except in children. 
• Mucus Production - The average daily mucus production from both ileum and colon when used as 
a cystoplasty segment is 35-40g. In its natural environment, mucus provides the gut epithelium 
with a layer of protection from contact with urinary carcinogens and other substances (Greenwell 
et al, 2001). Mucus accumulation can predispose to urinary tract infection and stone formation 
(Greenwell et al, 2001). 
• Bacteraemia and Urinary Tract Infection - All bowel segments are sites for bacteria. Recurrent 
bacteraemia (presence of bacteria in the urine with or without urinary tract infection) is found in 
50 to 100% of patients. These infections may become asymptomatic and may led to 
pyelonephritis (inflammation of the kidney and pelvis due to bacterial infection) (Greenwell et al, 
2001). 
• Stones - Stone formation is a common complication (Greenwell et al, 2001) and urease-producing 
bacteria are a likely causative factor. In addition, mucus can bind with urinary calcium to form 
the stone nidus (the focus of infection). In a small proportion of cases bladder cancer may form 
(Stonehill et al., 1996). 
• Clean Intermittent Self-Catheterization (CISC) - It is difficult to predict if CISC would be necessary 
for a patient treated using a TE bladder, this would depend on whether a TE graft could become 
innervated and functional. 
 
Other Outcomes 
Ileocystoplasty (cystoplasty involving the use of an isolated intestinal segment)  incurs an average 
inpatient length of stay (LOS) of 13.3 days (HES Online, 2007), which is partly attributable to the 
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healing of the bowel. With no need for bowel surgery TE would be likely to reduce hospital stay. Re-
implantation of ureters (urine carrying tubes) is a major bladder operation where bowel surgery is not 
involved. The average LOS is 9.6 days (HES Online, 2007). Using this as a plausible surrogate for 
LOS with a TE solution, an average saving of 4 days was calculated. 
 
Urethroplasty using buccal mucosa for Urethral Strictures 
The gold standard for urethroplasty is the use of buccal mucosa. This is successful in 90% of cases 
(Koraitim, 2003) and there are reports of 100% success rates for a mean stricture length of 3.4cm or 
less (Al-Qudah et al., 2005). However, success rates appear to gradually decline from 5 to 10 years 
(Wood et al, 2006).  
 
A disadvantage of this procedure can be complications relating to the buccal mucosa donor site. 
Donor site morbidity can be associated with intraoperative haemorrhage, postoperative infection, pain, 
swelling, damage to the parotid duct (duct from parotid gland, a salivary gland into the mouth), 
limitation of oral opening and loss of or altered sensation of the lip or cheek, however all are infrequent 
complications (Bhargava et al, 2004). A recent systematic review found these complications occur for 
1 in 25 patients (Markiewicz et al., 2008). The most common complaint, occurring for 1 in 2 patients is 
paraesthesia (numbness), which in most cases persist for the short term only (Bhargava et al, 2004) 
although this problem has been reported to persist for up to a year for 1 in 6 patients (Dublin et al., 
2004). Overall, this procedure is considered less painful than a tonsillectomy (Nigel Borley, 2006) and 
graft harvest from the buccal mucosa is preferable to harvest from inside the lips (Bhargava et al, 
2004).  
 
Another outcome worthy of consideration is stricture recurrence, a long-term complication. Recurrence 
rates have been reported to range from 5% to 15% (Al-Qudah et al, 2005). Five-year follow-up results 
reporting stricture recurrence rates of 12.5% (Fichtner et al, 2004) and a recent systematic review of 
urethroplasty articles, published between 2000 and 2008, reports a recurrence rate of 15.6% (Meeks 
et al., 2009). 
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TE urethral tissue – if produced successfully – would avoid the problems of the donor site while 
retaining the advantage of being autologous and not prone to rejection by the patient’s immune 
system. The patient would need to undergo an additional procedure to harvest urethral cells, unless 
some has been collected previously, say during an earlier attempt to overcome the urethral defect. On 
balance, though, the TE solution would be less morbid, yielding a higher HRQL than with the use of 
buccal mucosa (Atala, 2004), however, it is debatable if the TE solution would be functionally better 
(Nigel Borley, 2006) 
 
4.5.1 Utility of Clinical Effects 
As described in section 4.2.2 (page 87), the utility values for health state following a cystoplasty and 
an urethroplasty could not be derived from the literature so a questionnaire was devised to elicit the 
utility scores associated with each. Full details of the methods are described in section 4.2 (page 87). 
Below I summarise the key results of the questionnaires. All supplementary results can be found in 
appendix 4, following the relevant questionnaire. 
 
Cystoplasty using Bowel 
Four out of sixteen (25%) urologists completed and returned questionnaires. Two surgeons stated 
they did not wish to take part and although the others were followed up with phone calls, no other 
responses were received. A full descriptive analysis of the questionnaires is given in appendix 4.  
 
Using equation 4.1 (section 4.2.2, page 88), the TTO responses given in the questionnaire were 
converted into utility scores. In conclusion, the mean utility for the period of maximum symptoms was 
calculated as 0.96 (95% CI: 0.94, 0.97) from four responses. This value will be used in all subsequent 
CEA. The urologists were also asked how much they would be willing to pay to avoid the clinical 
effects of an ileocystoplasty. To conclude, the mean WTP to avoid a 0.04 QALY decrease in utility for 
6 months was calculated as £8,750 (95% CI: £1,400, £16,000) ($14,000, €9,900) from four responses. 
By combining the results of the above two questions, the mean WTP per QALY can be calculated as 
£275,000 (95% CI: £0 £617,993) ($445,000, €312,000) from four responses. 
104 
Urethroplasty using Buccal Mucosa 
One hundred and ten individuals completed the question about TTO. A full descriptive analysis of the 
questionnaires is given in appendix 4.  
 
Using equation 4.1 (section 4.2.2, page 88), the TTO responses given in the questionnaire were 
converted into utility scores. The distribution of the utility scores ranges from 0 to 1 and has a negative 
skew (figure 4.5). Two points are evident from this graph. Firstly, there appear to be a number of 
outliers. A number of the utility scores are close to zero. A utility of zero represents death. I find it 
difficult to imagine an individual would rate the health state following an urethroplasty using buccal 
mucosa donation as close to death. I think this may represent a misunderstanding of the question – it 
is conceivable that instead of recording life to trade an individual noted life they would prefer to keep. 
Alternatively, this could be a big error. Secondly, there is a tendency for the responses to be 
concentrated around the values of 0, 5 and 10 years, which is a possible exhibition of an anchoring 
effect (Lenert et al., 2001). To mitigate against the anchoring effect observed in figure 4.5, a summary 
measure more resistant to outliers than the mean is required (Huber, 1981). The median is the 
simplest of these to use (Ohkusa et al., 2006). In conclusion, the median utility for the period of 
maximum symptoms was calculated as 0.94 (95% CI: 0.89, 0.99) from 110 responses. This value will 
be used in the subsequent CEA. 
 
The participants were also asked how much they would be willing to pay to avoid the clinical effects of 
an urethroplasty and this was answered by 108 individuals. The WTP values recorded by the 
respondents ranges from £0 to £30,000 and is positively skewed. This indicates that the respondents 
were not willing to pay large amounts to avoid the clinical effects of urethroplasty using buccal 
mucosa. To conclude, the median WTP to avoid a 0.06 QALY decrease in utility for 6 months was 
calculated as £500 (95% CI: £0, £1,418) ($800, €560) from 68 responses. Finally, by combining the 
results of the above two questions, I calculate the median WTP per QALY as £10,000 (95% CI: £0, 
£32,285) ($16,300, €11,300) from 53 responses.  
 
105 
Figure 4.5: The distribution of utility values associated with the clinical effects of urethroplasty 
using buccal mucosa 
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Utility values calculated from TTO questionnaire from 110 respondents. 
 
4.6 Cost of Treatment 
The only costs of treatment considered in the model are those of the operations, as it is assumed that 
all outpatient costs would be equal between current and TE treatment. A cystoplasty procedure (HRG 
code L14: Bladder Major Open Procedures or Reconstruction) has an average cost of £4,286 ($7,000, 
€4,800) (Department of Health, 2006b). In addition is the potential saving in hospital bed days that a 
TE solution might deliver. The cost of a bed day is estimated at £317 ($500, €350) (Department of 
Health, 2006b)  (national average cost of an excess bed day).  
 
A urethroplasty procedure (HRG code L33: Urethra Major Open Procedures) has an average total cost 
of £3,480 ($5,700, €3,900) (Department of Health, 2006b). In addition, a 40-minute saving in operation 
time would result from avoiding the need to harvest buccal mucosa (Nigel Borley, 2006). Based on a 
75 minute operation time (Levine et al., 2001), the 40-minute saving in operation time was estimated 
(using unit cost of consultant surgeon and nurse, similar to Dong (Dong et al., 2006)) at £225 ($360, 
€250).  
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4.7 Cost-Effectiveness Analysis 
4.7.1 Headroom Analysis 
Cystoplasty using Bowel for Bladder Carcinoma 
The median utility for the period of maximum symptoms was calculated as 0.96 (95% CI: 0.94, 0.97) 
from four responses. The mean age of presentation of bladder carcinoma is 72 years (Sangar et al., 
2005). Survival rates vary widely, but it was assumed patients suitable for a TE solution will be 
younger than average and have a better than average survival, so a mean survival of 10 years of life 
was assumed among this group.  
 
Before calculating the headroom, I must firstly estimate the maximum potential change in 
effectiveness, measured using QALYs, this is calculated as 0.4 (see equation 4.3). This in turn 
suggests headroom of £12,000 ($19,500, €13,600) (see equation 4.4) based on a threshold value of 
£30,000 ($49,000, €34,000). Although a threshold value of £20,000 ($33,000, €23,000) gives 
headroom of just £8,000 ($13,000, €9,000). However, this headroom value is very dependent on 
survival time. A decrease in survival time would result in an equivalent decrease in headroom, i.e. if 
the mean survival time was halved to 5 years, the headroom would be halved to £6,000 ($9,700, 
€6,800).  
Equation 4.3: ∆QALY = 10 x (1 - 0.96) = 0.4 
Equation 4.4: max ∆Cost = £30,000 x 0.4 = £12,000 
 
In addition to the headroom, a TE solution might deliver a saving of four hospital bed days (Dr 
Almallah, 2006). Based on the cost of a bed day given in section 4.6 (page 105), four hospital days 
would result in a total saving of £1,268 ($2,000, €1,400), thus the total headroom would be £13,268 
($21,600, €15,000). The companies consulted (Sofradim, FAB and Tengion (referred to in section 4.2, 
page 87) were optimistic that a headroom of £13,000 was a potentially viable price (including 
production costs and the need to recoup development costs). However, profit would be volume 
dependant. This is likely to depend on whether sphincter saving surgery catches on. If not, then the 
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market even in a country the size of the USA would only be about 5,000 cases per year (section 4.4, 
page 94).  
Urethroplasty for Urethral Strictures 
The literature review and urologist consultations made clear there is negligible (if any) risk of mortality 
from using buccal mucosa as a urethra substitute. It follows that there is no difference in mortality 
between the two treatments (TE vs. non-TE) and only the period of time during which the utility values 
of the two operations differ needs be considered.  
 
The median utility for the period of maximum symptoms was calculated as 0.94 (95% CI: 0.89, 0.99) 
from 110 responses. In keeping with the literature review and urologist consultations, it was assumed 
this phase would last for 5 weeks (0.1 year) - this may be a little pessimistic for standard treatment but 
if so this is again in keeping with the headroom method philosophy.  
 
Before calculating the headroom, I must firstly estimate the maximum potential change in 
effectiveness, measured using QALYs. Using equation 4.5 populated with the data above, I calculate 
the maximum change in benefit as 0.006 QALY. Next, using equation 4.6 I calculate the headroom as 
£180 ($300, €200) based on a threshold of £30,000 ($49,000, €34,000) or £120 ($190, €136) based 
on a threshold value of £20,000 ($33,000, €23,000). If I also assume the disutility of the clinical effects 
may have been overestimated by as much as 5% (i.e. to give a utility of 0.987), the headroom would 
be reduced further to £39 ($63, €45), based on a threshold of £30,000 ($49,000, €34,000) or £26 
($42, €30) based on a threshold of £20,000 ($33,000, €23,000).  
Equation 4.5: ∆QALY = 0.1 x (1-0.94) = 0.006 
Equation 4.6: max ∆Cost = £30,000 x 0.006 = £180 
 
Avoiding harvest of buccal mucosa would lead to a cost saving associated with operation time of £225 
($360, €250) (section 4.6, page 105). This cost should be added to the headroom of £180 to give a 
headroom total of £405 ($650, €450). From my consultations with the industry and from the prices of 
existing products, I conclude that there is no prospect of producing a commercially viable cell-bearing 
product at this price. 
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4.8 Return on Investment 
The market size for a TE bladder relates mainly to patients with bladder cancer, most of whom are 
treated by radical cystectomy and urinary diversion by ileal conduit (isolated section of ileum). Only 4 
to 19% (Brannan et al, 1978;Faysal et al, 1979;Hayter et al, 2000;Jardin et al, 1984;Merrell et al, 
1979;Ojeda et al, 1983;Utz et al, 1973) are treated with the partial, or trigone sparing cystectomy 
suitable for bladder substitution cystoplasty. If this practice continues then only between 420 and 2000 
of the average 10,470 (Office for National Statistics, 2005) bladder cancer patients in a country of 60 
million such as the UK  will be eligible for RM bladders. This represents a small market and therefore, 
possibly not a very exciting investment opportunity. However, in some cases a radical cystectomy can 
be “nerve sparing” - retaining the innervation in urethral sphincter and thus providing an opportunity for 
an TE vestibule (Venn et al, 1998). However, as Venn and colleagues note, “there are very few 
centres where these procedures are actually performed. The vast majority of patients undergoing 
cystectomy still seem to be offered an ileal conduit and no alternative” (Venn et al, 1998). The 
potential market size for TE bladders is thus sensitive to the adoption of this technique. To an extent, 
therefore, any investors will be “betting on” increasing use of the nerve sparing operations and 
possible stimulation of this approach through the availability of a TE bladder.  
 
The revenue that can be generated is a function of headroom, the likely cost, and volumes, 
represented by equation 4.7. Here, R = revenue, max∆Cost = Headroom, C’ = expected cost of 
production and V = cases per year. 
Equation 4.7: R = (max∆ Cost - C’) x V 
 
In the case of a TE bladder, assuming each device costs £8,000 ($13,000, €9,000) and that there are 
500 cases per year, the estimated revenue is £2.5 million per year (equation 4.8) ($4,000,000, 
€2,800,000). The expected profit however, must be discounted over a time horizon chosen to reflect 
the company strategy. 
Equation 4.8: R = (£13,000 – £8,000) x 500 = £2,500,000 
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4.9 Discussion  
4.9.1 Summary of Main Findings  
Careful analysis of the clinical problem suggested urethral defects and bladder resection for cancer 
offer the most propitious applications for a TE urethral tissue technology. The headroom for TE urethra 
has optimistically been estimated to be £405 ($650, €450) over and above the current cost of a 
grafting operation. This is unlikely to be large enough to support the launch of a cell bearing TE 
product. This result can be attributed to two main reasons: Firstly, buccal grafts are very successful 
against the scale of healthcare outcomes, and secondly, the side effects are few, relatively short lived 
and benign. On the other hand, the headroom for TE bladders has been optimistically estimated at 
around £13,268 ($21,600, €15,000) over and above the cost of ileocystoplasty. It is likely a TE solution 
could come in cost below this, suggesting that if the market size were deemed large enough it could 
be worth proceeding with development. Two scenarios could lead to this: first, trigone/urethral 
sphincter sparing surgery does not catch on – therefore the market would be of limited size; and 
second, trigone urethral sphincter sparing surgery becomes widespread – in which case a substantial 
market could be grown. 
 
4.9.2 Elicitation of Utilities 
This chapter encompassed two questionnaires for the elicitation of utilities of two different health 
states, each of which had a different methodology.  
 
First, I discuss the elicitation of the health utility associated with cystoplasty using bowel. Since it was 
not possible to obtain the health utility directly from patients, the utility was elicited from clinicians. I 
believe clinicians were a good proxy for patients as the health state associated with cystoplasty using 
the bowel is complex and as caregivers, they have a high level of understanding of the impact of the 
health state on the HRQL of the patient. However, this analysis was limited due to the very small 
sample size (N=4). The urologists were identified using the NHS website from hospitals within the 
Birmingham and Black Country area. The restriction of the geographical area limited the number of 
clinicians available for selection. In hindsight, once the decision was made to email the questionnaires 
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rather than arrange face-to-face interviews it would have been preferable to identify more urologists 
from outside the Birmingham and Black Country area. This would have increased the number of 
questionnaires sent, and even if the response rate of 25% remained unchanged, the sample size 
would have been increased, although, a response rate of 25% is not particularly high; closer to 40% 
would have been desirable. Efforts were made to increase the response rate but without much 
success. The reason is probably due to being unable to speak directly with the clinicians; the follow up 
phone call was with secretaries who either advised they would bring the questionnaire to the attention 
of the clinician and send it back (which didn’t happen) or declined to assist. The success of this 
approach could have been improved by  either posting the questionnaires rather than emailing, or by 
conducting a telephone interview with the clinician, I believe this would have been quicker and easier 
to organise than a face-to-face interview and more successful than a postal survey. Despite the low 
sample size, I believe the utility value elicited (0.96) is acceptable and reliable, as it is based on the 
opinions of specialist surgeons whom had a strong familiarity with the procedure (appendix 4).  
 
Next, I discuss the elicitation of utility values associated with urethroplasty using buccal mucosa. Since 
it was not possible to obtain the health utility directly from patients, the utility was elicited from the 
general public. In this case, the sample size is more favourable at 112. However, a potential limitation 
of this analysis is associated with the sample of respondents. The sample should be representative of 
the general population. As the sample was taken from two sites, the university and the city centre of 
Birmingham, it could be argued that this is representative. However, those interviewed from the 
university site were all employees of the public health department and were more familiar with both the 
health state under investigation and the method of measuring preferences; therefore, it could be 
argued that this sample is not representative. Although interviewing a sample of the general public 
resulted in a larger sample size, I have reservations regarding how well the questions were 
understood. As described, there were a number of utility values of, or close to zero. This results in the 
headroom of TE urethra being based on quite severe utility values – although minimised by using the 
median rather than the mean,  a median utility value of 0.94 implies that more than half the population 
would run a greater than 1 in 20 risk of death to avoid a buccal mucosa donation, which is probably 
unrealistic. I believe there are three explanations for this. Firstly, it may indicate a general lack of 
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understanding by the general public of both the health state being described and the methods being 
used for measuring preferences. Secondly, there may have been an error made at some stage (as 
previously described the data was collected and entered into Excel by previous staff members). 
Finally, this could be just a natural occurrence, the result of eliciting utilities from the general public. 
This has previously been reported by Ubel and colleagues (Ubel et al, 2003), who found that the 
general population tend to exaggerate the impact of disease on HRQL as patients tend to rate their 
health states higher than the general population, underestimating their need for healthcare. The utility 
associated with urethroplasty using buccal mucosa may have been more accurately calculated from 
interviewing urologists, despite the low sample size. The two questionnaires could have been 
completed by the urologists identified and the time taken interviewing the general public could have 
been spent trying to increase the number of urologists in the sample. 
 
4.9.3 Implications of this Work 
This work has received a great deal of interest since its publication in 2007 in the journal of 
regenerative medicine and tissue engineering. This was the first example of the headroom method 
and demonstrated to the industry that there is an approach, which may be useful in guiding investment 
decisions and helping to focus on those applications that may be most successful and economically 
viable. 
 
This work has been of significant importance to the French TE firm, Sofradim, who had been working 
on the development of visceral tissue patches to be used in the urinary system for cystoplasty and 
urethroplasty. Following the completion of this CEA and the conclusion that the repair/replacement of 
urethra and bladder was not so promising Sofradim made the decision to scale back work on visceral 
tissue patches for the urinary system and focus their efforts on visceral tissue patches for the 
abdominal wall (will be explored in chapter 5).  
 
However, this has not been the case everywhere. Tengion, a US based clinical stage Biotechnology 
Company, focuses on developing, manufacturing, and commercialising human neo-organs and neo-
tissues. Their lead product is the Neo-Bladder AugmentTM for the treatment of neurogenic bladder in 
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Spina bifida in children. Since its foundation in 2003, Tengion has raised a total investment of $127 
million. Tengion’s CEO claims that “to procure an organ to show up in the operating room where it is 
about to be implanted – not the care of the patient who is about to get it or the after-surgical care – but 
just to get the organ to show up in the operating room is on the order of $50,000 to $150,000 per 
patient” (Filmore, 2007). It is unclear where Tengion intends to price and reimburse their product but 
they are “hopeful that if we deliver the safest and most effective product that we can deliver, we will 
have appropriate reimbursement” (Filmore, 2007). Only time will tell who is right. However, a break-
even price of about $30,000 would have to be significantly out to justify, a price tag of $100,000; even 
life saving left ventricular assist devices struggle at this price. Also, no reference is given for the 
number of augmentations, but if they are correct and the profit were $10,000 per case, total profits 
would be about $100 million per year. 
 
Another target for the Tengion Neo-Bladder is urge incontinence in patients, which have failed 
previous therapies. This application may have a particular appeal to the private healthcare market 
more than third party payer markets, for example, the retired person whose only wish is to be able to 
get through a round of golf without a break. This may well prove fruitful however to predict this would 
be an even greater challenge. 
 
4.9.4 Conclusion 
In this chapter, I have shown how the headroom method can be used early in product development to 
make a preliminary conclusion as to the potential cost-effectiveness of a new treatment, even when 
some of the parameters are extremely uncertain. There may be arguments for the development of TE 
urogenital tissue in terms of developing the general science, but in terms of clinical gain, it appears 
that it would be more profitable to redirect scarce resources to alternative applications. In the following 
chapter, I investigate the potential cost-effectiveness of TE visceral tissue for use in defects of the 
abdominal wall.  
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 CHAPTER 5 COST EFFECTIVENESS ANALYSIS OF A 
TISSUE ENGINEERED SOLUTION FOR THE 
TREATMENT OF ABDOMINAL WALL DEFECTS 
 
5.1 Introduction 
Using the methodology described in chapter 3, I aim to assess the most propitious opportunities for a 
TE solution in the repair of abdominal wall defects. Where existing treatments are successful in 
making good the defect, preventing recurrence and avoiding side effects, there is less headroom for 
further gains from a new treatment. By applying the headroom method, I will determine whether the 
costs of developing a TE solution for abdominal wall defects can be justified. 
 
Abdominal wall defects cover a broad spectrum of conditions, which occur following trauma, infection, 
or surgical resection. Some, such as an inguinal hernia are small, while others, such as an incisional 
hernia are massive. Some involve a defect in just one fascia (fibrous tissue) layer (e.g. a femoral 
hernia) while others involve loss of the entire abdominal wall, including muscle and skin. Clearly, the 
surgical challenges posed by these various lesions are very different. 
 
Until recently, abdominal wall repair relied on a suture line to close the defect. However, this places 
excessive pressure across the repair line. Tension-free repair avoids this by using a mesh, placed 
over the defect. The mesh is a support framework for cells to grow and differentiate. It augments the 
strength of the weakened abdominal wall resulting in a repair that is less painful and more likely to 
endure. However, the current generation of (non-TE) mesh materials are synthetic and prone to 
complications such as infections and adhesions because of the foreign material. Biological meshes, 
either acellular or cellular, have emerged as an alternative to synthetic mesh. Due to their natural 
sourcing biological meshes avoid the complications of synthetic materials and could reduce or possibly 
prevent infection, simplifying the healing process, as well as improving mechanical integrity.  
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5.2 Methods 
5.2.1 Overview 
My first task was to identify the clinical conditions where a TE biological mesh could have potential and 
to document the effectiveness, safety, and costs of the current best treatment. Next, I built up a 
realistic picture of anticipated benefits, problems, and costs for such a TE solution, which might rival 
the current gold standard (synthetic mesh). Finally, once the clinical problem was clearly defined I 
selected the condition with greatest potential headroom and applied the headroom method to establish 
the maximum cost for a TE solution, which could be supported by the UK health service.  
 
5.2.2 Defining the Clinical Problem 
Literature searches were conducted using the search strings shown in appendix 5. I worked closely 
with the French TE firm Sofradim who assisted with the technical aspects surrounding the 
development of such a mesh and with costs of current and future meshes. When necessary, I 
contacted a colorectal surgeon based at the University Hospital Birmingham already known to my 
team, to assist with the understanding of the clinical need.  
 
After careful analysis it appears synthetic meshes have problems when the defect is large and when 
there is infection. I decided the repair of infected or contaminated incisional hernias is worthy of further 
investigation. A systematic review of the relative effects of each treatment (synthetic versus biologic) is 
documented with special emphasis on overall recurrence rates, a long-term complication and on utility 
of the clinical effects. The methods of utility elicitation are described below. 
 
Utility of Clinical Effects 
In this chapter, a utility-based HRQL score associated with infected incisional hernia was required. A 
comprehensive literature search found no existing utility-based HRQL scores. I devised a 
questionnaire to elicit the utility scores required. The questionnaire is in appendix 6 and the 
justification for the wording of the questionnaire is in appendix 2. I used TTO and WTP approaches to 
measure preferences. In TTO, each interviewee is asked what amount of time they would give up from 
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a fixed specific length of time, to avoid the negative side effects of the procedure in question, and have 
perfect health for the remainder of their life. The TTO values are converted into utility scores using 
equation 5.1.  
Equation 5.1: HRQL = TTO ÷ t 
 
In WTP, each interviewee is asked how much they would pay for a treatment that would relieve them 
of the described health state. Combining the responses from each question makes it possible to 
calculate each individual’s WTP per QALY. 
 
Due to time and cost constraints, it was not possible to obtain a fully randomised sample of a national 
or international patient population. Instead, the HRQL weightings were elicited from a sample of 
colorectal surgeons (N=54). I sought to survey healthcare professionals rather than the general public 
due to the complex nature of the conditions. Ideally, patients are used to elicit utilities, but this was not 
possible for three reasons. Firstly, these patients are incredibly ill and most likely on intensive care. 
Secondly, there was insufficient time remaining in my project to seek ethics approval and finally, 
logistically it was easier and less time consuming to access a large sample of clinicians than it would 
have been to contact and visit the same number of patients.  
 
I gained access to a large sample of colorectal surgeons through the attendance of a conference for 
the Association of Coloprotology of Great Britain and Ireland, which took place in Harrogate in June 
2009. Using the internet search engine Google I found an advertisement for the conference and 
contacted the board to request permission to have a stand and handout my questionnaires to the 
delegates. With the help of a medical student on work experience and a temporary research associate 
within my team, 54 questionnaires were completed over two and a half days. 
 
5.2.3 Cost-Effectiveness Analysis 
Firstly, I reviewed previous CEA of incisional repair using suture, synthetic mesh, and acellular mesh. 
Secondly, I conducted the headroom analysis. Using the data collected from the survey of colorectal 
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surgeons, I calculated a utility-based HRQL score associated with the clinical effects of a large and 
infected incisional hernia. Using these utility scores, I populated equation 5.2 and calculated the 
headroom - the maximum cost for which a TE solution for cystoplasty and urethroplasty would be 
considered cost effective for two scenarios: i) assuming a TE solution eliminates early complications 
and results in more rapid wound repair, and ii) accounting for a reduction in recurrence rate (a long-
term complication). Overall, recurrence rates were calculated for each material using review manager. 
Equation 5.2: max∆Cost = max∆QALY x willingness-to-pay threshold 
 
Where, ∆Cost = ∆QALY x willingness-to-pay threshold, where ∆Cost is the maximum headroom, 
∆QALY is the change in benefit measured in QALYs and willingness-to-pay threshold is the threshold 
for reimbursement of £30,000 ($49,000, €34,000). 
 
5.3 Treatment 
5.3.1 Current Treatment 
Synthetic Mesh 
Types of Synthetic Mesh 
There are two main types of mesh (Millenium Research Group, 2007):  
1. A flatsheet mesh that is inexpensive at a cost of less than $100 (£60, €70) (Yves Bayon, 2008); 
2. A non-adhesive mesh, which has a protective coating placed on one side and is ultra 
lightweight. The additional coating on this mesh increases the cost of this product to between 
$500 - $700 (£300-430; €350-500) (Yves Bayon, 2008).  
 
The most common synthetic materials used are polypropylene (Marlex and Prolene), polyester 
(Mersilene and Parietex), and polytetrafluoroethylene (PTFE or Gore-Tex) (Lai et al., 2003;Park et al., 
2006).  
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Clinical Effects of Synthetic Mesh 
Four systematic reviews of RCTs comparing mesh with non-mesh repair for inguinal hernias have 
been identified (EUHTC, 2000;EUHTC et al., 2002;Grant et al., 2002;Scott et al., 2002). These studies 
have reported similar rates of haematomas (localised collection of blood, often clotted), seromas (a 
mass or swelling caused by the localised accumulation of blood plasma within a tissue or organ), and 
infections for mesh and non-mesh repair, but significantly fewer hernia recurrences for mesh repair. 
Operative time is  longer for mesh repair than for non-mesh repair (Scott et al, 2002). However, mesh 
repair is associated with reduced length of hospital stay (reported in 5 of 6 trials (p=0.22) (EUHTC, 
2000)) and a more rapid return to usual activities (reported in 7 of 10 trials (p=0.34) (EUHTC, 2000)). 
Levels of persisting pain are highly variable among trials however the 2002 (EUHTC et al, 2002;Grant 
et al, 2002) reviews found that pain was lower in patients receiving mesh repair compared to non-
mesh repair. A detailed review of these trials can be found in appendix 7. 
 
Despite the advantages of synthetic meshes over suture, they are not without limitations. 
Complications arise if there is contact between the abdominal viscera (intestines) and the synthetic 
mesh. The complications are due to infection and are classified as early (<1 month) complications and 
long-term (>1 month) complications: 
 
• Early complications - Bruising, haematoma and seroma are common complications following 
hernia repair of all types. The most frequent and significant early complication to occur following 
mesh repair is wound infection, which is frequently associated with pain. This in turn is related to 
wound dehiscence and repair failure. The risk of infection is increased with synthetic mesh. 
 
• Long-term complications – The most frequent and significant long-term complication is hernia 
recurrence and the rates vary depending on the type of defect being repaired (more detail given in 
later sections); however, the recurrence rates associated with synthetic mesh are lower than those 
associated with simple suture. Chronic pain (pain persisting for 3 months after repair) is another 
frequently reported complication. Less frequently reported nevertheless major long-term 
complications include small bowel obstruction, fistula (a permanent abnormal passageway 
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between two organs in the body or between an organ and the exterior of the body) formation, and 
enterocutaneous fistula (abnormal opening between two organs or from an organ to the outside of 
the body) all of which can result in infertility. 
 
Anatomical siting of the mesh  
Mesh is secured in either an intraperitoneal (within the peritoneal cavity, the area that contains the 
abdominal organs) or an extraperitoneal (outside of the peritoneal cavity) position. Current evidence 
on the relative advantages and disadvantages of these methods is equivocal. Two comparative 
studies using animal models demonstrate conflicting outcomes. The porcine model (N=15) (Attwood et 
al., 1994) compared the two placement techniques on the same animal; the left side received 
extraperitoneal mesh placement and the right side received intraperitoneal mesh placement. The 
evidence demonstrated that both methods were associated with adhesion formation to viscera. 
Conversely, the rat model (N=50) (Farmer et al., 1998), which used ten rats per treatment group 
(extraperitoneal pocket with and without mesh; intraperitoneal mesh; ischemic defect with and without 
mesh) concluded that, as might be expected, intraperitoneal placement was associated with a higher 
rate of intra-abdominal adhesion formation than extraperitoneal placement. 
 
More recently Arnaud and colleagues (Arnaud et al., 2003) carried out a prospective comparative 
clinical study to examine intraperitoneal placement and extraperitoneal placement using a mesh lined 
with a protective hydrophilic resorbable film (Parietex composite) on the side facing the abdominal 
cavity (N=51) compared to an unprotected Mersilene mesh (N=22). They found a reduction in the 
percentage of adhesions (18% for protected mesh compared to 77% for unprotected mesh (P<0.001)) 
when the mesh was placed in an intraperitoneal position. I consulted colorectal surgeons to obtain a 
current view; it appears that intraperitoneal placement of mesh is favoured for large defects associated 
with ventral (post-incisional) hernia. However, extraperitoneal placement, although technically more 
demanding, is favoured when the defect is small – as is the case for groin hernias. 
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Open or laparoscopic procedures 
Laparoscopic repair is a minimally invasive safe alternative to open repair but is technically more 
demanding (Reuben et al., 2006). There is not yet a consensus amongst surgeons on a preference for 
open or laparoscopic procedures. A systematic review (McCormack et al., 2005) of laparoscopic 
versus open procedures for inguinal hernia repair identified 37 RCTs and 14 cost-effectiveness 
studies. Overall, open surgery led to improved outcomes except for recurrence rate, which showed no 
difference. The economic evaluation of laparoscopic versus open repair found that laparoscopic repair 
is more costly to the health service. A comparison of laparoscopic and open techniques for incisional 
hernia repair (Bencini et al., 2003;Engledow et al., 2007) found no significant difference in overall rate 
of complications and concluded that there is insufficient evidence to determine the most superior 
technique. A detailed account of the evidence of laparoscopic versus open repair for inguinal and 
incisional hernia repair can be found in appendix 8.  
 
Lightweight or heavyweight mesh 
Synthetic mesh can be lightweight or heavyweight depending on mesh pore size, approximately 4mm 
for lightweight mesh and 1mm for heavyweight mesh. Two RCTs compared lightweight and 
heavyweight mesh. One in incisional hernia repair (Conze et al., 2005) and one in inguinal hernia 
repair (O'Dwyer, 2004).  
 
Conze and colleagues (n=165) compared lightweight composite mesh (n=83) with standard polyester 
(Atrium and Marlex) or polypropylene (Mersilene) mesh (n=82) for incisional hernia repair. Mean 
operating time was 1.8 hours for both groups. Mean number of days spent in hospital after surgery 
differed by 0.8 days (14.0 days for composite mesh and 13.2 days for standard mesh) but this was not 
significant (no p value given). Infection rate following mesh repair was similar in the two groups, 
varying between 4% and 16%. Infections were mainly subcutaneous and it was never necessary to 
remove the mesh. Overall, there were 20 recurrent hernias; 14 in the composite mesh group and 6 in 
the standard mesh group (no p value given). Time of recurrence varied from 131 to 742 days for 
composite mesh and from 164 to 833 days for standard mesh. HRQL score (measured using SF-36 
taken at day 21) for composite mesh and standard mesh was 50.4 and 48.4, respectively.  
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O’Dwyer and colleagues (n=321) compared lightweight mesh (n=162) and heavyweight mesh (n=159) 
in inguinal hernia repair and found significantly fewer patients in the lightweight group experienced 
pain (40% vs. 52%, p=0.033) but the recurrence rate was higher (5.6% vs. 0.4%, P=0.037), which 
concurs with the Conze et al. study.  
 
Myocutaneous Flaps 
A less common alternative to synthetic mesh is myocutaneous flaps (vascularised autologous tissue 
composed of, or supplying both muscles and skin) used to cover very large defects. If skin coverage 
over the defect is absent or unviable, myocutaneous flaps provide tissue transfers for reconstruction of 
abdominal wall defects. Such defects often result from saprophytic (gangrenous) infections through 
numerous layers of abdominal wall. They also result, when the surgeon wishes to avoid closing the 
abdomen under pressure in patients with severe intraabdominal pathology such as peritonitis and 
pancreatitis (Mathes et al., 2000). Drawbacks of myocutaneous flaps include necrosis of transposed 
tissue and complications associated with donor site (Mathes et al, 2000). This is a large operation only 
suitable for complicated cases requiring immediate importation of a composite viable tissue. 
 
5.3.2 State of the Art in Tissue Engineering 
A biological mesh is a construct composed of a biodegradable scaffold (either xenogenic (from 
another species) or allogenic (genetically different but from the same species)) that may or may not be 
seeded with viable cells (cellular or acellular). The ideal mesh should be a natural biodegradable 
substance, biocompatible, cause little or no foreign body response, and be resistant to bacteria and 
infection. It should be able to withstand physiological stress, cause no additional pain after 
implantation, promote strong tissue in-growth to help maintain mechanical strength, avoid substantial 
contraction and developing adhesions to visceral structures and be readily available and affordable 
(Bellows et al., 2006;Drewa et al., 2005;Lai et al, 2003).  Unlike synthetic meshes a biological mesh 
decreases in strength over time as the wound gains strength and new fascia is formed (Bellows et al, 
2006;Drewa et al, 2005;Lai et al, 2003;Parker et al., 2006). Table 5.1 (page 124) summarises the 
advantages and disadvantages of both synthetic and biological meshes, along with current costs. 
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Acellular Mesh 
Acellular mesh can be derived from dermis (connective tissue under skin), submucosa (tissue beneath 
mucus membrane) or pericardium (membranous sac which envelops and protects the heart) and 
these can be xenogenic or allogenic. The following are three of the most common acellular mesh 
currently available: 
 
i. Porcine Dermal Collagen - Permacol® (a Tissue Sciences Laboratories plc product) is derived 
from porcine dermal collagen with the cellular content removed.  
 
ii. Porcine Small Intestine Submucosa - Surgisis® (Cook Surgical, Bloomington, Ind., USA) is 
derived from porcine small intestinal submucosa (SIS). Preclinical studies showed that SIS is a viable 
alternative for placement of mesh in contaminated fields with respect to resistance of infection and 
maintenance of tensile strength (Franklin, Jr. et al., 2002). Acellular mesh derived from porcine SIS 
has been used for incisional hernia repair in animal studies (Adedeji et al., 2002;Park et al, 2006). This 
evidence suggests that acellular mesh is superior to synthetic mesh and enhances structural 
organisation of the new connective tissue (Adedeji et al, 2002).  
 
iii. Human Acellular Dermal Matrix - Alloderm® (Life Cell Corporation) is derived from freeze-
dried donated cadaver skin. Alloderm is more expensive than Permacol ($28.01/cm2 compared to 
$8.73/cm2 for Permacol) and unlike Permacol, Alloderm requires refrigeration and rehydration before 
use, a process which can take 15 to 20 minutes with some thicker implants. It is believed that Alloderm 
is theoretically capable of clearing bacteria, a property not found in synthetic meshes. In the past 
Alloderm® has been used in the treatment of severe burns, replacement of soft tissue, bladder 
support, and skin grafting (Buinewicz et al., 2004;Schuster et al., 2006). Unlike autologous materials 
such as skin grafts and muscle flaps, acellular dermal matrix can be used without subjecting the 
patient to additional morbidity in the form of donor site complications (Holton et al., 2005). 
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Cellular Mesh 
Creation of a cellular mesh involves the harvesting of cells from a patient and culturing in vitro before 
seeding onto a biogradeable material such as polyglycolic acid (PGA). The number of cells required 
depends on the defect size. Approximately 1 x 107 for 1cm2 of a 1-2 mm thick scaffold is 
recommended, but this varies depending on the cell type used (Drewa et al, 2005). The optimal cell 
type has yet to be determined but fibroblasts, skeletal muscle cells, and myoblasts are being 
investigated. Based on the cost of TE skin I estimate that a cellular TE solution is likely to cost at least 
£2,370 for an 8x8cm sheet ($3,800, €2,700) (Cristiano Occhipinti, 2007).  
 
There are no human studies and few animal studies using cellular mesh to repair abdominal wall 
defects. Cellular SIS mesh has been used successfully in diaphragmatic repair in a fetal lamb model 
(Fauza et al., 2001) and has been compared to acellular SIS mesh for the repair of large abdominal 
wall defects in syngenic (genetically identical) Lewis rats (Lai et al, 2003). The cellular mesh 
demonstrated better facilitation of tissue regeneration, improved tissue ingrowth, and better 
mechanical strength compared to acellular mesh (no data provided). The acellular mesh degraded 
gradually over 3 months and had a significantly higher hernia rate (p = 0.005) compared to cellular 
mesh; a hernia recurred in 16 of 21 (76%) acellular meshes versus 5 of 21 (23%) skeletal muscle cell 
meshes versus 6 of 24 (25%) fibroblast cell meshes (no significant difference (p = 0.82) in hernia rate 
between grafts seeded with fibroblasts or skeletal muscle cells)  (Lai et al, 2003). In separate studies 
hernia rate was reported as 63% for suture repair and 32% for synthetic mesh repair for large 
abdominal hernias in rats (Burger et al., 2006).   
 
Summary 
Observational studies of acellular grafts have shown they could be more effective than synthetic 
meshes. Unfortunately limited literature is available on the use of acellular mesh in humans, in 
particular there are no head-to-head studies comparing biologics to the synthetic mesh or biologics 
with each other. Based on preclinical studies, it appears cellular grafts could prove superior to acellular 
grafts; they have shown better cell infiltration, cell regeneration, mechanical performance, and a 
reduced inflammatory reaction, in addition to more rapid revascularisation (restoration of blood supply) 
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(Drewa et al, 2005;Lai et al, 2003). Whether a RM solution with better long-term mechanical strength 
can be devised has yet to be seen. The major limiting factor is the high cost of the mesh; any new 
product must prove to be more effective at improving healing of the defect and reducing complications.  
 
A market evaluation of synthetic meshes compared with biologic meshes was conducted in the US by 
Medpanel, Inc (Yves Bayon, 2008). The aim was to gain an understanding of potential market for 
biologics from a clinical perspective. It found agreement amongst surgeons that biologics offer 
improved clinical outcomes compared to synthetic mesh, but high cost restricts current use. A 
summary of the findings of this market research are in appendix 9. 
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Table 5.1: The advantages and disadvantages of synthetic and biological meshes 
Material Brand Cost Advantages Disadvantages 
Synthetic Mesh: Flatsheet 
Allow tension free repair(1,2);  
lower long-term hernia 
recurrence rates(2).  
Wound infection(1,3,4);  
bowel fistula(1,3,4);  
erosion into 
abdominal viscera(1,4);  
repair failure(1,4);  
mesh extrusion(1,4);  
early hernia 
recurrence rate of 
around 5%(2);  
dense adhesion(3);  
chronic sinus 
formation(3);  
mesh removal(3).  
Polypropylene 
Marlex 
<US$100 
Prolene 
Surgipro 
Polyester Mersilene 
Parietex 
Polytetrafluoroethylene 
(PTFE) 
Gortex 
Dualmesh 
Titanium-polypropylene 
composite Timesh 
Polypropylene-
polyglecaprone composite Ultrapro 
Synthetic Mesh: Non-adhesive 
Polyester with collagen-
polyethylene glycol-glycerol 
coating 
Parietex 
Composite 
US$500 
- 700 
Polypropylene with 
carboxymethylcellulose-
sodium hyaluronate coating 
Sepramesh 
Polypropylene-polydioxanone 
composite with oxidised 
cellulose coating 
Proceed 
Biological mesh: Acellular US$/cm2 
Resistant to infection(2, 3, 4);  
erosion(2);  
extrusion(2);  
rejection(2);  
allow tension free repair(1);  
lower recurrence rates(1, 2);  
fewer adhesions(3);  
incorporated into host 
tissue(3);  
improved biocompatibility(4) 
Can cause 
inflammatory 
response in 
neighbouring tissues 
leading to wound 
infection(4);  
Decreased strength 
over time compared 
to synthetic meshes(1) 
Dermis (Porcine) Permacol 8.33 CollaMend 16.00 
Dermis (Bovine) SurgiMend 22.00 
Dermis (Cadaveric) Alloderm 26.08 
Allomax 28.00 
Submucosa (Porcine) Surgisis 3.40 
Pericardium (Bovine) 
Tutopatch NA 
Veritas 8.60 
Periguard 1.90 
Tissue engineering meshes: Cellular 
Allows tension free 
repair(1,2);  
better mechanical 
strength(1);  
hernia recurrence rates do 
not increase over time(1);  
revascularisation(1,4);  
cell regeneration(1);  
resistant to infection(2, 4);  
erosion(2);  
extrusion(2);  
rejection(2);  
biocompatibility(4). 
Time delay required 
for cell proliferation 
(4). 
(1) Lai et al. 2003; (2) Park et al. 2006; (3) Adedeji et al. 2002; (4) Drewa et al. 2005 
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5.4 Potential Applications for a TE solution 
Having described the current treatment methods along with the state-of-the-art in TE I now consider 
different types of abdominal wall defects in turn. In each case, I use my knowledge of standard 
treatment to draw conclusions about the headroom for further improvements in clinical outcome.     
 
5.4.1 Hernia 
Hernia is defined as a protrusion of abdominal viscera outside the abdominal cavity through a natural 
or acquired defect (Gurusamy et al., 2006) (figure 5.1 and table 5.2). They occur mostly in the 
abdomen and result from weakening of the abdominal wall (Franz, 2006;Park et al, 2006). Risk factors 
include cigarette smoke, obesity, and family history. Mechanical strain can damage tissue which leads 
to hernia and makes it harder to repair (Franz, 2006). Growing evidence suggests that incisional 
hernias and recurrent hernias usually result from failure of early surgical wound healing (Franz, 2006). 
Research into a possible biochemical basis of incisional hernias is still in its infancy but it has been 
speculated that a dysfunction in collagen synthesis or deposition may predispose to hernias (Park et 
al, 2006). The size of hernias can vary greatly; they can be small (less than 4cm2) and relatively 
asymptomatic, or large (greater than 40cm2) and cause significant pain and discomfort. Life 
threatening complications can occur in the form of incarceration (trapped bowel), and strangulation of 
the bowel and other viscera (Park et al, 2006). In England and Wales in 2005/06 almost 160,000 
cases of hernia were reported (HES Online, 2007). Hernias are repaired surgically (herniorrhaphy) 
with the aim of reducing the herniated tissue and repairing the muscle tissue weakness. The current 
gold standard treatment is tension free closure using a synthetic mesh. 
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Figure 5.1: Diagram to illustrate the locations of different types of hernia 
 
Source: http://www.wsiat.on.ca/english/wsiatDocs/mlo/hernias_screen.htm  
 © Queen’s Printer for Ontario, 2006. Reproduced with permission. 
 
 
Table 5.2: Description of characteristics and location of the main hernia types 
Hernia Type Location Characteristics 
Diaphragmatic 
Hernia 
High in abdomen 
through defect in 
diaphragm 
Hiatus hernia - functional defect between stomach and chest 
Congenital diaphragmatic hernia - occurs in 1 in 2000 births 
Femoral 
Hernia 
Groin (just below 
inguinal hernia 
location) 
More common in women than men                                                                                                                             
Smaller and rounder than inguinal hernia                             
Bowel can become trapped (incarcerated) 
Incisional 
Hernia 
(Ventral 
Hernia) 
Abdominal wall 
Weakness in abdominal wall muscle resulting from 
uncompleted sealed wound                                                                                                                 
Bowel can become incarcerated                                                
Can be dangerous and difficult to treat 
Inguinal 
Hernia Groin 
Commonest type                                                                      
Predominant in men                                                                                                           
Can result after mechanical strain 
Parastomal 
Hernia 
An incisional hernia 
related to an 
abdominal wall 
stoma. 
Formation commonly occurs following an ileostomy or 
colostomy 
Umbilical 
Hernia Naval (belly button) 
Small and causes no problems                                                                                                 
More common in boys 
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Inguinal Hernia 
Inguinal hernias are the most common type of hernia (80% of abdominal wall hernias occur in the 
groin (Aufenacker et al., 2006)), and  their repair is the most frequent operation in general surgery 
(Amato et al., 2006). They are about eight times more common in males than females (Thaha et al., 
2007); in England and Wales in 2005/06 there were 83,500 hospital admissions for inguinal hernia 
compared to 4,000 for femoral hernia (HES Online, 2007). 
 
Surgical repair is the current mainstay treatment and can be performed as a day case procedure 
under local anaesthetic. There are three categories of operative approach; herniotomy (cutting for 
relief), herniorrhaphy (surgical repair, includes Bassini, Shouldlice and nylon darn methods) and 
hernioplasty (surgical repair, popularised by the Lichtenstein institute), now the most common method, 
which uses a mesh to generate a tension-free closure (Thaha et al, 2007) via an open or laparoscopic 
approach.  
 
The synthetic mesh technique works adequately for inguinal hernia repair. There is little risk of serious 
morbidity and frequency of complications is low. Recurrence rates and infection rates for repair of 
primary inguinal hernias are less than 2% and 3%, respectively. Pain is the most common 
complication, reported to last 2 to 3 weeks (Dion Morton, 2008). The headroom for future improvement 
for inguinal hernia repair is limited and the putative advantages of a TE solution are unlikely to justify 
their costs. 
 
Incisional Hernia 
Incisional (or ventral) hernias are one of the most common wound complications encountered by 
gastrointestinal surgeons (Mathes et al, 2000;Park et al, 2006) and the second most common 
abdominal wall hernia (Aufenacker et al, 2006). Following laparotomy (surgical incision into the 
peritoneal cavity) as many as 1 in 5 patients will develop an incisional hernia (Burger et al, 
2006;Gurusamy et al, 2006;Mathes et al, 2000;Park et al, 2006). In the US 4 to 5 million laparotomies 
are performed annually suggesting 400,000 to 500,000 incisional hernias develop each year (Burger 
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et al, 2006). In England and Wales there were 16,500 incisional hernias in 2005/06 (HES Online, 
2007).  
 
Risk factors for developing an incisional hernia may be surgical or medical (Kim et al., 2006b). 
Surgical risk factors include emergency procedures, early reoperation, type of original incision, suture 
material and closure technique. Medical risk factors include obesity, malnutrition, anemia, liver 
disease, pulmonary disease and wound infection. The biggest and most consistent causative factor is 
wound infection (Adotey, 2006;Franz, 2006;Kim et al, 2006b). Patients receiving peritoneal dialysis 
(removal of soluble substances and water from the body by transfer across the peritoneum) may be 
more susceptible to incisional hernias with a reported incidence of approximately 60% (Park et al, 
2006).  
 
Incisional hernias tend to be much larger than other types of hernia, with an average size of about 105 
cm2 (LeBlanc, 2005). They are a significant source of morbidity (Franz, 2006) and are associated with 
complications including pain and discomfort, which increases when standing and after eating meals 
(Dion Morton, 2008), incarceration (reported incidence of 10% and mortality rate of 25%) and  bowel 
strangulation requiring resection (reported in 20% of incarcerations and has a mortality rate of 20%) 
(Park et al, 2006). The frequency of complications is lower for synthetic mesh repair compared to 
suture, however complications still occur including hernia recurrence (occurring a third of all cases with 
mesh), pain and infection. The incidence of infection is less than 10% but the clinical consequences of 
infected intraperitoneal or abdominal wall mesh are severe (Helton et al., 2005). Complications 
sufficient to prompt re-operation occur in approximately 5% of incisional hernia cases (Adedeji et al, 
2002).  
 
There is headroom for improvement in effectiveness of incisional hernia repair but whether a TE mesh 
would perform better than a synthetic mesh for the repair of primary ventral hernias is uncertain. 
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Parastomal Hernia   
Parastomal hernia is an incisional hernia occurring in the gap between the intestinal segment forming 
the stoma and the surrounding tissue (Baig et al., 2006). It is a known complication of stoma surgery, 
such as a colostomy or ileostomy (surgical procedures to create an opening for removal of faeces), 
and occurs in up to 50% of stoma patients (Janes et al., 2004b). Risk factors associated with a 
parastomal hernia include obesity, prostatism (compression or obstruction of the urethra), malnutrition, 
urinary obstruction, and chronic cough (Baig et al, 2006). In England and Wales in 2005/06 there were 
around 500 hospital admissions for parastomal hernia, 3,776 for ileostomy and 2,019 colostomy (HES 
Online, 2007).   
 
Stomal hernias develop gradually, increasing in size over time during the first few years of stoma 
formation, but the risk of herniation persists for 20 years (Carne et al., 2003). Parastomal hernias are 
classified into four subtypes: interstitial, where the hernial sac lies within the layers of abdominal wall; 
subcutaneous, where the hernial sac lies in the subcutaneous plane; intrastomal, where the sac 
penetrates into a spout ileostomy; and peristomal, where the sac is within a prolapsing stoma (Carne 
et al, 2003). Parastomal hernias can be asymptomatic, induce mild symptoms or even life threatening 
symptoms (Baig et al, 2006). They are uncomfortable and cause embarrassment to the patient. 
Although rare, complications can arise, such as strangulation, obstruction and perforation, causing  
significant pain and discomfort (Carne et al, 2003).  
 
Recurrent peristomal (area of skin surrounding a stoma in the abdominal wall) pain is an indication for 
surgical repair (Carne et al, 2003). One in three parastomal hernias require surgical intervention 
(Janes et al, 2004b). The techniques for parastomal hernia repair fall into two categories:  
1. Local fascial repair, which keeps the stoma in place but removes the hernia;  
2. Stoma relocation followed by standard hernia repair (discussed earlier) (Carne et al, 2003).  
 
Controversy exists regarding which procedure should be used at which point in hernia development. 
Rubin and colleagues (Rubin et al., 1994) suggest first time hernia repair should be via stoma 
relocation and recurrent hernias should be treated by local repair using synthetic mesh. However, the 
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ideal solution is to prevent the formation of a parastomal hernia altogether. A mesh could be used in 
this situation.  
 
An RCT by Janes and colleagues observed the effect of synthetic mesh in prevention of parastomal 
hernia. Lightweight synthetic mesh was successful in preventing complications (including wound 
infection, fistula formation, or pain) and the development of parastomal hernia. The reported incidence 
of parastomal hernia, published in the British Journal of Surgery (Janes et al, 2004b) was 0 of 16 
patients in mesh group compared with 8 of 18 in non-mesh group, conversely, in a later publication in 
the Archives of Surgery (Janes et al., 2004a) incidence is reported as 1 of 27 patients in the mesh 
group compared to 13 of 27 in the non-mesh group. The mesh proved so successful at 12 months the 
trial was stopped on ethical grounds. The authors now employ a prosthetic mesh for all colostomies, 
including emergencies, and intend to follow these patients for 5 years to assess longer term 
effectiveness (Janes et al, 2004b). 
 
A parastomal hernia is a contaminated non-epithelialised defect. Hernia repair in a contaminated field 
represents one of the highest risks for failure and a difficult clinical problem (Kim et al, 2006b). 
Synthetic mesh use is contraindicated in a contaminated defect. Clinicians are not in favour of using 
synthetic meshes to repair parastomal hernias as potential complications can be severe (Dion Morton, 
2008). The general consensus is that prevention of parastomal hernias is the way forward. There is 
some headroom for improvement in treatments to prevent parastomal hernias, although, as with 
incisional hernias, the headroom may not be sufficient to justify the cost of a TE approach.  
 
5.4.2 Laparostomy 
Creation of a laparostomy (open abdominal management) occurs following:  
• Infection - Wounds are classified based on level of infection (table 5.3). Contamination can result 
from exposure to enteric (small intestine) contents, ostomy (surgical opening) creation, fistula, 
incarcerated (closed hernia, cannot be manipulated) or strangulated (constricted blood supply, can 
lead to gangrene) hernias, defects created after excision of infected mesh and defects associated 
with acute tissue loss after severe trauma. As previously stated, one of the main disadvantages of 
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synthetic mesh repair is infectious complications; PTFE and polypropylene have infectious rates 
that range from 0.5% to 7.7% (Ueno et al., 2004). When a permanent mesh becomes colonised 
with bacteria a recurrent hernia will almost always develop, necessitating further operations to 
remove the infected mesh and insert a new mesh (Helton et al, 2005;Kim et al, 2006b;Patton et 
al., 2007). The removal of mesh results in a larger defect, repair cannot happen immediately as 
there is a high risk of continuing infection.  
 
• Emergency Surgery - Abdominal Compartment Syndrome (ACS) is a potentially lethal condition 
defined by intraabdominal hypertension exceeding 20mmHg (Tons et al., 2000;Walker et al., 
2003). Primary abdominal compartment syndrome occurs prior to surgery, often as a 
consequence of intraabdominal inflammation and infection resulting from conditions such as 
pancreatitis (inflammation of the pancreas) and infective peritonitis (inflammation of the 
peritoneum). Secondary compartment syndrome is a result of previous medical or surgical 
treatment or trauma, including forced closure of the abdominal wall following abdominal surgery, 
again following serious intraabdominal pathology (Tons et al, 2000). Treatment of ACS is via an 
emergency decompressive laparotomy followed by creation of a laparostomy. 
 
Table 5.3: Classification of wound Infection 
Classification Description Infection Rates 
Clean (Class I) 
Uninfected operative wound 
No acute inflammation 
Closed primarily 
Respiratory, gastrointestinal and urinary tracts not entered 
No break in aseptic technique 
Closed drainage used if necessary 
<2% 
Clean-
contaminated 
(Class II) 
Elective entry into respiratory, gastrointestinal, urinary tracts 
with minimal spillage 
No evidence of infection or major break in aseptic technique 
<10% 
Contaminated 
(Class III) 
Nonpurulent inflammation present 
Gross spillage from gastrointestinal tract 
Penetrating traumatic wounds <4 hours 
Major break in aseptic technique 
20% 
Dirty-infected 
(Class IV) 
Purulent inflammation present 
Preoperative perforation of viscera 
Penetrating traumatic wounds >4 hours 
40% 
Table reprinted with permission from eMedicine.com, 2009.  
Available at: http://emedicine.medscape.com/article/188988-overview 
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Repair of a contaminated field represents a number of challenges in terms of wound management. A 
laparostomy can be used prophylactically if it is clear that primary closure under tension will create 
extensive intra-abdominal pressure. It is also used following mesh infection when there is a 2 to 3 
week delay to allow the infection to clear-up before attempting repair (Dion Morton, 2008). 
 
In a laparostomy the exposed contents are covered with a sterile mesh, which aids drainage of 
infectious materials, permits visual control of the underlying viscera, facilitates access to the 
abdominal wall, preserves the fascial margin and allows mobilisation of the patient (Schachtrupp et al., 
2002). However, there is currently no ideal mesh for use in these infected defects. The re-implantation 
of synthetic mesh into a contaminated area exacerbates wound infection resulting in infection rates as 
high as 50% to 90% (Kim et al, 2006b;Patton et al, 2007;Ueno et al, 2004). Following laparostomy 
repair is attempted. This staged approach carries increased morbidity compared to a single surgical 
approach and the initial phase provides minimal support (Patton et al, 2007).  
 
Four out of every six patients who end up in intensive care following a laparostomy as a result of 
infection will survive and require reconstruction of their non–epithelialised abdominal wall (Dion 
Morton, 2008). However, a laparostomy is often left to heal by secondary intention, which can take a 
very long time and almost always results in the development of a hernia, resulting in a prolonged stay 
in intensive care (Liyanage et al., 2006;Schachtrupp et al, 2002).  
 
A state-of-the-art primary repair technique that is resistant to infection or overlying skin breakdown is a 
worthy goal. A TE mesh could provide initial gains by overcoming primary morbidity through facilitation 
of early closure of the wound and later gains by aiding the formation of a stronger abdominal wall. The 
underlying hypothesis here is that a TE solution would be superior to synthetic mesh because, being 
natural tissue it would be less prone to infection.  
 
The role of TE could be limited by the time delay required to prepare the tissue, approximately 2 to 3 
weeks (Yves Bayon, 2008). This approach would not be appropriate for immediate primary closure in 
an emergency. However, in planned surgery a cellular TE solution could be suitable. For example, in 
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staged repair (following a laparostomy), an infection must be cleared prior to closure and thus there 
would be sufficient time to prepare the TE tissue. Cells can be taken during the initial surgery 
(laparotomy or mesh removal) or 3 weeks prior to the planned surgery (if it is expected patient will 
require longer recovery) and second surgery can be planned to coincide with finished tissue. It is 
thought this would still lead to more rapid recovery and would be preferable when the alternative is 
healing by secondary intention (Dion Morton, 2008;Yves Bayon, 2008). Consideration is required on 
how to store tissue if it is ready but surgery is delayed.  
 
5.4.3 Tissue Necrosis  
There are many causes of tissue necrosis (death) including infection, inflammation, and trauma. An 
abdominal wall defect may be caused by synergistic gangrene: a polymicrobial necrotising infection, 
caused by Beta-haemolytic streptococci Group A (Streptococcus pyogenes), a gram-positive organism 
that cause several serious infections plus Staphylococcus aureus gram negative aerobes or 
anaerobes (British Society for Antimicrobial Chemotherapy, 2007). These necrotising infections can 
present with a hernia and often follow local tissue injury, including surgery and abscess drainage. 
Diabetes is a common predisposing disease.  
 
Fournier’s gangrene is a rare but aggressive form of synergistic gangrene affecting the perineum (area 
between the opening of the vagina and the anus in a woman, or the area between the scrotum and the 
anus in a man). The condition presents with scrotal skin pain, itching, tenderness, oedema (swelling), 
and redness, with severe swelling of the scrotum, crepitation (a dry, crackling sound, or sensation) and 
necrosis of the skin. It progresses rapidly and can cause multiple organ failure and death, with 
mortality rates averaging between 20% to 30% (Paty et al., 1992). Diabetes Mellitus and alcoholism 
predispose to the condition and most cases are diagnosed in elderly patients with immunodeficiency 
(Yanar et al., 2006).  
 
The treatment for Fournier’s Gangrene requires rapid administration of antibiotics and immediate 
surgical debridement. In the majority of cases this is extensive and almost always results in loss of the 
scrotum and testes and often the penis (Pawlowski et al., 2004). This surgical intervention leaves 
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behind a large defect, and as with a laparostomy, the open wound results in fluid and protein loss, 
increasing recovery time, and hospital stay.  
 
Reconstructive surgery is essential following a gangrenous infection of the perineum. This is a 
complex and difficult challenge both cosmetically and functionally. Synthetic mesh use for open repair 
is generally contraindicated following debridement of infected tissues (Guzzo et al., 2007) because 
synthetic material may allow the infection to regain its foothold (Dion Morton, 2008). The current most 
commonly used approach to reconstruction is to use skin and tissue grafts such as a myocutaneous 
flap (Guzzo et al, 2007). Meshed, unexpanded skin grafts have shown to be highly successful for 
penile reconstruction, with graft up-take of 100% recorded and 6 month follow-up improvements in 
functional and cosmetic outcomes were reported as satisfactory (Black et al., 2004). However, there 
are drawbacks to skin grafting such as donor-site morbidity and post-operative complications.  
  
A TE mesh could provide an alternative, potentially superior solution to reconstructive surgery 
following tissue necrosis. One approach would be to develop a biological mesh. However, this could 
be difficult due to the large and irregular shape of the defect. Another approach would be engineered 
tissue as an alternative to autologous tissue, which would prevent skin graft shortage problems and 
complications relating to the donor site. In addition, eliminating a need to harvest tissue could reduce 
operating theatre time and thus reduce overall cost of treatment. These are highly contaminated and 
dirty wounds. However, they are infrequent and the small market might not justify the additional cost of 
TE products.  
 
5.4.4 Omphalocele 
Omphalocele is a congenital defect (the aetiology of which is unknown), characterised by herniation of 
intraabdominal viscera through an open umbilical ring, which fails to close during embryogenesis 
(Salomon et al., 2002). This condition causes significant morbidity and mortality (Wilson et al., 2004), 
and is often associated with chromosomal defects and additional congenital abnormalities. The birth 
prevalence has been estimated at 2.5 in 10,000 in Western countries. The prognosis for the patient is 
dependent on the size of the hernia and associated congenital abnormalities. Immediate postoperative 
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complications usually relate to significant changes in intra-abdominal pressures and are more frequent 
with giant defects. Short-term complications include necrotising enterocolitis (inflammation of the small 
intestine and colon), prolonged ileus (a partial or complete non-mechanical blockage of the small 
and/or large intestine), and respiratory distress. Long-term complications include parenteral nutrition 
dependence (given through the veins of the circulatory system, rather than through the digestive 
system), gastroesophageal (stomach and oesophagus) reflux, parenteral nutrition-related liver 
disease, feeding intolerance, and neurodevelopmental delay (McNair et al., 2006).  
 
Postnatal management includes protection of herniated viscera, maintenance of fluids and 
electrolytes, prevention of hypothermia, gastric decompression, prevention of sepsis, and 
maintenance of cardio respiratory stability (McNair et al, 2006). Current treatment strategies include 
delayed closure using a synthetic graft or large skin flaps, or topical treatment to promote 
epithelialisation. Drawbacks to these methods are wound infection, fascial separation, abdominal 
domain loss (Kapfer et al., 2006) and formation of an incisional hernia, requiring surgical intervention 
in the future  (Alaish et al., 2006).  
 
There is certainly headroom for improvement in treatment. The most attractive possibility for the 
surgical repair of congenital abdominal wall defects, would be the immediate availability of a non-
immunogenic and non-synthetic biomaterial that could guide the regeneration of normal tissue 
(Gamba et al., 2002). The size of the potential market may be limited as this is a rare condition. 
However, investigation into the use of TE products has already begun. 
 
5.4.5 Conclusion 
After careful analysis of the clinical problem it appears synthetic meshes have problems when the 
defect is large and when there is infection (table 5.4). In the latter situation, a mesh may be needed to 
replace skin as well as deeper tissue layers. Infected defects pose a particular challenge in terms of 
treatment as synthetic mesh use is contraindicated. In such circumstances an alternative product is 
desirable.  
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Table 5.4: Abdominal wall defects with potential for a TE/RM solution 
 
Size of defect 
Small Large 
Presence of contamination 
or infection 
No Little or no scope Possible potential for a TE 
solution 
Yes Possible potential for a TE 
solution 
Large potential for a TE 
solution 
 
Many of the indications discussed above have headroom for improvement in effectiveness, but many 
have low prevalence and therefore the potential market will be limited. I conclude that the applications 
with the greatest potential headroom for a TE solution worth further investigation are:  
i. Treatment of incisional hernias - when defect is infected or contaminated;  
ii. Prevention of parastomal hernias;  
iii. Laparostomy - planned staged repair and repair of non-epithelialised abdominal wall defects 
that result from infection following a laparostomy.  
 
In the following section I will apply the headroom method to large, infected incisional hernias. If a TE 
solution is cost-effective in this scenario, I predict it is likely to be cost-effective in the other two 
scenarios, which have greater headroom for improvement in effectiveness. 
 
5.5 Clinical Effectiveness 
Here I review the clinical effectiveness of different meshes used for incisional hernia repair before 
summarising the overall recurrence rate for different types of incisional repair. Next, I elicit the utility 
score associated with the clinical effects of having an infected incisional hernia. 
 
5.5.1 Synthetic Mesh for Incisional Hernia Repair 
There are currently no systematic reviews comparing mesh repair with non-mesh repair in the 
treatment of incisional hernias. Two RCTs (Burger et al., 2004;Luijendijk et al., 2000) comparing 
suture to synthetic mesh have been identified, but they involve the same patient cohort over different 
follow-up periods (n=200). Luijendijk and colleagues report 36-month follow-up and Burger and 
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colleagues report 10-year follow-up (table 5.5). In addition, one retrospective study (Conze et al., 
2007) assesses the challenges of reoperation following mesh repair, and a cost analysis (Israelsson et 
al., 2003) has compared hernia recurrence following suture and synthetic mesh in incisional hernia 
repair. 
 
The RCT by Burger and colleagues compared suture repair to mesh repair in patients undergoing 
primary incisional hernia repair (n=171) and first recurrent hernia repair (n=29). The 3-year cumulative 
recurrence rates were 23% for mesh repair (24% for primary repair and 20% for first recurrence repair, 
P=0.02) versus 46% for suture repair (43% for primary repair and 58% for first recurrence repair, 
P=0.10) (P=0.009) (Luijendijk et al, 2000). The 10-year overall cumulative hernia recurrence rates 
were 63% for suture repair and 32% for synthetic mesh repair (P<0.001). In a subgroup of 50 patients 
with small incisional hernia (<10cm2) the recurrence rates were 67% following suture repair and 17% 
following mesh repair (Burger et al, 2004). The independent risk factors identified for recurrence were 
abdominal aortic aneurysm (P=0.01) and infection (P=0.02). In addition mesh repair is associated with 
a higher rate of hernia repair-related complications (17% compared to 8% for suture repair, P=0.17) 
and a lower rate of abdominal pain (20% compared to 27% for suture repair, P=0.53) but these are not 
significant. The results for cosmetic results and patient satisfaction were also comparable between the 
suture and mesh groups. Israelsson and colleagues (Israelsson et al, 2003) followed up 44 patients 
who received suture repair (mean follow-up of 67 days) and mesh repair (mean follow-up of 30 days). 
Hernia recurrence was reported in none of 19 patients in the mesh group and 5 of 13 patients in the 
suture group (P<0.01).  
  
A retrospective study (n=77) by Conze and colleagues found the number of re-operations following 
initial incisional repair rises linearly over time in both mesh and suture groups. Half the patients 
required re-operation within 14 months and 75% within 24 months. Despite the improvements 
associated with mesh, hernia recurrence still occurs in 25% or more (compared with 1 in 50 or less 
with inguinal hernias) and these occur at the border of the implant. Local mesh-related problems, such 
as infection and adhesion (reported in 73% of cases in this study) are a further problem; severe 
adhesions can lead to a need for bowel resection. The authors conclude that every re-operation after 
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previous mesh repair remains a demanding and challenging procedure. This highlights again the 
headroom available for a treatment for a complicated incisional hernia. 
 
Table 5.5: Synthetic mesh repair versus non-mesh repair for treatment of incisional hernias  
Study Burger et al. 2004 
Type RCT 
N 200 
Follow-up 10 yr 
method of repair Suture (97 patients) Mesh (84 Patients) 
Type of hernia (patients) 171 patients primary repair; 29 patients first 
recurrence 
mean size of defect (cm2) 20 (range: 1-225) 24 (range: 1-160) 
Mean age of patient (years) 63 (25-82) 57 (23-85) 
Body mass index 26 (range: 20 - 41.5) 26.2 (range: 19.7 - 41.5) 
Duration of Operation 45 minutes 58 Minutes 
Number of recurrences 54* 27* 
10 yr cumulative 
Recurrence rate 
Overall 63%* 32%* 
Defects <10cm2 67%* 17%* 
risk factors for hernia recurrence abdominal aortic aneurysm*; infection* 
Complication rate 
Overall 8% 17% 
Small bowel 
obstruction 3% 8% 
Fistula 0% 6% 
Wound Infection 0% 1% 
Strangulated hernia 1% 0% 
Burst Abdomen 1% 0% 
Further hernia repair 35%*  12%*  
Pain Scar 23% 20% Abdominal 39% 18% 
Satisfaction Overall 64% 77% Cosmetic 46% 51% 
*Statistically significant (p<0.05) 
 
5.5.2 Acellular Grafts for Incisional Hernia Repair 
The effectiveness of porcine dermis, porcine submucosa, and cadaveric dermis has been assessed in 
humans with a complex (infected or contaminated) incisional hernia undergoing non-primary hernia 
repair (tables 5.6, page126). 
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Porcine Dermal Collagen 
There are no RCTs investigating the effectiveness of porcine dermis. A retrospective study of 9 
patients (Parker et al, 2006) and a prospective study of 20 patients (Shaikh et al., 2007) have been 
identified. Parker and colleagues retrospectively investigated the effectiveness of Permacol in 
complicated incisional hernias. Two post-operative complications were reported: 1 patient (11%) had a 
recurrent hernia after intentional removal of Permacol mesh following a wound infection at month 13 
and 1 patient (11%) developed skin separation with exposure of mesh but following general wound 
care went on to heal with no evidence of infection. The authors (Parker et al, 2006) conclude Permacol 
is a safe and acceptable alternative to synthetic mesh for repair of complicated incisional hernia repair.  
 
Shaikh and colleagues prospectively investigated the use or Permacol in large abdominal wall defects 
(8 patients) and complex incisional hernias (12 patients). Twelve of twenty (60%) patients experienced 
no complications and were sent home within 7 days, 7 (35%) patients  experience complications (2 
(10%) seromas, 2 (10%) minor wound infections, 1 (5%) wound haematoma, 1 (5%) skin edge 
necrosis, 1 (5%) superficial wound dehiscence) and 1 (5%) patient died of multiple organ failure. 
 
Overall, it can be concluded that the use of porcine dermal collagen or Permacol® for the repair of 
complex abdominal wall defects shows good outcomes, demonstrating good ease of handling, good 
tensile strength, non-immunogenicity, and good gradual incorporation by host fibrous tissue when 
used for abdominal wall repair (infected or contaminated) (Adedeji et al, 2002;Liyanage et al, 
2006;Parker et al, 2006;Shaikh et al, 2007;Ueno et al, 2004).  
 
An ongoing RCT aims to assess the effectiveness of preventing parastomal hernias using Permacol®, 
placed around the stoma to reinforce the tissue, versus the surgeons standard technique to construct 
a stoma with no reinforcement (Dion Morton, 2008). The pilot study preceding this RCT suggested 
collagen mesh is likely to result in less complications than synthetic mesh, particularly with regard to 
sepsis and erosion, as well as easier to manipulate and separate from surrounding tissues if re-
operation is required (Dion Morton, 2008). The major drawback is its cost; with a sheet of Permacol of 
size 18cm x 28cm costing around £3,700 ($6,000, €4,200) (Emma Rowley, 2007). 
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Porcine Small Intestine Submucosa 
Two prospective studies (Franklin, Jr. et al., 2004;Ueno et al, 2004) and one retrospective study 
(Helton et al, 2005) have investigated the effectiveness of porcine small intestine submucosa in 
contaminated abdominal wall defects.  
 
Franklin and colleagues (Franklin, Jr. et al, 2004) followed up 53 patients who underwent a total of 58 
hernia repairs (incisional (n=43) or inguinal (n=15)) in a partially contaminated setting for 2 years. 
Wound infection was reported in 2% of patients but no other mesh-related or hernia related 
complications were reported and histological analysis confirmed good incorporation of the mesh and in 
growth.  
 
Ueno and colleagues (Ueno et al, 2004) also prospectively investigated the use of porcine small 
intestinal submucosa in the management of infected (11 patients) and partially contaminated (9 
patients) abdominal defects (18 ventral and 2 inguinal hernias). Overall, wound infection occurred in 8 
of 20 (40%) cases, hernia recurrence occurred in 6 of 20 (30%) cases and seromas occurred in 2 of 
20 (10%) cases. As expected patients’ with prior infection reported greater incidence of recurrence 
(45% compared with 11%) whilst patients with contamination reported a greater incidence of wound 
infection (44% compared to 36%) and a greater number of seromas (11% compared to 9%).   
 
Finally, Helton and colleagues (Helton et al, 2005) retrospectively investigated the use of porcine small 
intestine submucosa (Surgisis) in 53 patients over 14 months. Patients were classified by wound class 
(see table 5.3, page 131); 31 of 53 (58%) patients had a clean wound, and 22 of 53 (42%) patients 
had a contaminated or dirty wound. The authors note that two important complications are related. The 
likelihood of a hernia recurrence is increased with mesh infection, which is increased by wound 
dehiscence. Overall, 13 (25%) patients experienced wound dehiscence and 9 (17%) patients 
developed a recurrent hernia. As might be expected the rate of both complications was higher in the 
contaminated repair group (table 5.6) and based on this finding the authors advise caution when using 
Surgisis in contaminated and infected defects. The authors conclude that the short-term results for 
Surgisis are equivalent to that of prosthetic mesh, when used in clean defects.  
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The drawbacks of Surgisis (porcine submucosa) are due to its anatomy; the maximum width is 8cm 
when manufactured into a four-ply sheet. This will limit its potential for use in large hernia repair. In 
such instances, more than one mesh is required, thus increasing the cost. A sheet of Surgisis, 7x10cm 
4-ply, costs around $500. Franklin and colleagues (Franklin, Jr. et al, 2004) suggest that the additional 
cost of Surgisis will be compensated by downstream benefits such as the abolition of further surgery. 
However, there are no head-to-head comparisons to back up such claims. 
 
Human Acellular Dermal Matrix (HADM) 
Using HADM has been investigated in a number of animal studies and a few human studies. It is well 
tolerated by the host immune system, has mechanical properties similar to synthetic materials and 
some ability to revascularise (Holton et al, 2005). More recently Alloderm has been investigated for 
use in contaminated sites when synthetic mesh is contraindicated and in patient cohorts whose 
defects would conventionally be closed by staged repair.  
 
Seven cohort studies assessed the effectiveness of HADM or Alloderm in contaminated (wound 
classification II, III, or IV; see table 5.3) or infected defects (primarily incisional hernias). Six were 
retrospective (Bellows et al., 2007;Buinewicz et al, 2004;Holton et al, 2005;Jin et al., 2007;Patton et al, 
2007;Schuster et al, 2006) and one prospective (Kim et al, 2006b).  
  
Bruinewicz and colleagues (N=44) found Alloderm exhibits good biomechanical properties and is 
successful for the repair of challenging hernias. The authors identified a 4.5% incidence of hernia 
recurrence, wound dehiscence and haematomas or seromas, and a 6.8% incidence of wound 
infection; the lowest complication rates reported in any study when using any material to repair a 
complex hernia. Holton and colleagues (N=49) reported a hernia recurrence rate of 10% and found 
that patients who developed a recurrence were younger and less obese on average. Wound infection 
occurred in 20% (of which 20% subsequently lead to reherniation and 10% lead to mesh removal), 
seromas occurred in 10% and 2% developed wound dehiscence. No complications were reported 
when HADM was used near a stoma (Buinewicz et al, 2004).  
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Schuster and colleagues (Schuster et al, 2006) concluded that Alloderm “works satisfactory” for 
primary closure of contaminated defects based on a retrospective study of 18 patients. Overall hernia 
recurrence was 50%; 33% was recorded amongst patients with primary closure compared to 83% 
amongst patients who did not have primary closure (p=0.03). Based on 20 patients, Bellows and 
colleagues (Bellows et al, 2007) concluded that Alloderm was safe for tension-free closure of large 
contaminated defects. Postoperative complications were experienced in 55%; 30% experienced a 
hernia recurrence after 8 months, 25% reported wound infection, 30% (6 patients) experienced wound 
dehiscence and 25% had the mesh removed. Complications were higher in dirty/contaminated wounds 
compared with clean-contaminated/clean wounds (p=0.049).  
  
Patton and colleagues (Patton et al, 2007) conducted a study of 67 patients with contaminated ventral 
hernia and found wound infection occurred in 16%, recurrent hernias occurred in 18% and mesh graft 
removal was required in 3%. The author has concluded that this was an improvement on synthetic 
mesh in contaminated defects and was comparable to synthetic mesh in non-contaminated defects.  
 
Finally, Jin and colleagues (N=37) used Alloderm in bridged hernia repair (an intraperitoneal 
interposition graft providing a single layer repair from the edges of the fascia under tension) (n=11) 
and reinforced hernia repair (graft placed in an onlay, underlay, or sandwich technique after primary 
re-approximation) (n=26) to investigate whether the method has an effect on effectiveness. Hernia 
recurrence rate was 35% overall (83% following bridged repair; 80% following reinforced repair). The 
method used to place Alloderm in the abdominal wall defect has a significant impact on recurrence 
rates; the only predictive value was the use of bridging technique. The authors concluded that 
Alloderm should be used only as reinforcement after primary fascia re-approximation (Jin et al, 2007).  
 
The only prospective study identified (N=29) (Kim et al, 2006b) found a success rate (determined by 
intact repairs at 182 days follow-up) of 89% with just 10% of patients experiencing a recurrence 
following repair using acellular dermal matrix. Postoperative complications were reported in 45% of 
patients wound infection was the most common (41%), of which 31% required further treatment and 
96% healed without further complication.  
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Table 5.6: Effectiveness of acellular meshes for treatment of incisional hernias  
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5.5.3 Recurrence Rate 
Table 5.6 above reports the hernia recurrence rate for each study identified. Here, I summarise the 
recurrence rate, by type of material. Using review manager, I conduct meta-analysis of recurrence 
rate. These results are shown in table 5.7 below. This information will be required later in the 
headroom analysis. As hernia recurrence is the most significant long-term complication. An ideal new 
generation mesh would reduce recurrence rate as well as reducing the early complications. 
 
From the results below it can be seen that for type 1 hernias the use of acellular mesh has resulted in 
a reduction in hernia recurrence, an improvement over the use of synthetic mesh and suture alone. 
However, for type 2 hernias the use of acellular mesh is not as effective, resulting in a larger 
recurrence rate. In conclusion, type 2 hernias have a larger headroom for improvement over type 1 
hernias and will be the focus of the headroom analysis to follow. 
 
Table 5.7: Summary of recurrence rate for each material 
Defect Material study N follow-
up (yrs) Recurrence rate 
Ty
pe
 
1 
Incisional 
hernia repair 
(primary and 
non-primary 
repair) 
suture Burger 2004 97 10.0 63% 63% 63% 
synthetic Burger 2004 84 10.0 32% 32% 32% 
Ac
e
llu
la
r 
porcine 
Helton 2005 22 1.2 5% 
10% 
11% 
Shaikh 2007 8 1.5 25% 
human 
Buinewicz 2004 44 1.7 5% 
12% Holton 2005 49 0.5 12% 
Schuster 2006 12 0.8 33% 
Ty
pe
 
2 
Complicated 
Incisional 
Hernia 
(contaminated 
or infected 
defects) 
Ac
e
llu
la
r 
porcine 
Franklin 2004 58 1.6 0% 
22% 
23% 
Helton 2005 31 1.2 26% 
Parker 2006 9 1.5 11% 
Shaikh 2007 12 1.5 8% 
Ueno 2004 20 1.3 30% 
human 
Bellows 2007 20 0.8 30% 
24% 
Jin 2007 37 1.8 35% 
Kim 2006 29 0.5 10% 
Patton 2007 67 0.9 18% 
Schuster 2006 6 0.8 83% 
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5.5.4 Utility of Clinical Effects 
Based on the evidence provided previously, I have concluded that the headroom analysis should 
focus specifically on infected and complicated incisional hernia repair as this particular type has the 
greatest headroom for improvement over current treatment. However, as previously described there 
were no utility values associated with a health state following repair of an infected incisional hernia 
available in the literature. Instead, I wrote a questionnaire and elicited this value directly from a sample 
of healthcare professionals. Full details of the methods are described in section 5.2.2 (page 114). The 
questionnaire used to elicit the health utility associated with the repair of an infected incisional hernia 
can be seen in appendix 6. 
 
The questionnaire was completed by 54 healthcare professionals. Fifty of fifty-four (93%) individuals 
answered the TTO question. Using equation 5.1 (section 5.2.2, page 114), the TTO responses given 
in the questionnaire were converted into utility scores. The utility scores elicited ranged from 0 to 1 and 
had a negative skew. Full descriptive analysis can be found in appendix 6 following the questionnaire. 
In conclusion the mean utility for the period of maximum symptoms was calculated as 0.85 (95%CI: 
0.79, 0.91) from 50 responses.  
 
Forty-four of fifty-four individuals completed the question about WTP. The WTP to avoid a 0.15 
decrease in utility for 10 years ranged from £500 to £250,000 with 64% (28 of 44) of healthcare 
professionals stating that they would be prepared to pay between £1,001 and £10,000 for the new 
treatment. Full descriptive analysis is in appendix 6. In conclusion, the mean WTP to avoid a 0.15 
decrease in utility for 10 years was calculated as £18,611 (95%CI: £9,262, 17,198) ($30,500, €21,350) 
from 44 responses. Finally, by combining the responses from the two questions I calculated the mean 
WTP per QALY as £273,846 (95%CI: £158,340, £389,353) ($448,200, €314,200) from 39 responses. 
 
5.6 Cost of Treatment 
Cost data of incisional hernia repair using synthetic and acellular mesh has been reported by Kaleya 
and colleagues (Kaleya et al., 2005). The average price for an 8x12cm sheet of synthetic 
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polypropylene mesh is $350 (£200, €240). However, the cost for the same amount of Alloderm is 
substantially higher at $2,580 (£1,600, €1,800). Although, elsewhere it has been reported that the 
average cost per patient for Alloderm is $4,680 (£2,800, €3,200) (Schuster et al, 2006).  
 
The 2007 NHS national average unit operative cost for an infected incisional hernia repair is estimated 
at £2,907 ($4,700, €3,300), based on the HRG code FA17A (Abdominal Hernia Procedures 19 years 
and over with Major CC) (Department of Health, 2007).  An additional consideration is the potential 
saving in hospital bed days that a TE solution might deliver. The cost of a bed day is estimated at 
£210 ($350, €240) (Department of Health, 2006b)  from the  national average cost of an excess bed 
day, based on HRG code FA17A. 
 
5.7 Cost-Effectiveness Analysis 
5.7.1 Review of Previous Cost Analysis Studies  
Cost Analysis of Incisional Hernia Repair by Suture or Synthetic Mesh 
Israelsson and colleagues (Israelsson et al, 2003) conducted a cost-analysis (n=44) of incisional 
hernia repair by suture and by synthetic mesh. Overall, the costs were 6034 SEK (£520, €600, $850) 
lower for mesh repair in working patients and in retired patients the costs were 1898 SEK (£160, €190, 
$270) lower with mesh repair. The authors conclude that lower postoperative costs due to shorter 
hospital stay and more rapid return to work outweigh the higher operative costs associated with mesh. 
 
Cost-Minimisation Analysis of Alloderm  
A cost-minimisation analysis comparing Alloderm to a synthetic mesh for the treatment of incisional 
hernias was conducted in 2005 by Lifecell (although the authors referred to as a cost-benefit analysis), 
the manufacturer of Alloderm (Kaleya et al, 2005). The risks of complications associated with each 
material were established from the literature and physician interviews. The total overall surgical cost, 
including material and procedure costs, related to the use of synthetic mesh and Alloderm has been 
estimated at $5,790 (£3,500, €4,000) and $8,170 (£5,000, €5,700), respectively (Kaleya et al, 2005). 
Although the synthetic material may be associated with lesser surgical costs, it is also associated with 
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greater complications and more challenging post-surgical care compared to Alloderm. Early 
complications (wound dehiscence with or without infection) result in an additional risk-adjusted, per-
patient cost of polypropylene of $765 (£470, €530), compared to $212 (£130, €150) for Alloderm. 
Long-term complications, including recurrence, small bowel obstruction, fistula formation, or planned 
reoperation, were estimated to add an average of $3,548 (£2,100, €2,500) to mesh hernia repairs, 
compared to $662 (£400, €460) with Alloderm, due to a lower incidence of long-term complications 
associated with Alloderm (Kaleya et al, 2005). 
 
After complications and long-term (>1 month) care costs are considered Alloderm is associated with 
risk-adjusted net savings of $2,170 (£1,300, €1,500); $554 (£340, €380) per-patient cost savings 
associated with minimising early complications, $2,887 (£1,700, €2,000) associated with reducing late 
complications, and $1,110 (£680, €770) related to gains in lost patient productivity (Kaleya et al, 2005) 
(table 5.7). However, this analysis is sensitive to effectiveness estimates and complication rates. Here 
these are estimated by the manufacturer and may be uncertain given the absence of head-to-head 
studies as detected by my review. 
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Table 5.8: Cost-benefit analysis of Alloderm versus synthetic mesh to repair incisional hernia 
 
Synthetic Alloderm Alloderm Savings (additional charges) 
Complication Rate 
Infection 6% 5.10%  
Dehiscence with exposure of mesh 1.80% 1.80%  
Recurrence 16.80% 5%  
Enterocutaneous fistulae 3.50% 0.50%  
Adhesive small bowel obstruction 5.40% 0.50%  
Cost Driver 
Materials cost $350 $2,580 ($2230) 
Procedure-related costs $5,440 $5,590 ($150) 
hospitalisation $3,190 $3,190  
OR costs $2,250 $2,400  
Risk-adjusted cost of complications $5,812 $1,261 $4,551 
direct cost of early complications           
(<1 month) $765 $212 $553 
inpatient $554 $94 $460 
other direct $211 $117 $94 
direct cost of long-term complications 
(>1 month) $3,548 $662 $2,886 
inpatient $3,429 $645 $2,784 
other direct $119 $17 $102 
Lost productivity $1,498 $388 $1,110 
Total $ 11,601 $   9,432 $2,169 
Table adapted from Kaleya et al. 2005. Early complications include infection, dehiscence with 
exposure of mesh and recurrence, and late complications include enterocutaneous fistulae and 
adhesive small bowel obstruction. 
 
5.7.2 Headroom Analysis 
Duration and Severity of Clinical effects 
If a synthetic mesh becomes infected the current treatment strategy is to leave the wound open for 3-6 
months to allow the infection to clear before undergoing second surgery to close the wound. Patient 
recovery is slow and complex and requires a further 6 months of hospital visits for wound 
management. Following consultations with clinicians (Dion Morton, 2008), I predict that a TE mesh 
could be used to close the wound after 1-2 weeks. Patient recovery would be more rapid and wound 
management reduced to around 1 month. Taking into account more rapid closure of the wound and 
reduced recovery time I estimate the best-case scenario for the duration of the improvement of the 
clinical effects associated with a TE mesh would be approximately 6 months. This will fit with the 
premise of the headroom method, which states that I must assume the most optimistic effectiveness of 
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the new treatment. The mean utility associated with the period of maximum symptoms following repair 
of a recurrent incisional hernia was calculated as 0.85 (95%CI: 0.79, 0.91) from 50 responses. The 
headroom method is based on optimistic assumptions of the new treatment, therefore I assume that 
the new TE biological mesh could give patients perfect HRQL i.e. a utility value of 1.0.  
 
Calculating the Headroom  
I predict a TE solution will do two things: firstly, eliminate early complications such as wound infection 
and the subsequent side effects, resulting in more rapid healing and recovery; secondly, eliminate late 
complications, primary hernia recurrence, and the need for further surgery, thus also eliminating the 
additional associated costs. 
 
Early complications 
Firstly, I calculate the effectiveness gap and the disutility of the current treatment. Using equation 5.3 
populated with the information given above I calculate the maximum potential change in effectiveness, 
measured using QALYs, as 0.15.  
Equation 5.3: ∆QALY = 0.5 x (1-0.85) = 0.075 
 
Next, using equation 5.4 I calculate the headroom (max∆Cost). Based on a reimbursement level of 
£30,000 ($49,000, €34,000), the headroom is calculated as £2,250 ($3,600, €2,600). However, based 
on a reimbursement threshold of £20,000 ($33,000, €23,000), the headroom is calculated as £1,500 
($2,400, €1,700). 
 
Equation 5.4: max ∆Cost = £30,000 x 0.075 = £2,250 
 
 
In addition, a TE solution might deliver a saving in hospital stay. Based on the findings in section 5.5 
(page 136) I will assume a reduction in hospital stay of four days. Based on the cost per bed day given 
in section 5.6 (page 147) this will give a total saving of £840 ($1,370, €960). Thus, the total headroom 
is now £3,090 ($5,000, €3,500). However, this value only takes account of the elimination of early 
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complications. As described above, a TE solution might also reduce long-term complications and thus 
the need for further surgery.  
 
Late complications 
Finally, I use the recurrence rates and costs of further surgery described in the sections above to 
calculate the headroom associated with eliminating late complications. Recurrence rate associated 
with infected incisional hernia repair using acellular mesh is 23% (section 5.5.3, page 146). I estimated 
the cost of a complex incisional hernia to be £2,907 ($4,700, €3,300) (see section 5.6, page 147). This 
gives an additional cost per case of approximately £668 ($1,000, €760). By adding this cost saving to 
the headroom calculated from eliminating early complications I calculate total headroom of £3,758 
($6,000, €4,300).  
  
5.8 Return on Investment 
The revenue that can be generated is a function of the headroom, the likely cost, and volumes, 
represented by equation 5.5. Here, R = revenue, max ∆Cost = headroom, C’ = expected cost of 
production and V = cases per year. 
Equation 5.5: R = (max ∆Cost – C’) x V 
 
In the case of a TE mesh, in the previous section, I found a headroom of £3,700 ($6,000, €4,300). I 
make an assumption about the cost of production, assuming this to be £3,000 ($4,800, €3,400) and 
based on the information gleamed from clinicians I estimate there are 1000 cases per year, the 
estimated revenue is £70,000 per year ($113,500, €80,700).  
 
5.9 Discussion  
5.9.1 Summary of Main Findings  
Tension-free mesh is the current gold standard approach for abdominal wall defect repair. Mesh 
augments the strength of the weakened abdominal wall resulting in a repair that is less painful and 
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more likely to endure. Current generations of (non-TE) mesh materials are synthetic and prone to 
complications such as infections and adhesions, particularly when the defect is large and/or infected. 
 
New generations of mesh are biological and due to their natural sourcing, could reduce, or prevent 
complications associated with synthetic mesh, simplifying the healing process as well as improving 
mechanical integrity of the abdominal wall. There are two alternatives for a biological mesh:  
i) acellular biological mesh (relatively new); 
ii) Cellular biological mesh (a new generation TE mesh, not yet available); the latter would 
undoubtedly be the most expensive option.  
 
Current data, from short-term non-randomised studies, suggests biologics are preferable to synthetic 
mesh for infected defect repair. Due to the lack of long-term, head-to-head studies it is unclear which 
biologics are more effective. However, the available literature seems to suggest that acellular meshes 
are still at risk of complications and may be quite expensive; therefore there could be headroom for 
cellular meshes in large and infected defects. 
 
The target of the headroom analysis was incisional hernias, focusing on large complicated defects. 
The headroom was calculated as £3,700 ($6,000, €4,300), based avoiding the short-term 
complications and a reimbursement threshold of £30,000 ($49,000, €34,000). Our consultations with 
industry suggest that this is sufficient headroom for an acellular mesh to be cost-effective for use in 
large, infected incisional hernias. However, this may not be sufficient headroom for a cellular TE mesh.  
 
5.9.2 Elicitation of Utilities 
Before conducting the headroom analysis, it was necessary to elicit a utility score associated with the 
negative effects of current treatment approach to a large infected incisional hernia. Since it was not 
possible to obtain the health utility directly from patients, the utility was elicited from clinicians. I believe 
clinicians were a good proxy for patients as the health state associated with incisional hernia repair is 
complex and as caregivers, they have a high level of understanding of the impact of the health state 
on the HRQL of the patient. I reviewed how the utilities were elicited for chapter 4 and decided that 
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emailing questionnaires to clinicians would not be successful in gaining an acceptable sample size. I 
considered arranging face-to-face interviews but thought this would be too time consuming. I decided 
that the less time consuming but reliable approach would be telephone interviews, although I was 
aware this would still take a considerable amount of time to arrange the appointments. However, I then 
found out about a conference of colorectal surgeons in Harrogate and as there were sufficient funds, I 
decided this would be the most efficient way in which to proceed. Around 500 surgeons were expected 
to attend the conference over the two and half days. I managed to collect 54 completed responses. I 
had expected that I would have had a larger sample size but not all attendees wished to complete the 
questionnaire, and I had not anticipated that some would find it difficult to complete and require more 
time and explanation. Overall, I am happy with the number of questionnaires I had completed, I do not 
think the sample size limits the interpretation of the results and I believe the utility value of 0.85 is 
acceptable and reliable, as it was based on the opinions of specialist surgeons whom were familiar 
with this type of repair and the associated complications. This impression was gleaned from 
conversations, which took place at the time the questionnaire was completed, as there was not a 
specific question asked regarding familiarity with the procedure as there had been for the 
questionnaires used in chapter 4. If I were to do this again, I might consider the inclusion of such a 
question. However, I did ask about experience, which could be used as a proxy for familiarity.  
 
5.9.3 Implications of Work 
It is always important to continue defining the clinical problem as new technologies may be produced 
that affect the potential headroom. For example, there may be advances in synthetic biomaterials or 
natural materials that may supersede the current generation of synthetic meshes, such as advances in 
coatings that can strike a balance between bacterial infection and tissue in growth. Furthermore, 
changes in the payment of current technologies may also affect the headroom. For example, in the 
UK, some PCTs are beginning to reimburse the cost of Permacol on a case-by-case basis (this 
information was gained from personal communication with a consultant at the conference for 
colorectal surgeons, where the utility questionnaires were completed). Therefore, anyone attempting 
to develop an expensive TE cellular construct needs to keep close track of new developments in 
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synthetic and acellular meshes. Improvements in either of these meshes will impact on and most likely 
diminish the headroom available for the TE mesh. 
 
5.10 Conclusion 
Once again, the headroom method has been shown to be a simple and rigorous way to make a 
preliminary conclusion as to the cost-effectiveness of a new treatment, even when some of the 
parameters are extremely uncertain, without having to build a complex model with very wide 
parameter uncertainty. The headroom method reduces the risk of industry investing in a TE 
technology that may never be cost effective. However, it by no means answers all the questions. It is 
important to remember that this method is based on many assumptions, notably the complete 
effectiveness of the new technology. Therefore, if a TE biological mesh does not work as one hopes, 
the headroom would be reduced.  
 
In the following chapter I demonstrate how health economics can be used as a negotiating and not 
just a rationing tool, illustrated using an example based on bone RM technologies 
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 CHAPTER 6 EARLY STAGE COST EFFECTIVENESS 
ANALYSIS OF BONE REGENERATIVE MEDICINE 
TECHNOLOGIES 
 
6.1 Introduction 
Bone has two main forms; cancellous and cortical (figure 6.1). It is an extraordinary living tissue, 
providing structural support and protection to bodily organs. Involved in metabolism and storage of 
minerals, it is a site of blood cell synthesis. It has the unique capacity to remodel and heal itself 
through a continual process, stimulated by mechanical stress, in which osteoclasts (bone cells that 
break down bone tissue) break down and resorb old bone of inferior quality, and osteoblasts (bone 
cells that build bone tissue) replace it with new bone. However, as we age the balance of this 
remodelling becomes negative, i.e. osteoclasts are more active than osteoblasts, resulting in a gradual 
loss of bone mass. 
 
An abnormal environment, both mechanical and biological, can affect the functional capacity of bone 
for healing and regeneration and there are times when this remodelling process may fail, such as in 
fracture nonunion and segmental defects. Currently, the mechanical environment is stabilised using 
metallic fixation devices and the biologic environment is aided by bone graft and ceramics, the former 
to stimulate healing and provide extra material, the latter as a bulking agent. The purpose of RM is to 
replace the need for bone graft and ceramics and to promote bone healing.  
 
The purpose of this chapter is to demonstrate how using the headroom method can be used as a 
pricing and negotiating tool. I illustrate how this might work using bone morphogenic protein (BMP) as 
an example. BMP is used to promote bone healing in vivo. It is an alternative to autograft. It prevents 
the need to harvest bone from the iliac crest and may also improve bone healing when compared to 
autograft.  
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Figure 6.1: Anatomy of the bone 
 
Diagram to show the anatomy of the bone and illustrate cancellous (spongy) bone and cortical 
(compact or solid) bone.  
Source: BBC GCSE BItesize 
http://www.bbc.co.uk/schools/gcsebitesize/pe/appliedanatomy/2_anatomy_skeleton_rev4.shtml 
 
 
6.2 Methodology 
6.2.1 Overview 
Firstly, I reviewed disorders of the skeleton to identify the main clinical conditions where a RM 
alternative to bone grafting may have a place and I documented the various RM and non-RM 
treatments proposed. Secondly, I selected two conditions which I felt had the greatest potential and 
were worthy of further investigation before comparing clinical effectiveness and costs of the current 
gold standard treatment (autograft) with in-vivo and in-vitro methods of bone production. Finally, I 
conducted economic analysis. This part had two stages. First, I reviewed standard demand side cost 
utility analysis of BMP. Second, I carried out a supply side analysis to determine the threshold price of 
BMP for each condition.  
 
6.2.2 Defining the Clinical Problem 
Literature was identified using the search strings shown in appendix 10. During the course of the 
literature search, I discovered a HTA systematic review and economic analysis by Garrison and 
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colleagues (Garrison et al., 2007), which I have critiqued and updated. When necessary, the 
information from the literature was supplemented by discussions with an Orthopaedic surgeon based 
at Birmingham Royal Orthopaedic Hospital. In addition, I had the opportunity to consult with other 
orthopaedic surgeons through technical meetings, which were part of the European STEPS project. 
The technical aspects surrounding the development of RM bone was discussed with tissue-engineers 
(these were known to me through the EPSRC REMEDI and EU STEPS projects). After careful 
analysis of the clinical problem, it appears the greatest market potential is in moderate to large 
defects. I conduct a systematic review of the relative effects and cost of BMP as an alternative for 
autograft for two conditions – spinal fusion and fracture healing. Finally, I document the clinical effects 
of donor site morbidity with special emphasis on HRQL and utility. 
 
6.2.3 Cost-Effectiveness 
This method has two stages. Firstly, I review the CEA of the use of BMP for two conditions where it is 
most widely advocated as an alternative to autograft. I was aided here by the economic analysis 
published in a HTA report by Garrison and colleagues (Garrison et al, 2007). However, I present the 
results based on costs per patient rather than costs per 100,000.  
 
Secondly, I carried out a supply side analysis to determine the threshold price of BMP for each 
condition. This section contains four stages: 
1. I calculate the mean cost per case associated with using BMP for spinal fusion and fracture 
repair. This is calculated by offsetting the total cost savings per case against the additional cost of 
BMP.  
 
2. I performed supply side analysis to find out the price at which BMP would demonstrate cost-
effectiveness for use in spinal fusion and fracture repair. Using Excel I replicate and update, 
where necessary, the model from the Garrison review but I keep the QALY gains the same. Using 
equation 6.1, I calculate the price at which BMP would be considered cost-effective by changing 
the unit cost of BMP until the ICER falls below the UK WTP thresholds. 
Equation 6.1: WTP threshold=∆cost/∆benefit 
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Where, ∆cost is the total incremental cost to the NHS; ∆benefit is total incremental benefit, 
measured in QALYs; WTP threshold is the reimbursement level i.e. the health care providers’ 
willingness to pay for 1 QALY – in the UK, this is assumed to be between £20,000 ($33,000, 
€23,000)  and £30,000 ($49,000, €34,000). 
 
3. I perform a cost minimisation analysis (CMA) of BMP. It is certain that BMP reduces operation 
time due to time saved by avoiding bone harvest. Here I consider only the cost saving associated 
with reduced operation time because of using BMP. No other clinical outcomes associated with 
BMP are accounted for. Using Excel I replicate and update, where necessary, the model from the 
Garrison report. Using equation 6.2 I calculate the price BMP would need to be in order to be cost 
effective, assuming incremental benefit is zero.  
Equation 6.2: ∆benefit = ∆cost/ willingness-to-pay threshold 
 
Where, ∆benefit = zero, ∆cost is the recalculated incremental cost to NHS and willingness-to-pay 
threshold is the reimbursement level of £30,000 ($49,000, €34,000).  
 
4. Finally, I use the headroom method, described in chapter 3, to calculate the maximum cost for 
which a RM bone product would be considered cost effective. I use the equation:  
Equation 6.3: ∆Cost = ∆QALY x willingness-to-pay threshold 
 
Where, ∆Cost is the maximum headroom, ∆QALY is the change in benefit measured in QALYs 
and willingness-to-pay threshold is the threshold for reimbursement of £30,000 ($49,000, 
€34,000). 
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6.3 Treatment 
6.3.1 Current Treatment 
The current gold standard treatment for bone healing is the use of autologous bone grafts; usually 
harvested from the patient’s iliac crest and implanted into the defect site to stimulate bone formation 
and add bulk. The success rate is high due to the presence of osteoconductive, osteoinductive, and 
osteogenic properties, but it has limitations, most commonly that of donor site morbidity (Dimitriou et 
al., 2005;Giannoudis et al., 2005a). The side effects of donor site morbidity include haematoma 
formation, blood loss, nerve injury, hernia formation, infection, arterial injury, ureteral injury, fracture, 
pelvic instability, cosmetic defects, tumour transplantation, and most frequently chronic pain at the 
donor site (Giannoudis et al., 2005c;Kessler et al., 2005) (discussed further in section 6.6, page 182). 
Furthermore, the technique is limited for large defects because of the exhaustible supply. This could 
be overcome through the use of allograft (donor bone grafts). However, the rate of healing and graft 
incorporation for allografts is lower than for autografts. A further alternative is demineralised bone 
matrix (DBM) - pulverised and decalcified allograft bone. This process reduces immunogenicity while 
improving osteoconductivity (Fleming, Jr. et al., 2000). The resulting material can be used as a gel, 
flexible strips, malleable putty, or injectable paste. However DBM is widely used as bone graft 
extender rather than as a bone graft substitute (Giannoudis et al, 2005a). 
 
6.3.2 State of the Art in Regenerative Medicine 
RM is seldom designed to provide immediate mechanical support, this will usually be provided by 
conventional internal fixation (use of internal metal plates, screws, or rods to stabilise bone fragments. 
Used when bone defect cannot be stabilised by casting or splinting) or external fixation (use of metal 
orthopaedic device (external fixator) placed outside skin, to stabilise regions of bone) using metals, 
however in due course the aim is that the regenerated bone will provide support.  
 
A scaffold for use in bone defects should be biocompatible and mimic the body’s natural matrix – 
topography, surface chemistry, porosity and osteoinductivity - to provide a suitable environment for cell 
attachment (Logeart-Avramoglou et al., 2005;Salgado et al., 2004). In addition, the scaffold needs to 
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degrade at the same rate as the growth of new tissue. A wide range of natural and synthetic materials 
has been suggested as scaffold materials for bone regeneration (table 6.1). Two materials that have 
particular promise are ceramics and collagen. Ceramics have been widely used with encouraging 
results although they do posses several limitations; they are brittle, have low mechanical stability, and 
have varying degradation rates. Collagen is a biodegradable polymer and provides an ideal alternative 
to ceramics with very few limitations. Although collagen is available naturally, synthetic biodegradable 
polymers are preferred due to their chemical versatility and processability (Salgado et al, 2004); they 
have less property variation and the materials used to produce them have much better traceability, 
which is important for the regulator. The performance of these scaffolds is improved with the addition 
of cells and growth factors.  
 
Osteogenic cells are integral to the development of new bone. They can either be implanted into the 
defect or attracted from the host by osteoinductive factors (Kneser et al., 2006). For implantation the 
cell type used must be reliable, easily isolated, stably expanded, and non-immunogenic (Salgado et al, 
2004). Osteoinductive growth factors are naturally occurring proteins, which function as signalling 
molecules to promote and modulate the proliferation and differentiation of osteogenic (bone forming) 
cells. The most potent of these growth factors are BMPs (Giannoudis et al., 2005b).  It is currently 
unknown which cell type and growth factors will be most suitable. Table 6.2 and 6.3 summarise the 
main characteristics of the most commonly used cells and growth factors.  
 
However to date no traditional TE (scaffolds plus cells) products that might replace bone have been 
found. My feeling is that the recent availability of growth factors is likely to change the nature of RM 
solutions in bone. Before growth factors became available, scaffolds (such as ceramics) that mimic the 
architecture of cancellous bone were the most promising materials. However, simpler polymer 
scaffolds impregnated with growth factors (particularly BMP) seem to work equally well or better, thus 
scaffolds that mimic the micro-architecture of cancellous bone may no longer be necessary. 
Traditionally RM solutions have been produced in vitro and efforts to generate ceramics with similar 
architecture to bone, and perhaps impregnate these with cells, were consistent with this idea. 
However, I perceive a strong move to use the body as a factory and to stimulate in vivo bone 
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production by means of simple polymer scaffolds impregnated with growth factors. I feel this will prove 
to be the most effective and cost-effective approach. 
 
In the following section, I consider a variety of applications for bone RM and discuss whether the 
potential RM solutions might surpass the current treatment with the purpose of identifying which 
applications will have greatest benefit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
Table 6.1: Summary of materials used for scaffolds and their various characteristics 
Material Characteristics 
Ceramics 
Hydroxyapatite Brittle  Low mechanical stability 
Tricalcium Phosphate Small grain size - making for easier osteoclastic resorption 
Coralline Hydroxyapatite Performs as well as well as autograft for metaphyseal defects 
Natural biodegradable polymers 
Collagen 
Low immune response  
Good substrate for cell adhesion  
Chemotactic 
Scaffolds with low mechanical properties 
Fibrin 
Promotes cell migration and vascularisation  
Promotes Osteoconduction 
Usually is used as a cell carrier for cell seeding on scaffolds 
Chitosan Hemostatic  Promotes osteoconduction and wound healing 
Starch 
Thermoplastic behaviour  
Good substrates for cell adhesion 
Non-cytotoxic and biocompatible 
Bone bonding behaviour when reinforced with hydroxylapatite 
Scaffolds based on these materials have good mechanical properties 
Hyaluronic acid  
Minimal immunogenicity  
Chemotactic when combined with appropriate agents 
Scaffolds with low mechanical properties 
Poly(hydroxybutyrate) 
Natural occurring hydroxyacid 
Adequate substrate for bone growth  
Utility is limited due to brittle nature 
Synthetic Biodegradable Polymers 
Poly(a-hydroxy acids) 
Extensively studied aliphatic polyesters 
Degradation by hydrolysis 
Already approved for other health related applications 
Acidic by products (e.g. lactic acid, glycolic acid), that enter the tricarboxylic acid 
cycle or in alternative (e.g. glycolic acid) are excreted in the urine  
It can present problems regarding biocompatibility and cytotoxicity in the 
surrounding area of the implantation site 
Poly(e-caprolactone) 
Aliphatic polyester 
Degraded by hydrolysis or bulk erosion  
Slow degrading 
Degradation products incorporated in the tricarboxylic acid cycle 
Low chemical versatility 
Some problems related with withstanding mechanical loads 
Poly(propylene fumarates) 
Unsaturated polyester consisting of alternating propylene glycol and fumaric acids 
Main degradation products are fumaric acid and propylene glycol 
Satisfactory biological results 
Poly(BPA iminocarbonates) Good biocompatibility when implanted in a bone canine chamber model 
Poly(phosphazenes) 
Contain alternating nitrogen and phosphorous with no carbon atoms in the 
backbone structure 
Degradation through hydrolysis 
Poly(anhydrides) 
Mainly developed as drug delivery carriers  
Biocompatible 
Support both endosteal and cortical bone regeneration 
Adapted from (Salgado et al, 2004) 
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Table 6.2: Osteogenic cells and their characteristics 
Cells 
Characteristics 
Reference 
Immunogenic Isolated 
Cell 
number 
yields 
Expansion 
rates Other 
Osteoblasts No Easily via biopsies Low Low in vitro  
(Salgado et 
al, 2004) 
Mesenchymal 
stem cells 
(MSCs); 
No 
Easily from 
connective 
tissue, bone 
marrow 
or muscle 
biopsy 
Low High in 
vitro 
High 
differentiation 
potential                                                                                                                    
which is not 
lost during 
expansion 
process 
(Heath, 
2000;Salga
do et al, 
2004)  
Bone marrow 
stromal cells No 
From bone 
marrow 
Low High in 
vitro 
Lose stem 
cell 
properties 
during in vitro 
expansion 
(Bianco et 
al., 
2001;Chen
g et al., 
1994) 
Periosteal 
cells No Enzymatically Low 
High in 
vitro  
(Nakahara 
et al., 1990) 
Genetically 
Modified cells No 
From patient 
and 
genetically 
modified  
Low High in 
vitro 
Genetically 
engineered 
with BMPs. 
Enhanced 
Osteogenic 
capacity 
relative to 
unmodified 
cells 
(Sugiyama 
et al., 
2003;Taba
ta, 2005)  
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Table 6.3: Growth factors: their functions, characteristics, and potential application 
Growth Factor (GF) Main Functions Characteristics Potential applications and where tested Reference 
Bone 
morphogenetic 
proteins 
(BMPs) 
BMP 
• Recruit 
mesenchymal 
cells to defect site 
• Modulate MSC 
differentiation into 
osteoblasts and 
chondroblasts 
• There are some 20 BMPs  
• BMP 2, 4, 6 & 7 are most 
osteoinductive                                                                                         
• Stored in bone matrix and 
released following injury                                                                                                    
Expression rates vary causing 
up or down regulation of other 
BMPs                                                                             
• Intervene in expression of other 
GFs                                                                                                                                                     
• Main signal regulating skeletal 
formation and repair 
The role of BMP's as a bone stimulating 
agent is safe, well established and an 
application in clinical practice is promising 
for the treatment of challenging clinical 
conditions. 
(De Biase P. et al., 
2005;Giannoudis et 
al, 2005a;Hing, 
2004;Salgado et al, 
2004) 
BMP-
2 
• Role in the 
expression of 
osteogenic 
markers 
• Significantly improve bone 
healing                                                                                                   
• A necessary component of 
signalling cascade for fracture 
repair 
Used in repair of skull and mandibular 
bone in rat, dog and monkey                                                                                                  
Preclinical and clinical studies have  
shown potential use in bone defects, non-
union fractures, spinal fusion, 
osteoporosis and root canal surgery. 
(Chen et al., 
2004;Hing, 
2004;Salgado et al, 
2004;Tabata, 
2005;Tsuji et al., 
2006) 
BMP-
7 
• Regulate 
osteoblast 
differentiation and 
expression  
 Potential use in non-union fractures (Giannoudis et al, 2005c;Hing, 2004)  
Transforming growth 
factor-b (TGF-b) 
• Stimulate cell 
proliferation  
• Enhance 
osteoblast activity 
• Most prevalent GF in bone                                   
• Diverse biological actions                                                                                                   
• Released during bone 
absorption                                                                                                                   
• Regulated by conversion into an 
active peptide 
Repair of skull bone in rabbit and monkey 
(Hing, 2004;Salgado 
et al, 2004;Tabata, 
2005) 
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Fibroblast growth 
factors (FGFs) 
• Bone remodelling                                                                                                                             
• Regulates balance 
between bone 
forming cells and 
bone resorbing 
cells 
• Improves vascularisation of 
engineered tissues 
Repair of mandibular (jaw) bone in dog; 
Repair of skull and long bone in rat, rabbit 
and monkey 
(Salgado et al, 
2004;Tabata, 2005) 
Insulin growth factor 
(IGF) 
• Maintain collagen 
integrity in bone                                                                                                            
• Maintenance of 
normal bone mass 
• IGF-1 and IGF-2 are produced 
by fibroblasts and osteoblasts, 
and have similar effects on bone 
metabolism                                                                                                                        
• IGF-1 more potent than IGF-2                                                                                                                            
Potential therapeutic use in treatment of 
age-associated bone conditions, such as 
osteoporosis. Studies currently performed 
in old rats. 
(Salgado et al, 
2004;Tanaka et al., 
2002;Wakisaka et 
al., 1998)  
Platelet derived growth 
factor (PDGF) 
• Role in migration 
of MSCs to defect 
site                                                                                                                  
• A local cytokine 
regulator, 
attracting 
inflammatory cells 
to fracture site 
• Produced by osteoblasts, 
platelets, monocytes / 
macrophages 
Studies in old rats for potential use as 
agent for use in age-related bone 
conditions 
(Salgado et al, 
2004;Tanaka et al, 
2002;Wakisaka et 
al, 1998) 
Interleukins (ILs) 
• Promotes 
proliferation and 
differentiation of 
osteoclasts 
• IL-1 is a powerful stimulant of 
bone resorption                                                                                                              
 
 
www.worldortho.com 
Vascular Endothelial 
growth factor (VEGF) 
• Induces 
angiogenesis 
• Commonly found in bone 
fracture sites and plate growth                                                                                                       
• Regulates vascularisation  
VEGF delivery systems to enhance 
angiogenesis and bone formation at sites 
where blood supply has been 
compromised 
(Kaigler et al., 
2006;Salgado et al, 
2004)  
Parathyroid hormone 
(PTH), commonly 
called teriparatide 
• Major hormonal 
regulator of 
calcium 
homeostasis 
• An anabolic agent, which 
reduces fracture incidence by 
improving bone qualities, 
including bone mass                                                                               
• Directly stimulates bone 
formation                                                                                                                    
Clinical use in treatment of osteoporosis 
(Girotra et al., 
2006;Hodsman et 
al., 2006)  
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6.4 Potential Indications for a RM solution 
In this section, I review the conditions where the capacity for bone to heal and regenerate has broken 
down and discuss which application has the greatest potential for a RM bone product before 
proceeding with the CEA. The bony defects reviewed are divided into three groups:  
i. Defects in the spine - degenerative disc disease (DDD) and osteoporotic fractures of the spine 
ii. Non-healing Fractures – non-union of fractures and segmental defects 
iii. Bone cysts 
 
6.4.1 Degenerative Disc Disease  
DDD (also known as intervertebral disc (IVD) degeneration) results from weakening of the 
intervertebral disc through loss of water. Triggered predominantly by genetic risk factors (Battie et al., 
2006), although environmental factors, such as heavy or repetitive loading can have an affect (Adams 
et al., 2006;la-Kokko, 2002), it is characterised by chronic low back pain. It is the leading cause of pain 
and disability for adults in the US and UK and has an incidence which increases with age. An 
epidemiological review (Battie et al, 2006) reveals extreme variations in prevalence rates, possibly due 
to inconsistencies in definitions - measurements of disc degeneration are usually qualitative and lack 
precision. Each year in England and Wales there are approximately 9,000 cases of DDD (HES Online, 
2007).  
 
Initial treatment is conservative care (non-surgical) in the form of medication (NSAIDs) or physical 
therapy. Surgery is considered if symptoms persist beyond 6 months. Spinal fusion is the current gold 
standard surgical treatment and approximately 1400 are carried out each year in the UK (the UK is 
more conservative in its use of spinal fusion compared to the USA (Brigitte Scammell, 2007)).  There 
is potential for a RM alternative to autograft in spinal fusion. However, over recent years, many other 
surgical treatments have emerged. The focus is shifting away from strengthening the bone towards 
improving mobilisation, which is increasing the number of treatments targeted towards the disc (both 
mechanical and biological) rather than stabilisation of the spine. Furthermore, recent research, 
prompted by the notion that repair and restoration of function is the ideal therapeutic approach, is 
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targeting new areas of the disc, predominantly the nucleus pulposus - the fluid filled centre portion of 
the disc. Figure 6.2 illustrates the structure of the disc, its location within the spinal cord and the 
targets of various treatments for DDD, each of which is summarised below with a full comparative 
review in appendix 11.  
 
Figure 6.2: The intervertebral disc 
 
 
 
 
 
 
 
 
 
Reprinted with permission from Spine Restoration, inc. 
 www.spinalrestoration.com/patients/index.html 
 
 
Operations to Stabilise the Spine 
a) Spinal Fusion - is the surgical fusion of the vertebrae of the spine so motion no longer occurs 
between them. Gold standard approach uses a metal plate and screws reinforced with autograft. 
Although spinal fusion is the current mainstay treatment, there is continued debate in the literature 
surrounding its appropriateness and effectiveness. Alternative treatment options are being 
examined, both surgical (disc and nucleus pulposus replacement) and non-surgical (intensive 
rehabilitation), but currently, although some preliminary results have been encouraging, no 
intervention has shown to be significantly superior to spinal fusion.  
 
Nucleus Pulposus 
Replacement / 
Regeneration 
IDET 
Anterior Spinal Fusion 
Total Disc 
Replacement 
Posterior Dynamic 
Stabilisation 
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b) Posterior Dynamic Stabilisation - (or soft stabilisation or flexible stabilisation) is an alternative to 
spinal fusion designed to control rather than eliminate motion between vertebrae (Schnake et al., 
2006;Sengupta, 2005).  
 
Operations on the Disc  
a) Intradiscal Electrothermal Therapy (IDET) - is a minimally invasive technique, involving the 
placement of an intradiscal catheter with a temperature controlled thermal resistive heating coil to 
a position at the inner posterior annulus (the outer core of the disc) (Freeman, 2006).   
 
b) Total Disc Replacement - artificial discs are used to replace painful discs in the spine, with the 
goal of preserving normal motion, unlike fusion, which eliminates motion at the painful spinal 
segment. The use of artificial discs should, in theory, prevent adjacent level degeneration (a 
complication which can be associated with spinal fusion) (Freeman et al., 2006).  
 
c) Whole Disc Transplantation - disc transplantation has the theoretical advantage over artificial disc 
replacement and disc regeneration, of providing a young, non-degenerated scaffold that could 
offer the best environment for the cells to survive or regenerate (Ruan et al., 2007).  
 
d) Nucleus Pulposus Replacement – a recent alternative to total disc replacement, designed to 
provide stable motion, increased space height, and minimise transmission of shear forces on the 
remaining annulus, facet joints and stabilising structures (Goins et al., 2005). Nucleus pulposus 
replacement exchanges just the inner part of the disc for prosthesis, leaving the remainder intact, 
with the aim of restoring biomechanical function. 
 
e) Nucleus Pulposus Regeneration – this form of disc regeneration uses gene therapy to repair 
damaged tissue and re-populate the Nucleus pulposus with cells, this has the potential to make 
the greatest clinical impact (Ruan et al, 2007;Zigler et al., 2003).  The next step is to move this 
technology forwards from the lab into clinical trials. 
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6.4.2 Osteoporotic Fractures of the Spine 
Osteoporotic vertebral compression fractures affect over 700,000 people in the US each year; this is 
twice the number of hip fractures (Lieberman et al., 2005). These fractures (figure 6.3) result in spinal 
pain, loss of height, spinal instability, and, in many cases, kyphotic deformity (curvature of the back), 
which can further lead to depression, decreased appetite, decreased pulmonary function and impaired 
mobility (Hulme et al., 2006). The most significant risk factor is osteoporosis, which affects an 
estimated 3 million post-menopausal women in the UK (NICE, 2005a). Spinal fractures is reported to 
affect 1 in 4 of all post-menopausal women  (Kim et al., 2006a).  
 
Figure 6.3: Spinal compression fracture  
 
Image courtesy of Medical Multimedia Group LLC, www.eOrthopod.com  
Source: http://www.eorthopod.com/public/patient_education/6547/spinal_compression_fractures.html 
 
 
Primary treatment is targeted at increasing bone density for which there is a variety of treatments 
(documented elsewhere (NICE, 2005a)). There are two main surgical treatment options for vertebral 
compression fractures: vertebroplasty and kyphoplasty (Kim et al, 2006a) (for more information see 
videos at http://www.spine-health.com/video/kyphoplasty-osteoporosis-fracture-treatment and 
http://www.spine-health.com/video/vertebroplasty-interactive-video). Both are technically similar 
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minimally invasive treatments designed to target pain relief through fracture stabilisation, but the latter 
has the addition of using an inflatable balloon in order to restore height to the vertebrae before 
insertion of the filler material (Hulme et al, 2006). Rates of pain relief and functional improvement have 
been reported as equivalent  at between 78% and 90% in short-term follow-up (Kim et al, 2006a).  
 
The potential for RM is as an injectable biological filler material. Bone cements (particularly 
polymethylmethacrylate (PMMA)) and ceramics (particularly calcium sulphate) are currently the most 
frequently used filler materials but each has a long list of disadvantages (Lieberman et al, 2005). The 
most severe is bone cement leakage – a common complication occurring in both kyphoplasty and 
vertebroplasty – which produces heat as it hardens it can result in burnt nerves (Kim et al, 2006a). An 
ideal filler material would be biocompatible, have good biomechanical strength and stiffness, and have 
radiopacity for the fluoroscopy guided procedures (Lieberman et al, 2005). Vertebroplasty requires a 
material with a long liquid phase and working time, combined with a very short set time, whereas 
kyphoplasty requires a material with a short liquid phase and a longer partially cured “doughy” phase 
(Lieberman et al, 2005). The School of Mechanical engineering in Atlanta, US, is investigating the use 
of gene therapy to stimulate the surrounding cells to make bone. The hope is that this gene could lead 
to an increase in bone density, preventing or delaying the onset of osteoporosis and thus decreasing 
the incidence of ventral compression fractures (Sanders et al., 2001).  
 
6.4.3 Non-Healing Fracture Repair 
Here, I use the term non-healing fractures to refer to fracture nonunions and large segmental defects. 
A fracture nonunion is a fracture that has failed to achieve bony healing at a fracture site within six 
months. This can lead to significant pain and inhibition of function (Garrison et al, 2007). There are 
around 300,000 fractures per year in England and Wales (HES Online, 2007) and nonunions occur in 
4% to 10% (Garrison et al, 2007). They can be either hypertrophic (caused by insufficient fracture 
stability) or atrophic (the result of insufficient blood supply or insufficient bone forming cells) - the 
proportion of each depends on the site of fracture. The first can be treated using stable internal fixation 
to improve the mechanical environment (Panagiotis, 2005). The latter is more difficult to treat; 
requiring stabilisation of the fracture and support of the biologic environment. The current best 
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treatment for atrophic nonunions is stable fixation with autograft (Ring et al., 1997). Segmental defects 
result from bone loss due to trauma, necrosis, or tumour resection. They are much larger defects than 
those seen in fracture nonunion; for example, they can affect the full length of the shaft of a long bone. 
There is greater damage to the soft tissues surrounding segmental defects, which reduces the 
chances of a blood supply forming (a necessary part of healing), which in turn reduces the chance of a 
biological response to healing. As a result, segmental defects can never heal without intervention. As 
with atrophic nonunion, the principles of conventional treatment of segmental defects involves metal 
fixation to stabilise mechanical environment and support to biological environment, currently using 
autograft (figure 6.4).  
 
There are a number of other non-RM approaches to segmental defect repair:  
i. Insertion of a cortical bone graft, which incorporates into the distracted bone ends but 
does not become viable throughout its length; 
ii. Filling the defect with autologous bone granules; 
iii. The Ilizarov procedure of external fixation for limb lengthening which allows bone to grow 
and bridge the gap; 
iv. Use of a fibula free vascularised graft, especially in large defects 
 
There are severe and common drawbacks to all treatments and in extreme cases if the above fail 
amputation may be necessary (DeCoster et al., 2004). Table 6.4 summarises the benefits and 
drawbacks along with the proposed management of segmental defects based on defect size. 
 
The potential for RM in this area is as a functional support to the biological environment in atrophic 
nonunion and segmental defects as a direct replacement for autologous bone graft. The ideal material 
to bridge a defect would be one that is easily cut into shape and able to maintain its shape (Kon, 
2007). 
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Figure 6.4: Conventional treatment of segmental defects  
  
 
 
Conventional treatment uses stable fixation (metal plate, nail or blot) and a material to bridge the 
defect. This diagram illustrates the conventional treatment in weight-bearing bone segmental defects 
from a canine femur (A), a sheep tibia (B) and a rabbit tibia (C). Kindly provided by Yuehuei An, MD. 
Source: http://www.musc.edu/orthores/Labs%20and%20Models%20htmls/jpg.BoneDefect.html 
 
Table 6.4: Summary of treatments for Segmental Defects  
Treatment Major Benefits Major Drawbacks Length of Defect (cm) Cost 
Amputation Shortest treatment time Total loss of limb function 10-30 £110,000 
Limb 
shortening 
Short treatment time; 
fewest complications 
Some loss of limb 
function 0.1-1  
Autologous 
non-
vascularised 
cancellous 
bone graft 
Generally applicable; 
reasonable results 
Slow, unreliable 
consolidation; donor 
site; morbidity; less 
applicable to large 
defects 
0.5-3 £68,500 
Bone transport 
distraction 
osteogenesis 
Ultimately, the best quality 
of bone; applicable to large 
defects 
Frequent complications; 
long time to heal 2-10 
£36,000 - 
£51,000 
Free 
vascularised 
graft 
Acute fill of defect with 
living bone; micro-vascular 
capability; applicable to 
large defects 
Donor site morbidity; 
fracture; lack of 
hypertrophy 
5-12 £41,500 
Local fibula 
Acute spanning of defect; 
donor morbidity limited; no 
special equipment required 
Not always possible; 
not very strong; poor 
muscle function 
  
Adapted from DeCoster et al, 2004 
A B C 
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6.4.4 Bone Cysts 
A bone cyst is a benign serum filled cavity in the bone, which causes weakening, increasing the 
likelihood of fracture. The aetiology is poorly understood but the primary cause is reported as 
obstruction of venous drainage and an increase in internal pressure (Chigira et al., 1983). There are 
two main types of cysts: the simple bone cyst and the aneurysmal bone cyst. The unicameral (or 
solitary cyst) is the classical form of simple cyst, mostly affecting long tubular bones in boys, although 
have also been reported in flat bones of the pelvis, jaw, rib cage, or skull. There are three less 
common varieties of simple cysts: non-tubular bone cysts – accounting for 4-10%; multiple cysts - an 
underestimated category; epiphyseal cysts - accounting for around 2% (Abdel-Wanis et al., 2002). The 
aneurysmal bone cyst is a blood-filled cyst caused by specific pathological change, a result of trauma. 
It is less common than the simple bone cyst and 75% occur in 10-20 year olds, primarily women. More 
than half occur in long bones, 12-30% occur in the spine and half of all flat bone cysts occur in the 
pelvis (Kransdorf et al., 1995). Pain and swelling result although symptoms are reported to last less 
than six months (Kransdorf et al, 1995). In a third of all cases the aneurysmal cyst occurs as a 
secondary defect in a pre-existing lesion, most frequently a giant cell tumour (Schreuder et al., 1997).  
 
Conventional treatment is directed at surgical removal; the most common approach is curettage with 
bone grafting (cyst removal and cavity filled with autograft). Simple cysts usually heal without 
intervention. In contrast, aneurysmal cysts are associated with a high recurrence rate (149 in 484 
cases) (Schreuder et al, 1997), with 90% recurring in two years (Kransdorf et al, 1995;Schreuder et al, 
1997). The risk of recurrence is eliminated by wide resection, but this leads to greater bone loss and 
the need for greater reconstruction (Schreuder et al, 1997). There are variations on the standard 
techniques and debate about which is best, but each is associated with disadvantages and occasional 
serious complications.  
 
The potential for RM is as a biological filler material, an alternative to autograft or allograft. The 
biomaterial should be biocompatible, have good mechanical stability, be easy to handle, lack of 
radiopacity, and non-antigenic (Pradel et al., 2006).  
175 
6.4.5 Conclusion 
The information suggests RM could have an application in a variety of defects. However, I feel the 
greatest market potential is in moderate to large defects such as DDD and non-healing fracture repair 
(nonunion and segmental defects). However, there may also be a relatively large market an improved 
filler material for use in small to moderate defects such as those following spinal fractures and bone 
cyst removal. 
 
The literature suggests it seems seldom necessary to provide immediate mechanical strength with 
rigid bone structures. Instead, it appears quite adequate to induce the body to form bone across the 
area to be bridged, and mechanical strength can come later once new bone is laid down. This means 
that many traditional TE applications consisting of a firm body platform populated by cells and/or 
growth factors is unnecessary.  
 
In conclusion, I discern three broad alternatives for the management of a moderate size bone defect.  
1. Autograft using bone graft harvested from the iliac crest (the current gold standard approach) 
2. In vivo bone production (via implantation of growth factors and/or uncultured cells on some 
form of matrix/scaffold) 
3. In vitro bone production using cells grown on a scaffold (with or without growth factors) 
 
A RM solution provides an alternative to autograft and avoids the time, pain, and complications 
associated with harvesting bone. In-vivo production uses the body as a factory and avoids the 
logistical difficulties and cost of culturing the patient’s cells in-vitro. Currently growth factors are 
preferred; they have the advantage over cells of being able to be used immediately. However, this 
method can use different types of scaffold with different costs and benefits.  
 
In the following sections, I aim to summarise the incremental costs and benefits of autograft versus the 
alternatives and establish the likely cost at which in vivo and in vitro methods could be deemed cost-
effective within the UK NHS. I will illustrate the economic analysis by taking spinal fusion and nonunion 
of fractures as examples of conditions that could use each of the methods discussed above.  
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6.5 Clinical Effectiveness 
6.5.1 Union Rates  
Spinal Fusion 
The Garrison review (Garrison et al, 2007) identified eleven RCTs (Assiri et al., 2004;Boden et al., 
2000;Boden et al., 2002;Burkus et al., 2002;Burkus et al., 2005;Dimar et al., 2006;Haid, Jr. et al., 
2004;Johnsson et al., 2002;Kanayama et al., 2006;Shapiro et al., 2005;Vaccaro et al., 2004) 
comparing spinal fusion using autograft with spinal fusion using BMP (N=631). The authors 
determined the quality of the included studies as low to moderate. Overall, the meta-analysis showed 
that BMP improves fusion rates compared to autograft in spinal fusion surgery (85% in BMP group 
versus 73% in autograft group (OR=2.27, 95%CI: 1.55 to 3.32)) (table 6.5).   
 
The literature does not report on the success rate for in vitro bone production, as there have not yet 
been any trials of this method. However, in vitro bone production is almost certain to be more 
expensive than an in vivo method using BMPs. In vitro methods are therefore dominated unless they 
are more effective than in vivo methods. Success rates for in vivo methods have been reported as 
85% (above). The headroom for in vitro methods is therefore 12%.  
 
Table 6.5: Fusion success rates of BMP versus autograft in DDD  
 
Adapted from Garrison et al.2007 
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Non-Healing Fracture Repair 
The Garrison review (Garrison et al, 2007) identified seven RCTs (Chen et al., 2000;Cook, 
1999;Friedlaender et al., 2001;Govender et al., 2002;Jones et al., 2006;Maniscalco et al., 2002;Perry 
et al., 1997) comparing autograft with BMP for fracture healing. Again, the authors concluded that the 
quality of the included studies was low to moderate. The meta-analysis showed that rate of successful 
union favoured BMP (68% in BMP group versus 63% in autograft group, OR=1.21, 95%CI: 0.83 to 
1.75) (table 6.6). It should be noted, the trial of nonunion with the second largest sample size 
(Friedlaender et al, 2001) reported differences in baseline characteristics between the autograft and 
BMP group. Of most importance was the significantly higher number of atrophic nonunions in the BMP 
group (41% versus 25%, P = 0.048). Atrophic non-unions are more difficult to heal because they lack 
a blood supply, which is one of the main components necessary for fracture healing.  
 
Once again, the literature does not report on the success rate for in vitro bone production. As 
previously stated, in vitro bone production is almost certain to be more expensive than an in vivo 
method using BMP. In vitro methods are therefore dominated unless they are more effective than in 
vivo methods. Success rates for in vivo methods for non-healing fracture repair are reported as 68%. 
The headroom for in vitro methods is 32%.  
 
Table 6.6: Fracture repair rates of BMP compared to autograft  
Adapted from Garrison et al. 2007.  
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6.5.2 Operative Results 
BMP impacts on the global costs of surgery by avoiding bone harvesting. The meta-analysis in the 
Garrison review finds that using BMP in spinal fusion reduces operation time by 25 minutes (range: 11 
to 37 minutes) and hospital stay by 0.75 days (table 6.8). However, I note the meta-analysis of 
reduction in hospital stay omits the largest trial (Burkus et al, 2002). Therefore, I re-perform the meta-
analysis (table 6.7) to include this missing trial and found a reduction in hospital stay of 0.41 days 
(table 6.8). The data for fracture healing is limited. Two studies (Friedlaender et al, 2001;Jones et al, 
2006) report an average reduction in operation time of 14 minutes and two studies (Friedlaender et al, 
2001;Maniscalco et al, 2002) report an average reduction in hospital stay of 0.35 days (table 6.8). 
 
Table 6.7: Mean hospital stay for patients receiving BMP and autograft 
 
Adapted from Garrison et al, 2007. 
 
6.5.3 Other Clinical Outcomes 
The Garrison review finds that secondary interventions in fracture healing are reduced by 2% in favour 
of the BMP group (34% for BMP group versus 36% for autograft group, OR=1.43, 95% CI: 1.03, 2.00). 
The Garrison review also reports findings of two studies (Friedlaender et al, 2001;Govender et al, 
2002) with respect to reduction in infection rates associated with using BMP in fracture healing. The 
average reduction in infection is calculated as 19%. These results, along with those reported above 
are summarised in table 6.8. 
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Table 6.8: Overall effectiveness of BMP compared to autograft 
Outcomes Spinal Fusion Non-Healing Fracture Repair 
Increase in union rates 9% 5% 
Reduction in operation time  25 minutes 14 minutes 
Reduction in hospital stay 0.41 days 0.35 days 
Reduction in secondary interventions NA 2% 
Reduction in infection rates NA 19% 
 
6.5.4 Disutility of Autograft 
Donor Site Morbidity 
Donor site morbidity has been investigated in 6 retrospective and 2 prospective observational studies 
(Ahlmann et al., 2002;Arrington et al., 1996;Goulet et al., 1997;Robertson et al., 2001;Sawin et al., 
1998;Schnee et al., 1997;Skaggs et al., 2000;Younger et al., 1989) and 3 RCTs (Banwart et al., 
1995;Sasso et al., 2005;Singh et al., 2005). Reported complications include haematoma formation, 
infection, hyperaesthesia, hypoaesthesia, blood loss, arterial injury, hernia formation, urethral injury, 
fracture, pelvic instability, cosmetic defects, tumour transplantation, and most frequently chronic pain 
at the donor site. Younger and Chapman (1989) were one of the first to conclude that morbidity 
associated with harvesting bone was low but significant and the first to establish definitions for major 
and minor complications occurring at early and late stages (table 6.9). The reported frequency of 
major complications is from 2% (Goulet et al, 1997) to 6% (Ahlmann et al, 2002), and for minor 
complications is from 9% (Ahlmann et al, 2002) to 39% (Banwart et al, 1995). The high rate of minor 
complications is primarily due to chronic pain which is still present in some 30% of patients at 2 years 
(although pain intensity is low) (Banwart et al, 1995;Robertson et al, 2001;Sasso et al, 2005;Sawin et 
al, 1998;Singh et al, 2005;Skaggs et al, 2000). 
 
The literature suggests using two separate incisions for harvest and surgery is preferable to using one 
incision (major complication rate 17.9% verses 5.1% and minor complication rate 23.9% verses 19.3% 
(p=0.002)) (Younger et al, 1989). In addition, a posterior approach is preferable to an anterior 
approach (major complication rate 5.7% versus 20.4% and minor complication rate 12.6% versus 
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27.8% (p=0.008) (Younger et al, 1989)) (major complication rate 0% versus 2% and minor 
complication rate 8% versus 15% (no p value given) (Ahlmann et al, 2002)).  
 
Table 6.9: Definition of complications  
 
Early Complications Late Complications 
Major 
Complications 
Deep Infection; Prolonged wound 
drainage; Large Haematoma; 
Reoperation 
Sensory Loss; Chronic severe pain; 
Chronic infection; Unsightly scar; Large 
bony defect 
Minor 
Complications 
Haematoma; Wound drainage; Severe 
pain; Temporary sensory loss 
Chronic mild pain; Superficial infection; 
Delayed Wound healing; Minor wound 
problems 
Adapted from Younger et al. 1989 
 
Consultation with orthopaedic surgeons contradicted some of the literature. It is suggested the 
literature may be out if date in terms of surgical procedures and hence may overestimate morbidity. It 
was claimed the use of minimally invasive techniques is resulting in decreases in the frequency, 
intensity, and duration of donor site morbidity. The surgeons consulted suggested there is no 
significant difference between anterior and posterior approach and between using one or two incisions 
for harvesting and surgery, if the surgical technique is minimally invasive. I observed harvesting of 
bone from the iliac crest using a technique, which leaves the soft bone attached to the muscle. Bone is 
then removed from inside the crest and the hole covered using the flap of soft bone attached to the 
muscle. This is not by all accounts a standard procedure. However, those that have adopted this 
technique claim to have seen decreases in donor site morbidity, believed to be the result of increased 
bone healing at the harvest site and less interruption to the surrounding muscle area. However, this 
technique has not been subjected to a trial and I found no competitive studies of any type.  
 
Health-related quality of life and Utility  
As discussed, a major limitation of the current treatment is the need to harvest bone and the 
associated donor site morbidity. BMP could affect the HRQL of the patient in the short term by 
avoiding donor site morbidity and in the longer term by increased fusion rates. For spinal fusion, 
improvements in Oswestry low back pain scores in favour of the BMP group were observed in 6 of the 
7 trials identified in the Garrison review (improvement ranged from 24.5 to 33.4 for BMP group and 
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from 15 to 29.5 for autograft group (no p values)). General health status was measured using the SF-
36 questionnaire in 6 of the 7 trials identified in the Garrison review. Higher mean score improvements 
for the BMP group compare to the autograft group were seen in all but one study (Dimar et al, 2006).  
 
For economic analysis, I need a utility-based HRQL score. Garrison and colleagues concluded that 
there was limited data on utility score. I corroborate this finding and report their results. The Garrison 
review calculated utility scores for spinal fusion using the Brazier Index from SF-36 scores reported in 
an RCT by Burkus and colleagues (Burkus et al., 2003). The results are summarised in table 6.10. A 
24-month utility difference of 0.0056 in favour of those patients who received BMP is reported.  
 
As all other aspects of the spinal fusion operation are constant apart from the harvesting of bone, I 
assume the difference in utility represents the disutility of donor site morbidity. This may overestimate 
this effect; however, a pessimistic view of the current treatment is consistent with the headroom 
approach. The information gleamed from the literature and discussions with surgeons suggest the 
maximum duration of donor site morbidity is 12 months. I calculate the disutility of donor site morbidity 
from table 6.10. A patient experiences a disutility of 0.0087 for 3 months, 0.003 for a further 3 months 
and 0.0018 for 6 months. This results in an overall disutility of 0.0038 
[(0.0087*0.25)+(0.003*0.25)+(0.0018*0.5)]. This value will be used later in the headroom analysis. 
 
I have not used the utility difference stated at 24 months, as it is inconceivable that the disutility would 
then increase between months 12 and 24. Instead, I believe this difference is due to the long-term 
effectiveness of BMP over autograft. 
 
Table 6.10: Utility scores associated with using autograft and BMP in spinal fusion  
Period Preoperative 3 months 6 months 12 months 24 months 
BMP 0.5387 0.5948 0.6191 0.6332 0.6537 
Control 0.5417 0.5861 0.6161 0.6314 0.6481 
Difference  
(BMP – Control) -0.003 0.0087 0.0030 0.0018 0.0056 
Adapted from Garrison et al, 2007  
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The Garrison review estimated a QALY gain of 0.032 per nonunion repair, in favour of BMP, 
calculated from additional well patient weeks (derived from the RCT by Govender et al. 2002), and 
disutility values extrapolated from estimates of hip and general fractures.  
 
A search of the database of utility weights held by TUFTS (Tufts Medical Centre, 2009) identified a 
study (Sprague et al., 2002) which reports the utility (based on expert opinion) of a nonunion fracture 
requiring reoperation as 0.5.  This value will be used later in the headroom analysis. 
 
6.6 Costs of Treatment 
I review the costs associated with BMP, including health service costs. Costs of treatment were 
ascertained, where available, from published papers (primarily the Garrison review) supplemented by 
the 2006 NHS national schedule of reference costs (Department of Health, 2006b) and the 2006/07 
national tariff  (Department of Health, 2006a). Some of the unit costs for spinal fusion I calculate differ 
from those in the Garrison review. These differences were due to a) errors, which have been 
subsequently rectified following personal communication (as for cost per bed day); b) differences in 
raw data used in calculations (as for cost per hour operating time); and c) more recent department of 
health reference costs (revisional procedures). As an addition to the Garrison review, I calculated the 
cost per hour of operating time and the cost per bed day associated with fracture repair. However, the 
necessary data to calculate these values was limited. The cost of the in vivo method of bone 
production for spinal fusion is dependent on the additional cost of BMP. The cost of BMP was given as 
£1,790 ($2,900, €2,000) and was obtained from Wyeth Pharmaceuticals. The tissue engineers I 
consulted agreed that the cost provided in the HTA review remains accurate and therefore I have not 
updated this cost. A summary of the unit costs associated with spinal fusion and nonunion repair are 
provided in table 6.11 and table 6.12, respectively. The updated unit costs are used in all subsequent 
analysis. 
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Table 6.11: Unit costs associated with spinal fusion  
Parameters Garrison Review Source 
Updated 
Unit 
Costs 
Source 
Initial 
treatment 
cost  
 £  5,283  National schedule of Reference 
costs: HRG R03, 2005  £  5,308  
National schedule of Reference 
costs: HRG R03, 2006  
BMP  £  1,790  Wyeth Pharmaceuticals  £  1,790  Wyeth Pharmaceuticals 
Revisional 
Procedures  £  4,452  
National Schedule of 
Reference costs: HRG R09, 
2005 
 £  4,430  National Schedule of Reference 
costs: HRG R09, 2006 
Cost per 
hour 
operating 
time 
 £  1,034  
Based on total cost of 
£2863.07 and average duration 
of 182 minutes (both extracted 
from (Rivero-Arias et al. 2005 )) 
 £  1,966  
Based on total operation cost 
above and mean operation time of 
162 minutes (extracted from meta-
analysis in (Garrison et al. 2007)) 
Cost per bed 
day  £     264  
National tariff: R03, 2006/07 
(long-stay payment for days 
exceeding trimpoint)  
 £     242  
National tariff: R03, 2006/07 (long-
stay payment for days exceeding 
trimpoint) 
 
Cost per bed day in Garrison review was incorrectly given as HRG R02 instead of HRG code R03. I used data 
from 2006 rather than the more recent 2007 as the HRG coding system has changed and I would 
have been unable to make comparisons with the 2005 results given in the HTA report.  
 
 
Table 6.12: Unit costs associated with fracture repair  
Parameters Garrison Review  Source 
Updated 
Unit 
Costs 
Source 
Initial 
treatment 
cost  
 £3,521 National schedule of reference 
costs: HRG H35, 2005  £  3,521  
National schedule of reference 
costs: HRG H35, 2005 
BMP  £1,790  Wyeth Pharmaceuticals  £  1,790  Wyeth Pharmaceuticals 
Infections  £1,952 National schedule of reference 
costs: HRG S20, 2003  £  1,952  
National schedule of reference 
costs: HRG S20, 2003 
secondary 
interventions  £2,738  
National tariff: H16 and H17, 
2006 (admitted patient care, 
non elective) 
 £  2,738  
National tariff: H16 and H17, 2006 
(admitted patient care, non 
elective) 
Cost per hour 
operating 
time  
 NR  NA  £  1,017  
Based on total treatment cost 
above and total operation time of 
178 minutes (Friedlaender et al. 
2001) 
Cost per bed 
day  NR  NA  £     194  
National tariff: H35, 2006/07 (long-
stay payment for days exceeding 
trimpoint) 
 
Cost per infection not updated as the code is no longer available. NR=Not reported, NA= Not applicable. 
 
 
184 
6.7 Cost-effectiveness 
6.7.1 Review of Previous Cost-Effectiveness Analysis  
Three previous cost-effectiveness analyses (Dahabreh et al., 2006;Garrison et al, 2007;Polly, Jr. et al., 
2003) of BMP versus autograft exist. Dahabreh and colleagues conducted a prospective cost analysis 
study (n=29) of BMP in nonunion fractures. BMP was applied to the nonunion site either alone or in 
addition to autograft. The authors found a 47% reduction in the average cost of treatment compared to 
all previous unsuccessful treatments of a nonunion (p<0.05) and concluded that the use of BMP would 
probably be of benefit in the treatment of fracture nonunions where the conventional treatment is 
expected to be difficult, lengthy, and possibly unsuccessful. Polly and colleagues assessed the cost-
effectiveness of BMP in spinal fusion and suggested that the initial cost of BMP would be offset by 
avoiding bone harvesting (and related complications) and improving successful fusion. However, the 
input estimates were based on expert opinion rather than empirical evidence and will not be 
considered here. 
 
Here I will discuss the findings of the Garrison economic analysis of BMP for spinal fusion and for 
fracture healing. The economic models were provided by ABACUS International (healthcare 
consultancy). The spinal fusion economic model was populated with effectiveness data from an RCT 
by Burkus and colleagues (Burkus et al, 2002) and the unit costs reported above. The fracture repair 
model was populated with effectiveness data from an RCT by Govender and colleagues (Govender et 
al, 2002) and the unit costs reported above. Garrison and colleagues reported their results on a per 
100,000 basis; here I present these findings as cost per treatment. 
 
BMP increases initial treatment costs by £1,790 ($2,900, €2,000) per surgery (the cost of BMP itself). 
After taking account of savings associated with reduced operating time, hospital stay, and secondary 
interventions, BMP increases initial treatment costs of spinal fusion by £1,242 ($2,000, €1,400) and is 
associated with a 0.011 QALY gain per spinal fusion. The estimated incremental cost per QALY gain 
was £120,390 ($197,000, €138,000) and the probability that BMP is cost-effective in the UK is only 
6.4% (table 6.13). Garrison and colleagues conclude that using BMP in spinal fusion is unlikely to be 
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cost-effective. After taking account of savings associated with reduced infections, secondary 
interventions, and outpatient contacts BMP increases initial treatment cost of fracture repair by £1,055 
($1,700, €1,200) and is associated with a 0.032 QALY gain per fracture repair. The estimated 
incremental cost per QALY gain was £32,603 (95% CI £14,085 to £61,257) ($53,400, €37,400) and 
the probability that BMP is cost-effective in the UK is 35.5% (table 6.13).  
 
Table 6.13: Results from previous cost-effectiveness analysis  
Main Results Spinal Fusion Non-Healing Fractures 
Initial cost impact per treatment £1,790 £1,790 
Costs offset by avoiding bone harvesting £496 £736 
Net cost per treatment £1,294 £1,054 
Additional QALY per treatment 0.011 0.032 
Incremental cost per QALY gained £120,390 £32,603 
Probability of BMP being cost effective at £30,000 6.4% 35.5% 
The results here are given on a per treatment basis based on the results given in the Garrison review. 
Results are presented to the nearest pound.  
 
6.7.2 Mean Incremental Cost per Case 
Here I calculate the mean incremental cost per case associated with using BMP compared to 
autograft. Using the effectiveness data (table 6.8, page 179) and the updated unit costs (table 6.11 
and 6.12, page 183) reported above I calculate the potential cost savings associated with BMP and 
offset this against the cost of BMP (table 6.14). The cost savings consist of:  
i. Cost savings contingent on improvement in success rates – this is estimated by using the 
unit costs associated with resurgery (secondary interventions) multiplied by the probability of 
having a resurgery (based on union success rates). 
ii. The costs associated with avoiding donor site morbidity – this is linked with two savings. 
Firstly, the reduction in operation time, calculated using the cost per hour of operation calculated 
in section 6.8, and secondly, the reduction in hospital stay, calculated using the cost per bed day. 
iii. Reduction in infections – applies to fracture repair only and is estimated by using the unit 
costs associated with infections multiplied by the reduction in infections associated with BMP 
reported in the Garrison report.  
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Table 6.14: The incremental cost per case associated with the use of BMP  
 
Spinal Fusion Nonunion repair 
BMP Autograft BMP Autograft 
Cost saving associated with reduction in 
reoperations (A) £532  £137  
Cost of reoperation £4,430 £4,430 £2,738 £2,738 
Probability of reoperation 0.15 0.27 0.32 0.37 
Total cost of Reoperations £5,095 £5,626 £876 £1,013 
Cost Saving associated with reduction in 
operation time (B) £819  £283  
Cost per hour of operation £1,966 £1,966 £1,214 £1,214 
Reduction in operation (minutes) 25  14  
Cost savings associated with reduction in 
hospital bed days (C) £99  £68  
Cost per bed day £242 £242 £194 £194 
Reduction in length of stay (days) 0.41  0.35  
Cost saving associated with reduction in 
infections (D) NA NA £371  
Cost of treating infection   £1,952 £1,952 
Probability of an infection   0.19  
Total Cost Saving (A+B+C+D) £1,450  £859  
Cost of BMP (E) £1,790  £1,790  
Overall Cost Difference (E-A+B+C+D) £340  £931  
 
 
In conclusion, although BMP does appear to be slightly more effective than autograft, the current 
increase in effectiveness is insufficient to offset the additional cost of BMP, resulting in an incremental 
cost of approximately £340 ($560, €400) per spinal fusion and £930 ($1,500 €1,000)  per fracture 
repair. There is a lower incremental cost per case associated with spinal fusion compared to non-
healing fracture repair. This result may be surprising considering the findings from the previous cost-
analysis. There are a number of possible explanations for this. Firstly, the unit costs used in this 
analysis differ from those used in the Garrison report (table 6.11 and 6.12, page 183). Secondly, the 
economic models in the Garrison report used clinical outcome data from one RCT only (Govender et 
al, 2002). Finally, here, the clinical data is taken from all trials but is heavily based on a trial 
(Friedlaender et al, 2001) where the baseline characteristics of the two treatments differ. Furthermore, 
this analysis accounts for just one aspect of the CEA, the cost savings associated with surgery costs 
and avoiding bone harvest. To demonstrate cost-effectiveness a product must also increase 
effectiveness and patient HRQL (if new treatment is more expensive than current treatment). 
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6.7.3 Supply-Side Analysis on Price of BMP 
Here, I recreate and use the economic model from the Garrison review. I keep the QALY gains the 
same as stated in the Garrison review but I use the updated unit costs (table 6.11 and 6.12, page 
183). I calculate the price at which BMP may be cost-effective in the UK. Using equation 6.4 I vary the 
cost of BMP until the ICER falls below the WTP thresholds of £30,000 ($49,000, €34,000) and 
£20,000 ($33,000, €23,000). 
Equation 6.4: ICER =∆cost/∆QALY 
 
For spinal fusion, the cost at which BMP would be cost-effective, at a threshold of £30,000, is £1,370 
($2,200, €1,500) (a 28% reduction in current price) and, at a threshold of £20,000, is £1,260 ($2,000, 
€1,400) (a 30% reduction in current price). For fracture repair the cost at which BMP would be cost-
effective, at a threshold of £30,000, is £1,660 ($2,700, €2,000) (a 7% reduction in current price) and, 
at a threshold of £20,000, is £1,340 ($2,200, €1,500) (a 35% reduction in current price), after savings 
associated with infections and avoiding outpatient contact are taken into account. This analysis 
demonstrates that BMP is very nearly cost-effective, particularly for non-healing fracture repair, and a 
slight decrease in the price of BMP could make this product reimbursable in the UK NHS. The results 
are shown in table 6.15 and figure 6.5.  
 
Table 6.15: Supply side analysis of BMP 
Parameter Spinal Fusion 
Non-healing Fracture 
Repair 
Initial cost impact per treatment £1,790 £1,790 
Costs offset by avoiding bone harvesting £736 £639 
Net cost per treatment £1,054 £1,151 
Cost of BMP to achieve cost-effectiveness at £30,000 
threshold £1,370 £1,660 
Price reduction compared to current cost of BMP 23% 7% 
Cost of BMP to achieve cost-effectiveness at £20,000 
threshold £1,260 £1,340 
Price reduction compared to current cost of BMP 30% 25% 
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Figure 6.5: The cost at which BMP could be cost-effective at different thresholds of willingness-to-pay for healthcare interventions 
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This figure illustrates graphically the maximum cost for BMP to be determined cost-effective at different WTP thresholds 
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6.7.4 Cost-Minimisation Analysis  
Current data suggests that BMP is slightly more effective than standard treatment. However, the effect 
to which these results translate into improved long term outcomes is very uncertain. What is certain is 
that operation time is reduced by use of BMP due to time saved by avoiding bone harvest. The 
difference in operating time between BMP and autograft was 0.41 hours (25 minutes), which results in 
a cost saving of £891 ($1,500, €1,000) (table 6.14, page 186). Since this is the case, I have performed 
a CMA on autograft versus BMP and have assumed that the effectiveness of the two treatments is the 
same, the only difference being operating time. I use the economic model used in the Garrison review. 
Firstly, I recalculate the incremental cost of BMP (∆cost). Secondly, using equation 6.5 (where WTP 
threshold is £30,000), I calculate the price at which BMP would be cost-effective by varying the price 
of BMP until the ∆QALY is equal to zero. 
Equation 6.5: ∆QALY =∆cost/WTP threshold 
 
For spinal fusion, the cost at which BMP would be cost-effective, if there was no difference in benefit, 
is £806 ($1,300, €900) (a 55% reduction in current price). For fracture repair the cost at which BMP 
would be cost-effective, if there was no difference in benefit, is £417 ($680, €500) (a 77% reduction in 
current price). This analysis demonstrates that a reduction in operation time is not sufficient to offset 
the incremental cost of using BMP and confirms that BMP needs to improve success rates and clinical 
outcomes including health-related quality of life, before it can be deemed cost-effective. 
 
Table 6.16: Cost Minimisation Analysis of BMP  
Parameter Spinal Fusion  Non-healing Fracture Repair 
Initial cost impact per treatment £1,790 £1,790 
Costs offset by avoiding bone harvesting £806 £417 
Net cost per treatment £984 £1,374 
Cost of BMP in order to achieve cost-effectiveness £806 £417 
Reduction compared to current cost of BMP 55% 77% 
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6.7.5 Headroom Analysis 
Finally, I calculate the headroom - the maximum incremental cost of the new treatment over the 
comparator, which could still be deemed cost effective – for a new RM technology, either in vitro or in 
vivo, compared to the gold standard, autograft. This will determine whether it is worthwhile investing in 
the potentially more expensive in vitro technology. 
 
As previously discussed, before calculating the headroom I must estimate the maximum potential 
change in effectiveness, measured using QALYs. For spinal fusion, I calculate the disutility associated 
with donor site morbidity as 0.003825 from table 6.10 (section 6.5.4, page 179). I assume the effects 
of avoiding donor site morbidity last a maximum of 12 months. Using equation 6.6, I determine a 
maximum change in effectiveness of 0.0038 QALY (equation 6.6).  
Equation 6.6: ∆ QALY = 1 x 0.0038 = 0.0038 
 
Next, I calculate the headroom (max∆Cost). Based on a reimbursement level of £30,000 ($49,000, 
€34,000), the headroom is calculated as £114 ($180, €130) (equation 6.7). Finally, I take account of 
cost savings associated with reduced operating time from avoiding bone harvest (£819). This gives 
total headroom of £933 ($1,500, €1,000). If a new bone RM technology for spinal fusion is going to be 
deemed cost-effective, it needs to be marketed at a price that would keep the max∆Cost below £933 
($1,500, €1,000). 
Equation 6.7: max∆Cost = 0.0038 x £30,000 = £114 
 
For non-healing fractures, I will use the utility value identified through the TUFTs database, reported in 
section 6.5.4 (page 179). Here, I assume an optimistic maximum duration of this health state of nine 
months. Based on the classification of a nonunion fracture as failure to heal within six months, and 
assuming a period of three months before the patient receives a reoperation. Therefore, I calculate a 
maximum change in effectiveness of 0.5 QALY (equation 6.8). 
Equation 6.8: ∆ QALY = 0.75 x (1-0.5) = 0.375 
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Next, I calculate the headroom (max∆Cost). Based on a reimbursement level of £30,000 ($49,000, 
€34,000), the headroom is calculated as £11,250 ($18,400, €12,900) (equation 6.9). Finally, I take 
account of cost savings associated with reduced operating time from avoiding bone harvest (£283). 
This gives total headroom of £11,533 ($18,900, €13,200). If a new bone RM technology for nonunion 
fracture repair is going to be deemed cost-effective, it needs to be marketed at a price that would keep 
the max∆Cost below £12,000 ($19,600, €13,000). 
Equation 6.9: max∆Cost = 0.375 x £30,000 = £11,250 
 
However, as described above, changes in the duration of the negative effects of can have a large 
impact on the headroom. Furthermore, advances in vivo technology could make BMPs cost-effective 
and thus reduce the effectiveness gap, limiting the headroom further. 
 
6.8 Discussion  
6.8.1 Summary of Findings 
When the natural healing properties of bone break down, intervention is required. Following careful 
analysis of the clinical problem, I discern there are three broad alternatives for the management of a 
moderate size bone defect. Firstly, autograft using bone graft harvested from the iliac crest (the 
current gold standard approach), secondly, in vivo bone production (via implantation of growth factors 
and/or uncultured cells on some form of matrix/scaffold) and thirdly, in vitro bone production using 
cells grown on a scaffold (with or without growth factors). The first method (autologous bone graft) is 
the current standard. However, this method has a number of limitations primarily that of donor site 
morbidity, which reduces health-related quality of life and increases recovery time, ultimately 
increasing the cost of treatment. The solution to these problems could rest in RM. This technology 
could avoid the time, pain, and complications associated with harvesting from the bone as well as 
having a higher rate of effectiveness i.e. lower rate of failed fusion. In vivo production uses the body as 
a factory and avoids the logistical difficulties and cost of culturing the patient’s cells in vitro. Using the 
examples of spinal fusion and non-healing fracture repair, I have assessed the cost-effectiveness of 
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bone autograft versus in vivo bone production (illustrated using growth factor BMP) and made 
predictions about the headroom for improvement for in vitro bone production.  
 
Although the studies are not perfect, BMP does appear to be slightly more effective than autograft, 
which is essential if it is to be cost-effective. At the current price BMP is borderline cost-effective in the 
UK for non-healing fractures (see figure 6.5). For spinal fusion, at the current price, the results are 
much less encouraging and BMP will probably not be cost-effective, even at a much higher WTP 
threshold. However, if the price of BMP is halved, or if the effectiveness of BMP can be improved, it 
could become extremely cost-effective in the UK. Currently the increase in effectiveness appears to be 
insufficient to offset the additional cost of BMP.  
 
The headroom method has shown that under pessimistic assumptions of the side effects of the current 
treatment (i.e. donor site morbidity) there is large headroom for improvement. It is highly likely that an 
in vivo solution could be brought in at a price below the headroom. It is also possible that an in vitro 
solution could be brought to market within such a headroom. However, as I have said BMP saves the 
need for bone harvesting (contingent saving in cost and morbidities) without all the difficulties of in 
vitro production and is currently the favoured approach. Furthermore, the utility used here could be an 
overestimation of the true effects of donor site morbidity. For example, if the effects of donor site 
morbidity were to last 12 months rather than 24 months then the headroom would be reduced to 
around £12,000 ($19,600, €13,000) - a figure, which could be too low to support an in vitro approach. 
 
6.8.2 Limitations  
Going forward, utility estimates need to be improved if accurate estimates of cost-effectiveness are to 
be made. The utility estimates used in this analysis are heavily based on the data from the Garrison 
review and could very well be out of date with respect to bone repair using autograft. New RCTs 
conducted in this area should incorporate utility-based HRQL data collection into their studies. This will 
give a more accurate picture of the effectiveness of BMP and the headroom for more sophisticated 
technology.  
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6.8.3 Implications of this Work 
This work has been of great interest to the tissue engineers with whom I collaborated. Interestingly 
when I started this work there were two camps of thought. There were those advocating the ‘body as a 
factory’ approach - using growth factors embedded in a scaffold, and those who wanted to make bone 
outside the body. Although the science of developing such a tissue as bone outside the body may be 
worthy of research, in terms of developing a product likely to be reimbursed, I have demonstrated that 
the ‘body as the factory’ approach will almost certainly win. As I have previously stated the use of BMP 
compared to autograft is very nearly cost-effective, therefore I suggest resources and time are best 
spent on improving this technology. Indeed, this work has convinced some partners within the STEPS 
consortium, to scale back work on developing bone per se and invest more resources on using the 
“body as a factory” approach i.e. scaffold plus growth factors.  
 
Contradiction to my Findings 
Despite the conclusions, that suggest BMP is not cost-effective at its current price and effectiveness, 
in the USA INFUSE (or BMP) is (allegedly) the best selling RM product, with sales currently at $700 
million per year and growing rapidly (Lysaght et al., 2008). This contradicts my findings, so clearly in 
the US market other factors are at play. There are three possible explanations for this high sale 
volume in the US: 
1. Purchasers could be negotiating a large reduction in cost;  
2. The WTP threshold is higher (say £50,000 ($82,000, €57,000)) and purchasers negotiated a 
small reduction in cost (however, this would suggest that the system is based on evidence 
based medicine);  
3. BMP has been brought in “under the radar” – that is to say, the opportunity cost of its use has 
been ignored – i.e. its use is not based on cost-effectiveness analysis. 
 
My initial thought is that it is probably a combination of all three explanations. This however, may not 
be much use to the UK industry, who may hope to sell their products in the US. To inform the UK 
industry it would be helpful to know why this is the case. This was beyond the scope of this PhD but is 
something that is being investigated by another work package within the REMEDI consortium.  
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Pricing to a Threshold 
Our supply-side analysis showed that to achieve cost-effectiveness BMP requires a reduction in price 
of 7% and 23% for non-healing fracture repair and spinal fusion, respectively (based on current levels 
of effectiveness and a WTP threshold of £30,000). If I also consider market size the returns could be 
greater for non-healing fracture repair than for spinal fusion, thus profitability could be maximised if the 
price of BMP is reduced to cover its application in non-healing fracture repair but not to cover spinal 
fusion. Alternatively, different prices could be set for different applications. 
 
There are dangers for the industry in pricing to a threshold. Firstly, the industry might inadvertently 
over shoot and set too high a price – the health service may use different assumptions when coming 
to model cost-effectiveness moreover the cost-effectiveness threshold is allowed to vary to some 
extent – elsewhere the effect of uncertainties in the affordable price on optimised pricing strategy  has 
been modelled (Girling et al., 2008). Secondly, industry may undershoot, especially if consumer 
pressures for the product are high or other emotional or political factions come into play to support the 
product. Thirdly, pricing in other countries may be deflated by prices in those with the lower thresholds. 
This is a rather weak argument because many manufacturers set different prices already. Moreover, a 
negative rationing decision in one country might exert deflationary pressures elsewhere to a greater 
degree than a price reduction. 
 
There are also dangers to the health service, although, in England the government seems to have 
crossed this crucial point by introducing risk sharing schemes where costs are adjusted according to 
accumulating information over the years. There is a risk that the service might create a hostage to 
fortune by binding itself to a methodology that precludes negotiation of a lower price. This seems a 
weak argument for a patented medicine where rationing decisions apply. Once the patent has expired, 
other manufacturers are free to undercut the threshold price. Difficulties arise when a product has 
more than one application with different incremental cost-effectiveness ratios (as in this case). 
However, different approaches can be taken in this scenario, including different prices for different 
applications or weighted average prices across applications.   
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The issue of pricing to a threshold has been discussed by Claxton and colleagues in a recent paper 
(Claxton et al., 2008). The principles of value based pricing means that drugs will be approved for use 
only at prices that ensure that their expected health benefits exceed the health displaced. In the longer 
term this means prices based on value to the health service will provide incentives for manufacturers 
to develop technologies that are more likely to be of value i.e. cost-effective (Claxton et al, 2008). 
Price negotiation and guidance will then depend on the value of the technology and the responsibility 
for rejecting or restricting access to a new technology will be shared between the NHS, that cannot 
afford the cost-ineffective technology, and the manufacturer who is unwilling to accept a price that 
would make it cost-effective. Of course, for this to work, it requires NICE to signal, clearly, to the 
industry what is of value. It is then for manufacturer’s to choose to invest in technologies they believe 
will be both cost-effective for the NHS and give satisfactory return on investment (Claxton et al, 2008).  
The industry is free to follow a mechanism of pricing to a threshold and does not need to have 
permission from a third party payer to do so. However, an iterative process, where by the price can be 
adjusted to accommodate outputs of independent models that have withstood challenge may be more 
efficient from an industry and societal perspective. 
 
6.9 Conclusion 
Here I have shown that health economics has a role in strengthening the supply side, not just the 
demand side of the health economy. 
 
This application of the headroom method has been very different compared to the previous example 
given in chapters 4 and 5. The differences have arose due to the existence of an autograft substitute 
already on the market having already undergone CEA RM bone is further along the development 
process than visceral TE products. In this instance, supply side analysis, based on the premise of the 
headroom method, was conducted to find out the price at which the product would be cost-effective. 
This analysis has shown that BMP is very close to being cost-effective, which has been informative for 
the industry. It has indicated that small increases in effectiveness, such as changes in delivery 
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systems or BMP concentrations, could be sufficient to make BMP a cost-effective solution relative to 
autograft, and therefore it is likely to be worthwhile continuing to invest in this technology.  
 
RM has the potential to revolutionise the treatment of bone conditions resulting in treatments, which 
are less invasive, more effective, and less expensive. Future RM research may move towards cell-
based therapies, developing the ability to influence stem cells and direct their differentiation into cells 
that can be used directly for repairing defects, and developing appropriate biodegradable scaffolds for 
use in cell implantation into the body. The headroom analysis shows that there could be scope for 
these solutions to be a cost-effective alternative to autograft. However, the time between cell 
extraction, proliferation, and implantation must be reduced. Currently growth factors are the preferred 
option for a RM solution as they have the advantage over cells of being able to be used immediately. 
Furthermore, advances in the BMP delivery systems may prove to be more effective, and at lower 
concentrations, thus being less costly than current scaffolds.  
 
In the following chapter, I consider the final clinical application for a RM solution; cartilage defects of 
the knee. 
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 CHAPTER 7 COST EFFECTIVENESS ANALYSIS OF 
REGENERATIVE MEDICINE IN CARTILAGE DEFECTS 
OF THE KNEE 
 
7.1 Introduction 
Cartilage is connective tissue, more flexible than bone, but harder than muscle, which often serves as 
an early skeletal framework, becoming mineralised as the animal ages. Cartilage consists of 
chondrocytes; specialised cells, representing 10% of the volume of cartilage, essential for cartilage 
formation and functionality (L'Hermette et al., 2006;Lin et al., 2006). Unlike other connective tissues, 
cartilage does not contain blood vessels. The chondrocytes are fed by diffusion generated through a 
pumping action of the articular cartilage and, as a result, compared to other connective tissues, 
cartilage grows and repairs more slowly.  
 
There are three main types of cartilage each with slightly different properties that make each type the 
most appropriate to fulfil its function (ICRS, 2009): 
1. Elastic cartilage – contains large amounts of elastin and it is present in the ears and parts of the 
nose  
2. Fibrocartilage – is characterised by the dense population of type I collagen and has a high tensile 
strength and it is found in areas exposed to frequent stress such as intervertebral discs  
3. Hyaline cartilage – is hard and contains high amounts of type II collagen (collagen unique to 
cartilage) and it covers the end of bone to form the smooth articular surface of joints, such as the 
knee, which permits friction-free movement of the bony ends. 
 
This chapter will focus on defects of hyaline cartilage of the knee joint (also referred to as articular 
cartilage). Articular cartilage is prone to injury from trauma or overuse, and from loss of blood supply to 
an area of subchondral bone. Cartilage damage can have immediate dramatic consequences on knee 
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function and detrimental long-term degenerative effects on the joint. Articular cartilage defects fail to 
heal spontaneously and left untreated the defects progressively enlarge with time and predispose to 
OA, a joint disease involving degeneration of hyaline cartilage. In the western world, OA is second 
only to cardiovascular disease as a cause of disability (Salaffi et al., 2005), representing a large 
socioeconomic burden. OA is the most prevalent disorder of the musculoskeletal system and leads to 
joint pain and tenderness, limitation of movement, occasional effusion and variable degrees of 
inflammation (Risbud et al., 2002).  
 
The poor healing potential of hyaline cartilage makes cartilage defect repair a prime target for RM 
solutions. RM has the potential to enable the body to repair, replace, restore, and regenerate 
damaged or diseased cells, tissues, and organs. An ideal RM therapy for cartilage defects would 
prevent onset of OA altogether, but a delay in OA onset would be valuable and arguably a more 
plausible objective. Such a treatment would delay, if not prevent, the need for a total knee 
replacement (TKR) (or total knee arthroplasty (TKA)), which in turn should prevent the need for 
secondary knee replacements and further surgery.  
 
The purpose of this chapter is to provide the RM industry and the clinical world with up to date 
information regarding the current state of research into RM treatments for cartilage defects and the 
likely cost-effectiveness of RM solutions.  
 
7.2 Methods 
7.2.1 Overview 
I begin by summarising the natural progression of cartilage defects of the knee. I identify the existing 
and emerging treatment options proposed to repair a cartilage defect of the knee and go on to 
compare the clinical effectiveness and costs of the each. Next, I conduct CEA. This has two parts. 
First, I review previous cost-effectiveness analysis of RM solutions to treat cartilage defects of the 
knee. Second, I build on this analysis using the headroom method and estimate the maximum 
potential cost of an ideal RM solution.  
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7.2.2 Defining the Clinical Problem 
I conducted a systematic literature review of the relative effects and costs of each cartilage repair 
treatment, using the search strings shown in appendix 12. I was aided by a HTA systematic review 
and economic analysis by Clar and colleagues (Clar et al., 2005), which I identified during the course 
of the literature search. A great deal of the literature found referred to knee and hip defects, OA, and 
replacement. However, it was decided from the outset that the focus of this work would be on defects 
of the knee and therefore only studies related to the knee were extracted. Finally, I identified the 
HRQL and utility associated with different health states: 
a) Cartilage defect of the knee and its treatments – I was unable to identify a utility score from the 
literature associated with having a cartilage defect prior to any treatment. Utility gains associated 
with cartilage repair treatments are reported; however, the baseline values are not reported.  
 
b) OA of the knee - Four prospective studies were identified that had each measured HRQL 
associated with knee OA using SF-36. The SF-36 sub-scores were converted into SF-6D and EQ-
5D utility scores using two different algorithms described in the papers by Ara and Brazier (Ara et 
al., 2008a;Ara et al., 2008b). In addition, a cost benefit study was identified. This study described 
two hypothetical scenarios (based on EQ-5D domains); one related to mild-moderate knee OA 
(some problems with walking, no problems with self-care or performing usual activities, moderate 
pain or discomfort, not anxious or depressed), and one related to severe knee OA (problems with 
walking, self-care, performing usual activities, extreme pain or discomfort, and moderately 
depressed). Individuals indicated preferences for each state, elicited through VAS (visual analogue 
scale), TTO, and SG. The author also calculated WTP per QALY for each of the health states 
described. Utilities were also sourced from a report by Dong and colleagues (Dong et al, 2006) as 
part of the MATCH (multidisciplinary Assessment of Technology Centre for Health) collaboration. 
This study used a Markov model to assess cost-effectiveness of conventional TKR versus 
computer-assisted TKR. The utility scores associated with OA identified during the course of this 
work are reported here. 
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c) Primary and secondary knee replacement – Here, I report the utility gains identified from two 
systematic reviews (Clar et al, 2005;Ethgen et al., 2004) and a MATCH report by Dong and 
colleagues (Dong et al, 2006), discussed above. The Ethgen review reported HRQL scores 
following a TKR, measured using SF-36. As above I determined utility (SF-6D and EQ-5D) scores 
from the SF-36 scores using the algorithm described by Ara and Brazier (Ara et al, 2008a;Ara et 
al, 2008b).  
 
7.2.3 Cost-Effectiveness 
This section has two stages. Firstly, I review previous short- and long-term CEA of RM treatments. 
Secondly, I conduct my own supply side analysis, based on the headroom method described in 
chapter 3. Here, I ask two questions: 
1. What is the minimum incremental effectiveness a competitive treatment should have in the short 
term to be more cost-effective than microfracture? 
2. What is the maximum incremental cost a competitive treatment could be to be cost-effective in the 
long term? 
 
7.3 Indication for a RM Solution 
There are three main types of cartilage injury:  
(a) Matrix disruption – damage to extra-cellular matrix, usually not extreme, and repair is via remaining 
viable chondrocytes; 
(b) Partial thickness defect – is disruption of cartilage surface but not extending to subchondral bone. 
Nearby cells begin to proliferate but, for reasons unknown, discontinue proliferation before filling 
defect;  
(c) Full thickness defect - traverses entire cartilage thickness, penetrating subchondral bone, resulting 
in exposure of progenitor cells from bone marrow, which migrate to fill defect. The lesion is filled with 
an intermediate tissue between fibrocartilage and hyaline cartilage, which is less stiff and more 
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permeable than native hyaline cartilage and which degrades over a period of years (Temenoff et al., 
2000).  
 
This chapter focuses on partial and full thickness cartilage damage in the knee, resulting from trauma 
in otherwise young, healthy patients. Cartilage defects become apparent many months or years after 
initial insult, making it difficult to calculate prevalence and incidence accurately. In the UK an estimated 
10,000 patients per year - mostly young adults - suffer hyaline cartilage damage in knee joints of 
sufficient severity to cause symptoms (NICE, 2005b). Ultimately, these injuries can result in OA (figure 
7.1). On average, patients who have suffered cartilage damage develop OA five to ten years earlier 
than patients who have not (Gelber et al., 2000;Hangody et al., 2006). When OA symptoms (pain, 
stiffness and swelling) become disabling, joint replacement surgery is necessary, the longer this can 
be delayed the better, for two reasons. Firstly, surgery carries risks (for example of osteomyelitis 
(inflammation of the bone)). Secondly, the earlier the joint replacement, the greater the chance of a 
secondary knee replacement (Bhosale et al., 2008). The current treatment strategy for OA in younger, 
active patients is to decrease symptoms and delay time to surgery. Since OA progression cannot be 
halted if early events are not prevented, the current challenge is to develop treatments that target 
cartilage repair to delay or even avoid surgical treatments for incapacitating OA (Goldring, 2006).  
 
Figure 7.1: Diagram to illustrate the degeneration of cartilage in osteoarthritis 
 
Image courtesy of Medical Multimedia Group LLC, www.eOrthopod.com  
Source: http://www.eorthopod.com/public/patient_education/6516/osteoarthritis_of_the_knee.html 
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7.4 Treatment 
There are several surgical therapies available for the treatment of cartilage damage of the knee but 
currently there is no truly effective strategy. The aim of these treatments is to restore normal, long-
term, and pain free motion of the joint by promoting the formation of repair tissue with the structure 
and durability of natural hyaline articular cartilage (Saris et al., 2008). However, the quality of the 
tissue formed by each method is not always identical and has been reported as hyaline-like cartilage 
or fibrocartilage rather than regenerated hyaline articular cartilage (Simon et al., 2006;Williams et al., 
2008).   
 
7.4.1 Current Treatment 
Current interventions include: 
i. Conservative management - involves a combination of exercise and non-steroidal anti-
inflammatory drugs. 
 
ii. Arthroscopic debridement - a clean up process removing loose fragments of damaged tissue and 
trimming sharp margins. 
 
iii. Microfracture (or arthroscopic marrow stimulation) - involves boring holes into subchondral plate 
bone to stimulate ingrowth and metaplasia (change in cells) of mesenchymal stem cells (MSCs) to 
repair cartilage damage. This technique is used in small defects (<2cm2) (figure 7.2). 
 
iv. Mosaicplasty (or osteochondral autologous transfer (OATs) – involves transfer of healthy mature 
cartilage and bone dowels from non-weight bearing joint areas to defective load bearing areas. This 
technique is associated with donor site morbidity and suited to small defects only (figure 7.2). 
 
7.4.2 State of the Art in Regenerative Medicine 
State of the art treatment involves the introduction of a defect-filling matrix, either containing cartilage 
precursor cells or signalling substances that will induce their local recruitment. The underlying principle 
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is that the cartilage precursor cells (transplanted or locally recruited) will differentiate into cartilage-
producing chondrocytes (ICRS, 2009). These cartilage-engineering strategies are summarised below:  
 
i. Autologous Chondrocyte Implantation (ACI) is a 2-step RM procedure. Firstly, autologous 
chondrocyte cells are harvested, via arthroscopy from a non-load bearing region of articular cartilage. 
Secondly, chondrocytes are cultured in vitro for 4-5 weeks and implanted, held in place under a 
membrane or mesh (Brittberg et al., 1994;Saris et al, 2008) (figure 7.2). 
 
ii. Matrix-induced Autologous Chondrocyte Implantation (MACI) – used when chondral lesions 
are deep (>2 cm2), to encourage further cell migration. Cells are harvested and cultured in vitro before 
implantation where they are held in place using a collagen or collagen-imitating membrane, which will 
degrade over time. The scaffold does not require stitching to cartilage and is a quicker procedure than 
ACI. 
 
iii. Characterised Chondrocyte Implantation (CCI) (ChondroCelect, Tigenix) - is a variation on 
conventional ACI. The expansion of autologous cells in conventional ACI leads to dedifferentiation and 
loss of chondrogenic capacity (the ability to form cartilage). The basic premise of CCI is to improve 
articular regeneration leading to more durable joint surfaces. This is achieved by using a cell 
population capable of making stable hyaline-like cartilage in vivo (Saris et al, 2008). 
 
iv. Osteochondral Scaffolding - a more recent addition to cartilage regenerative repair. The scaffold, 
made from a resorbable polymer plug mimics composition and structure of natural articular joints and 
can be used with current surgical procedures such as microfracture or mosaicplasty to improve 
outcomes (Simon et al, 2006;Williams et al, 2008). 
 
 
 
 
 
204 
Figure 7.2: Illustrations of microfracture, mosaicplasty, and ACI 
Microfracture 
 
Mosaicplasty 
ACI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images courtesy of Yorkshire Knee Clinic  
Source: 
http://www.yorkshirekneeclinic.co.uk/jointsurfa
ceinjuries.htm 
 
7.5 Clinical Effectiveness of Treatment 
7.5.1 Short-Term Results (based on clinical trials) 
Eight RCTs have assessed short-term (<2 years) clinical effectiveness of RM therapies for articular 
cartilage defects of the knee. Three compare ACI with mosaicplasty (Bentley et al., 2003;Dozin et al., 
2005;Horas et al., 2003). One compares ACI with microfracture (Knutsen et al., 2004); one compares 
MACI with microfracture (Basad et al., 2004). One compares CCI and microfracture (Saris et al, 2008). 
One compares ACI with MACI (Bartlett et al., 2005) and finally one compares two different approaches 
of ACI (Gooding et al., 2006). The results are summarised below and in table 7.1 to 7.3 (page 208-
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211). Four of these trials (Basad et al, 2004;Bentley et al, 2003;Horas et al, 2003;Knutsen et al, 2004) 
were included in a Cochrane review (Wasiak et al., 2006), which found there is no evidence of 
significant difference between ACI and other cartilage repair treatments but concluded there is a 
requirement for high quality RCTs with long-term follow-up. No past or current trial or study has 
compared ACI or MACI with conservative management. In all trials, the main clinical outcome 
measure is knee function, but each trial uses different specific outcome measures. Therefore, a 
quantitative meta-analysis of clinical outcome results is not possible. 
 
Bentley and colleagues reported statistically significant results in favour of ACI over mosaicplasty, with 
improved outcomes on the International Cartilage Repair Society (ICRS) arthroscopic grading system 
at 12 months. However, only 30% of patients underwent 12-month arthroscopic follow-up. The 
improved arthroscopic appearance did not translate to a statistically significant difference in knee 
function on the Cincinnati scale, except in the (retrospectively defined) subgroup of patients with 
lesions of the medial femoral condyle (rounded articular surface at the extremity of a bone). Dozin and 
colleagues randomised 47 patients to ACI or mosaicplasty 6 months after initial arthroscopic 
debridement of the lesion. However, nearly a third of patients did not receive the allocated treatment 
due to sufficient improvement following debridement alone. A further 7 patients were lost to follow-up 
leaving just 23 patients for evaluation of treatment effect. Complete recovery was reported in 88% of 
mosaicplasty group and 68% of ACI group (P=0.093) (measured using Lysholm knee scoring scale 
90-100). Horas and colleagues reported a statistically significant difference in function in favour of the 
mosaicplasty group compared to the ACI group, using the Lysholm scores at 6, 12 and 24 months, but 
significance disappears using Meyers or Tegner scores.  
 
Knutsen and colleagues found a difference at 2 years favouring microfracture, using the SF-36 
physical component (P<0.05), the Lysholm score (P>0.05) and in need for further surgery (25 % of 
ACI group versus 10% of microfracture group). Basad and colleagues rendered improved results for 
MACI compared to microfracture based on the Lysholm-Gillquist score (P<0.05) at 24 months, the 
Meyers score (P<0.05) at an undefined period and the Tegner-Lysholm score (P>0.05) at 24 months. 
Saris and colleagues found a statistically significant difference in terms of quality of tissue restoration 
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in favour of CCI compared with microfracture, at 18 months. However, clinical outcome using KOOS 
(Knee injury and Osteoarthritis Outcome Score) was similar for both groups. The authors conclude 
that CCI is not demonstrably inferior to microfracture in the short-term and hypothesise that clinical 
benefit of CCI may not be observed until mid to long term follow-up. Bartlett and colleagues compared 
ACI with MACI in 91 patients. Both treatments showed improvement at 12 months, measured using 
modified Cincinnati knee score (ACI, 41.1 to 59.0 (P=0.01) and MACI, 44.5 to 64.1 (P=0.002)).  
 
Finally, one trial compared different ACI approaches. Gooding and colleagues compared periosteum 
(connective tissue) -covered ACI to type I/II collagen covered ACI over 2 years. There is debate about 
whether the periosteum cover acts simply as a watertight seal or whether it secretes growth factors 
essential for development of hyaline cartilage (Gooding et al, 2006). There is no significant difference 
in clinical or arthroscopic outcomes. This study supports previous findings that a periosteum cover is 
not essential to development and maturation of hyaline cartilage. The only difference found was a 
greater incidence of graft hypertrophy (enlargement) in the periosteum-covered group, a result of 
increased morbidity due to longer surgery required to harvest the patch of periosteum.  
  
Many of these trials are head-to-head comparisons of in vivo methods to stimulate cartilage production 
(e.g. mosaicplasty with or without scaffolding) with in vitro methods (e.g. ACI). There may be some 
evidence favouring the latter in arthroscopic appearances but, if anything, the in vivo methods are 
associated with improved functional performance. The ‘acid-test’ lies in longer-term outcomes.
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Table 7.1: Short-term results of RCTs comparing ACI to mosaicplasty 
Study Bentley et al. 2003 Horas et al. 2003 Dozin et al. 2005 
R
C
T
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
Trial ACI vs. Mosaicplasty ACI vs. Mosaicplasty ACI vs. Mosaicplasty 
Mean follow-up 19 months  24 months   
N 100 40 47 
Mean Age 
(years) 31.3 (range: 16 - 49) 33.4 (range: 18 - 44) 28.7 (range: 21 - 36) 
Mean defect 
Size (cm2) 4.66 3.75 1.9 
Aetiology of 
defect 
trauma 46%, unknown 21%, osteochodritis dissecans 
19%, chondromalacia patellae 14%   100% from trauma and all full thickness 
Femoral condyle 71%, medial 84%, 
lateral 16%, patella 30%. Grade III 
23%, grade IV 78%. 
Mean duration 
of symptoms 7.2 years None reported None reported 
Previous 
surgery 94% (excluding Arthroscopy) 
Overall 40% (abrasion 20%, incomplete resection of the medial 
meniscus 7.5%, extraction of osteochondral bodies 5%, 
arthroscopy alone 5%, incomplete resection of the medial 
meniscus 7.5%, drilling 2.5%) 
None 
C
l
i
n
i
c
a
l
 
O
u
t
c
o
m
e
 
 
Cincinnati Rating System Modified Lysholm Score Lysholm Knee Scoring Scale 
ACI n=58 Mosaicplasty n=42 ACI n=20 Mosaicplasty n=20 ACI n = 19 Mosaicplasty n = 18 
poor 0% poor 17% baseline 24.9 baseline 28.4 <60 4.5% <60 0% 
fair 12% fair 14% 3 months 27.5  3 months 27.9 60-90 23% 60-90 9% 
good 48% good 48% 6 months 45.7 6 months 53.4 90-100 45% 90-100 63% 
excellent 40% excellent 21% 12 months 57.5 12 months 68.2     
Excellent + good 88% Excellent + good 69% 24 months 66.7* 24 months 72.7* subjective 
improvement 
14% 
subjective 
improvement 5% medial femoral condoyle defects Meyers Score 
ACI n=24 Mosaicplasty n=29 baseline 24.9 baseline 7.8     
poor 0% poor 14% 3 months 8.5 3 months 7.8     
fair 12% fair 14% 6 months 12.0 6 months 13.7     
good 42% good 52% 12 months 14.1 12 months 15.9     
excellent 46% excellent 21% 24 months 15.9 24 months 16.7     
Excellent + good 88%* Excellent + good 74%*         
lateral femoral condyle defects 
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ACI n=13 Mosaicplasty n=5 
       
poor 0% poor 20%        
fair 8% fair 40%        
good 38% good 0%        
excellent 54% excellent 40%        
excellent+good 92% excellent+good 74%        
patellar defects 
       
ACI n=20 Mosaicplasty n=5 
       
poor 0% poor 40%        
fair 15% fair 0%        
good 60% good 60%        
excellent 25% excellent 0%        
excellent+good 85% excellent+good 60%        
Complication 
3% low to mobilise required manipulation under 
anaesthesia; 1 arthroscopy and artrolysis to mobilise 
knee; 1 calf-vein thrombosis, required anticoagulants; 1 
superficial infection.  
ACI - 12; Mosaicplasty - 12 None reported 
Failure of treatment None reported None reported None reported 
Need for further 
surgery None reported ACI - 8; Mosaicplasty - 9 None reported 
*P<0.05 
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Table 7.2: Short-term results of RCTs comparing ACI to microfracture 
Study Basad et al. 2004 Knutsen et al. 2004 Saris et al 2008 
R
C
T
 
c
h
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r
a
c
t
e
r
i
s
t
i
c
s
 
Trial MACI vs. microfracture ACI vs. microfracture CCI vs. Microfracture 
Mean follow-up 12 months 2 years 18 month 
N 46 80 118 
Age (years) 33 32.2 (range: 18-45) 18 - 50 
Mean defect Size 
(cm2) 2-10 4.8 1 - 5  
Aetiology of 
defect 
  
  
full thickness 96%, trauma 65%, OCD 28%, other 7%, partial 
thickness 4% 
symptomatic cartilage lesion of the femoral 
condoyle 
Mean duration of 
symptoms   36 months CCI 1.97 years; Microfracture 1.57 years 
Previous surgery   
  
Overall 94% (arthroscopic lavage and debridement 36%, anterior 
cruiciate ligament reconstruction 19%, meniscal surgery 18%, 
drilling or fixation of a fragment 16%, pridie drilling 4%) 
CCI 50%; microfracture 47% (greater than 2 
previous surgeries: CCI 21%; microfracture 
13%) 
C
l
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i
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a
l
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t
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MACI n=10 Microfracture 
n=9 ACI n=40 Microfracture n=40 Knee injury and osteoarthritis outcome score 
Meyers Score Improvement Lysholm Score CCI n=51 Microfracture n=61 
12 months 6.5 12 months 1.9 baseline 57 baseline 55 baseline 56.30 baseline 59.53 
    12 months 68 12 months 77 6 months 70.56 6 months 72.63 
Lysholm-Gillquist Score 
Improvement 24 months 70 24 months 75 12 months 73.26 12 months 73.10 
12 months 27.4 12 months 4.1 Pain (VAS, 0 to 100) 18 months 74.73 18 months 75.04 
    baseline 54 baseline 53     
Tegner -Lysholm Score Improvement 12 months 40 12 months 35     
12 months 32.6 12 months 15.3 24 months 35 24 months 31     
    
Short form-36: physical component 
    
    baseline 41 baseline 37     
    12 months 42.5 12 months 41     
    24 months 42* 24 months 46*     
Complications 
None reported 
ACI group: symptomatic tissue hypertrophy; Microfracture group: 1 
patient had arthrofibrosis, 3 patients had minor debridement’s; No 
serious complications such as deep infection 
mild or moderate: CCI 88% vs. microfracture 
82%; Severe: CCI 12% vs. microfracture 13% 
Failure of treatment ACI 5%; Microfracture 2.5% None reported 
Need for further 
surgery 
ACI: Biopsy 80%, Arthroscopic debridement 25%; Microfracture 
Biopsy 88%, Arthroscopic debridement 10% None reported 
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Table 7.3: Short -term results of RCTs comparing ACI to MACI and ACI 
Study Bartlett et al. 2005 Gooding et al. 2006 
R
C
T
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
Trial ACI vs. MACI ACI - Periosteum vs. ACI - Collagen 
Mean follow-up 12 months 24 months 
N 91 46 
Age (years) 33.4 years 31.6 
Mean defect Size (cm2) 6.0 4.66 
Aetiology of defect 
  disabling pain associated with an isolated full thickness chondral defect 
Mean duration of symptoms 9.87 years 7.09 years (range: 1-27 years) 
Previous surgery ACI 2.3; MACI 2.1 2.09 
C
l
i
n
i
c
a
l
 
O
u
t
c
o
m
e
 
 
Modified Cincinnati Rating System Modified Cincinnati Rating System 
ACI n = 44 MACI n = 47 ACI-perisoteum n=33 ACI-collagen n=35 
Poor 18.2% Poor 12.8% Poor 27.3% Poor 23% 
Fair 22.7% Fair 14.9% Fair 33.3% Fair 43% 
Good 36.4% Good 40.4% Good 39.4% Good 34% 
Excellent 22.7% Excellent 31.9%     
    
International Cartilage Research Society 
International Cartilage Research Society 12 months 
poor 0% poor 5.6% Poor 3.2% poor 3.4% 
Fair 20.8% Fair 27.8% Fair 16% Fair 17.2% 
Good 62.5% Good 44.4% Good 71% Good 69% 
Excellent 16.7% Excellent 22.2% Excellent 9.7% Excellent 10.3% 
    International Cartilage Research Society 
Type of cartilage  24 months 
hyaline like 28.6% hyaline like 27.3% poor 0% poor 11.1% 
hyaline/fibrocartilage 14.3% hyaline/fibrocartilage 9.1% Fair 18% Fair 33.3% 
fibrocartilage 57.1 fibrocartilage 63.6% Good 73% Good 55.5% 
    Excellent 9% Excellent 0% 
Complications 
 hypertrophy (n=4) hypertrophy (n=3) 
1 major (Deep vein thrombosis); 12 minor 
  
Failure of treatment 
    2 
Need for further surgery 
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7.5.2 Medium-Term Results 
Clinical Trials 
Medium-term (5-15 years) clinical effectiveness of RM therapies has been reported in one RCT 
(Knutsen et al., 2007) comparing ACI with microfracture (table 7.4). After five years, there is no 
statistically significant difference in knee function using the Lysholm score, the Tegner score or Visual 
Analogue Scale (VAS). There was a difference favouring microfracture using SF-36 physical 
component, but this was not significant. Major complications such as complete treatment failure 
(defined as lack of healing of primary treated defect) and need for TKR were not statistically different.  
 
Observational Studies 
Longer-term follow-up (10 years) has been assessed in several observational studies (Blevins et al., 
1998;Hangody et al., 2003;Hangody et al., 2004;Hangody et al., 2008;Peterson et al., 2000;Peterson 
et al., 2002;Peterson et al., 2003;Steadman et al., 2003;Szerb et al., 2005) (table 7.4). These studies 
have been reviewed by the HTA (Clar et al, 2005) and NICE (NICE, 2005b). They conclude that 
longer-term defects require hyaline cartilage for lasting benefit as fibrocartilage will eventually crumble. 
 
Several other observational studies, not included in NICE and HTA reviews (Brittberg et al., 
2003;Erggelet et al., 2003;Gillogly et al., 2006;Lohmander, 2003;Marcacci et al., 2002) have also 
assessed the effectiveness of ACI and found success regarding total number of improved patients 
(detailed results not reported). The criticism of these studies is the lack of head-to-head studies 
comparing ACI to other cartilage repair techniques, and the lack of sufficiently long-term follow up. 
 
More recently, there have been two prospective studies published (table 7.4). Asik and colleagues 
(Asik et al., 2008) found microfracture is effective with regard to improvement in daily activities and 
pain relief after 5 years. Zaslav and colleagues (Zaslav et al., 2009) assessed ACI in patients with 
failed prior treatment and found ACI can provide sustained and clinically meaningful improvement in 
pain and function. There was a higher than normally reported rate of subsequent surgical procedures 
(49% overall with 40% related to ACI). However, the authors stated that a need for subsequent 
surgical procedure was not a predictor of failure.  
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Table 7.4: Medium-term results of observational studies of ACI and alternative treatments  
Study Knutsen et al. 2007 Zaslav et al. 2009 Asik et al. 2008 
Steadman et 
al. 2003 
Blevin et al. 
1998 
Hangody et al. 2001, 
2003, 2004, 2008, Szerb 
et l. 2005 
Peterson et al. 2000, 
2002, 2003 
R
C
T
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
Type of 
study RCT: ACI vs. microfracture ACI Microfracture Microfracture Microfracture Mosaicplasty ACI 
Mean follow-
up 5 years 4 years 
5 years 
(range: 2 - 9) 2-11 years 2-5 years 1-15 years 2 - 11 years 
N 80 (ACI = 40; Microfracture = 40) 154 90 72 178   58 - 101 
Age (years) 32.2 (range: 18-45) 34.5 34.5 (range: 20-58) 13-45 13-68 27 (range: 16-47)   
Mean defect 
Size (cm2) 4.8 5.74 
68 < 2cm2; 22 
> 2 cm2      1 - 4 cm
2
   
Aetiology of 
defect 
full thickness 96%, trauma 65%, 
OCD 28%, other 7%, partial 
thickness 4% 
chondral defect > 
4cm2 
Grade IV full 
thickness  
lesions  
    
66% - grade III or IV 
lesion, 33% - OCD 
moderate to large full 
thickness defects 
Mean 
duration of 
symptoms 
36 months   
          
Previous 
surgery 94% 100% 
          
Type of 
previous 
surgery 
arthroscopic lavage and 
debridement 36%, anterior 
cruiciate liagment reconstruction 
19%, meniscal surgery 18%, 
drilling or fixation of a fragment 
16%, pridie drilling 4% 
 48% 
debridement, 27% 
microfracture, 
10% drilling, 6% 
arthroscopy, 5% 
osteochondral 
autograft, 2% 
chondroplasty, 1% 
marrow 
stimulation           
C
l
i
n
i
c
a
l
 
O
u
t
c
o
m
e
 
 Lysholm Score Modified Cincinati score 
Lysholm 
Score 80% rated 
themselves as 
improved at 7 
years. Patients 
younger than 
35 years had 
greater 
improvement 
77% of high 
level athletes 
returned to 
competition, 
71% reported 
to be equal or 
superior to 
preinjury level 
overall results  
Good and excellent 
results recorded in 
82% at 2 years, 84% 
at 5-11 years (92% 
isolated femoral 
condyle, 67% multiple 
lesions, 89% OCD, 
65% patella, 75% 
femoral condyle with 
anterior cruiciate 
ACI Microfracture baseline 3.26 baseline 52.4 good-to-excellent results 
were achieved in 92% of 
the patients treated with 
femoral condylar 
implantations, 87% of 
those treated with tibial 
resurfacing, 79% of 
those treated with 
baseline 57 baseline 55 6 months 4.99 68 months 84.6* 
12 months 68 12 months 77 12 months 5.58 Tegner Score 
24 months 70 24 months 75 24 months 5.90 baseline 2.6 
5years 78* 5years 80* 36 months 5.84 68 months 5.2* 
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Pain (VAS, 0 to 100) 48 months 6.31 Oxford Knee 
questionnaire 
patellar and/or trochlear 
mosaicplasties, and 94% 
of those treated with 
talar procedures. 83% 
had good gliding surface 
ligament 
reconstruction).  ACI Microfracture Global VAS 
baseline 54 baseline 53 baseline 28.8 baseline 23.1 
12 months 40 12 months 35 6 months 60.1 68 months 44.8* 
24 months 35 24 months 31 12 months 64.4 
  
5 years 25* 5 years 24* 24 months 68.2 
Short form-36: physical 
component 36 months 64.4 
ACI Microfracture 48 months 69.9 
baseline 41 baseline 37 Knee-related HRQL  
12 months 42.5 12 months 41 baseline 20.9 
24 months 42* 24 months 46* 12 months 38.6 Talar Implantations 
n=36 
5 years 48 5 years 47 24 months 44.6 Hannover scoring 
system 
  
36 months 44.9 excellent  28 
48 months 52.2 good 6 
SF-36 overall 
health moderate 2 
baseline 33.0 competitive sports 
athletes n=93 12 months 39.8 
24 months 42.0 64% returned to same 
level, 19% returned to 
lower level, 17% had to 
discontinue 
36 months 42.5 
48 months 44.4 
Complications None reported 
84% overall 
(14.9% 
hypertrophy, 
12.3% 
arthrofibrosis, 
11% cartilage 
injury) 
None reported None reported None reported 
3% donor site morbidity; 
4 deep infections; 36 
haemarthroses; 2 
thromboembolic 
complications 
50% (3 wound 
infections, 1 fever, 2 
haematomas, 10 
intrarticular 
adhesions, 26 
Periosteal 
hypertrophies and 7 
graft failures) 
Failure 23% 23% 39% of those with 
complication           
Need for further 
surgery 
TKR, and 
repeat 
microfracture.  
Repeat 
microfracture, 
mosaicplasty, & 
ACI 
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7.5.3 Long-Term Results 
The findings from medium term observational studies suggest that even in the longer term, there is no 
clear advantage in terms of clinical effectiveness of using ACI or MACI over other treatments. 
However, there are several trials underway with large numbers and long-term follow-up (>15 years) 
comparing ACI or MACI with alternative treatments. One of the largest trials is a Medical Research 
Council funded multicentre RCT, the ACTIVE trial, led by Professor James Richardson of Keele 
University. This trial includes 24 hospitals and started in March 2004. Patient randomisation is in a 
one-to-one ratio to receive ACI or non-ACI treatment. Non-ACI treatments include debridement, 
abrasion, microfracture, and mosaicplasty and clinical preference determines treatment selection. 
Preliminary results are expected after 2010 but follow-up is to continue until at least 2017. Health 
economics is an integral part of the study, which will determine an incremental cost per QALY for each 
intervention from a societal perspective. Additional information, including the trial protocol, can be 
found at http://www.active-trial.org.uk (last accessed 9 October 2009). Wasiak and colleagues (Wasiak 
et al, 2006) list another nine ongoing studies, which unfortunately do not offer public access to their 
protocol or any trial detail. 
 
It is possible RM solutions are better than non-RM solutions. In that case, the most interesting 
comparison would not be ACI against ‘all common’ treatments but in vitro versus in vivo RM solutions. 
The latter are cheaper and do not involve two taxing procedures. Although the Keele based study will 
provide interesting results, it may leave the most interesting questions unanswered.  
 
7.6 Health-related quality of life and Utilities  
For economic analysis, I need a utility-based HRQL score. As discussed, the main health economic 
gains/losses from treatment of cartilage defects lie in the longer term where OA develops. To conduct 
long-term analysis first I need to identify the utility associated with cartilage defects, OA, TKR, and 
revisions. Table 7.5 (page 219) shows the utility scores identified for each of the health states, which 
will be used later in my economic analysis.  
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7.6.1 Utility of Cartilage Damage 
I have been unable to identify a utility score from the literature associated with a having a cartilage 
defect prior to any treatment. Although, as you will see, when utility gains associated with cartilage 
repair treatment are reported the baseline values are not reported. The implications of this are 
discussed further in 7.9.2 (page 229).  
  
7.6.2 Utility of a Repaired Cartilage Defect 
Clar and colleagues (Clar et al, 2005) report a short-term (1-2 years) annual utility gain of 0.1 QALY in 
the first two years after surgery. This value was based on the findings of a report by Jobanputra and 
colleagues (Jobanputra et al., 2001), which stated (based on expert opinion) that ACI was associated 
with a HRQL improvement of 0.107. This finding was similar to that from an earlier observational study 
(Minas, 1998), where 44 ACI patients were assessed over 24 months and a HRQL improvement of 
0.11 associated with ACI was reported (elicited indirectly using SF-36 questionnaires, no 
methodological details given).  
 
Derrett and colleagues conducted a cost and health status two year retrospective analysis of ACI 
versus mosaicplasty and calculated utility gains using EQ-5D (in principle this should elicit more 
reliable estimates than those based on expert opinion). A QALY gain of 0.23 following ACI and 0.06 
following mosaicplasty was reported. These values were based on a mean preoperative score of 0.41 
(elicited using EQ-5D from a third group of patients whom were waiting for ACI). The postoperative 
EQ-5D score for ACI (0.64, n=41) was higher than for mosaicplasty (0.47, n=11) but this difference 
was not statistically significant. I note the QALY gain following ACI reported in this study is double that 
of the QALY gain reported by Clar et al. I would like to remind the reader that the baseline results are 
from a different group of patients than the group whom received either ACI or mosaicplasty; therefore, 
I feel these results are extremely suspect. Furthermore, the difference in total QALY gain between ACI 
and mosaicplasty is rather large, once again casting further doubt on this study. For these reasons, I 
have decided not to use the results of this study in my CEA.  
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7.6.3 Utility Associated with Osteoarthritis of the Knee 
As previously discussed, longer-term benefits, are found in avoiding OA and TKR. The next two 
sections aim to identify the utility associated with OA of the knee and a TKR. Here, I report the utility 
values associated with OA of the knee, identified from four prospective studies (Boutron et al., 
2008;McHugh et al., 2008;Salaffi et al, 2005;Yilmaz et al., 2008); a cost benefit analysis (Byrne et al., 
2005); and a report by Dong and colleagues (Dong et al, 2006), produced as part of the MATCH 
collaboration.  
 
All four prospective observational studies assessed HRQL associated with knee OA using SF-36. 
Overall, as might be expected, the physical components of the measure had lower scores than the 
emotional, mental, or general health components. I divided the studies into mild and severe OA based 
on the mean duration of OA symptoms in the cohort of patients for each study. The overall average 
age of the patients is 64.8, with an average of 63.8 years for mild OA and 68.0 years for severe OA. I 
converted the SF-36 scores into SF-6D and EQ-5D utility scores using the algorithms described by 
Ara and Brazier (Ara et al, 2008a;Ara et al, 2008b). The overall average utility is 0.60 (using SF-6D) 
and 0.47 (using EQ-5D). For mild OA, the average utility is 0.61 (using SF-6D) and 0.51 (using EQ-
5D). For severe OA, the average utility is 0.56 (using SF-6D) and 0.37 (using EQ-5D). These scores 
are summarised in table 7.5 (page 219) and I will use both scores in subsequent analysis. 
 
Byrne and colleagues reported utility values (table 7.5, page 219) associated with mild and severe OA, 
elicited using VAS (0.73 vs. 0.46), TTO (0.81 vs. 0.66), SG (0.73 vs. (0.61). The authors also reported 
a WTP per QALY for each measure. Using VAS, the WTP/QALY for mild and severe OA was $2,019 
and $1,221, respectively; using TTO, the WTP/QALY was $4,040 and $3,802, respectively; and for 
SG, the WTP/QALY was $2,844 and $3,020, respectively. TTO consistently elicits a higher 
preference, whilst VAS elicits the lowest. Finally, the MATCH report gives a utility of 0.72 associated 
with OA of the knee. 
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7.6.4 Utility following Total Knee Replacement (TKR) 
Here, I report the utility gains associated with a TKR,  identified from two systematic reviews (Clar et 
al, 2005;Ethgen et al, 2004) the report by MATCH (Dong et al, 2006), discussed above. 
 
The Clar review reported that TKR gives a utility gain of 0.1 QALY. This was obtained from an average 
of the HRQL gains reported from three studies. i) Drewett and colleagues (Drewett et al., 1992), using 
the Rosser scale, observed a HRQL increase of 0.064; ii) James and colleagues (James et al., 1996) 
used two different measures (EQ-5D and Rosser scale) on patient’s and consultants. EQ-5D gave an 
average HRQL gain of 0.201 among patients and 0.40 among consultants. Rosser gave a HRQL gain 
of 0.044 among patients and 0.069 among consultants; iii) Lavernia and colleagues (Lavernia et al., 
1997), using the Quality Well Being scale, calculated that TKR results in a HRQL improvement of 
0.0702 at 1 year and 0.055 at 4 years. Note the wide spread of values (0.04 to 0.4) in the study by 
James and colleagues, and the rather implausible gains obtained using EQ-5D, particularly those from 
consultants, which imply a patient would be willing to sacrifice nearly half their remaining life 
expectancy in order to undergo a TKR. Interestingly, if I take out the scores elicited using EQ-5D the 
average HRQL gain is 0.06, which seems more plausible. 
 
The Ethgen review reported HRQL scores following a TKR, measured using SF-36, from eight 
prospective studies (Bennett et al., 1997;Brazier et al., 1999;Dawson et al., 1998;Heck et al., 
1998;Lingard et al., 2001;Sharma et al., 1996;van Essen et al., 1998). Once again the utility scores 
were calculated using the algorithm described by Ara and Brazier (Ara et al, 2008a;Ara et al, 2008b). 
Two of the eight studies (Lingard et al, 2001;Sharma et al, 1996) did not report scores for all eight 
subgroups of the SF-36, necessary to calculate utility, and these studies were discarded. The average 
preoperative utility is 0.531 (using EQ-5D) and 0.617 (using SF-6D). The average postoperative utility 
is 0.695 (using EQ-5D) and 0.702 (using (SF-6D). The total QALY gain at 2 years following TKR is 
0.09 (using the SF-6D approach) and 0.16 (using the EQ-5D approach). Finally, the MATCH report 
gives a utility value of 0.78 associated with TKR at 24 months (assuming no problems).  
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7.6.5 Utility following Secondary Knee Replacement 
I have been unable to identify a utility score from the literature that is associated with a secondary 
TKR. The Ethgen review (Ethgen et al, 2004) reports physical function of hip replacement was 
significantly higher for those following primary surgery compared to those who had a revision. 
However, the review does not give any data on secondary knee replacements.   
 
7.6.6 Summary 
Table 7.5 shows the average utility scores associated with OA and TKR. I combined the results for 
severe OA with the pre-op scores of patients who received TKR; an indication for TKR is severe OA 
so I would expect all preoperative patients to be classified as having severe OA of the knee. I will use 
these scores in my subsequent CEA. The utility elicited by EQ-5D will be referred to as model 1 and 
the SF-6D as model 2 and the utility from the MATCH report as model 3. The VAS, TTO and SG 
results from Byrne and colleagues are shown for comparison however, these will not be used in 
subsequent analysis as this study only assessed OA and not TKR. The utility scores taken from the 
MATCH report are higher than those calculated using the algorithm by Ara and Brazier. 
 
Table 7.5: Average utility associated with osteoarthritis and total knee replacement  
state 
Utility 
Utility 
(Model 3) EQ-5D 
(Model 1) 
SF-36 
(Model 2) VAS TTO SG 
Source Calculated from literature* Byrne et al. 2005 Dong et al. 2006 
OA 
mild 0.51 0.61 0.73 0.81 0.73 
0.72 
severe  0.46 0.59 0.46 0.66 0.61 
TKR 
3 mth 0.71 0.69         
6 mth 0.65 0.68         
12 mth 0.72 0.72       
  
24 mth 0.70 0.70       0.78 
*The number of studies used to calculate the utility scores were as follows: mild OA – 3; severe OA – 7; Total 
Knee Replacement (TKR) – 6. 
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7.7 Costs of Treatment 
The total surgical costs for cartilage defect repair including days as an inpatient and follow-up 
physiotherapy rehabilitation sessions are given in the HTA monograph (obtained from the Aberdeen 
Royal Infirmary) (Clar et al, 2005) and summarised below and in table 7.6. These were updated where 
possible using the NHS national schedule of reference costs (Department of Health, 2006b). 
 
Mosaicplasty has a cost of £3,710 ($6,000, €4,200), an operation time of 120 minutes, a length of stay 
of 2.5 days and requires 15-20 physiotherapy sessions. Microfracture has a cost of £2,348 ($3,800, 
€2,700), an operation time of 60 minutes, a length of stay of 2 days and requires 15-20 physiotherapy 
sessions. Arthroscopic ACI has a cost of £3,184 ($5,200, €3,600), and operation time of 90 minutes, a 
length of stay of 1.5 days and requires 12 (2 inpatient and 10 outpatient) physiotherapy sessions. 
Open knee ACI has a cost of £5,446 ($8,900, €6,200), an operation time of 90 minutes, a length of 
stay of 7.5 days and requires 18 (8 inpatient and 10 outpatient) physiotherapy sessions. In addition to 
these procedure costs, ACI has an additional cost of £3,200 ($5,200, €3,600) for cell culturing. 
Microfracture is associated with a cost saving of £1,362 ($2,200, €1,500) over mosaicplasty and 
microfracture is associated with a cost saving over ACI of £4,036 ($6,600, €4,600) or £6,298 ($10,300, 
€7,200), depending on the type of ACI used (arthroscopic versus open knee) (Clar et al, 2005).  
 
The burden of TKR is considerable. In England and Wales in 2005/06 there were around 52,000 
primary TKRs (HRG code H04) at a cost of £5,843 ($9,500, €6,700) (Department of Health, 2006b). A 
TKR has an operation time of around 150 minutes (Clar et al, 2005), an average length of stay of 7 
days (Department of Health, 2006b) and requires 9 rehabilitation sessions (6 inpatient and 3 
outpatients) (Clar et al, 2005). On average patients can expect no more than 15-20 years before their 
joint replacements fail. For patients in their 70’s or 80’s this remaining life expectancy is generally 
sufficient to live out their life pain free. Patients in their 50’s or 60’s will generally out live their 
replacement and require further surgery. In England and Wales in 2005/06 there were 4,639 revisional 
procedures to the knees (HRG code H72) at a unit cost of £7,245 ($11,800, €8,300) (Department of 
Health, 2006b). A revisional knee procedure has an operation time of 270 minutes (Clar et al, 2005), 
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an average length of stay of 9 days (Department of Health, 2006b) and requires 17 physiotherapy 
sessions (12 inpatient and 5 outpatients) (Clar et al, 2005).  
 
Table 7.6: Procedure costs and resource usage associated with cartilage defect repair and 
knee replacement 
procedure Total cost 
operation 
time 
(minutes) 
length of 
stay (days) 
Rehabilitation 
(days) 
Cell 
Culture 
Cost 
Arthroscopy (day 
case)* £1,458 20 0 0   
Mosaicplasty £3,710 120 2.5 15-20   
Microfracture £2,348 60 2 15-20   
ACI arthroscopic £6,384 90 1.5 2 IP, 10 OP £3,200 
ACI open knee £8,646 90 7.5 8 IP, 10 OP £3,200 
First Knee 
Replacement* £5,843 150 7 6 IP, 3 OP   
Second Knee 
Replacement* £7,245 270 9 12 IP, 5 OP   
Adapted from Clar et al 2005; * 2006 NHS reference costs (Department of Health, 2006b) 
 
7.8 Cost-Effectiveness 
7.8.1 Review of Previous Cost-Effectiveness Analysis 
I identified two cost-effectiveness studies of ACI (Clar et al, 2005;Derrett et al., 2005). The first (Clar et 
al, 2005), used clinical outcome data from four RCTs and observational studies backed up by expert 
opinion. Short-term (1-2 years) and long-term (10-20 years) modelling was conducted. Note this CEA 
was conducted before publication of the five-year follow up results of Knutsen’s RCT. The lack of long-
term follow up clinical outcomes (such as later OA and knee replacement) made it impossible for the 
researchers to calculate the ICER with any accuracy. Illustrative modelling compared ACI with 
microfracture, mosaicplasty, and arthroscopic debridement. The researchers needed to formulate a 
broad range of assumptions concerning effectiveness and costs of each treatment. Sensitivity analysis 
was undertaken for several parameters, including the cost of ACI, the average time to TKR, the long-
term HRQL gains from all interventions (including TKR), and the discount rate. The latter (Derrett et al, 
2005), also conducted in 2005, is a two year retrospective comparison of costs and effectiveness of 
ACI and mosaicplasty. Some participants had previously been involved in the RCT that compared ACI 
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with mosaicplasty in 2003 (Bentley et al, 2003). This assessment is less ambitious than the Clar 
review, comparing just two treatments, and there was no long-term modelling. The results give QALY 
gains based on utilities obtained using EQ-5D. 
 
Short-Term Modelling 
Clar and colleagues assume all treatments provide a utility gain of 0.1. The health economic exercise 
becomes a CMA and, because it entails the lower costs, microfracture dominates all treatments. 
Sensitivity analysis assumes ACI gives an additional 0.1 QALY over microfracture per year. However, 
this gain is not sufficient for ACI to be cost-effective relative to microfracture. To be cost-effective at 2 
years, the gain from ACI would have to be 0.17 to 0.20 additional QALYs over microfracture; however, 
over 10 years the gain from ACI would have to be 0.11 to 0.12 additional QALYs over microfracture 
(given the £20,000 to £30,000 per QALY threshold recommended by NICE).  
  
Derrett and colleagues observe average higher costs and improved clinical outcomes (P>0.05) for ACI 
relative to mosaicplasty. Given the point estimate for utility differences of 0.17, the authors calculate 
an ICER for ACI relative to mosaicplasty of £16,349 ($26,700, €18,700). This falls beneath the implicit 
funding threshold for the UK NHS of £30,000 ($49,000, €34,000). Table 7.7 summarises the costs, 
utility gains and short term results of the two CE studies reviewed here.  
 
Table 7.7: Short-term cost-effectiveness results for different surgical treatments  
study treatment Average cost per patient(a) 
QALY gain over lavage 
and debridement 
ICER of ACI over 
alternative treatment 
Clar et al 
(HTA, 2005) 
ACI 
(arthroscopic) £6,384 0.30
(b)
  
Microfracture £2,348 0.20 £40,360 
Mosaicplasty £3,710 0.10  
Derrett el al 
(2005) 
ACI 
(arthroscopic) £10,600 0.23
(d)
  
Mosaicplasty £7,948 0.06(d) £16,349 
Adapted from Clar et al 2005 
a
 All average costs include immediate preoperative care, surgery, and cell culture. Derrett et. al. also 
includes costs of follow up to two years. 
b
 Assuming ACI gives an additional 0.1 QALY over microfracture and microfracture gives an additional 
0.1 QALY over mosaicplasty (based on expert opinion). 
c
 Not calculated because mosaicplasty is fully dominated by microfracture. 
d Calculated using EQ-5D. 
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Long-Term Modelling 
The only long term modelling identified is reported in the HTA study (Clar et al, 2005). Assuming 
principal long-term benefits are avoidance of OA and TKR, and TKR gives a utility gain of 0.1 QALY, 
the long-term modelling (20-30 years) shows mosaicplasty performs consistently poorly in terms of 
cost-effectiveness while ACI falls in second place behind microfracture the most cost-effective 
treatment.  
 
Assuming that among a cohort of 100 patients, all those offered a TKR accept it, the move from 
microfracture to ACI would reduce the number of patients requiring a TKR. However, this reduction 
would not be sufficient to outweigh the higher costs of ACI, making ACI roughly as cost effective as 
mosaicplasty and somewhat less cost effective than microfracture. The lack of long-term data and the 
fact that key data on which the model was constructed is subject to considerable uncertainty makes us 
question the soundness of these results. 
 
In summary, there is no evidence at present to say ACI is cost-effective compared to microfracture 
and mosaicplasty (Clar et al, 2005;NICE, 2005b). These results seem to be further supported by the 
latest evidence from Knutsen et al (2007), which compares ACI to microfracture after five years. Given 
that no significant differences in utility gain or failure of treatment between the procedures are found, 
and given the relatively high cost of ACI, currently microfracture is the most cost-effective treatment. 
 
ACI has great promise as a treatment for chondral lesions, and could be cost-effective in the future 
provided the technology fulfils expectations regarding the production of hyaline cartilage in the longer 
term (Clar et al, 2005). However, based on current evidence, NICE does not recommend ACI or MACI 
for  treatment of articular cartilage defects on the knee, except in the context of ongoing or new clinical 
studies designed to generate relevant clinical outcome data (NICE, 2005b).  
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7.8.2 My Cost Effectiveness Analysis 
Here I perform an extension on the CEA just reviewed. Microfracture is the current treatment of choice 
– the comparator for any new treatment. Firstly, I assess the headroom based on short term 
effectiveness. As a RM technology is already developed and the cost is known, the conventional use 
of the headroom method – to determine the maximum change in cost is not of much use, instead I use 
the headroom method, to find the minimum change in effectiveness, rather than cost, for a RM 
technology to be cost-effective. Secondly, I assess the headroom based on long-term effectiveness. 
Here I use the headroom method, to calculate the maximum change in cost of a RM technology. 
 
Short-Term Modelling  
This modelling takes account of short term changes in clinical outcome between different cartilage 
defect repair treatments only; it assumes no change in long term clinical outcome. Here I ask:  
 
“What is the minimum incremental effectiveness a competitive treatment should have in the short term 
to be more cost-effective than microfracture?” 
 
If the incremental cost (∆Cost) of the new technology is known, the minimum required incremental 
benefit (∆Effectiveness) can be calculated. I rearrange equation 1.3 (page 40) and calculate 
∆Effectiveness (equation 7.1). 
Equation 7.1: ∆Effectiveness = ∆Cost / WTP threshold 
 
I assume the ∆Cost of ACI over microfracture is £4,000 ($6,500, €4,500) (table 7.6, page 221). Using 
£30,000 ($49,000, €34,000) as the WTP threshold, I populate equation 7.1, and calculate that for ACI 
to be cost effective it needs to provide a gain of 0.13 QALYs relative to microfracture. If the WTP 
threshold is £20,000 ($33,000, €23,000) ACI would need to yield 0.2 QALYs more than microfracture 
to be cost-effective. Figure 7.3 illustrates the necessary total QALY gain required for different 
incremental costs.  
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Figure 7.3: Minimum incremental benefit for a new treatment based on different incremental costs of that same treatment 
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Assuming you know how much extra your new treatment/technology will cost, the minimum incremental QALY gain of required by the new 
treatment/technology compared to the current gold standard can be calculated. This figure illustrates the relationship between incremental QALY gain and 
incremental cost (up to an incremental cost of £5000). 
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Long-Term Modelling 
As previously discussed, the ideal RM solution would prevent or at least delay the onset of OA and 
ultimately abolish the need for a TKR. Here I endeavour to take account of long term changes in 
clinical outcome i.e. changes in the onset time of OA and need for a TKR, using the headroom 
method. All studies to date only measure effectiveness of cartilage repair treatment in the short term 
and the potential gains i.e. the effectiveness group, for a new treatment appears to be limited. 
Therefore, if expensive treatments are to be cost-effective their gain needs to be in the long term, in 
maintaining a pain free knee for the patient and delaying the onset of OA. Here I ask: 
 
“What is the maximum incremental cost a competitive treatment could be to be cost-effective in the 
long term?” 
 
Figure 7.4 illustrates the estimated disease progression over the long-term for different treatments. I 
illustrate the disease progression following microfracture (the current gold standard) and a new RM 
treatment as effective as microfracture in the short-term but with longer-term effects.  
 
Figure 7.4: Natural progression of disease for treatments with differing effectiveness 
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Estimating the Change in Effectiveness (∆QALY) 
Firstly, I use the utility values identified in section 7.7 (summarised in table 7.5, page 219) to calculate 
the disutility. I propose three models to account for varying utility scores. Model 1 illustrates the most 
optimistic scenario and model 3 illustrates the most pessimistic scenario. Secondly, I estimate the 
duration of the clinical effects of OA and TKR from the same studies, identified in section 7.7, which 
reported utility. Using this information, I estimate the maximum incremental QALY gain for the new 
treatment (table 7.8).  
 
Table 7.8: The maximum incremental QALY gains for a new RM treatment  
MODEL State Utility Disutility (1-Utility) Duration (yrs) Total QALY gain 
MODEL 1 
mild OA 0.51 0.49 7.5 3.7 
Severe OA 0.46 0.54 7.5 4.0 
TKR 0.70 0.30 15 4.6 
Total  
 
30 12.3 
  
    
MODEL 2 
mild OA 0.61 0.39 7.5 2.9 
Severe OA 0.59 0.41 7.5 3.1 
TKR 0.70 0.30 15 4.5 
Total  
 
30 10.5 
  
    
MODEL 3 
mild OA 
0.70 0.30 15 4.5 
Severe OA 
TKR 0.78 0.22 15 3.3 
Total 
  
30 7.8 
These tables show the total QALY gains possible over the duration of disease (assumed to be 30 
years) when compared to no treatment. Model 1 refers to utility values elicited from EQ-5D 
questionnaires. Model 2 refers to utility values elicited from SF-36 scores. Model 3 is utility data 
obtained from the literature (Dong et al, 2006).  
 
 
Calculating Headroom   
I calculate the headroom using equation 3.1 (page 76). Using the information given in table 7.8, I 
calculated the total number of QALYs saved per year; for model 1, this was 0.41, for model 2, this was 
0.35, and for model 3, this was 0.26. I created different scenarios for the effectiveness of the new 
treatment. At one extreme, I imagine the new treatment is so effective OA and TKR are avoided for the 
duration of remaining life of the patient (30 years), however, if possible the question would be a no 
  
227 
brainer but included for completeness. At the other extreme, I imagine the new treatment delays onset 
of OA by just 1 month. The results are shown in table 7.9. QALY gain is discounted by 1.5% per year 
and headroom (maximum change in cost) is discounted by 3.5% per year. In general, the results using 
model 3 (the least optimistic model), are £200 - £300 less for each given scenario than those using 
model 1 or 2.  
 
Table 7.9: The headroom for new treatment when compared to no treatment  
Model Scenario 
QALYs 
gained per 30 
years 
Headroom 
£30,000 threshold £20,000 threshold 
Model 1 
avoid OA and TKR 11.85 £355,646 £237,097 
delay onset of OA for 10 years 3.95 £118,549 £79,032 
delay onset of OA for 5years 1.98 £59,274 £39,516 
delay onset  of OA for 4 years 1.60 £47,869 £31,913 
delay onset of OA for 3 years 1.19 £35,565 £23,710 
delay onset of OA for 2 years 0.79 £23,710 £15,806 
delay onset of OA for 1 years 0.40 £11,855 £7,903 
delay onset of OA for 6 months 0.20 £5,927 £3,952 
delay onset of OA for 3 months 0.09 £2,841 £1,894 
 
  
  
Model 2 
avoid OA and TKR 10.02 £314,041 £209,360 
delay onset of OA for 10 years 3.34 £104,680 £69,787 
delay onset of OA for 5years 1.67 £52,340 £34,893 
delay onset  of OA for 4 years 1.35 £41,872 £27,915 
delay onset of OA for 3 years 1.00 £31,404 £20,936 
delay onset of OA for 2 years 0.67 £20,936 £13,957 
delay onset of OA for 1 years 0.33 £10,468 £6,979 
delay onset of OA for 6 months 0.17 £5,234 £3,489 
delay onset of OA for 3 months 0.08 £2,512 £1,675 
  
 
  
Model 3 
avoid OA and TKR 7.35 £220,499 £146,999 
delay onset of OA for 10 years 2.45 £73,500 £49,000 
delay onset of OA for 5years 1.23 £36,750 £24,500 
delay onset  of OA for 4 years 1.00 £29,850 £19,900 
delay onset of OA for 3 years 0.74 £22,050 £14,700 
delay onset of OA for 2 years 0.49 £14,700 £9,800 
delay onset of OA for 1 years 0.25 £7,350 £4,900 
delay onset of OA for 6 months 0.12 £3,675 £2,450 
delay onset of OA for 3 months 0.06 £1,759 £1,173 
Model 1 refers to utility values elicited from EQ-5D questionnaires. Model 2 refers to utility values 
elicited from SF-36 scores. Model 3 is utility data obtained from the literature (Dong et al, 2006).  
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If the treatment is successful in delaying the onset of OA by 5 years then the headroom for the cost of 
the new treatment is £36,750 ($60,000, €42,000) (based on model 3 in table 7.9). Table 7.9 can be 
interpreted another way and if the new treatment was expected to have an incremental cost of £1,000 
then commensurate benefit is an additional 0.04 QALYs over 30 years (based on equation 7.1, page 
224), equivalent to a delay in onset of OA by 2 months (based on model 3). 
 
7.9 Discussion 
7.9.1 Summary of Findings 
Studies conducted to evaluate the efficacy of microfracture, mosaicplasty and ACI have been of poor 
quality and the results conflicting. Currently no evidence base consensus has emerged regarding the 
best treatment option, for this reason NICE only recommends ACI and MACI for use in clinical trials. 
All existing CEA has found microfracture to be the current most cost-effective cartilage repair 
treatment. Using the headroom method, I have found that in the short term, based on an incremental 
cost similar to that currently held by ACI, a new RM treatment would need to provide an incremental 
gain of 0.13 QALYs. However, there is sufficient headroom for a new RM treatment, which is 
associated with long-term benefits i.e. delay in the onset of OA. 
 
7.9.2 Limitations  
The quality of the data is very poor with very few RCTs and no systematic reviews comparing cartilage 
repair treatments to each other or to no treatment. However, it would be difficult to conduct a 
systematic review until there is more consistency in measuring outcomes used to measure knee 
function and utility, following cartilage repair. Current studies use too many different specific 
measures, which cannot be compared in a meta-analysis. This is illustrated in tables 7.10 and 7.11. 
Essentially, until this issue is addressed, the evidence base in this area will be limited.  
 
Only one of the RCTs discussed (Knutsen et al, 2007) used a clinical outcome measure, which could 
be used to elicit utility. However, the author only gave results for the physical component score and at 
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present, all eight sub-scores of the SF-36 system are required to calculate utility. I contacted the 
author to request the data for the unpublished sub-groups but unfortunately this data was not available 
and therefore, I could not elicit a utility associated with having a cartilage defect and following cartilage 
repair treatments.  
 
The literature identified no utility values associated with having a cartilage defect prior to treatment. 
Either the studies have not reported this information, presumably because it was never collected, or 
the HRQL has been measured using a clinical outcome measure, which cannot be used to elicit a 
utility. 
 
The utility value associated with OA and TKR were calculated from SF-36 clinical outcome measures. 
However, this measure was used in a limited number of observational studies and no clinical trials. In 
addition there were variations between the utility scores calculated using the two methodologies by 
Ara and Brazier (Ara et al, 2008a;Ara et al, 2008b). These variations are due to differences in the 
importance of certain attributes for the two systems used; for example, SF-6D takes account of vitality 
whereas EQ-5D does not. Finally, I feel that the utility associated with OA and TKR are very low, and 
therefore may have overestimated the disutility of the clinical effects and consequently overestimated 
the headroom - the maximum incremental cost.  
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Table 7.10: Illustrates the number of clinical outcome measures used in short term RCTs 
Study 
RCT characteristics Clinical outcome scoring system 
Type 
Mean 
follow-up 
(months) 
N 
Cincinnati 
rating 
scale 
Modified 
Lysholm 
Score 
Lysholm  
Score 
Meyers 
Score 
Lysholm-
Gillquist 
Score 
Tegner-
Lysholm 
Score 
Pain 
(VAS) SF-36 (PC) KIOO 
Bentley et al. 2003 ACI vs. Mosaicplasty 19 100                  
Horas et al. 2003 ACI vs. Mosaicplasty 24 40                 
Dozin et al. 2005 ACI vs. Mosaicplasty NR 47                 
Basad et al. 2004 MACI vs. microfracture 12 46                
Knutsen et al. 2004 ACI vs. microfracture 24 80                
Saris et al 2008 CCI vs. Microfracture 18 118                  
Bartlett et al. 2005 ACI vs. MACI 12 91                  
Gooding et al. 2006 ACI - Periosteum vs. ACI 
- Collagen 24 46                  
 
Table 7.11: Illustrate the number of clinical outcome measures used in medium term RCTs 
Study 
RCT characteristics Clinical outcome scoring system 
Type 
Mean 
follow-up 
(years) 
N 
Modified 
Cincinnati 
rating scale 
Lysholm  
Score 
Tegner 
Score 
Pain 
(VAS) 
Global 
VAS 
SF-36 
(PC) 
SF-36 
(overall) 
Oxford 
knee 
score 
Hannover 
score 
Knutsen et al. 2007 ACI vs. 
microfracture 5 80               
Zaslav et al. 2009 ACI 4 154                
Peterson et al. 2003 ACI 11 101                  
Asik et al. 2008 Microfracture 5.5 90                
Hangody et al. 2003 Mosaicplasty 6 578                  
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7.9.3 Future Work 
To assess accurately the cost-effectiveness of ACI relative to other treatments, it is essential to 
have medium to long-term outcome data on durability of different types of cartilage repair and 
the utility associated to them (Clar et al, 2005;NICE, 2005b). Without these data evidence based 
modelling is impossible. It is also highly desirable that future studies on ACI provide comparable 
outcome scales, to facilitate the conduction of a meta-analysis. Research comparing accuracy 
and robustness of different scales relative to measurement of knee functionality is necessary. 
There is also a need for basic research into the genes and molecules that influence stem cells 
to become chondrocytes and to produce high-quality cartilage (Clar et al, 2005). 
 
7.10 Conclusion 
ACI is an RM technology already on the market, but which has been unable to get 
reimbursement (in the UK) due to its high cost for the incremental benefit gained. However, this 
is a rapidly changing field and there is a great deal of interest in developing cartilage repair 
technologies. As I have shown, if these technologies can sustain benefits for the long term, the 
technology has the potential to be a blockbuster. However, the difficulty is that trials with very 
long follow-up are required to prove effectiveness in the long-term. Currently no trial has 
produced such results although there are a number of ongoing trials, the results of which are 
eagerly awaited. 
 
Here the application of the headroom method has shown how it can be used to provide 
evidence for a business case. The supply side analysis has been used to calculate the 
incremental benefit required if the technology is to cost the same as ACI. On the other hand, if 
manufacturers believe their technology could generate effectiveness equal to that of ACI but for 
a fraction of the cost then they can demonstrate to investors they have increased probability of 
obtaining reimbursement.  
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 CHAPTER 8 AN ALTERNATIVE APPROACH TO THE 
CHALLENGE OF ELICITING UTILITIES 
 
8.1 Introduction 
One of the main advantages of the headroom method is that it is a relatively simple approach of 
obtaining the ‘headroom’, which can be applied by SME’s. When utilities are available in the 
literature they can be easily incorporated in the method. However, when they are not available 
separate studies are needed as described in the examples in chapters 4 and 5. However, the 
demand of formal elicitation of public preferences undermines the idea behind the Headroom 
Method, which is to provide a quick and simple thinking tool for the busy industrialist. A more 
pragmatic approach is required for this method to be routinely applied in practice. SMEs need to 
be able to make common-sense estimates of a utility value for a given health state based on 
information already available. In the following section, I describe a new approach I have 
developed, which aims to address the issues above.  
 
The forgoing discussion highlights an issue for the headroom method. On the one hand, eliciting 
utilities is a complicated process that is prone to error and beset with conceptual difficulties that 
have not been solved, many of which are underpinned by methodological challenges which may 
prove enduring. Furthermore, it is not the case that these problems can be resolved by a 
measurement of benefit, such as that obtained from WTP exercises. While such an approach 
may have many advantages over other methods, many of the same methodological issues 
remain. The point I am trying to make is that utilities are ephemeral in a way parameter 
estimates are not. In the case of parameter estimates there is broad agreement on what it is 
that is being measured, and how this should be done. In the case of utilities, however, there is 
much less agreement on the optimal methodology.  
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Faced with these issues, what is the manufacturer to do? On the one hand, expensive exercises 
to elicit utilities both violate the sprit of the headroom method and are likely to yield results of 
questionable value. On the other hand, utility (or benefit) values are necessary for economic 
modelling. The conundrum can therefore be simply stated as follows: utilities (or some other 
measure of benefit) are a requirement for headroom calculations. Yet primary studies to elicit 
these utilities are unlikely to be cost effective within this method. My approach to this problem is 
to provide manufacturers with a simple toolkit to obtaining utilities themselves. The method is 
based on using a ‘ladder’ of utility scores for well-known conditions to assist the user to assign a 
utility score to a condition for which no such score can be gleaned from the literature.  
 
8.2 Methodology 
My approach to this problem is to use ‘example’ utility values from the literature. My method 
relies on the decision makers’ judgements, prompted by a simple ladder of utilities, such as that 
illustrated in figure 8.1, which provides the range of utility estimates over a set of well-known 
disease states that cover a wide range of disability and distress. The idea is to provide a frame 
of reference against which decision makers can form a judgement concerning the disutility of/ 
utility of, states that have not yet been studied from the point of view of human preferences. 
 
Figure 8.1. Ladder of utilities scores 
1.0 Perfect Health 
0.8 Asthma 
0.6 Blindness 
0.4  
0.2 Severe depression 
0 Death 
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The second problem was to find a source of these utilities. The obvious place to start was the 
TUFTs database of utilities (Tufts Medical Centre, 2009). The TUFTS database consists, of a 
large matrix (7874 utility values, across 1654 studies and 68 disease classifications) and it can 
be quite difficult to select a limited number of values from a somewhat bewildering array of 
different values obtained from similar but not necessarily identical health states, elicited by one 
of eight different utility measurements. I tried to address this issue by grouping the utilities by 
method of elicitation, which to an extent was successful. However, this did not help overcome 
the issue that the descriptions of the health states were vague and often overlapping, such that 
it was difficult to summarise utilities across different diseases. I tried to overcome this problem 
by referring back to the relevant publication in an attempt to define the health state more 
precisely, but this was not as straightforward as I had originally hoped it would be. It was time 
consuming and raised issues around the quality of the utility values reported in the literature and 
subsequently reported in the database. Appendix 12 summarises the information gathered from 
the TUFTS database. 
 
An alternative source of utilities was required. I considered other sources of utilities where I 
could borrow strengths from previous work and identified NICE appraisals as one such source. 
The advantage of NICE appraisals was that i) the health states are reasonably tightly defined, 
and ii) NICE committees review the quality of the appraisals. Therefore, I decided it would be 
reasonable to assume that these utilities would offer the best estimates currently available in the 
literature.   
 
My first task was to identify the NICE appraisals and assign a disease topic to each of the 
appraisals. I identified 191 appraisals up to June 2010. Many of these were updates of an 
earlier appraisal so I removed any that had been superseded by a more recent review. I ended 
up with 138 appraisals, which covered 78 disease topics (see appendix 13). My second task 
was to identify the utility values. I did not intend to look through all 138 NICE appraisals. Rather, 
I surveyed the list to pick out conditions that on the face of it would cover a wide range of 
diseases/ sub-diseases, varying from psoriasis to motor neurone disease for example. This was 
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still a time consuming process as not all the NICE appraisals state the baseline utility score, 
(they frequently state only the QALY gain between the comparative treatments/ interventions). 
In these cases, I sourced the corresponding NICE Evidence Review Group (ERG) report and/or 
the NICE Technology Assessment Report (TAR) to gather the required information. Both the 
ERG report and TAR can be found via the advanced search function under published HTA 
report (http://www.hta.ac.uk/project/htapubs.asp), from here, there is a link to the corresponding 
NICE report and access to the ERG report and TAR.  
 
8.3 Results 
From the 138 appraisals identified I selected a range of diseases, which I thought would cover 
the spectrum of the utility scale (from 0 to 1) to be used to create a hierarchy or ‘ladder’ of 
utilities. This gave me 47 appraisals to scrutinise.  
 
For my first task, I collated the utility values from NICE TAR, ERG, or HTA reports. Where more 
than one utility value for a given health state was reported I selected the utility value based on 
the following hierarchy: TAR, ERG, and HTA. If this did not result in one utility for one health 
state, I then selected the most recent NICE appraisal, as was the case for psoriasis. In 23 of the 
appraisals, I could not identify a utility value. Thus, 24 appraisals were reviewed, resulting in 61 
utility values. The results are shown in table 8.1 below.  
 
Next, I constructed a utility hierarchy or ‘ladder’ using the selected utilities (shown in yellow in 
table 8.1) to provide a frame of reference against which decision makers can form a judgement 
concerning the disutility/ utility of health states that have not yet been studied from the point of 
view of human preferences. Not all the information in table 8.1 was illustrated graphically. There 
were two reasons for this i) some utilities are too unrealistic. For example, a utility of 0.86 was 
reported for inguinal hernia repair 3 months postoperative, implying a person would risk a 14% 
risk of death or give up 14% of there remaining life to escape from this state, and ii) some health 
states are too diffuse to be meaningful. For example, non-fatal stroke/ myocardial infarction. The 
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reader must be able to envisage the impact of the health state being described in order to make 
a sensible judgement about where the health state to be defined may lie.  
 
Finally, I chose to convey the selected utilities from table 8.1 across three utility ‘ladders’ 
(illustrated in figures 8.2 through to figure 8.4). There was an unmanageably large number of 
utilities reported in table 8.1, which could not all be presented clearly in one graph. Using figures 
8.2 through to 8.4, the industrialist can estimate the utility value required to conduct the 
Headroom Method by making a judgement based on the utility values stated for given disease 
states.  
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Table 8.1. Summary of Utility values gathered from NICE Technology Appraisals across a range of disease topics and health states 
NICE 
reference Disease Topic Health state Definition Utility 
NICE TA 
Utility 
ERG 
Utility 
HTA 
Utility 
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 8.5-9.5 
Totally helpless bed patient; unable to communicate 
effectively or eat/swallow -0.19  -0.19  
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 8.5-9.5 
Totally helpless bed patient; unable to communicate 
effectively or eat/swallow -0.15  -0.15  
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 7.5-8 
Essentially restricted to bed or chair or perambulated in 
wheelchair, but may be out of bed itself much of the 
day; retains many self-care functions; generally has 
effective use of arms 
-0.05  -0.05  
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 7.5-8 
Essentially restricted to bed or chair or perambulated in 
wheelchair, but may be out of bed itself much of the 
day; retains many self-care functions; generally has 
effective use of arms 
-0.01  -0.01  
TA59 Depression & Anxiety Severe depression Severely depressed, receiving inpatient treatment 0.09   0.09 
TA111 Alzheimer’s Disease Alzheimer’s Disease patients - Full time care  0.30 0.3   
TA146 Psoriasis Severe psoriasis DLQI > 10 and PASI > 10 0.31  0.31  
TA59 Depression & Anxiety Moderate depression Relapsed from maintenance therapy 0.32   0.32 
TA97 Depression & Anxiety Severe depression  0.38 0.38   
TA186 Rheumatoid Arthritis Severe active rheumatoid 
arthritis for more than 6 months 
disease has responded inadequately to conventional 
disease-modifying anti-rheumatic drugs 0.38 0.38   
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 6.5-7 
Unable to walk beyond approximately five meters even 
with aid, essentially restricted to wheelchair; wheels 
self in standard wheelchair and transfers alone; up and 
about in wheelchair some 12 hours a day 
0.39  0.39  
TA134 Psoriasis severe psoriasis DLQI > 10 and PASI > 20 0.41  0.41  
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 6.5-7 
Unable to walk beyond approximately five meters even 
with aid, essentially restricted to wheelchair; wheels 
self in standard wheelchair and transfers alone; up and 
about in wheelchair some 12 hours a day 
 
0.44  0.44  
TA20 Motor Neurone Disease 
Terminal Motor Neurone 
Disease 
Non-functional use of at least two regions and/or 
moderate or non-functional use of the third region 0.45   0.45 
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NICE 
reference Disease Topic Health state Definition Utility 
NICE TA 
Utility 
ERG 
Utility 
HTA 
Utility 
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 5.5-6 
intermittent or unilateral constant assistance (cane, 
crutch, brace) required to walk about 100 meters with 
or without resting 
0.45  0.45  
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 5.5-6 
intermittent or unilateral constant assistance (cane, 
crutch, brace) required to walk about 100 meters with 
or without resting 
0.49  0.49  
TA152 Coronary Artery Disease Severe angina  0.50   0.502 
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 4.5-5 
Ambulatory without aid or rest for about 200 meters; 
disability severe enough to impair full daily activities 
(work a full day without special provisions) 
0.51  0.51  
TA155 Macular Degeneration Blindness visual acuity < 20/400 0.52 0.518   
TA68 Macular Degeneration Blindness visual acuity 20/200 - 20/400 0.52   0.52 
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 4.5-5 
Ambulatory without aid or rest for about 200 meters; 
disability severe enough to impair full daily activities 
(work a full day without special provisions) 
0.56  0.56  
TA68 Macular Degeneration Severe visual acuity visual acuity 20/60 - 20/100 0.57   0.57 
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 2.5-3 
Moderate disability in one FS, or mild disability in three 
or four FS. Fully ambulatory 0.57  0.57  
TA97 Depression & Anxiety Moderate to severe depression  0.58 0.58   
TA97 Depression & Anxiety Depression in symptomatic phase  0.59 0.59   
TA59 Depression & Anxiety Mild depression  0.59   0.59 
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 2.5-3 
Moderate disability in one FS, or mild disability in three 
or four FS. Fully ambulatory 0.61  0.61  
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 3.5-4 
 
 
Fully ambulatory without aid, self-sufficient, up and 
about some 12 hours a day despite relatively severe 
disability; able to walk without aid or rest some 500 
meters 
 
0.61  0.61  
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 3.5-4 0.65  0.65  
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NICE 
reference Disease Topic Health state Definition Utility 
NICE TA 
Utility 
ERG 
Utility 
HTA 
Utility 
TA152 Coronary Artery Disease 
Coronary Artery Disease Post-
revascularisation  0.66   0.66 
TA48 Renal Failure End-stage renal failure patients 
on hospital haemodialysis 
Usually specialist units. A renal physician and a team 
of specialised nursing staff are on call at all times 0.66   0.66 
TA73 Angina and Myocardial Infarction 
Angina patients following 
diagnosis for coronary artery 
disease with a high risk 
myocardial infarction 
3VD and poor left ventricular function or left main 
vessel disease 0.67   0.67 
TA20 Motor Neurone Disease 
Moderate Motor Neurone 
Disease 
Mild deficit in all three regions 
Moderate to severe deficit in one region while the other 
two regions are normal or mildly affected 
0.67   0.67 
TA111 Alzheimer’s Disease Alzheimer’s Disease patients - pre-full-time care  0.69 0.69   
TA184 Lung Cancer Relapsed lung cancer  0.70 0.7   
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 1.5-2 Mild disability in one FS 0.70  0.7  
TA79 Epilepsy Child with epilepsy and learning disabilities  0.71   0.707 
TA20 Motor Neurone Disease Severe Motor Neurone Disease 
Needs assistance in two or three regions 
Speech is dysarythric and/or patient needs assistance 
to walk and/or needs assistance with upper extremity 
functions and activities of daily living 
0.71   0.71 
TA157 Venous Thromboembolism 
Deep Vein Thrombosis acute 
phase  0.73  0.73  
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 1.5-2 Mild disability in one FS 0.74  0.74  
TA98 ADHD Children with ADHD who do not 
respond to drug treatment 
Outcome was the same regardless of treatment (drug) 
type 0.77 0.773   
TA97 Depression & Anxiety Mild to moderate depression  0.78 0.78   
TA20 Motor Neurone Disease Mild Motor Neurone Disease 
Recently diagnosed. Mild deficit only in one of the three 
regions (speech, arm, leg). 
Functionally independent in speech, upper extremity, 
activities of daily living and ambulation 
0.79   0.79 
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NICE 
reference Disease Topic Health state Definition Utility 
NICE TA 
Utility 
ERG 
Utility 
HTA 
Utility 
TA59 Depression & Anxiety Depression in remission Responded to treatment, receiving maintenance therapy 0.79   0.79 
TA97 Depression & Anxiety 
OCD patients not responding to 
computerised cognitive 
behaviour therapy 
they have a Y-BOCS equivalent to the mean treatment 
score assumed to be 25 0.80 0.8   
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 0.5-1 No disability, minimal signs in one functional system 0.80  0.8  
TA73 Angina and Myocardial Infarction 
Angina patients following 
diagnosis for coronary artery 
disease with a moderate risk of 
myocardial infarction 
single or two vessel disease 0.81   0.81 
TA68 Macular Degeneration Moderate Visual Impairment visual acuity20/30 - 20/50 0.81   0.81 
TA48 Renal Failure End-stage renal failure patients 
on satellite haemodialysis 
Centres tend to be in smaller district general hospitals 
and have a reduced level of medical cover compared 
with specialist units. 
0.81   0.81 
TA98 ADHD Children with ADHD who 
respond to drug treatment  0.84 0.837   
TA76 Epilepsy Adult epilepsy poorly controlled  0.84   0.84 
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 0.5-1 No disability, minimal signs in one functional system 0.84  0.84  
TA79 Epilepsy Child with epilepsy  0.85   0.846 
TA131 Asthma Asthma patients - poorly 
controlled  0.85 0.85   
TA138 Asthma Asthma patients - poorly 
controlled  0.85   0.85 
TA83 Hernia Inguinal hernia repair 3 months postoperative period  0.86   0.855 
TA73 Angina and Myocardial Infarction 
Angina patients following 
diagnosis for coronary artery 
disease with a low risk of 
myocardial infarction 
No significant heart disease present 0.87   0.87 
TA127 Multiple Sclerosis Relapsing remitting multiple 
sclerosis EDSS 0 Normal neurological examination 0.87  0.87  
TA68 Macular Degeneration Normal Vision visual acuity 20/20 - 20/25 0.89   0.89 
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NICE 
reference Disease Topic Health state Definition Utility 
NICE TA 
Utility 
ERG 
Utility 
HTA 
Utility 
TA155 Macular Degeneration Normal vision visual acuity > 20/40 0.90 0.9   
TA127 Multiple Sclerosis Secondary progressive multiple 
sclerosis EDSS 0 Normal neurological examination 0.91  0.91  
TA97 Depression & Anxiety 
OCD patients responding to 
computerised cognitive 
behaviour therapy 
they have a Y-BOCS equivalent to a post treatment 
score of 6 0.92 0.92   
TA48 Renal Failure End-stage renal failure patients 
on home haemodialysis 
the same equipment and consumables are used in the 
home as are used for hospital haemodialysis 0.92   0.92 
TA76 Epilepsy Adult with epilepsy – well 
controlled  0.94   0.94 
TA182 Acute Coronary Syndrome 
Non fatal stroke / Myocardial 
Infarction  0.95 0.9476   
TA182 Acute Coronary Syndrome Acute coronary syndrome  0.96 0.9591   
TA131 Asthma Asthma patents 'symptom free'  0.97 0.97   
TA138 Asthma Asthma patents 'symptom free'  0.97   0.97 
TA97 Depression & Anxiety Depression free period  1.00 1   
 
Key: DLQI - Dermatology Life Quality Index, EDSS – Expanded Disability Status Scale, PASI – Psoriasis Area Severity Index , RRMS – Relapsing 
remitting Multiple Sclerosis, SPMS – Secondary progressive multiple sclerosis,  Y-BOCS – Yale-Brown Obsessive Compulsive Scale
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Figure 8.2. Hierarchy of utility values: range of conditions spread between 0 and 1.0 
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Figure 8.3. Hierarchy of utilities: focus on utilities between 0.5 and 1.0 
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Figure 8.4. Hierarchy of utilities: utilities for neurological disorders 
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For full definitions of 
these health states 
please refer to table 
8.1  
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8.4 Discussion 
The work in this chapter is designed to overcome one of the pitfalls of the headroom method, as 
applied in chapters 4-7. A measure of utility is a requirement for headroom calculations. If this utility 
value cannot be sourced from the literature, several complex methods of eliciting the required utilities 
exist. This formal approach to the elicitation of utilities goes against the premise of the headroom 
method, which is to provide a simple approach for use by manufacturer’s  (or those with little prior 
health economic knowledge and experience), to guide them through the challenge of conducting early 
economic evaluation.  
 
My approach to this problem was to provide manufacturers with a practical approach that would assist 
with the estimation of utilities for the relevant health state. For this, I needed to identify ‘example’ utility 
values from the literature, which could form a hierarchy of utilities upon which judgments about other, 
currently unidentified, utility values could be made.  
 
The main challenge I encountered here was identifying a suitable source of utilities. I first sought to 
source the utilities from the TUFTs database but this proved unsuccessful for the purposes of this 
work. The description of the health states were too vague and often overlapping, the range of values 
for a given health state were vast, and the quality of the utility values reported was unknown without 
further exploration. The TUFTs database provides useful information, such as the types of measure 
used but due to the difficultly in making comparisons across health states and determining what the 
‘true’ utility values were I could no longer continue with this option (see appendix 12). For this reason, I 
sought an alternative source and identified NICE appraisals as one such source. I felt it was relevant 
and appropriate to use these values as part of the Headroom Method, particularly as the headroom 
method has been demonstrated in the context of the NHS in this thesis. The advantage of NICE 
appraisals was that i) the health states are reasonably tightly defined, and ii) NICE committees review 
the quality of the appraisals. 
 
The second problem I encountered concerned the production of a visual scale that would be functional 
from the point of view of the manufacturer. The scale needed enough health states to be useful but not 
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so many that it was impossible to read. The presentation of the utility ladder has been an evolutionary 
process that has resulted in the production of three utility ladders to be used either alone or in 
conjunction with each other to aid utility estimation. In the end, I believe I have selected a suitable 
array of health states, which reflect a range of morbidities. The only criticism perhaps is that there are 
no health states corresponding to values between 0 – 0.3 on the utility scale. Although, this does 
reflect the fewer heath states that report such low utility-based QoL scores as well as the well known 
‘ceiling effect’ of the EQ-5D measure (utility estimation instrument recommended by NICE) (Bharmal 
et al., 2006).  
 
8.5 Conclusion 
Utilities are a requirement for headroom calculations. Yet, if utilities are not available in the literature, 
several complex methods of eliciting the utilities exist. Primary studies to elicit these utilities undermine 
the premise of the Headroom Method and are unlikely to be a cost effective use of resources within 
this method. I set out to devise a quick and easy solution to this problem and believe I have achieved 
this. The solution is based on the manufacturer being able to make common-sense estimates of a 
utility value for a given health state based on information already available. The existing information is 
provided in the form of a utility ladder (or utility hierarchy) and is designed to provide a frame of 
reference against which a manufacturer can make a judgement concerning the utility of a health state 
not yet studied from the point of view of human preferences. This pragmatic solution is consistent with 
the “back of the envelope” nature of the headroom method. 
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 CHAPTER 9 DISCUSSION  
 
9.1 Overview 
RM is an emerging multidisplinary field of medicine which focuses on the replacement or regeneration 
of human cells, tissues or organs, to restore or establish normal function (Mason et al, 2008). Despite 
a rapid proliferation of start up companies in the 1990’s as well as many scientific advances, RM has 
had few products make the transition from laboratory bench to large-scale production and ultimately 
patient bedside. The failed attempts have been due largely to insufficient marginal effectiveness 
delivered for marginal costs incurred. The aim of this work was to demonstrate to the RM industry how 
using health economics, the tools used to assess the most efficient (i.e. best value for money) use of 
available resources in the allocation of health and healthcare, could help the industry assess the 
economic potential of their products early in development. 
 
Economic evaluation is used to assess if increased costs of a new technology are justified by a 
sufficient increase in effectiveness. This CEA is usually performed after a product has been 
developed, i.e. from the demand side, and is used to provide compelling evidence to healthcare 
purchasers for its adoption within the healthcare systems. As a result, CEA is now considered the 
fourth hurdle to market. If, at the final product development stage, prior to market launch, a product is 
deemed not cost-effective and not appropriate for reimbursement the risk of commercial failure is high. 
Therefore, to effectively aid the RM industry CEA needs to be conducted before the product is 
developed (i.e. from the supply side). Over the last decade, interest in early economic evaluation has 
grown in all sectors of the healthcare industry. As explained in detail in chapter 2, the benefits of early 
economic evaluation extend beyond the assessment of future reimbursement and include, at the 
earliest stages helping to rationalise product development decisions (DiMasi et al, 2001) and further 
downstream to inform price determination (Brown et al, 2007).  
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As previously discussed, to effectively aid the RM industry, to reduce the risk of investment and secure 
future commercial success, economic evaluation needs to be conducted earlier in the product 
development cycle. However, a judgement of cost-effectiveness must start with effectiveness. This is 
all very well for conventional CEA but what if effectiveness is unknown – what if the product is yet to 
be developed? Chapter 2 details various methodologies that have been suggested for conducting 
economic evaluation earlier in product development. However, a number of limitations have been 
reported. Firstly, manufacturers are unfamiliar with some of the suggested methodologies and decision 
makers are reluctant to base decisions on them (Hartz et al, 2008). Secondly, manufacturers may not 
have the resources to conduct such complex modelling, particularly the case in the small companies 
that make up the RM industry. Based on these findings I propose a simple approach, termed the 
headroom method, which can be used to help healthcare industries avoid investing in a technology 
that is unlikely to be cost-effective. This methodology provides an alternative, at least in the first 
instance, to complex health economic modelling.  
 
The headroom method is useful as a barrier to misguidedly investing in those technologies that are 
unlikley to be cost-effective and reimbursed by the healthcare providers. This approach provides a 
framework to support investment decisions, which illuminates a situation that may otherwise be hard 
to fathom. I have focused on two key stages of this framework; defining the clinical problem – I have 
done this where others previously had not - and the headroom analysis itself. Firstly, after defining the 
clinical problem an effectiveness gap can be established – the room for improvement between the 
current treatment and the new treatment, this is an essential but not always a straightforward aspect. 
Secondly, the headroom can be calculated – the maximum additional cost, compared to the current 
best treatment, that a technology can be brought to market and still be considered cost-effective. If 
there is, little or no chance the technology could be marketed at a price that would keep the maximum 
incremental cost below the threshold (i.e. maximum change in cost) then the technology should not 
attract further investment.  
 
In chapters 4 through to 7, I demonstrated the headroom method with real examples from the RM 
industry. The technologies discussed had all passed strategic consideration stage and are under 
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active consideration for development. For each application, my first task was to define the clinical 
problem; this is essential risk assessment for anyone considering investing their time or money in a 
RM technology. This differentiated those applications with small headroom for improvement from 
those where the headroom is larger. My second task was to identify the most propitious applications 
for a RM technology and compare clinical effectiveness, with special emphasis on HRQL and utility, 
and costs of current treatment. Finally, I calculated the disutility of the clinical effects of the current 
treatment and conducted the headroom analysis to find the maximum additional cost of the new 
technology, which would still be considered cost-effective. The clinical applications considered 
included defects of the bladder, urethra, abdominal wall, bone, and cartilage. The specific findings 
relating to each application are discussed in the following section. 
 
9.2 Overall Findings 
9.2.1 Introduction 
The aim of this thesis has to help the RM industry reduce the risk of investing in a new technology that 
once developed is unlikely to be reimbursed by the healthcare providers. The objectives of this thesis 
were:   
i. To assess whether headroom method can be used, before the development process begins, to 
understand the scale of the market and clinical opportunity 
ii. To develop a novel method using health economic principles that can be used early in healthcare 
technology development and that is simple enough to be used by Small and Medium enterprises 
(SME’s) 
iii. To demonstrate to the RM industry how this method can be used to assess the economic 
potential of their products at early stage product development 
 
9.2.2 The Headroom Method 
The headroom method is an approach which has been demonstrated in this thesis to be a simple and 
rigorous way to make a preliminary conclusion as to the cost-effectiveness of a new treatment, even 
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when some of the parameters are extremely uncertain, without having to build a complex model with 
very wide parameter uncertainty.  
 
The Headroom Method arose from work on the use of economics to inform supply side decisions and 
had an intellectual and practical provenance. From the practical point of view, the purpose of the 
headroom method was to assist manufacturers and investors to assess the health economic value of 
proposed healthcare technology developments. From the intellectual point of view, the task proposed 
the challenge of performing a CEA in the absence of effectiveness parameter values. Both the 
practical and intellectual problem could be addressed by reversing the question that usually motivates 
a CEA, thus to establish the cost effectiveness gap, or the “headroom”, within which the technology 
could prove cost-effective. This methodology recognises that the limiting case is defined by the 
epidemiology of the condition, most notably the effectiveness of the current best treatment and an 
optimistic assumption concerning the effectiveness of the new technology.  
 
This thesis concentrated on the clinical definition and headroom analysis stages of the headroom 
method framework. However, each part of the framework plays a role in supporting decision-making. 
The key to successful exploitation is to know which tools to use and when.  
 
9.2.3 The Clinical Applications 
I illustrated the headroom method using five real clinical examples taken from the nascent RM 
industry. The main findings are summarised in table 8.1. In chapter 4, I investigated the potential for a 
TE technology in the repair of urethral strictures and bladder resection following cancer. The current 
treatment for urethral strictures is urethroplasty using buccal mucosa, which reports good 
effectiveness and therefore the headroom is unlikely to be large enough to support a TE tissue 
product populated with cells. Following bladder cancer, the current treatment is bladder augmentation 
cystoplasty using bowel. In this case, the headroom was more viable but this application has a limited 
market size, which reduces potential profitability. These findings were reported to a TE company who, 
at the time, were investing in TE bladders. Based on the findings they decided to reduce investment, 
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but not completely cease development, in TE bladders and channel the extra resources to more 
potentially profitable areas. 
 
In chapter 5, I investigated the application with the greatest potential for a TE solution for the repair of 
abdominal wall defects. Current treatment of abdominal wall defects is via tension free repair using a 
synthetic mesh. The headroom analysis found that the greatest room for improvement in effectiveness 
is when a defect is large and infected. I focused the headroom analysis on incisional hernias, 
specifically infected incisional hernias, those undergoing non-primary repair. In this case, the 
headroom was sufficient to support a new generation acellular mesh and it may be sufficient to 
support a cellular TE mesh, in other words, at this stage, the headroom was not too low to rule out 
supporting further investment, and further economic analysis could be conducted as development 
continues.  
 
In chapter 6, I demonstrated supply side analysis using an example based on a RM alternative to 
bone for use in bony defects. The current best treatment of a bony defect is to use autograft, usually 
taken from the iliac crest. The greatest potential for a RM bone product is in moderate to large defects 
and I focused on spinal fusion repair for degenerative disc disease (DDD), and on non-healing fracture 
repair for fracture nonunions and segmental defects. I discerned three broad alternatives for treatment, 
autograft harvested from the iliac crest (the current best treatment), in vivo bone production, via 
implantation of growth factors (i.e. using the body as a factory), and in vitro bone production (i.e. 
making bone outside the body). The body as a factory approach, specifically the growth factor BMP 
has gathered a lot of interest in the literature. However, recent cost-effectiveness analysis in the UK 
has found that this approach is not cost-effective compared to using autograft. Therefore, I decided to 
ask the question ‘What would the price of BMP need to be to become cost-effective?’ I found that BMP 
is very close to being cost-effective but currently the increase in effectiveness is insufficient to offset 
the additional cost of BMP. However, with a small decrease in the price or an improvement in 
effectiveness, it could be extremely cost-effective in the UK. Finally, in this chapter I conducted the 
headroom analysis based on pessimistic assumptions of the clinical effects of autograft. For both 
applications, the headroom was sufficient to support an in vivo approach of RM solution and possibly 
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for an in vitro solution. However, advances in in vivo approaches could mean that compared to in vivo, 
there would be insufficient headroom for an in vitro approach. 
 
In chapter 7, I focused on articular cartilage defects of the knee. There are several surgical 
approaches available but currently there is no truly effective strategy. There are already RM solutions 
on the market but they have not yet proved to be cost-effective compared with microfracture, the 
current best non-RM solution. Here I conducted supply side analysis similar to that used in chapter 6. 
Firstly, I asked ‘What is the minimum incremental effectiveness a new treatment should have in the 
short term to be more cost-effective than microfracture?’ and I found that a new RM treatment needs 
to provide an incremental gain of 0.13 QALYs, based on a cost similar to that held by the current RM 
products on the market. Secondly, I used the headroom analysis to answer the following question, 
‘What is the maximum incremental cost a new treatment could be to be cost-effective in the long 
term?’ Here, I used different scenarios based on delaying the onset of OA. In the long term if a new 
treatment was successful in delaying the onset of OA the cost-effectiveness issue is a bit of no 
brainer, however, by modelling the expected headroom based on different scenarios I can make 
predications about the expected headroom. For example if a new treatment could delay the onset of 
OA for 5 years, the headroom is approximately £36,000 ($60,000, €41,000).   
 
Above and in table 9.1 I have summarised the main findings from this work. However, there were a 
number of limitations and assumptions associated with this work, which one must be aware of when 
interpreting the findings. These are summarised in the following section. 
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Table 9.1: Summary of the main findings from the application of the headroom method 
Clinical 
Area Urogenital Abdominal Wall Bone 
Cartilage 
 
Indication 
for an RM 
solution 
Bladder 
Carcinoma 
Urethral 
Strictures 
Recurrent 
Incisional Hernia Spinal fusion 
Nonunion of 
Fractures & 
Segmental 
Defects 
Articular 
Defects of the 
Knee 
Current 
Treatment 
Bladder 
Cystoplasty 
using bowel 
Urethroplasty 
using buccal 
mucosa 
Tension free 
synthetic mesh 
repair 
Autograft Autograft Microfracture 
Disutility of 
Clinical 
Effects of 
Current 
Treatment 
0.04 0.06 0.15 0.0038 0.5 
Osteoarthritis: 
0.3 
Total knee 
replacement: 
0.22 
Duration of 
Clinical 
Effects (yrs) 
10 0.1 1 1 0.75 30 
Max∆QALY 0.4 0.006 0.075 0.0038 0.375 7.8 
Headroom 
(WTP 
threshold 
£30,000) 
£12,000 £180 £2,250 £114 £11,250 £234,000 
Additional 
Cost 
Savings 
£1,268 £225 
Early 
complications: 
£840 
Late 
complications: 
£668 
£819 £283 
Costs 
discounted at 
3.5%, benefit 
discounted at 
1.5% 
Max∆Cost £13,268 £405 
Early 
complications: 
£3,090 
Late 
complications: 
£3,758 
£933 £11,533 £220,500 
Conclusion 
Viable 
headroom 
but a limited 
market size 
reduces 
potential 
profitability 
Insufficient 
headroom 
 
Sufficient to 
support new 
generation 
acellular mesh 
and likely to be 
sufficient for a 
cellular TE mesh 
Headroom is sufficient to 
support an in vivo approach 
and likely to be sufficient for 
an in vitro solution. 
Advances in in vivo 
approaches could mean that 
compared to in vivo, there 
would be insufficient 
headroom for an in vitro 
approach. 
There is 
sufficient 
headroom for 
a new RM 
treatment if it 
can produce 
long-term 
benefits - 
delay the 
onset of OA 
and TKR 
 
9.3 Limitations of the Headroom Method 
As previously described, the headroom method is based on a number of assumptions: the most 
pessimistic scenario for the current treatment along with the most optimistic scenario for the 
new treatment. The reason for this is that, if under this scenario the new treatment is unlikely to 
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be cost-effective then, if the current is more effective than was thought and the new treatment 
less effective than hoped for, the new treatment will certainly not be cost-effective. 
 
The headroom method is designed to give a crude estimation of the potential cost-effectiveness 
of a new technology. Therefore, it is probably not necessary and would not be a good use of 
time and resources to try to calculate the parameters within a high level of accuracy. In fact, this 
would be difficult, given that the technology is not yet developed and there is no evidence of 
effectiveness from direct studies. However, with the presence of many assumptions comes a 
high level of uncertainty around the parameter estimates. Uncertainty in economic evaluations is 
usually explored using sensitivity analysis (described in chapter 1). Sensitivity analysis 
examines the effect on the result of using different assumptions around the parameter 
estimates. I have dealt with uncertainty within the analysis for each of the applications I describe 
(chapters 4-7). In all cases, I have calculated the headroom based on both a £20,000 and 
£30,000 threshold limit, to assess the impact of threshold limit on the headroom. In chapter 6 
(page 189), I illustrated the effect of threshold variation on the cost of the new technology. In 
addition, I have examined the impact on the headroom of varying the utility estimate or survival 
time (chapter 4, pages 106 & 107) and using utility values elicited from a number of methods 
(chapter 7) as it is well-known that method of elicitation impacts on the utility value obtained.  
 
The headroom has been calculated based on the threshold values applicable to a UK setting 
i.e. £30,000 ($49,000, €34,000) and £20,000 ($33,000, €23,000). These threshold values were 
selected because the UK has been more transparent than most other countries in clarifying a 
range where the threshold limit lies. However, any threshold value deemed to be appropriate by 
the manufacturers and investors can be applied. Thus, the headroom method is not restricted to 
use in a UK setting only. In fact, it could be regarded as a strength of the headroom method that 
the impact on cost-effectiveness for a range of threshold limits could be evaluated relatively 
quickly. Although, it should be noted that the value of applying these methods at the supply side 
is dependent on the planned technologies being aimed at the third party payer (an organisation 
other than the patient (first party) or health care provider (second party)). 
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Finally, I would say that the biggest limitation of the headroom method has been surrounding 
the elicitation of the health utilities. Ideally, these values would be sought from patients every 
time but this is not always practical which means other methods must be employed. I discuss 
the issue of health utilities including their limitations and impact on the headroom analysis in 
more detail in the following section. 
 
9.4 Health Utilities 
9.4.1 Introduction 
The headroom method is based on the health economic concepts used by NICE i.e. cost-utility 
analysis (CUA). As previously described (chapter 1, page 30), CUA is a particular kind of CEA 
where the benefits are measured on a utility scale, and QALYs are such a scale. Measured on a 
cardinal scale, from 0 to 1, health utilities measure the strength of an individual’s preference for 
a particular health state. Preferences can be measured using formal methods, of which there 
are a number of approaches, described in further detail elsewhere (section 1.2., page 30). 
Alternatively, a health utility may be identified in the literature. A health utility score is required in 
order to conduct the headroom analysis. Throughout the course of this work, I have used both 
approaches to identify a health utility. The methods used are described briefly below, followed 
by a summary of the limitations of the methods used. 
 
9.4.2 Summary of Methods  
Here I summarise the methods used to elicit utilities in chapters 4 through to 7 of this thesis. In 
chapter 4 and 5, there were no values reported in the literature so I elicited the utility values 
using formal methods, TTO and WTP. For TTO, each interviewee was asked what amount of 
time they would be willing to sacrifice from 10 years of remaining life, to avoid the negative side 
effects of the condition described to them. In WTP, participants were asked how much they 
would be willing to pay for a treatment that would relieve them of the described health state. 
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Combining the responses from both the WTP and TTO questions allowed me to calculate each 
individual’s WTP per QALY. 
 
Two of the three questionnaires used in chapter 4 and 5 were completed by specialist clinicians 
and the other was completed by a sample of the general public, selected at random from the 
public health building at the University of Birmingham and from two locations within Birmingham 
city centre. The urologists contacted as part of chapter 4 were identified from hospitals within 
the Birmingham area through the NHS website. Here the urologists were emailed the 
questionnaire. On the other hand, for chapter 5 I arranged to attend the conference of the 
Association of Coloprotology of Great Britain and Ireland and asked the attending clinicians. 
This decision was made in an attempt to achieve a larger sample size than was obtained 
through the emailing of questionnaires, yet to complete as many questionnaires as possible in a 
short time period.  
 
In chapters 6 and 7, I used the alterative approach to identify the health utilities; I sourced them 
from the literature. In chapter 6, I identified the utility associated with spinal fusion using 
autograft in a HTA report and the utility associated with nonunion fractures through a search of 
the database held by TUFTS (Tufts Medical Centre, 2009). In chapter 7, I needed to identify 
several utility values for different health states. For OA of the knee I identified four prospective 
studies, which had measured HRQL using SF-36. Using an algorithm described by Ara and 
Brazier (Ara et al, 2008a;Ara et al, 2008b) I was able to covert the sub-scores of SF-36 data into 
SF-6D and EQ-5D utility scores, from which I took the average to use in my analysis. I also 
identified a report by Dong and colleagues (Dong et al, 2006) which stated health utilities for OA 
and TKR. Health utilities associated with TKR were also identified from two systematic reviews 
(Clar 2005; Ethgen 2004). The Ethgen review reported HRQL scores measured using SF-36 so 
the same algorithms referred to earlier were used to calculate the utility values. 
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9.4.3 Limitations 
The analysis of the headroom for a TE bladder was limited by the small sample size used to 
elicit the health utility associated with cystoplasty using the bowel. Sixteen urologists were 
contacted but only four completed the questionnaire. I feel the failure to obtain a greater sample 
of clinicians was due to the emailing of the questionnaire. With high numbers of emails received 
everyday, it is easy to see how a questionnaire from an unknown individual could simply be 
missed. The success of this approach could have been improved by posting the questionnaires 
or arranging a telephone interview, or through increasing the sample of urologists who were 
initially contacted. Despite the low sample size I do believe that the utility value (0.96) elicited is 
acceptable and reliable. In comparison, the limitation of the utility values elicited for 
urethroplasty using buccal mucosa was concerned with a potentially unrepresentative sample of 
the general population. Those interviewed from the university were more familiar with both the 
health state under investigation and the methods of measuring preferences. Although, the 
sample size was larger than that for the previous questionnaire, I have reservations about 
whether this questionnaire was fully understood and feel the resulting utility value is slightly 
unrealistic. I offer three explanations for this. Firstly, a misinterpretation of the health states 
being described, secondly, a big error, and finally, a natural occurrence. It has been reported 
that the general public tend to exaggerate the impact of disease on HRQL (Ubel et al, 2003). In 
chapter 7, the health utility associated with OA and TKR were elicited from SF-36 scores using 
algorithms for SF6D and EQ-5D. There were two limitations here. Firstly, the SF-36 measure 
was only used in a small number of observational studies and no RCTs. Secondly, there were 
variations in the utility values calculated due to the variations in the importance of different 
attributes between SF-6D and EQ-5D.  
 
One of the main advantages of the headroom method is in its simplicity. However, when utility 
values are not available from the literature, several complex methods exist to obtain utilities 
using formal methods. This violates the spirit of the headroom method. Eliciting utilities is a 
complicated process, beset with conceptual difficulties that have not been solved. In addition to 
the complexity, these formal methods can be costly to conduct and therefore unlikely to cost-
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effective within this method. So faced with these issues, what is the manufacturer to do? Utilities 
are a requirement for headroom calculations. In the following section, I summarise my solution 
to this problem of utility elicitation in the context of the headroom method. 
 
9.4.4 An alternative approach to the challenge of eliciting utilities 
As discussed above, the current approaches to estimating the utility value of a given health 
state not previously reported in the literature go against the premise of the headroom method 
and a more pragmatic approach is required if the headroom method is to be routinely used in 
practice. A quick and easy approach, akin to the headroom method itself is required. A 
manufacturer needs to be able to make a common-sense estimate of a utility value for a given 
health state based on information already available. My approach was to provide a ‘toolkit’ for 
this purpose. For this, I needed to identify ‘example’ utility values from the literature, which could 
form a hierarchy or ‘ladder’ of utilities upon which judgements about other, currently unidentified, 
utility values could be made.  
 
The main challenge I encountered was identifying a suitable source of predefined utility values. 
My first idea was to use the TUFTS database of utilities but this proved unsuccessful for the 
purposes of this work. The descriptions of the health states were too vague and often 
overlapping, the range of values for a given health state were vast and the quality of the utilities 
reported were questionable without further exploration. For these reasons, I sought an 
alternative and hit upon the idea of using utility values reported in NICE appraisals. The 
advantages of the NICE appraisals were that i) the health states are  reasonably tightly defined, 
and ii) NICE committees review the quality of the appraisals. I concluded that it was reasonable 
to assume these utilities would offer the best estimates currently available in the literature. 
 
Having selected an array of health states to reflect a range of morbidities, I created a hierarchy 
of utilities. This is shown in figures 8.2 through to 8.4 (page 242) and is accompanied by table 
8.1 (page 237) which proves further detail of the definition of each health state. Together this 
information provides a frame of reference against which a manufacturer can make a judgement 
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concerning the utility of a health state not yet studied from the point of view of human 
preferences. This solution is consistent with the ‘back of the envelope’ nature of the headroom 
method.  
 
9.4.5 Discussion 
The quickest and easiest way to elicit health utilities is from the literature. However, there are 
two limitations here. Firstly, utilities have not been measured for all conditions, and therefore 
there may be no utility values reported at all, as was the case in chapter 6 for example. 
Secondly, the utility values reported in the literature vary in quality, or may be out-of-date. This 
makes it difficult to assess the accuracy and reliability of the health utility values reported. 
Overall, there needs to be an increase in the number of RCTs incorporating utility-based HRQL 
data collection. 
 
In the case where the literature did not report the utility values I required, (I believed) I had no 
option but to elicit this value myself. Therefore, I had to make a decision about which formal 
methods to employ, who to ask and how to ask them. I believe the approach I took in chapter 5 
was favourable over the approach used in chapter 4. In chapter 5,I took a more direct approach 
to the completion of the TTO questionnaires, and spoke directly with the clinicians. Obviously, it 
may not always be possible to attend a conference but I feel this experience taught me that a 
face-to-face interview is much more effective than an email or postal questionnaire where there 
is no contact with the interviewee. I also believe that a telephone interview approach would be 
preferable to a postal approach. However, I appreciate that arranging to call or meet with people 
is more time consuming to coordinate and conduct and therefore not always practical. In these 
cases, however, I acknowledge that it would have been ideal to elicit utilities directly from 
patients receiving the healthcare, but this is not always possible. I believe that clinicians are a 
better proxy for patients than the general public. Although, I do not disagree with the point that 
the general public are those who pay for healthcare and who represent public opinion, but I do 
not believe that the general public always have a full understanding of the condition being 
described to them. The disadvantage with asking clinicians, however, is around WTP as the 
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income between a clinician and the general public could be vastly different and therefore be 
unrepresentative. Despite this, I would still favour the clinician as a proxy due the reasons 
already outlined above. 
 
However on reflection after applying the headroom method to the examples given in chapters 4 
through to 7, I believe the concept of the headroom method is floored if a manufacturer is 
required to elicit the utility-based QoL measures directly (or indirectly) themselves, in order to 
calculate the headroom. One of the main advantages of the headroom method is in its simplicity 
and the use of complex formal methods goes against this premise. Chapter 8 is dedicated to a 
search to addressing this challenge and I believe I have achieved a solution that is quick and 
easy to use, akin to the nature of headroom method itself. This solution is by no means 
designed to replace the use of formal methods to eliciting utility values, but to be used as guide 
to estimate the potential headroom in effectiveness that may be available.  
 
9.5 Barriers to Innovation of RM Technologies 
As development progresses and nears market, further difficulties may arise. Some of these 
further barriers to innovation are discussed briefly below.   
i. Uncertainties – a major barrier to the adoption of technology is the requirement to provide 
sufficient evidence of effectiveness. Evidence on the effectiveness of a technology should 
ideally come from RCTs.  
ii. Silo budgets – silo budgeting is a major barrier to the adoption of technology. The 
segmentation of the delivery of healthcare by departments means you have to provide an 
economic argument for a single department. This is often very difficult, because while the 
cost may lie in one department, the benefit is accrued in another. For example, less 
invasive surgery may increase cost in the operating theatre, yet the benefit and cost saving 
is made on the ward. Ultimately a more joined-up system is required (Mark Sansom, 2005). 
Silo budgeting is a concern for manufacturers developing treatments that will benefit the 
long term but incur large up front costs.   
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iii. Business strategy – some products will aim at more than one application e.g. bone 
morphogenic proteins (BMPs). Each application may have a different ICER and headroom. 
Furthermore, the first application might not necessarily be the ‘big one’.  
 
9.6 Final Conclusion 
This thesis is inspired by the idea that health economics could reduce the risk of commercial 
failure and is concerned with the adoption of health economics in decision making at the supply 
side. The underlying idea is that the adoption of new technologies is determined (at least in 
part) by its cost-effectiveness and manufacturers and investors would be well advised to take a 
view on how their projects are likely to be assessed in the procurement of healthcare. 
 
The headroom method is an approach to the challenge of conducting supply side analysis. It is 
designed to help industry avoid misguidedly investing in those technologies that will never be 
cost-effective. It is intended for use in the first instance before substantial investments are made 
to inform investment decisions and indicate which products have the greatest potential. My 
thesis has demonstrated the headroom method in the context of the RM industry, which has had 
difficulties translating RM products from laboratory bench to patient bedside, due largely to 
insufficient marginal effectiveness delivered for marginal costs incurred.  
 
The advantage of the headroom method is in its simplicity. Designed to allow a manufacturer to 
conduct their own early economic evaluation and assess the potential for investment in their 
product. In addition, the headroom method, compared to full health economic modelling, is 
relatively cheap to conduct. During the early stages of product development, it is probably not a 
cost-effective use of a researcher’s time and resources to conduct a full health economic model. 
However, as I have already discussed, as development continues it is important to repeat the 
economic evaluation as further evidence becomes available. More sophisticated health 
economic tools will be required at this stage.  
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Investing in Medical 
Technologies: 
The Headroom Method  
 
 
The headroom method is an approach to help avoid misguidedly investing in 
those technologies that will never be cost-effective. This is a step-by-step guide 
for industry which will take you through conducting your own headroom 
analysis. 
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Introduction 
The changing face of health care purchasing                                                      
Health economics manages the scarcity of resources. It provides the tools necessary to assess 
the most efficient use of available resources in the allocation of health and health care. Cost-
effectiveness analysis, defined in terms of costs and consequences, is the comparative analysis 
of alternative courses of action. It tries to identify where more benefit can be produced at the 
same cost, or lower cost can be achieved for equal benefit*. 
  
Cost-effectiveness of a technology is compelling evidence for its adoption by healthcare 
providers. Healthcare markets are increasingly competitive. Health services are using cost-
effectiveness analysis to a greater extent to guide purchasing and reimbursement decisions. 
 
Cost-effectiveness analysis tells us the cost of achieving a particular goal. Assessment of 
whether this is worthwhile is made through reference to an external standard (e.g. specified 
budget or threshold limit). In the UK, the National Institute for Health and Clinical Excellence 
(NICE) is the body which assesses the evidence of clinical and cost-effectiveness of a particular 
technology and gives recommendations about whether and in what circumstances the 
technology should be used. NICE uses this approach to assesses the incremental cost-
effectiveness ratio (ICER) of the technology. This is the extra cost per extra unit of benefit 
achieved when comparing one technology against another. It determines whether an increase 
in cost is justified by a sufficient increase in effectiveness. Decisions are made based on a 
threshold level for an ICER†. Our purpose was to adapt cost-effectiveness analysis to inform 
investments and development decisions. 
 
Applying Health Economics Early in the Development Cycle 
Cost-effectiveness analysis is typically conducted from the demand side i.e. after the product 
has been developed and parameter estimates made available from direct studies. In the case of 
a technology yet to be developed, or in early stages of development, the very nature of the 
product is uncertain and no effectiveness studies have been conducted. We argue for the 
adoption of health economic principles at the supply side i.e. early stage development when 
                                                     
*
 A useful source of further information on health economics and cost-effectiveness analysis can 
be found in Drummond et al. 2006. Methods for the economic evaluation of health care 
programmes, 3rd Edition(1) 
†
 NICE is an independent organisation responsible for providing guidance on promoting good 
health and preventing and treating ill health. NICE produced guidance on its threshold level in 
2004(2). For technologies with an ICER below £20,000 per QALY this should be sufficient to 
obtain acceptance. For technologies with an ICER between £20,000 and £30,000 per QALY 
other factors need to be present to favour acceptance of the technology. For technologies with 
an ICER above £30,000 per QALY these additional arguments favouring treatments need to be 
strong. For more information on NICE see www.nice.org.uk 
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effectiveness is unknown. This will help inform investment decisions and indicate which 
products have greatest potential.  
We describe a method of cost-effectiveness analysis to be used at the supply side. We have 
called this the Headroom Method(3). This is a simple threshold approach, which estimates the 
maximum cost that a technology can be brought to market and still be considered cost-
effective. This document is a step-by-step guide of how to conduct your own headroom 
analysis. We illustrate the method using examples from the field of regenerative medicine.  
 
 
The Headroom Method 
The headroom method simply looks at the potential of a clinically defined market. Instead of 
asking, “How cost-effective will the technology be?” - The question for conventional cost-
effectiveness analysis of a technology already developed - we ask, “Would it be cost-effective if 
it works as well as one would hope?” In other words, optimistic assumptions are made about 
the incremental effectiveness of the proposed treatment over the best alternative. We then ask, 
“At what cost would this new technology be cost-effective?” This gives the maximum potential 
cost of the new treatment (including development costs), factoring in any health service 
savings.  
 
If this cost [the headroom] is too low - if the incremental cost of the product could not 
realistically be held below this level - then investment funds should be channelled elsewhere. Of 
course, the reverse is not true - the new technology might still fail despite adequate headroom. 
For example, it might turn out to be less effective or more expensive than hoped or novel 
competing alternatives may emerge. However, the headroom method can lower the risk of 
embarking on an investment that is doomed from the outset. 
 
The headroom analysis fits into a broader decision framework, illustrated in figure 1 below. In 
this guide, we will discuss stages 1-4 of the framework. We focus primarily on the aspects 
directly involved with understanding and undertaking the headroom method – stages 2 and 3 – 
defining the clinical problem and the headroom analysis. 
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Figure 1: Algorithm for investment Decisions for new Technologies(4) 
*
 
                                                     
*
 Discussed in a publication(5) 
2. Clinical Problem Definition 
•Epidemiology 
•Current treatments, including side 
effects 
•Market analysis 
3. Headroom Analysis 
•Establish effectiveness gap 
•Net maximum cost for the 
intervention 
Favourable 
Need more information 
Possibly cost-effective 
4. Return on Investment Analysis 
•Headroom x volume 
Favourable 
Wish to make an  
intuitive decision? 
5. Further Economic Evaluation 
•Bayesian probability distributions* 
No 
Favourable Revisit market analysis 
Negativ
e 
Discard 
No 
Brainer 
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discard as 
appropriate 
Insufficient 
Headroom Discard 
Judged 
Unfavourabl
e 
Discard 
Negative Discar
d 
Yes 
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appropriate 
1. Strategic Considerations 
•Strategic fit 
•PEST and SWOT Analysis 
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Stages in the Decision Algorithm 
1. Strategic Considerations 
You will be fully aware that an organisation needs to begin by addressing strategic fit issues and 
that management tools, such as PEST (political, economic, social, technology) and SWOT 
(strength, weaknesses, opportunities, threats) analysis, exist for structuring and defining a 
business problem situation. This process may do no more than formalise existing knowledge. It 
will however provide rigour to the decision and exclude obviously futile schemes. At the very 
least it reduces the risk that some important considerations will be accidentally omitted from the 
deliberations. In regenerative medicine there is an additional specific question you must ask 
yourself, “What changes to the regulations are in the pipeline?” If the technology is not ruled out 
by strategic considerations, then the investigation should move to the next stage; a study of the 
clinical problem and an analysis of how the technology may help.  
 
 
2. Defining the Clinical Problem 
In some circumstances, the decision to invest in a technology can 
be made without the need of any formal method of evaluation. If an 
unmet clinical need can be identified and resolved - such as curing 
a common, chronic disease at low cost – then the decision makes 
itself. These blockbuster discoveries come along only seldom. The 
cost-effectiveness of most proposed new technologies is much 
more difficult to predict. In such cases, it is important not to be 
carried away by enthusiasm for the technology or to over estimate 
the size of the potential market. 
 
All the conditions where a new technology may have an application 
need to be examined in turn; at least to the point where it is clear 
there is a material clinical problem to be solved. It is important to 
be as specific as possible about the clinical problem. A clearly 
defined clinical need based on a good understanding of the 
strengths and weaknesses of current treatment, including side 
effects is crucial to the uptake of a new technology. It is essential 
to complete this prior to conducting the headroom analysis.  
 
This point may sound obvious but, in our experience, investors and even inventors typically 
have a very vague, even naïve, understanding of the clinical problem. Table 1 below outlines 
the questions to aid you to establish a clear definition of the clinical problem.  
 
There is always a 
limit on how cost 
effective a new 
technology may be. 
The epidemiology 
and clinical features 
of the condition in 
question limit the 
potential benefit. 
This is the 
effectiveness gap – 
the room for 
improvement in 
effectiveness 
between the current 
best treatment and 
that which the new 
technology might 
plausibly achieve.  
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Table 1: Defining the clinical problem  
Questions Definition 
What is the 
technology? 
A precise description of new technology being considered, including a 
description of any uncertainties. For example, in the field of 
regenerative medicine it is uncertain whether a tissue-engineered 
bladder will become re-innervated with nerves. 
What is the 
disease/condition? 
A precise description of disease and natural history. This includes 
analysis of disease sub-groups where the new technology may be 
more or less applicable. For example, there may be a greater need for 
tissue-engineered bone for fracture nonunion repair than for spinal 
fusion surgery to treat degenerative disc disease. 
What is the 
prevalence and 
incidence of the 
disease/condition? 
This information can be obtained through a literature search of 
published studies. Hospital episode statistics (www.hesonline.nhs.uk/) 
can be a useful source of data on incidence. This data will need to be 
broken down by relevant sub-groups, since the effectiveness gap may 
vary widely by sub-group, as it does, for example in hernia repair. 
What are the current 
treatments? 
The current gold standard is the comparator for the new technology. 
However, new developments must also be reviewed as this may 
change the shape of the market. For example, the availability of bone 
morphogenic proteins is replacing the need for complicated bone 
scaffolds, especially those populated by living cells in vitro.  
What is the 
effectiveness of 
current treatments? 
The effectiveness, including any side effects and complications of the 
current gold standard treatment must be clearly described. Any side 
effects or complications, which could potentially be avoided by the 
new treatment, must be identified. For example, a tissue-engineered 
solution to repair complex hernias would avoid adhesions and 
infections, which result from current treatment. 
 
The vast majority of this information can be obtained through a systematic review of the 
literature. The sources that follow will be useful*, but it is important to back up this information 
with clinical opinion and experts in the industry.  
 
• NICE guidance (http://www.nice.org.uk/guidance/index.jsp) – is there any current NICE 
guidance regarding the treatment of the condition/disease you wish to target?  
• The Cochrane library (http://www.cochrane.org/) or clinicalTrials.gov (www.clinicaltrials.gov) 
– will contain any systematic reviews or economic evaluations that have been performed on 
                                                     
*
 Note that these sources are focused on UK information only. 
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the topic in question. It may also give you information on any ongoing clinical trials and 
when are the results due to be published. 
• PubMed (www.ncbi.nlm.nih.gov/pubmed/), Google Scholar (http://scholar.google.co.uk/), 
and EMBASE (www.embase.com/) – can be used to search for clinical trials (and 
observational studies). It is important to search for trials, which may have been published 
since the most recent systematic reviews, economic evaluations or NICE guidance. 
• Hospital episode statistics (HES), available from the NHS information centre, 
(www.hesonline.nhs.uk/) – contains information regarding admission numbers, defined by 
diagnoses and main operations, for England and Wales. 
• Department of health NHS reference costs 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/index.htm) - contains 
information on cost of treatment/procedures in England and Wales. 
 
 
3. Headroom Analysis 
The headroom method involves two key aspects: 
1. Establishing the ‘headroom’ in effectiveness – the effectiveness gap i.e. the room 
for improvement in effectiveness between the current best treatment and that which 
the new technology might plausibly achieve.  
2. Calculating the headroom - the maximum incremental cost (maximum additional cost 
compared to the current best treatment) of the new technology which could still be 
considered cost effective. This is based on optimistic but plausible estimates of 
effectiveness of the technology being assessed.  
 
Before we can do the calculation, we must go over some basic health economics principles: 
1. Incremental Cost-Effectiveness Ratio (ICER) 
Cost-effectiveness analysis aims to quantify the incremental cost-effectiveness ratio (ICER). 
This is the extra cost per extra unit of benefit when comparing one technology against another. 
This is most often done on a cost per quality adjusted life year (QALY)* basis† (QALYs are 
discussed below).  
                                                     
*
 For a quick and easy introduction to QALYs see ‘what is a QALY’ by Phillips et al.(6) 
†
 There are different types of economic evaluation each using different measures of 
effectiveness: i) cost-minimisation analysis (CMA) – a comparison of costs; ii) cost-effectiveness 
analysis (CEA) – effectiveness measured in  natural units e.g. life years gained; iii) cost-benefit 
analysis (CBA) – effectiveness and costs measured in monetary units; iv) cost-utility analysis 
(CUA) – effectiveness measured on a utility scale e.g. QALY. More information can be found in 
any health economics textbook, such as Drummond et al. 2006. Methods for the economic 
evaluation of health care programmes, 3rd Edition(1) 
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The comparator for the new technology should always be the current gold standard treatment. 
Only an improvement on this performance, in terms of cost-effectiveness, will support the 
reimbursement of a new technology. The current gold standard treatment should have been 
identified during stage 2 - defining the clinical problem. 
 
An ICER is calculated as in equation 1, using the incremental cost (change in cost from 
treatment A to treatment B (∆C)) and the incremental effectiveness (change in effectiveness 
from treatment A to treatment B (∆E)). This gives a cost per additional unit of effectiveness, or 
an incremental cost per QALY (see box 1).  
Equation 1: ICER = ∆C / ∆E 
 
2. Quality Adjusted Life Year (QALY) 
A QALY is a measure that takes into account both the quantity and the quality of life generated 
by healthcare. Quantity is expressed in years, in terms of survival or remaining life expectancy. 
Quality is measured by health utilities*.  
 
A health utility measures the strength of an individuals’ preference for a particular health 
outcome. It is measured on a scale from 0, death, to 1, perfect health (see figure 2). A greater 
preference for a particular health outcome will result in a greater utility for that health outcome. 
A year of perfect health is worth 1 i.e. 1 QALY is equal to 1 year of perfect health.  
 
Figure 2: Health utility Scale 
 
 
 
 
 
 
 
 
 
Total incremental QALY (∆QALY) for a technology is calculated as in equation 2. It is a function 
of improvement in health utility (∆utility) and the duration over which this improvement is 
sustained (see Box 2), when the new technology is compared to the current gold standard.  
Equation 2: ∆QALY = ∆Utility x duration of time (years) with that health state 
                                                     
*
 Utilities place a value on a particular health state and are used to calculate QALYs, unlike 
quality of life scores which directly measure the impact of a disease or treatment on people’s 
ability to function in life and which cannot be used to calculate QALYs. For a quick and easy 
introduction to health utilities see ‘what is a utility’ by Petrou(7). 
Total Knee replacement 
= 0.78 
Perfect Health = 1.0 
Death = 0 
A health utility is expressed on a scale 
from 0 to 1. For example, a total knee 
replacement gives an average utility of 
0.78. The quality of life is 0.78. A 50-year-
old patient with a life expectancy of 80 
years has a quantity of life of 20 years. The 
QALY gain would be 0.78 x 20 = 15.6 
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Box 2: Calculating incremental QALY gain 
∆QALY = (utility score of treatment B x duration (years) of that health state) 
- (utility score of treatment A x duration (years) of that health state) 
Where,  
QALY is Quality adjusted life year (measure of effectiveness). 
 
Example: 
Treatment A is current gold standard. Following treatment A, the patient lives for 15 years 
with a health state of 0.6. Treatment B is the new treatment. Following treatment, B the 
patient lives for 15 years with a health state of 0.8. 
 
∆QALY = (0.8-0.6) x 15) = 0.2 x 15 = 3 QALYs 
 
Thus, treatment B results in 3 additional QALYs compared to treatment A. in other words, 
treatment B results in the equivalent of 3 additional years of perfect health compared to 
treatment A. 
Box 1: Calculating an Incremental Cost Effectiveness Ratio (ICER) 
1. ∆C = cost of Treatment B – cost of Treatment A 
2. ∆E = benefit of Treatment B – benefit of Treatment A 
3. ICER = ∆C / ∆E 
Where,  
∆C is the difference in cost between the new treatment and the gold standard comparator, 
∆E is the difference in effectiveness between the new treatments and the gold standard 
comparator 
 Note: ∆E can be measured in different terms, in the UK, this is most frequently the QALY, 
calculated using the formula in box 2. ∆QALY becomes the measure of the change in 
effectiveness between the two treatment options thus, ICER = ∆C / ∆QALY  
 
Example: 
Treatment A is current gold standard it costs £50,000 and gives 9 QALYs. Treatment B is 
the new treatment it costs £100,000 and gives 16 QALYs. 
1. ∆C = £100,000 – £50,000 = £50,000 
2. ∆QALY = 16 – 9 = 7 QALYs  
3. ICER = ∆C / ∆QALY = 50,000 / 7 = £7,142 per QALY 
 
Treatment B costs an additional £7,142 per QALY compared to Treatment A. The 
healthcare provider must now decide whether this is an acceptable cost per QALY.  
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QALY  
Quality adjusted 
life year – takes 
into account both 
quantity and 
quality of life 
generated by 
healthcare (pg 8). 
ICER   
Incremental cost-
effectiveness 
ratio - the extra 
cost per extra 
unit of benefit 
when comparing 
one technology 
against another - 
most often done 
on a cost per 
QALY basis (pg 
8). 
3. Cost Effectiveness Plane 
New technologies can be represented graphically according to their cost and effectiveness on a 
cost-effectiveness plane (figure 3)(8). This can determine which interventions are cost-effective 
and which are not i.e. which technologies may be eligible for reimbursement by the healthcare 
system.  
 
In figure 3, a straight line passes through the origin, where cost is 
equal to benefit. The gradient of this line is dependent on the 
threshold limit of the ICER. This is the maximum cost a healthcare 
provider will pay for 1 QALY. It is also referred to as the maximum 
willingness to pay (WTP) threshold i.e. the maximum WTP for 1 
QALY. This will vary from country to country.  
 
The line divides the plane into cost-effective (right half) and non-
cost-effective (left half) sections. The ICER for the technology can 
then be plotted on the plane. Depending on their position, the 
technology may either be accepted or rejected for reimbursement 
by the healthcare provider. 
 
As stated earlier, assessment of cost-effectiveness needs to be 
compared to an external standard. In the UK, NICE carries out this 
assessment and uses a WTP threshold limit of £20,000 to £30,000 
per QALY. In other words, the healthcare provider in the UK is 
willing to pay £30,000 for 1 QALY.  
 
The ICER of a regenerative medicine technology is mostly likely to be in quadrant ii (better but 
more expensive). You need to make sure the additional costs of the technology are equal to the 
additional benefits. This will bring the ICER of the new technology below the WTP threshold, 
making it more likely to receive reimbursement. 
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Figure 3: Cost effectiveness Plane illustrating reimbursable region 
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Calculating Headroom  
Now we know how to calculate an ICER we can work out how to calculate the headroom. We 
rearrange equation 1 into equation 3 below. We substitute ‘ICER’ with ‘WTP threshold’. We 
assume the WTP threshold is £30,000 - the most optimistic scenario for the UK NHS. Next, we 
need to estimate the maximum ∆QALY. 
 
Equation 3:  max ∆Cost = WTP threshold x max ∆QALY 
 
 
 
 
 
 
 
 
 
max∆cost is the headroom – the 
maximum additional cost of new 
treatment over the comparator 
(current gold standard) for the new 
treatment to be deemed cost-
effective. It is important to note 
that max∆Cost is the net 
difference in cost [to the health 
service] of the proposed new 
technology. It includes any net 
savings or costs to the health 
service along with the costs of the 
product itself.  
WTP threshold is 
maximum threshold 
for the incremental 
cost effectiveness 
ratio. In the UK, we 
assume this to be 
£30,000 per QALY. 
Equation 3 can also 
be expressed as: 
max ∆Cost = 
£30,000 x max 
∆QALY.  
 
max∆QALY is the 
effectiveness gap - 
the maximum 
additional benefit 
that could be 
obtained from the 
new treatment, this 
must be estimated 
before we calculate 
the headroom (see 
below). 
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Estimating the Maximum ∆QALY – the Effectiveness Gap 
When the current treatment is sub-optimal, an effectiveness gap can be estimated. For those 
conditions with treatments, which are ineffective for large proportions of patients or have 
significant side effects, the maximum potential increase in effectiveness over current treatment 
may be used as the optimistic assumption. Specifically we are looking for those side effects that 
could be eliminated by the new treatment – these should have been identified during stage 2 
(defining the clinical problem).  
 
There are two steps required to calculate the effectiveness gap (max∆QALY): 
 
1. Health utility associated with the current treatment 
Having defined the clinical problem and existing treatment, it is possible to identify the clinical 
outcome that the new treatment should improve – in the simplest case, there will be one target 
outcome. Next, it is necessary to identify the health utility value associated with that clinical 
outcome. Health utilities can often be identified in the literature or in the database of utilities (9) 
held by TUFTS. If not, the utility values will have to be established by conducting a primary 
survey. Methods of utility estimation are summarised in the box 3.  
Finally, we define the effectiveness gap. We subtract the utility value we have identified from 1 
(perfect health). Since we do not know the true effectiveness of our new technology, we assume 
the most optimistic scenario. This would be for the new technology to return the patient to 
perfect health (health utility = 1).  
 
For example, the current gold standard treatment for people with severe osteoarthritis is total 
knee replacement. This treatment has an average utility of 0.78(10). The effectiveness gap for 
the new treatment would be 0.22.  
 
 
 
 
 
 
 
 
Maximum potential health utility 
of new technology = 1 (perfect 
health). 
Health utility of current treatment 
(total knee replacement) = 0.78. 
Maximum potential effectiveness 
gap for a new technology = 1 – 
0.78 = 0.22 
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2. Estimation of duration of the improvement in effectiveness 
We have defined the maximum potential effectiveness gap for the new technology compared to 
the current treatment. The next step is to identify the maximum potential duration of the clinical 
benefit expected from the new treatment. If there is no difference in life expectancy, it is 
necessary only to consider the period of time during which the health utility values differ. If there 
is likely to be a difference in life expectancy with your new treatment then this must be included 
in the calculation.  
 
For instance, a new generation alternative to total knee replacement would be unlikely to 
increase life, but it is likely to improve the health utility of the patient. As there is no extension in 
life, only the duration of the improvement in clinical benefit is taken into account, i.e. the 
duration of the side effects of the current treatment that would be abolished by the new 
treatment.  
Box 3: Measuring Utilities 
 
Measuring utilities involves three stages:  
1. define a set of health states of interest (e.g. side-effects of current treatment); 
2. identify individuals to obtain utilities from (e.g. patients, clinicians, general public); 
3. total across the individuals to determine average values for each health state 
 
There are formal methods for measuring utilities: 
 
- Firstly, those elicited from general population (recommended by NICE), such as 
rating scale, standard gamble and time trade-off. The most common approach is time 
trade-off (TTO). The subject is offered two alternatives: a) health outcome U for time t 
(life expectancy of an individual with chronic condition, e.g. 10 years) followed by 
death; b) healthy for time x < t followed by death. Time x is varied until subject is 
indifferent between the two alternatives at which point the required preference score 
for health outcome U is given.  
 
- Secondly, those elicited from patients directly who are using the technology. These 
are pre-scored multi-attribute health classification systems such as EuroQol (EQ-5D 
– www.euroqol.org).  
 
For more information on these techniques, refer to a standard health economics textbook, 
such as Drummond et al. 2006. Methods for the economic evaluation of health care 
programmes, 3rd Edition, Oxford (1). 
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For example, a patient receives a total knee replacement at an average age of 55 years and 
has an average life expectancy of 70 years. The improvement in clinical benefit associated with 
the new generation alternative to total knee replacement would have duration of 15 years. We 
now calculate the incremental QALY gain as illustrated in box 2. This gives a maximum 
incremental QALY (max ∆QALY) gain of 3.3 QALYs. 
 
 
 
 
 
 
 
Now we have all the necessary parameters to populate equation 3 we can calculate the 
headroom (max∆cost). For example, the headroom (max ∆Cost) for a new generation 
alternative to total knee replacement is calculated as £99,000.  
 
 
 
 
 
The headroom tells us that a new generation alternative to total knee replacement could be 
cost-effective if it costs under £99,000. This is based on an assumption that it restores perfect 
health to the patient and lasts for the remainder of the patient’s life.   
 
Two examples of the headroom method from the field of regenerative medicine are given in the 
boxes below. Both have “passed” the strategic considerations stage and are under active 
consideration for development in industry. More detailed accounts of this work can be found in a 
publication by McAteer et al.(11).  
Maximum potential effectiveness gap for a 
new technology = 1 – 0.78 = 0.22 
Maximum potential duration of 
effectiveness gap = 70-55 = 15 
Maximum incremental QALY gain = 
0.22x15 = 3.3 
Maximum incremental QALY gain (max 
∆QALY) = 0.22x15 = 3.3 
Headroom (max ∆Cost) = WTP threshold x 
max ∆QALY = £30,000 x 3.3 = £99,000 
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Box 4: Regenerative Medicine for Urethral Stricture 
 
1. Defining Clinical Problem 
An urethroplasty is the current treatment option for long or complicated urethral strictures. A urethral 
stricture is an abnormal narrowing of the urethra, which adversely affects the passage of urine. In an 
urethroplasty, the narrowed section of the urethra is surgically opened or removed, and the urethra 
repaired with a tissue graft. Buccal mucosa (tissue making up the lining of the cheek) is the gold 
standard urethral substitute. Like urethral tissue, it is a mucous membrane, with similar physical 
properties, although it has disadvantages relating to morbidity at the donor site. TE aims to replace 
the use of tissue grafts in this procedure. 
 
2. Estimation of Parameters 
We assume that a tissue-engineered substitute would avoid donor site morbidity and perform as well 
as natural autologous tissue with no difference in mortality. Estimates will be required for the utility of 
avoiding donor site morbidity and the time over which the utilities for the treatments would differ. 
 
A systematic review of the literature revealed no utility values for patients following an urethroplasty 
using buccal mucosa. Instead, the quantity was obtained from the general public using the time trade-
off (TTO) method (see box 3). The utility associated with side effects of buccal mucosa was 0.94. 
After consultation with clinicians, the duration of the side effects was estimated as 0.1 years. 
 
The effectiveness gap is: 1 - 0.94 = 0.06, and max∆QALY is: 0.1 x 0.06 = 0.006 
 
3. Headroom Analysis 
The headroom is calculated using: max ∆Cost = WTP threshold x max ∆QALY. Thus, £30,000 x 0.006 
= £180 per patient treated. 
 
However, this does not take into account the saving in operation time resulting from avoiding the 
harvesting of tissue. There is a saving of about 40 minutes in operating time. This is calculated as 
£225 per patient (based on a total operation cost of £3480 (HRG code L33, Department of Health 
reference costs) and a total operation time of 75 minutes). Thus, total headroom is £405. 
 
4. Conclusion 
The headroom for tissue-engineered urethral tissue has been optimistically estimated to be £411 over 
and above the current cost of a tissue grafting operation. It is unlikely that this is large enough to 
support the launch of a cell-bearing TE product, according to consultations with the industry. 
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Box 5: Regenerative Medicine for Surgical Treatment of Bladder Cancer 
1. Defining the Clinical Problem 
When bladder capacity or function has been substantially reduced current best surgical intervention is 
by means of an augmentation cystoplasty procedure (bladder reconstruction surgery). This increases 
the bladder capacity by directly increasing the volume of the bladder by stitching a section of small 
intestine into the bladder. A tissue-engineered bladder would most likely be used as an alternative to 
bowel in cystoplasty following bladder removal for cancer. Other indications (dysfunctional bladder 
and bilharzia) are not favourable due to the existence of non-invasive treatments and market forces, 
respectively. 
 
2. Estimation of Parameters 
We assume that a tissue-engineered bladder would avoid complications relating to the use of bowel 
and there would be no difference in mortality. Estimates will be required for the utility of avoiding use 
of bowel and the time over which the utilities for the treatments would differ. 
 
A systematic review of the literature revealed no utility values for patients following a cystoplasty using 
bowel. Due to the complex nature of the problem, we obtained the health utility from urologists using 
the time trade-off (TTO) method (see box 3). The utility value relating to the use of bowel in 
cystoplasty was 0.95. We assume the improvement in clinical benefit will last for the remainder of the 
patient’s life. The average age of presentation of this condition is 72 years. We assume that the 
duration of the improvement to be an average of 10 years. 
 
The effectiveness gap was: 1 – 0.96 = 0.04, and the max∆ QALY of: 10 x 0.04 = 0.4 
 
3. Headroom Analysis 
The headroom is calculated using: max∆Cost = WTP threshold x max∆QALY. Thus, £30,000 x 0.4 = 
£12,000 per patient treated. 
 
However, this does not take into account savings in hospital bed days by avoiding bowel surgery of 
£1,268 per patient (based on a hospital bed day cost of £317 (Department of Health national average 
cost of excess bed day) and a mean saving of 4 hospital bed days).  
Headroom is hence £13,268 per patient treated. 
 
4. Conclusion 
The headroom for TE bladders has been optimistically estimated at around £16,000 over and above 
the cost of ileocystoplasty. The industry experts we consulted were optimistic that this was a 
potentially viable price. However, profit would be volume dependent and in this case, market size may 
not be large enough. 
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4. Return on Investment 
For technologies that appear to have headroom, continuing development and investment would 
appear to be justified. At this stage we focus on whether or not the technology has the potential to 
succeed once brought to market. Return on investment may be affected by the rarity of a condition or 
because it occurs, only in economies unable to support high cost remedies.  
 
The revenue that can be generated is a function of the headroom, the likely cost and volumes (see 
equation 4). The expected profit should also be discounted over a time horizon chosen to reflect the 
company strategy. 
 
Equation 4: Revenue = (max ∆Cost – C’) x Volume 
 
 
For example, in the case of tissue-engineered bladder, the return on investment is estimated as £4 
million. This is assuming each device costs £8,000 and there are 500 cases per year.  
 
 
 
Conclusion 
The framework discussed here provides a structure for investment decisions. The headroom analysis 
is useful as a barrier to misguidedly investing in those devices, which can never be cost- effective. If 
there is little or no chance the technology could be marketed at a price that would keep the maximum 
incremental cost below the threshold (i.e. at the max∆cost or below) then the technology should not 
attract further investment.  
 
Following the headroom analysis, two further possibilities exist: 
 
1. The investor can make an intuitive decision to invest based on the outcome of the headroom 
method.  
 
2. The investor can perform more formal value of investment analysis (see figure 1, involving the 
testing of Bayesian probability (discussed in another paper(5)).  
 
As research and development progresses, it is important to update estimates of costs and 
effectiveness and recalculate the headroom. Continual economic assessment at various stages of the 
development cycle will enable more accurate predictions of a product’s cost-effectiveness and hence 
of its market potential(12;13). It should be noted that the value of applying these methods at the supply 
Where, max ∆Cost is the 
headroom, C’ is the expected 
cost of goods and volume is 
expected sales. 
R = (£16,000 – £8,000) x 500 = £4,000,000 
   
302 
side is dependent on the planned technologies being aimed at the third party payer (an organisation 
other than the patient (first party) or health care provider (second party) involved in the financing of 
personal health services). 
 
As development progresses and nears market, further difficulties can arise. Some of these are 
discussed briefly below.  
 
i. Uncertainties – a major barrier to the adoption of technology is the requirement to provide 
sufficient evidence of effectiveness. Evidence on the effectiveness of a technology should ideally 
come from randomised control trials.  
 
ii. Silo budgets – silo budgeting is a major barrier to the adoption of technology. The segmentation of 
the delivery of healthcare by departments means you have to provide an economic argument for a 
single department. This is often very difficult, because while the cost may lie in one department, 
the benefit is accrued in another. For example, less invasive surgery may increase cost in the 
operating theatre, yet the benefit and cost saving is made on the ward. Ultimately a more joined-
up system is required(14). 
 
iii. Business strategy – some products will aim at more than on application e.g. bone morphogenic 
proteins. Each application may have a different ICER and headroom. Furthermore, the first 
application might not necessarily be the ‘big one’.  
 
 
Related Articles  
It is worth mentioning that there is another tool(15), devised by the MATCH group at University of 
Nottingham (www.nottingham.ac.uk/match), which has been developed for the assessment of cost 
effectiveness of medical devices. This tool is a software model based on a decision tree. The aim is to 
give a quick estimation of cost-effectiveness and to preserve core data while reducing the burden of 
data collection. The decision tree does not aim to capture every possible outcome. It is a simplified 
representation of the treatment pathways being considered so is based on several assumptions (as is 
the headroom method). For further information see the website above or contact the team at 
match@nottingham.ac.uk. 
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 Appendix 2: Search Strings used in Chapter 4 
2.1 Urethral Applications 
Search Database Term Yield 
1 Medline Common conditions of the urethra 6 
2 Medline Urethral strictures 180 
3 Medline Problems buccal mucosa in urethra 8 
4 Medline Hypospadias Problems 151 
5 Medline Hypospadias surgery 2167 
6 Medline Epispadias buccal mucosa 10 
7 Medline Epispadias surgery techniques 95 
8 Medline Quality of life economics urethra 2 
9 Medline Quality of Life urethra 2 
10 Medline Quality of life urethral strictures 18 
11 Medline Health economics urethra 2 
12 Medline Health economics urethral strictures 1 
13 Medline Health economic urethra 17 
14 Medline Health economic hypospadias 3 
15 Medline Economic hypospadias 10 
16 Medline Quality of life Hypospadias 4 
17 Medline QoL hypospadias 0 
18 Medline Epispadias Quality of life 7 
19 Medline Cost of urethra 182 
20 Medline cost of stricture 144 
21 Google Scholar Quality of life economics urethral strictures 34 
22 Google Scholar Quality of life urethral strictures 788 
23 Medline Quality of life lower urinary tract 459 
24 Medline Quality of life urethroplasty 5 
25 Medline Quality of life free graft 0 
26 Medline Cost of hypospadias 15 
27 Medline cost of epispadias 0 
28 Google Scholar cost of epispadias 124 
29 Google Scholar economic cost of epispadias 27 
30 Google Scholar Health economic urethra 1280 
31 Medline Economic cost of epispadias 0 
32 Google Scholar health economics urethral strictures 43 
33 Google Scholar health economics hypospadias 73 
34 Google Scholar quality of life hypospadias 1140 
35 Google Scholar QoL hypospadias 36 
36 Google Scholar Epispadias Quality of life 243 
37 Google Scholar Cost of urethra 3990 
38 Google Scholar cost of stricture 5450 
39 Google Scholar Quality of life urethroplasty 217 
40 Google Scholar Quality of life urethra free graft 482 
41 Google Scholar Cost of hypospadias 644 
42 Google Scholar Quality of life buccal mucosa 1600 
43 Medline Quality of life buccal mucosa 83 
44 Medline Quality of life economics urethra 2 
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45 Medline Quality of Life urethra 2 
46 Medline Quality of life urethral strictures 18 
47 Medline Health economics urethra 2 
48 Medline Health economics urethral strictures 1 
49 Medline Health economic urethra 17 
50 Medline Health economic hypospadias 3 
51 Medline Economic hypospadias 10 
52 Medline Quality of life Hypospadias 4 
53 Medline QoL hypospadias 0 
54 Medline Epispadias Quality of life 7 
55 Medline Cost of urethra 182 
56 Medline cost of stricture 144 
57 Google Scholar Quality of life economics urethral strictures 34 
58 Google Scholar Quality of life urethral strictures 788 
59 Medline Quality of life lower urinary tract 459 
60 Medline Quality of life urethroplasty 5 
61 Medline Quality of life free graft 0 
62 Medline Cost of hypospadias 15 
63 Medline cost of epispadias 0 
64 Google Scholar cost of epispadias 124 
65 Google Scholar economic cost of epispadias 27 
66 Google Scholar Health economic urethra 1280 
67 Medline Economic cost of epispadias 0 
68 Google Scholar health economics urethral strictures 43 
69 Google Scholar health economics hypospadias 73 
70 Google Scholar quality of life hypospadias 1140 
71 Google Scholar QoL hypospadias 36 
72 Google Scholar Epispadias Quality of life 243 
73 Google Scholar Cost of urethra 3990 
74 Google Scholar cost of stricture 5450 
75 Google Scholar Quality of life urethroplasty 217 
76 Google Scholar Quality of life urethra free graft 482 
77 Google Scholar Cost of hypospadias 644 
78 Google Scholar Quality of life buccal mucosa 1600 
79 Medline Quality of life buccal mucosa 83 
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2.2 Bladder Applications 
Search Database Term Yield 
1 Medline Bladder cancer epidemiology 4424 
2 Google scholar Radical cystectomy 5640 
3 Medline Radical cystectomy (reviews only) 318 
4 Medline Partial cystectomy 936 
5 Google scholar Bladder cancer  237000 
6 Google scholar Bladder augmentation 6520 
7 Medline Bladder augmentation 1098 
8 Medline Ileocystoplasty (reviews only) 13 
9 Medline crab ileocystoplasty 0 
10 Medline Irritable bladder number (reviews only) 14 
11 Google scholar Irritable bladder "bladder augmentation" 24 
12 Medline Irritable bladder "bladder augmentation" 0 
13 Google scholar Post "bladder cancer" "bladder augmentation" 93 
14 Google scholar "Irritable bladder" 305 
15 Medline "Irritable bladder" 74 
16 Medline Overactive bladder symptoms and treatment 930 
17 Medline Overactive bladder calm cystoplasty 12 
18 Medline Cystoplasty overactive bladder 12 
19 Google scholar Neurologic bladder "bladder augmentation" 126 
20 Google scholar Cloacal exstrophy "bladder augmentation" 161 
21 Medline Cloacal exstrophy "bladder augmentation" 26 
22 Google scholar Post Irritable bladder "bladder augmentation" 13 
23 Medline Complications AND cystoplasty 304 
24 Medline Complications AND cystectomy 280 
25 Google scholar Complications AND cystectomy AND Partial cystectomy 1700 
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 Appendix 3: Quality of Life Elicitation Questionnaire for 
Cystoplasty and Urethroplasty 
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Questionnaire 1: Cystoplasty using Bowel 
 
Augmentation ileocystoplasty is a surgical procedure that seeks to increase the capacity of the bladder 
by suturing a folded segment of the patient’s bowel around an incision of the bladder. It is used after 
an excision of the bladder, especially when the trigone has been spared. 
 
We would appreciate your help in estimating what quality of life people associate with the 
complications arising from this procedure. We are working on a tissue-engineering project and need 
this information in order to estimate the potential benefit from such an approach. This in turn will help 
us work out whether such an approach could ever be a cost-effective solution. To do this analysis we 
require the quantity of life-years and amount of money that an informed person would be willing to 
trade in order to avoid having to suffer the complications.  
 
The side effects of the operation are: 
Stones – these can be painful and require surgical treatment before they become too large 
Mucus – the bowel naturally produces mucus, which in the bladder can lead to Urinary Tract Infection 
(UTI). This can cause a frequent urge to urinate and a painful, burning feeling in the area of the 
bladder or urethra during urination 
Metabolic disturbance – serum acidosis can develop, leading to weakness, fatigue and thirst 
Diarrhoea 
 
We would like you to imagine that you were about to have the procedure. Taking into account your 
knowledge of how likely, these problems are and how seriously they affect patients on average, we 
would like your estimation of how much you would be prepared to forgo in order to avoid experiencing 
the morbidity arising from an ileocystoplasty. 
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The Questionnaire 
How familiar were you with the augmentation cystoplasty operation described, where 1 is “not at all”, 
and 5 is “extremely well”? 
1 2 3 4 5 
 
Question 1: The Time Trade-Off Method 
In the Time Trade-Off (TTO) method, you are asked the maximum amount of life you would be willing 
to trade, as a patient, out of your remaining lifespan, in return for avoiding the restrictions and effects 
of a condition. The trade off can be any period of time up to the maximum, e.g. no time, 1-day or 1 
year. For example, your maximum life span might be a further 10 years, but during that time you would 
be suffering from blindness. You might therefore be willing to trade 9 of those years to live a perfectly 
healthy life for the time remaining, in this case 1 year. 
 
Were you already familiar with the TTO method, where 1 is “not at all”, and 5 is “extremely well”?  
1 2 3 4 5 
 
Now assume that your remaining life span is 10 years. You can either have the condition described in 
scenario 1 for all those 10 years, or perfect health for a shorter period of time.  
 
What is the maximum amount of time you would be willing to trade of those 10 years to have a perfect 
quality of life, instead of suffering from the complications outlined on the explanation sheet? Please 
specify in days, weeks, months, or years. ____________ 
 
You may optionally provide us with any comments you have on why you responded thus. 
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Question 2: The Cost-Benefit Method 
In this method, you must consider the benefits of using an alternative treatment and decide how much 
you would pay to receive those benefits. For example, in the case of avoiding blindness for a 
remaining lifespan of 10 years, you might be willing to pay £25,000. 
 
Were you already familiar with the Cost-Benefit method, where 1 is “not at all”, and 5 is “extremely 
well”. 
1 2 3 4 5 
 
Now assume you are suffering from the symptoms described on the explanation sheet. You can either 
have the condition described on the explanation sheet for six months, or perfect health for six months.  
 
How much money would you be willing to pay to have a perfect quality of life, instead of the condition 
outlined? ____________ 
 
You may optionally provide us with any comments you have on why you responded thus. 
 
 
Please select the category from below into which your personal (not household) yearly income falls. 
This is to assist us with the analysis of your response to question 5. 
 
Under £10 000 
£10 000 to £27 000 
£ 27 000 to £40 000 
£ 40 000 to £100 000 
£100 000 or over 
 
This is the end of the questionnaire. Thank you very much for your time. 
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Results: Cystoplasty using Bowel 
The questionnaire was completed by urologists, working within the hospitals close to Birmingham 
University (identified through the NHS website).  Four out of sixteen (25%) completed questionnaires 
were returned from the urologists. Two surgeons stated they did not wish to take part and although the 
others were followed up with phone calls, no other responses were received. As urologists were asked 
to complete the questionnaire it should be safe to assume that they would be familiar with the 
augmentation cystoplasty procedure and this was the case, with 3 out of 4 (75%) indicating ‘5’ 
(extremely well) on the 5 point Lycart scale and the other indicating a ‘4’. 
 
The time trade-off method 
This part of the questionnaire asked participants to state how much time, out of a period of 10 years, 
they would be willing to sacrifice in order to forgo the effects of an augmentation cystoplasty 
procedure. The participants were also asked about their familiarity with the TTO approach. 2 out of 4 
urologists had no knowledge of the TTO approach, with the other two indicating medium to good 
knowledge (recording results of ‘3’ and ‘4’ on the 5 point Lycart scale). It was difficult to draw any 
conclusions regarding correlation of the amount of time willing to trade against the familiarity of the 
TTO approach and against the familiarity with augmentation cystoplasty as the sample size was so 
small.  
 
Using equation 1 the time traded was converted into utility scores. The summary statistics of the utility 
scores elicited from the TTO responses are shown in table 1. The mean utility for the period of 
maximum symptoms was calculated as 0.96 (95% CI: 0.94, 0.97) from four responses and will be 
used in the subsequent cost-effectiveness analysis in chapter 4. 
 
Equation 1: QoL = 1 – (TTO ÷ t) 
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The cost benefit method 
In this question participants were asked to state how much they would be willing to pay for a treatment 
that would avoid the clinical effects of augmentation cystoplasty. They were also asked about there 
familiarity with the cost-benefit approach. As with the previous section, it was difficult to draw any 
conclusions regarding correlation of the amount willing to pay against the familiarity of the cost benefit 
approach as the sample size was so small.  
 
The summary statistics of the amount willingness to pay (WTP) elicited from the questionnaires are 
shown in table 1. The mean willingness to pay to avoid the period of maximum symptoms was 
calculated as £8,750 (95% CI: £1,400, £16,000) from four responses. The large confidence intervals 
are due to a small sample size. By combining the results of the above two questions, the mean WTP 
per QALY can be calculated as £9, 076 (95% CI: £1,603, £16,548) from four responses. 
 
Table 1: Summary statistics for the clinical effects of ileocystoplasty  
Statistic Utility WTP WTP/QALY 
N 4 4 4 
Mean 0.96 (0.94, 0.97) £8,750 (£1,400, £16,100) £9,076 (£1,603, £16,548) 
Median 0.95 (0.94, 0.96) £5,000 (£0, £12,350) £5,263 (£0, £12,730) 
Minimum 0.95 £5,000 £5,263 
Maximum 0.98 £20,000 £20,513 
Standard Deviation 0.01 £7,500 £7,625 
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Questionnaire 2: Urethroplasty using Buccal Mucosa 
 
Buccal mucosa is the skin which forms the inside lining of the mouth. It is extremely useful in treating 
certain diseases. The mucosa is surgically removed from the mouth, after which it can be used in a 
number of applications. We would appreciate your help in estimating how much people would be 
willing to sacrifice in life-years or money in over to avoid having to undergo the buccal mucosa 
donation.  
 
The side effects of the donation are: 
A degree of pain, comparable to a large and deep cut of the lip or cheek, but not to the extent that it 
would stop you sleeping.  
Pain upon eating that would be bad enough to prevent consumption of particularly dry or hard food, 
but would in no way limit you to a liquid diet. 
Your mouth would be slightly numb, comparable to the feeling of a weak dose of the local anaesthetic 
you may have had during dentistry, but without affecting taste or speech.  
You would have slight difficulty opening your mouth, but not so much that it would prevent any desired 
actions. 
There would be slight reduction in the ability to move your bottom lip. 
 
These side effects would last continuously and would not diminish with time.  
Considering these side effects, please complete the questionnaire which follows. 
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The Questionnaire 
How familiar were you with the buccal mucosa donation previously described, where 1 is “not at all”, 
and 5 is “extremely well”? Please circle your response. 
1 2 3 4 5 
 
Question 1: The Time Trade-Off Method 
In the Time Trade-Off (TTO) method, you are asked the maximum amount of life you would be willing 
to trade, as a patient, out of your remaining lifespan, in return for avoiding the restrictions and effects 
of a condition. The trade off can be any period of time up to the maximum, e.g. no time, 1 day or any 
time upwards. For example, your maximum life span might be a further 10 years, but during that time 
you would be suffering from blindness. You might therefore be willing to trade 9 of those years to live a 
perfectly healthy life for the time remaining, in this case 1 year.  
 
Were you already familiar with the TTO method? Please circle your response, where 1 is “not at all”, 
and 5 is “extremely well”. 
1 2 3 4 5 
 
Now assume your remaining life span is 10 years. You can either have the condition described on the 
explanation sheet for all those 10 years, or perfect health for a shorter period of time. How much time 
would you be willing to trade to have a perfect quality of life, instead of having the condition outlined?  
Please specify in days, weeks, months, or years. _________________________ 
 
Comments: 
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Question 2: The Cost-Benefit Method 
In this method, you must consider the benefits of using an alternative treatment and decide how much 
you would pay to receive those benefits. For example, in the case of avoiding blindness for a 
remaining lifespan of 10 years, you might be willing to pay £25,000. 
 
Were you already familiar with the Cost-Benefit method? Please circle your response, where 1 is “not 
at all”, and 5 is “extremely well”. 
1 2 3 4 5 
 
Now assume you are suffering from the symptoms described on the explanation sheet. You can either 
have the condition described on the explanation sheet for six months, or perfect health for six months. 
How much money would you be willing to pay to have a perfect quality of life, instead of the condition 
outlined? ____________ 
 
Please select from below the category into which your personal (not household) yearly income falls. 
This is to assist us with the analysis of your response. 
 
Under £10 000 
£10 000 to £27 000 
£ 27 000 to £40 000 
£ 40 000 to £100 000 
£100 000 or over 
 
Comments: 
 
 
 
 
This is the end of the questionnaire. Thank you very much for your time. 
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Results: Urethroplasty Using Buccal Mucosa 
The questionnaire was completed by individuals located within the public health building at the 
University of Birmingham, (unknown to those collecting the data) and from Birmingham city centre 
(outside Birmingham Central Library and New Street Station). In total 112 questionnaires were 
completed.  Figure 1 shows the number of completed questionnaires categorised by place of 
completion. 80 of 112 (72%) questionnaires were completed from individuals located in Birmingham 
city centre. It could be hypothesised that these individuals would have less medical knowledge and 
may have less understanding of how the clinical effects would impact on quality of life. To investigate 
this hypothesis further I analysed the results of the first part of the questionnaire - familiarity with 
buccal mucosa donation – also by place. The respondents indicate their familiarity on a 5 point Lycart 
scale from 1 to 5, where 1 represented no familiarity and 5 represented very good familiarity. Of those 
interviewed in Birmingham city centre 79 of 81 individuals (97.6%) were not familiar with buccal 
mucosa donation procedure compared to 28 of 31 (90%) (Figure 2).  
 
Figure 1: Number of completed questionnaires categorised by place of survey 
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Figure 2: Familiarity with buccal mucosa donation categorised by place of survey 
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The time trade-off method 
Of the 112 completed questionnaires, two (1.8%) did not provide a response to the TTO question. One 
of the individuals who did not answer this question said they “would not like to answer due to lack of 
knowledge about disease”. The other individual offered no reason for not completing this part of the 
questionnaire.  
 
This part of the questionnaire asked participants to state how much time, out of a period of 10 years, 
they would be willing to sacrifice in order to forgo the effects of buccal mucosa donation. The 
participants were also asked about there familiarity with the TTO approach. Once again I would expect 
that those interviewed from the public health building would be more familiar with this approach than 
those interviewed from Birmingham city centre. I found that 77 out of 80 patients (96%) interviewed in 
Birmingham city centre were not familiar with the TTO approach compared with 15 out of 30 (50%) 
interviewed from the public health building. I would have speculated that those who were more familiar 
with the TTO approach would have been willing to trade less time than those less familiar, but this was 
not the case, as is illustrated in figure 3. However, a comparison of time willing to trade versus 
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familiarity with buccal mucosa donation does show that those more familiar with buccal mucosa 
donation are willing to trade less, although, it is difficult to draw conclusions due to the very small 
numbers of individuals expressing a familiarity with buccal mucosa donation (figure 2).  
 
Figure 3: Individual time willing to trade compared with familiarity of the TTO method 
categorised by place of survey 
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Using equation 1 the time traded was converted into utility scores. The distribution of the utility scores 
ranges from 0 to 1 and has a negative skew (see figure 4.5, chapter 4.7). The summary statistics of 
the utility scores elicited from the TTO responses are shown in table 2.  I calculate the utility with and 
without the outliers identified in chapter 4.7. However I decide to select the final utility score based on 
all elicited values.  The median utility for the period of maximum symptoms was calculated as 0.94 
(95% CI: 0.89, 0.99) from 110 responses. This value will be used in the subsequent cost-effectiveness 
analysis in chapter 4. 
Equation 2: QoL = 1 – (TTO ÷ t) 
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Table 2: Summary statistics for the clinical effects of urethroplasty using buccal mucosa 
Summary Measure Utility (With Outliers) Utility (Without Outliers) 
Sample Size 112 112 
Missing data 2 11 
Mean 0.81 (0.76, 0.86) 0.87 (0.84, 0.91) 
Median 0.94 (0.89, 0.99) 0.98 (0.94, 1.0) 
Minimum 0.0 0.5 
Maximum 1.0 1.0 
Standard Deviation 0.28 0.18 
 
 
The cost benefit method 
Of the 112 responses, 4 (3.6%) did not answer this question, 30 (26.8%) furnished a WTP value for 
avoiding the condition but refused to trade any life for the TTO question and 5 (4.5%) were willing to 
sacrifice some of their life expectancy but not to pay any money for the treatment. No reasons were 
given for none completion of this part of the questionnaire. 
 
In this question participants were asked to state how much they would be willing to pay for a treatment 
that would avoid the clinical effects of urethroplasty using buccal mucosa. The participants were also 
asked about their familiarity with the cost-benefit approach, which they indicated on a 5 point Lycart 
scale. I found that 68 out of 78 patients (87%) interviewed in Birmingham city centre were not familiar 
with the cost-benefit approach compared with 9 out of 30 (30%) interviewed from the public health 
building. As with the TTO question, I expected those with a greater familiarity of this approach to 
express a lower WTP for an alternative treatment to urethroplasty using buccal mucosa. This is shown 
in figure 4. In this case I have not separated the results by place of survey due to small numbers in 
each of categories on the familiarity of cost-benefit approach Lycart scale. A comparison of time willing 
to trade versus familiarity with buccal mucosa donation does show that those more familiar with buccal 
mucosa donation are willing to trade less, although, it is difficult to draw conclusions due to the very 
small numbers of individuals expressing a familiarity with buccal mucosa donation. The effect of 
individual income on amount willing to pay is illustrated in figure 5. As I would have expected an 
increase in amount willing to pay as income increased. The summary statistics of the amount WTP 
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elicited from the questionnaires are shown in table 3. The mean WTP to avoid the period of maximum 
symptoms was calculated as £500 (95% CI: £0, £1,418) from 108 responses. 
 
Figure 4: Overall individual WTP compared to familiarity of the cost-benefit method  
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Figure 5: Individual WTP compared to personal income  
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I combined all the responses from the above two questions to assess whether the distribution of 
amount of time willing to trade and amount willing to trade compare. This is illustrated in figure 6. It 
can be seen from the figure that the responses are not perfectly correlated. However those willing to 
trade the most amount of life do correspond with those willing to pay the most amount of money.  
Finally, I calculate the mean WTP per QALY as £857 (95% CI: £0, £2,462) from 108 responses (table 
3).  
 
Figure 6: distribution of individual amount willing to trade versus amount willing to pay 
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Table 3: Summary statistics for the clinical effects of urethroplasty using buccal mucosa 
Measure WTP WTP per QALY 
Sample Size 108 102 
Missing data 4 10 
Mean £2,627 (£1,709, £3,545) £3,930 (£2,326, £5,535) 
Median £500 (£0, £1,418) £857 (£0, £2,462) 
Minimum £0 £0 
Maximum £30,000 £40,00 
Standard Deviation £4,867 £8,269 
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 Appendix 4: Search Strings used in Chapter 5  
 
Search Database Term Yield 
1. PubMed Abdominal wall defects 2054 
2. PubMed 1 AND management 301 
3. PubMed 1 AND Wound Management 260 
4. PubMed 1 AND management of open wound 11 
5. PubMed Temporary closure of abdominal wall 87 
6. PubMed 3 AND temporary closure 20 
7. PubMed 3 AND 5 6 
8. PubMed Mesh repair 3704 
9. PubMed mesh versus non mesh repair 14 
10. PubMed 1 AND 8 236 
11. PubMed 3 AND 8 15 
12. PubMed Hernia 40086 
13. PubMed Abdominal wall defects AND Hernia 829 
14. PubMed Abdominal wall repair AND 5 101 
15. PubMed Abdominal wall repair AND 5 AND 8 60 
16. PubMed Inguinal hernia 9978 
17. PubMed Abdominal wall defects AND inguinal hernia 50 
18. PubMed 17 AND 8 15 
19. PubMed 16 AND cost analysis 226 
20. PubMed 16 AND Economic analysis 180 
21. PubMed 16 AND Quality of life 16 
22. PubMed laparoscopic versus open hernia repair 121 
23. PubMed 16 AND 22 88 
24. PubMed incisional hernia 1634 
25. PubMed 24 AND 8 505 
26. PubMed 24 AND biological OR synthetic mesh repair 279 
27. PubMed 24 AND cost analysis 23 
28. PubMed 24 AND economic analysis 18 
29. PubMed 24 AND laparoscopic versus open hernia repair 15 
30. PubMed parastomal hernia 151 
31. PubMed parastomal hernia AND mesh repair 65 
32. PubMed Abdominal wall defect  AND tissue necrosis 34 
33. PubMed Abdominal wall defect AND gangrene 8 
34. PubMed Fournier’s gangrene 316 
35. PubMed contaminated abdominal wall defects 40 
36. PubMed omphalocele 3310 
37. PubMed giant abdominal wall defects 56 
38. PubMed omphalocele AND 8 74 
39. PubMed giant abdominal wall defects AND 8 17 
40. PubMed Cellular grafts 5190 
41. PubMed Cellular grafts AND Abdominal wall defects 3 
42. PubMed Acellular grafts 518 
43. PubMed Acellular grafts AND Abdominal wall defects 5 
44. PubMed AlloDerm 256 
45. PubMed AlloDerm AND Abdominal wall defects 13 
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46. PubMed Permacol 46 
47. PubMed Permacol AND Abdominal wall defects 6 
48. Cochrane Hernia 1457 
49. Cochrane Inguinal hernia 882 
50. Cochrane Incisional hernia 136 
51. Cochrane incisional hernia OR ventral hernia 167 
52. Cochrane parastomal hernia 6 
53. Cochrane laparoscopic versus Open hernia repair 53 
54. Cochrane mesh versus non mesh repair 8 
55. Cochrane incisional hernia OR ventral hernia 170 
56. Cochrane incisional hernia AND ventral hernia 8 
57. Cochrane incisional hernia OR ventral hernia AND Quality of life 128 
58. Cochrane incisional hernia OR ventral hernia AND utilit* 128 
59. Cochrane incisional hernia AND ventral hernia AND Quality of life 1 
60. Cochrane incisional hernia AND ventral hernia AND utilit* 0 
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 Appendix 5: Health State Questionnaire to Elicit Utility-
Based Quality of Life associated with Abdominal Wall 
Defects  
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Quality of life associated with abdominal wall defect repair: A questionnaire for key opinion 
leaders 
 
We are based in the team of Professor Richard Lilford in public health at the University of Birmingham, 
UK. We are a partner in the EU STEPS (a systems approach to tissue engineering processes) project 
and our work is centred on the cost-effectiveness analysis of potential new tissue engineering 
products. Cost-effectiveness analysis aims to identify where more benefit can be produced at the 
same cost, or a lower cost can be achieved for the same benefit. Based on a decision-making 
philosophy, this analysis assumes the decision maker seeks to maximise achievements of a defined 
objective, by using a given budget. 
 
We have been working in collaboration with a European medical technology company involved in 
Tissue Engineering to investigate the potential applications of a new generation, tissue engineered 
mesh. We have reviewed the epidemiology and current treatments of many abdominal wall defects 
and concluded that there is a potential gap in the market for a mesh that could be used when defects 
are large and infected.  The next stage of the project requires us to estimate the potential benefit that 
could be gained from a new generation mesh compared to existing treatments. This new technology 
will be very expensive and it is necessary for the costs to be justified by an increase in benefit. 
Estimation of the potential benefit can be quantified by directly measuring preferences for a given 
health state using two approaches called time trade-off and willingness-to-pay. 
 
We would appreciate your help in estimating the quality of life associated with complications arising 
from current treatment by completing the short questionnaire overleaf and returning it to me in the 
envelope provided.  
 
We thank you in advance for your cooperation and greatly appreciate the time you have given us. If 
you have any questions or wish to discuss anything further please do to hesitate to ask one of the 
team here today or following the conference contact Helen McAteer on the number below. All 
questionnaires will be anonymous. 
 
 
 
Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, 
University of Birmingham, Edgbaston, B15 2TT 
Tel: 0121 414 8465 Email: hlm569@bham.ac.uk 
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Before completing the time trade-off (page 3) and the willingness-to-pay (page 4) questions please 
could you answer the five short questions below (please tick where applicable): 
 
1. What is your gender?  
Male  
Female  
 
2. What is your age group?  
<30 years  
31 – 40 years  
41 – 50 years  
51 – 60 years  
> 61 years  
 
3. How many years have you been a surgeon?  
<10 years  
11 – 20 years  
21 – 30 years  
31 – 40 years  
> 41 years  
 
4. Have you used an acellular mesh in the past?  
Yes  
No  
 
5. If yes, which meshes have you used?  
Porcine dermal collagen (e.g. Permacol)  
Acellular dermal matrix (e.g. AlloDerm)  
Porcine small intestine submucosa (e.g. Surgisis)  
Other (please specify)  
Don’t Know  
 
 
 
 
 
 
Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, 
University of Birmingham, Edgbaston, B15 2TT 
Tel: 0121 414 8465 Email: hlm569@bham.ac.uk 
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In the following questions we ask you to imagine that you are the patient. 
 
We would like you to imagine that you (as a patient) have had an incisional hernia repaired using a 
synthetic mesh. The mesh became infected (for whatever reason, the detail of which is not necessary 
here), and therefore has been removed.  We envisage two possible scenarios for further treatment: 
 
Scenario 1: The open wound infection is treated and the wound is kept open for 3 – 6 months before 
the patient can undergo second surgery to close the defect. Patient recovery is slow and closure of 
defect is complex. Ongoing medical attention is required.   
 
Scenario 2: The open wound infection is treated and wound is closed after 3 – 7 days using a new 
generation cellular mesh. This speeds up patient recovery and reduces treatment management time to 
around 1 month. 
 
Using your knowledge of the repair of infected abdominal wall defects and the effect this has on the 
patient we would like you to answer the following two questions. 
 
1. Time Trade-off (TTO) 
In the time trade-off (TTO) approach you are being asked the maximum amount of life you would be 
willing to trade, as a patient, out of your remaining lifespan, in return for avoiding the effects of a 
condition for the rest of your life. The trade-off can be any period of time up to the maximum stated.  
 
Imagine you have 10 years of remaining life. You could experience an open abdominal wall 
defect requiring regular medical attention for 10 years followed by death or you could 
experience perfect health for a period of time less than 10 years followed by death.  
 
How many days, weeks, months or years would you be willing to forgo in order to have a treatment 
that would avoid an open abdominal wall defect and give you perfect health?  
Answer:  
 
 
Any additional comments: 
P.T.O 
Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, 
University of Birmingham, Edgbaston, B15 2TT 
Tel: 0121 414 8465 Email: hlm569@bham.ac.uk 
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2. Willingness-to-pay (WTP) 
 
In the WTP approach you are asked how much money you are willing to pay to avoid the effects of a 
condition for the rest of your life. One way of measuring value is to ask you what you would be 
prepared to give up to receive this treatment i.e. how much money you would be willing to pay for it.  
Of course, if this treatment did come into existence then it would be provided free by the NHS.  We 
also believe that people should not have to pay for health care.  This is simply a method of measuring 
how strongly you feel about having this treatment in place and how much you would value such a 
treatment. 
 
Imagine you have 10 years of remaining life. You could experience an open abdominal wall 
defect requiring regular medical attention for 10 years followed by death or you could 
experience perfect health for a period of time less than 10 years followed by death.  
 
How much money would you be willing to pay for a treatment that would avoid an open abdominal wall 
defect and give you perfect health?  
Answer:   
      
 
To assist us with the analysis of these results could you please estimate the annual income of your 
household before deducting tax and national insurance? 
<£70,000  
£70,001 - £90,000  
£90,001 – £110,000  
£110,001 - £130,000  
£130,001 - £150,000  
> £150,001  
 
Any additional comments: 
 
 
- End of questionnaire - 
Thank you  
 
 
Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, 
University of Birmingham, Edgbaston, B15 2TT 
Tel: 0121 414 8465 Email: hlm569@bham.ac.uk 
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Quality of life associated with abdominal wall defect repair: Results 
Preliminary analysis 
Population 
The questionnaire was completed by 54 healthcare professionals, comprising of: 37 Consultants, 8 
Trainees, 5 Nurses, 3 Registrars and 1 Senior Registrar. It was calculated that of those that had 
completed the questionnaire; 44 (81%) were male and 10 (19%) were female. The distribution of 
healthcare professionals whom completed the questionnaire is illustrated in figure 1. 
 
Age 
Twenty-one of fifty-three (39%) respondents were aged between 31 and 40 years, 28% were aged 
between 41 and 50 years, with 17% being aged between 51 and 60 years. Only 11% were aged below 
30 years; and those that were aged over 61 years made up the smallest proportion consisting of just 
4%. This information is illustrated in figure 2. 
 
Number of years experience as a surgeon 
The majority of the healthcare professionals (39%) had between 11 and 20 years experience as a 
surgeon, 35% had had less than 10 years experience and 22% had between 21 and 30 years of 
experience. Both the 31 to 40 years and above 41 years of experience categories had the same 
number of clinicians (2%). This is illustrated in figure 3. 
 
Meshes 
Forty-three of fifty-four (80%) respondents stated that they had used an acellular mesh in the past.  Of 
those that had used an acellular mesh some had used more than one type. A result of 38 of 56 (68%) 
had used Permacol, 23% had used Surgisis, 4% had used AlloDerm, 4% had used another mesh and 
2% did not know exactly which mesh they had used. These results are illustrated in figure 4. 
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Figure 1: Distribution of healthcare professionals whom 
completed questionnaire 
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Figure 2: Age distribution of healthcare 
professionals
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Figure 3: distribution of years of experience of healthcare 
professionals 
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Figure 4: distribution of the different types of meshes used by the 
clinicians 
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Analysis of time trade-off question 
Of the 54 completed questionnaires, 50 (93%) had satisfactorily answered this question. The general 
feedback received from the healthcare professions upon answering this question was that there are a 
variety of factors (including social/family circumstances, level of symptoms, site and size of defect, co-
morbidity of problem and degree of problem with infection) that need to be considered before any 
reasonable judgment can be established; hence it was a difficult question to answer.  
 
 
Of those that had adequately completed this question it was found that consultants would be prepared 
to trade the most amount of time, equating to an average of 1.7 years. Nurses were willing to forgo 1.4 
years, and trainees 1.1 years on average. Senior Registrars and Registrars were prepared to forgo the 
least amount of time, 0.13 and 0.09 years respectively. The overall average time trade-off across all 
50 healthcare professionals was calculated as 1.47 years. 
 
Using equation 1 the time traded was converted into utility scores. The distribution of the utility scores 
ranges from 0 to 1, has a negative skew and a modal utility score of 0.9 (figure 5). The summary 
statistics of the utility scores elicited from the TTO responses are shown in table 1. The mean utility for 
the period of maximum symptoms was calculated as 0.85 (95% CI: 0.79, 0.91) from four responses 
and will be used in the subsequent cost-effectiveness analysis in chapter 4. 
Equation 1: QoL = 1 – (TTO ÷ t) 
 
 
Table 1: Summary statistics for the clinical effects of incisional hernia repair 
Statistic Utility 
Sample Size 50 
Missing Data 4 
Mean 0.85 (0.79,0.91) 
Median 0.94 (0.88, 1.0) 
Minimum 0 
Maximum 1.0 
Standard Deviation 0.22 
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Figure 5: Distribution of utility scores 
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Analysis of willingness to pay question 
Of the 54 completed questionnaires, 44 (81%) had satisfactorily answered this question. Again the 
general feedback received from the healthcare professions upon answering this question was that it 
was a difficult question to answer. As a result 13% completely failed to answer this question and 6% 
gave an answer which was too vague to convert into a certain sum of money for example; “a few 
months”, “all my money” and “as much as it takes”.  
 
Of those whom answered this question, 64% (28 of 44) of healthcare professionals stated that they 
would be prepared to pay between £1,001 and £10,000 for the new treatment. Fourteen percent would 
be willing to pay in excess of £20,001, 11% would pay between £10,001 and £15,000; and just 7% 
stated they would pay between £15,001 and £20,000. Only 5% were willing to pay between £500 and 
£1000. These findings are shown in figure 6. 
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Figure 6: Distribution of amount healthcare professionals are willing to pay for new treatment 
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Figure 7: Distribution of amount healthcare professionals are willing to pay for a new treatment 
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A comparison of willingness to pay between the five categories was also made. On average the 
consultants were willing to pay the most amount of money for a new treatment (£23,317) and nurses 
willing to pay the second highest amount (£7,500). On average, Senior Registrars were willing on to 
pay £10,000 and Trainees £5,375. Registrars were willing to pay the least amount for the new 
treatment (£5,167). Figure 7 illustrates the average amount willing to pay and the average amount of 
life years willing to trade for each of the five categories.   
 
Upon analysis of the answer to this question we encountered one potential anomalous result, with one 
professional stating a WTP figure of £250,000. The discussion of this anomalous result as well as its 
impact upon the overall findings can be found within the willingness-to-pay for consultants only section 
below. The overall average amount one would be willing to pay across all professions was calculated 
to be £18,611.29 (inclusive of the anomalous result) and £13,230.15 (omission of the anomalous 
result). The full summary statistics regarding the amount the respondents were WTP (with and without 
the outlier) is shown in table 2. 
 
Table 2: Summary statistics for the clinical effects of incisional hernia repair 
Statistic 
WTP (with 
outlier) 
WTP (without 
outlier) 
WTP/QALY (with 
outlier) 
WTP/QALY 
(without outlier) 
Sample Size 44 43 42 42 
Missing Data 10 11 12 12 
Mean 
£18,611 (£7,374, 
£29,848) 
£13,230 (£9,262, 
£17,198) 
£32,475 (£7,853, 
£57,096) 
£21,072 (£10,485, 
£31,658) 
Median 
£10,000 (£1,237, 
£21,237) 
£10,000 (£6,032, 
£13,968) 
£10,256 (£0, 
£34,878) 
£10,256 (£0, 
£20,843) 
Minimum £500 £500 £501 £501 
Maximum £250,000 £50,000 £500,000 £200,000 
Standard Deviation £38,029 £13,275 £81,414 £34,585 
 
 
Analysis of the outlier   
Upon taking into account the consultants income, and then calculating the average a consultant would 
be willing to pay for each income band; the subsequent result was that those who were in the lowest 
   
335 
income band (£<70,000) were willing, on average, to pay the most amount of money (£59,063). The 
£110,001-£130,000 band was willing to pay the second highest amount, an average of £26,667, 
followed by the £130,001-£150,000 band, willing to pay £16,667. In the highest income band 
(>£150,000), the average amount a consultant was willing to pay equated to just £14,571; whereas in 
the second to lowest band (£70,001-£90,000) the average amount was calculated to be £14,354. 
Finally in the £90,001-£110,000 band, the average amount a consultant would pay for this new 
treatment was £10,800. This resulted in a surprising downward trend (figure 8) illustrating the fact that, 
the greater the annual income, the lower the amount of money a consultant would be willing to pay for 
this new treatment. The overall average amount a consultant would be willing to pay for the new 
treatment was calculated to be £23,317. 
 
However, a point to note is that in the lowest band category (<£70,000) there was one consultant who 
had stated that they would pay £250,000 for a new treatment; which was a relatively extortionate 
amount of money considering all other consultants stated a figure of less than £51,000. This affected 
the results drastically and had upset the overall trend. A new chart was implemented in order to show 
what the results and trends would have been like, if this excessive amount of money had been omitted 
(figure 9). The result of this omission was that the trend had changed from being a downward trend i.e. 
the greater the annual income, the lower the amount of money a consultant would be willing to pay for 
this treatment; to an upward trend i.e. the greater the annual income, the greater the amount of money 
a consultant would be willing to pay for this treatment. The overall average amount a consultant would 
be willing to pay for the new treatment, excluding this anomaly, was calculated to be £16,005, which is 
£7,312 less than the average calculated in the previous section. 
 
This pattern can also be seen when all the WTP data form the healthcare professionals are plotted 
against income band. Figure 10 shows the amount all the healthcare professionals were willing to pay 
to based on income, including the outlier.  From this graph it appears that those in the lower income 
band appear are willing to pay more for the new treatment. However figure 11 shows the same 
distribution excluding the outlier and here the line of best fit indicates that the amount willing to pay for 
the new treatment increases as income increases, as would be expected. 
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Figure 8: Average amount a consultant would pay for a new 
treatment dependent on their annual income 
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Figure 9: average amount a consultant would pay for a new 
treatment dependent on their annual income, excluding outlier 
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Figure 10: Amount willing to pay categorised by income (including 
outlier) 
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Figure 11: Amount willing to pay categorised by income 
(excluding outlier) 
0
2
4
6
8
10
12
<£70,000 £70,001 -
£90,000
£90,001 -
£110,000
£110,001 -
£130,000
£130,001 -
£150,000
>£150,001
Income
N
u
m
b
e
r
 
o
f
 
I
n
d
i
v
i
d
u
a
l
s
£0.00
£5,000.00
£10,000.00
£15,000.00
£20,000.00
£25,000.00
£30,000.00
A
m
o
u
n
t
 
w
i
l
l
i
n
g
 
t
o
 
p
a
y
Number 
WTP
 
   
337 
 Appendix 6: Review of Effectiveness of Mesh Versus Non-
Mesh for Inguinal Hernia Repair 
 
There are four systematic reviews of RCTs comparing mesh with non-mesh approaches to inguinal 
hernia repair. Three of the four reviews were published by the EU hernia trials collaboration and they 
evaluated 15 trials (EUHTC, 2000), 20 trials (Grant et al., 2002) and 58 trials (EUHTC et al., 2002) 
respectively, the fourth review, published by Scott and colleagues, appraised 20 trials (Scott et al., 
2001a). I have also identified an RCT (Vrijland et al., 2002) assessing quality of life and cost, and a 
recent RCT (van Veen et al., 2007) assessing long term follow-up.  In addition I have identified two 
systematic reviews of RCTs investigating wound infection following inguinal hernia repair (Aufenacker 
et al., 2006;Sanchez-Manuel et al., 2007). The findings are summarised below and in table 1.  
 
Overall the reviews conclude that mesh repair is associated with a number of improved outcomes 
compared to simple suture. The rates of haematomas, seromas and infections were similar for mesh 
and non-mesh groups (EUHTC, 2000;Grant et al, 2002;Scott et al., 2001b) and significantly fewer 
hernia recurrences were reported in the mesh group in all of the reviews (OR=0.39, P<0.001 (EUHTC, 
2000)), (OR=0.43, P<0.001 (EUHTC et al, 2002)), (OR=0.37, (Scott et al, 2001b)). Operative time was 
reported to be 1-4 minutes longer for mesh repair than for non-mesh repair (Scott et al, 2001b). 
However, in one of the earliest reviews (EUHTC, 2000) mean operative time was lower in the mesh 
group in 6 out of 15 trials, lower in the non-mesh group in 3 out of 15 trials and unclear in 6 out of 15 
trials (P=0.51). Length of hospital stay was reported as shorter for the mesh group in 5 of 6 trials 
(p=0.22) (EUHTC, 2000) and reported to be shorter by between 0.22 and 0.35 days (Scott et al, 
2001b). A more rapid return to usual activities was indicated for mesh repair in seven out of 10 trials, 
more slowly in 2 out of 10 trials and similar in one trial, P=0.34  (EUHTC, 2000). In two of the reviews 
(EUHTC, 2000;Scott et al, 2001b) it was concluded that there was insufficient evidence to determine 
whether the use of mesh reduces levels of pain. However, in the 2002 reviews (EUHTC et al, 
2002;Grant et al, 2002) the meta-analysis showed that the levels of persisting pain were reduced after 
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mesh repair (OR=0.36, P<0.001(EUHTC et al, 2002)),  (OR=0.68, P=0.04 (Grant et al, 2002)) 
although they did also state that the definition and results were highly variable among trials.      
 
Vrijland and colleagues (n=300) assessed quality of life (measured using EQ-5D and VAS) and cost 
(based on Dutch hospital costs) in addition to clinical outcomes. Just one outcome (recurrence rate) 
that was significantly different between the two groups. Recurrence rates were reported as 7% and 
1% for non-mesh and mesh repair, respectively (P=0.009). There was no difference between the two 
groups with regard to operation-related factors (median surgery time was 45 min for both groups and 
median hospital stay was 2 days for both groups) and quality of life score at any time point (85 for EQ-
5D and 81 for VAS), therefore cost-effectiveness was determined by the cost of mesh and the number 
of recurrences. It was concluded that €6821 ($10,000, £6,100) could have been saved if mesh repair 
was standard treatment and thus mesh repair is a cost-effective treatment for inguinal hernia repair. 
 
The RCT by Van Veen and colleagues (n=300) found that the ten year cumulative hernia recurrence 
rates were 17% and 1% for non-mesh and mesh repair, respectively (P=0.005) (of which half occurred 
in the first three years) suggesting that recurrence rates may be generally underestimated. There was 
no significant correlation between recurrence and age, obesity, history of pulmonary disease, 
constipation, or prostate cancer. The authors of both RCTs reported here recommend mesh repair as 
primary treatment for inguinal hernia repair. 
 
Inguinal hernia repair is a clean wound and thus postoperative infection rates are expected to be low 
and not exceed 2% (Sanchez-Manuel et al, 2007). However, incidence of infection has been reported 
to vary between 0 to 9% (Aufenacker et al, 2006). A number of trials have been conducted to assess 
the effect of antibiotic prophylaxis in prevention of wound infection after mesh repair here we 
summarise the results of two systematic reviews on the topic. In 2006 a systematic review of eight 
trials (Aufenacker et al, 2006) found an incidence of infection of 3% in the control group and 1.5% in 
the antibiotic group but this was not significant (OR=0.54, P=0.18). The incidence of deep infections 
was reported as 0.6% in the control group and 0.3% in the antibiotic group (OR=0.50). A more recent 
systematic review of twelve randomised controlled trials (Sanchez-Manuel et al, 2007) (six 
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hernioplasty and six herniorrhaphy) found overall infection rates of 3.9% in the control group  and 
2.9% in the antibiotic group (OR=0.64). For herniorrhaphy (non-mesh repair) the infection rates were 
4.9% in the control group and 3.5% in the antibiotic group (OR=0.71), whereas hernioplasty (mesh 
repair) showed infection rates of 2.9% in the control group and 1.4% in the antibiotic group (OR=0.48). 
This review shows that mesh repair is associated with lower rates of infection. Both the reviews 
suggest that antibiotic prophylaxis may be useful in preventing wound infection.  
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Table 1: Summary of the effectiveness of synthetic mesh versus non-mesh repair of inguinal hernias 
Study EUHTC 2000 Scott et al. 2001 Grant 2002 EUHTC 2002 Vrijland et al. 2002 Van Veen et al. 2007 Aufenacker et al. 2006 Sanchez-Manuel et al. 2007
Type Systematic review Systematic review Systematic review Systematic review RCT RCT systematic review systematic review
No of trials 15 20 20 58 8 12
No of Patients 4005 5016 11,174 300 300
Hernia recurrence 
rates
Mesh = 1.4%, Non-
mesh = 4.4%, 
OR=0.39, P<0.001
Mesh = 50% to75% 
reduction, OR=0.37, 
P<0.001
Mesh = 50% to 75% 
reduction, OR=0.37, 
P<0.001
Mesh = 2%, Non-
mesh = 5%, OR = 
0.43, P<0.001
Mesh = 1%, Non-
mesh = 7%, P=0.009
mesh = 1%, Non-
mesh = 17%, P = 
0.005
Hematomas OR=0.93 OR=0.93, P=0.6
Seromas OR=1.52 OR=1.52, P=0.1
Wound infection OR=1.24 OR=1.24, P=0.3 3% (deep infection = 0.6%)
mesh = 2.9%, non-
mesh = 4.9%
Operative time
open mesh 7 to 10 
minutes less than 
Shouldice repair but 1 
to 4 minutes longer 
than other non-mesh 
methods
Both groups = 45 mins
Hospital stay
Mesh = 1.1 to 6.7 
days, Non-mesh  = 1.3 
to 7.2 days, P=0.22
Mesh repair shorter by 
between 0.22 and 
0.35 days
Both groups = 2 days
Return to usual 
activities
mesh quicker in 7 out 
of 10 trials, slower in 2 
out of 10 trials and 
similar in 1, P=0.34
HR=0.81 HR=0.81, P<0.001
Persisting pain OR=0.68 OR=0.68, P=0.04
Mesh = 5%, Non-
mesh = 10.1%, OR = 
0.36, P<0.001
Persisting 
Numbness OR=0.70 OR=0.70, P=0.4
Quality of life score EQ-5D = 81, VAS = 85
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 Appendix 7: A Review of Laparoscopic Versus Open 
Mesh Repair 
 
Laparoscopic repair is considered a safe alternative to open repair but is technically more demanding 
(Reuben et al., 2006). The two most common laparoscopic techniques used for hernia repair are 
transabdominal preperitoneal (TAPP) repair and totally extraperitoneal (TEP) repair. The approaches 
differ in terms of whether the peritoneal cavity is entered; TAPP repair requires access to the 
peritoneal cavity to place the mesh through a peritoneal incision, whereas for TEP repair the 
peritoneal cavity is not entered and the mesh seals the hernia from the outside of the peritoneum; and 
the later is generally considered more demanding (Wake et al., 2005).  
 
A systematic review (Wake et al, 2005) identified 1 RCT, 5 studies with concurrent comparators, 1 
study with a non-concurrent comparator and 3 case series comparing TAPP (n=28) repair with TEP 
(n=24) repair and found no significant difference between the two groups in a number of outcomes, 
including operation time (52.3 minutes for TEP compared with 46 minutes for TAPP, P=0.06), number 
of hematomas (1 in 28 vs. 0 in 24, P=0.6), time to return to usual activities (no overall figure, but 
several separate activities listed in the paper) and hernia recurrence (1 in 28 Vs. 0 in 24, P=0.6). 
There was a significant difference found between the two groups with regard to length of stay which 
was shorter for the TAPP group (mean of 3.7 days for TAPP vs. 4.4 days for TEP). It was concluded 
that there was insufficient evidence to determine which approach was most effective (Wake et al, 
2005).   
 
i. Inguinal Hernia 
Writing in the annals of the royal college of surgeons of England Michael Bailey {Bailey, 2005 321 /id} 
and Andrew Kingsnorth {Kingsnorth, 2005 320 /id} respectively argue the cases for and against 
laparoscopic repair. Both acknowledge laparoscopic repair is more challenging and is associated with 
a learning curve. However, Bailey claims training is straightforward, with surgical competency of TEP 
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achieved after 30-40 procedures and trainee surgeons having no increase in morbidity compared to 
open repair, followed by a reduction in complications to below that reported for open repair with 
increasing experience. Conversely, Kingsnorth claims that training takes much longer, around 100 
procedures, and therefore puts patients at unnecessary risk of complications. Bailey and Kingsnorth 
state that direct hospital costs are probably greater for laparoscopic repair, but do not agree on by how 
much. Laparoscopic repair requires a general anaesthetic (GA) unlike open repair which can be 
performed under local anaesthetic (LA), but how often LA is used compared to GA for open repair 
remains contentious, as does the additional direct cost associated with laparoscopic repair. However if 
societal costs relating to quicker recovery and return to employment are taken into account 
laparoscopic repair may not be the most expensive. In conclusion this debate continues and it may be 
sometime before a consensus is reached. However there are four systematic reviews comparing 
laparoscopic to open repair methods (EUHTC, 2000;EUHTC et al., 2002;McCormack et al., 
2003;McCormack et al., 2005) and the results are summarised below (in chronological order).  
 
The first review (EUHTC, 2000) published by the hernia trialists collaboration identified 34 trials and 
found that laparoscopic repair had significantly improved outcome (P<0.05) with regard to operative 
time (no data) and return to work (24 out of 34 trials). Also, laparoscopic repair is associated (but not 
significantly) with less haematomas, less reoperations (8 for laparoscopic repair compared to 12 for 
open repair), reduced pain (reported in 12 out of 16 trials, P=0.08) and reduced length of hospital stay 
(hospital stay ranged from 225 min to 4.9 days for laparoscopic repair and 134 min to 7.3 days for 
open mesh repair, 12 out of 20 trials reported a reduction associated with laparoscopic repair, 
P=0.50). Furthermore, laparoscopic repair showed a reduction in recurrence rate (2.3% and 2.9% for 
laparoscopic versus open repair, respectively, OR=0.76) but no significance value was stated. In 2002 
(EUHTC et al, 2002) the hernia trialists collaboration conducted a meta-analysis of 58 trials on groin 
hernia repair compared the use of synthetic mesh to no mesh (described in appendix 7) and 
laparoscopic technique to open technique. The only outcomes measured were hernia recurrence rate 
and persisting pain. The use of laparoscopic repair compared to open surgery showed no difference in 
recurrence rate (OR 1.26, 95%CI: 0.76-2.08, P=0.36), but there was a reduction in persisting pain (OR 
0.64, 95%CI: 0.52-0.78, P<0.001) (EUHTC et al, 2002).  
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McCormack and colleagues identified 41 RCTs (McCormack et al, 2003). The evidence suggested 
that laparoscopic repair had a number of benefits over open repair, including decreased post-
operative pain (overall, 13.1% and 19.1% for laparoscopic and open repair, respectively; OR=0.54, 
P<0.0001), persisting numbness (overall, 7.2% and 13.4% for laparoscopic and mesh repair, 
respectively, OR=0.38, P<0.0001), fewer haematomas (8.7% and 10.5% for laparoscopic and open 
repair, respectively, P<0.01), less frequent wound infection (OR=0.45, P<0.0001) and early return to 
normal activity (HR=0.56, P<0.001). However, the laparoscopic technique also had drawbacks 
including increased operation time (mean difference=14.81 minutes, P<0.0001) and a higher rate of 
seromas (5.8% and 3.8% for laparoscopic and open repair, respectively, P=0.001). There was no 
significant difference between laparoscopic and open mesh repair with regard to hernia recurrence 
(2.7% and 3.1% for laparoscopic and open repair, respectively, OR=0.81, P=0.16) and there was 
insufficient evidence to make any conclusions regarding hospital stay. It was concluded that it is the 
use of mesh rather than the surgical approach which is associated with the greatest improvement in 
outcomes.  
 
A HTA review (McCormack et al, 2005) of laparoscopic surgery for inguinal hernia repair identified 37 
RCTs and 14 cost-effectiveness studies. The benefits associated with laparoscopic repair are similar 
to those mentioned in the previous McCormack trial. Faster return to usual activities (P<0.0001), less 
persisting pain (RR0.77, P=0.004 for TEP vs. open repair and RR0.72, P=0.001 for TAPP vs. open 
repair) and numbness (RR0.67, P=0.002, for TEP vs. open repair and RR0.26, P<0.0001 for TAPP vs. 
open repair). There were fewer cases of wound infection (RR0.62, P=0.41 for TEP vs. open repair and 
RR0.41, P=0.0001 for TAPP vs. open repair) and haematomas (RR0.44, P<0.0001 for TEP vs. open 
repair and RR0.76, P=0.009 for TAPP vs. open repair). However laparoscopic repair was also 
associated with longer operative time (mean difference = 13.33, P<0.0001) and increased number of 
seromas (RR0.73, P=0.17 for TEP vs. open repair and RR1.97, P=0.003 for TAPP vs. open repair). 
There was no significant difference between laparoscopic and open repair with regard to recurrence 
rates (2.5% and 2.07% for laparoscopic and open repair, respectively, P=0.5). The economic 
evaluation of laparoscopic versus open repair found that laparoscopic repair is more costly to the 
health service than open repair for the treatment of inguinal hernias. This has been shown by UK 
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based studies, which estimate an extra cost of about £300-350 (€450-520, $600-700) per patient, and 
point estimates of cost provided by an economic model, which amount to an additional cost of £100-
200 per patient after 5 years (McCormack et al, 2005).  
 
Overall, laparoscopic surgery compared to open surgery has led to improvements in clinical outcomes 
although no difference has been found in recurrence rate, the most frequent complication. Operative 
time can be longer with laparoscopic repair but it appears as though these additional hospital costs 
may be balanced out when social costs of more rapid return to work are taken into account.  
 
ii. Incisional Hernia Repair 
One retrospective of 91 patients (Bencini et al., 2003) compared laparoscopic (n=42) and open (n=49) 
techniques for incisional hernia repair along with one prospective study of 31 patients (Engledow et 
al., 2007) investigating whether day case laparoscopic repair for incisional hernias is feasible, 
acceptable and cost-effective.  
 
Bencini and colleagues found that there was no significant difference between laparoscopic and open 
repair in terms of operative time (108 min and 112 min for laparoscopic and open repair, respectively, 
P=0.73), overall rate of complications (26% and 44% for laparoscopic and open repair, respectively, 
P=0.10), incidence of seroma (14% and 10% for laparoscopic and open repair, respectively, P=0.93) 
and recurrence rate (0% and 6% for laparoscopic and open repair, respectively, P=0.30). There was a 
significant difference between the two groups in terms of hospital stay (5days vs. 8 days for 
laparoscopic vs. open repair, respectively, P<0.0001) and this lead to a difference, in favour of 
laparoscopic repair, in mean hospital cost (€2357 for laparoscopic repair vs. €3890 for open repair, 
P=0.0011) and overall cost (mesh + hospital stay) (€3091 for laparoscopic repair vs. €3936 for open 
repair, P=0.017). However it should be noted that the hernia defect was significantly larger in the open 
repair group (122cm2) compared to the laparoscopic repair group (83cm2, P=0.0006).  
 
Engledow and colleagues concluded that laparoscopic day case repair is possible as the previously 
documented advantages of laparoscopic methods over open methods lend themselves to day case 
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surgery, including the use of local over general anaesthetic. They do state that community support 
would need to be available to all but do not include these costs in their cost analysis. They find that an 
analysis of direct hospital costs for day case laparoscopic repair leads to an overall saving of £616 per 
procedure, due to shorter operative time and lack of inpatient stay. Overall, currently there is 
insufficient evidence to determine whether laparoscopic or open repair is better. 
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 Appendix 8: Clinical Market Analysis of Meshes  
 
Here I summarise the key findings of a market evaluation, conducted in the US by Medpanel, Inc. 
(MedPanel 2007), of synthetic versus biologic meshes used to repair complex defects. The aim is to 
gain an understanding of market potential for biologics from a clinical perspective. The evaluation 
questioned 40 surgeons with the following criteria: board certified as a general surgeon, greater than 2 
years surgical experience, spent a minimum of 75% of  time on clinical practice and perform a 
minimum of 20 hernia repairs a month if positioned in an academic setting and 10 per month if in a 
non-academic setting. They were asked to complete a 20-minute questionnaire comprised of 5 
sections: surgery classification; product comparison; cost considerations; comparisons of sales 
representatives; and alternative product applications.  
 
The key factors contributing to a complex ventral hernia classification were significant loss of 
abdominal fascia, presence of mesh from a previous repair followed by infection and bowel 
contamination. Currently about one third of ventral hernias are classified as complex however, 48% 
felt this was likely to increase (although no reason given). As expected synthetic mesh is the current 
treatment choice for ventral hernia repair although 70% had used a biological implant at some stage.  
 
It is widely believed that biologics will and do perform better than synthetics when used in complex 
defects; 85% said they would prefer to use biologics for a complex or infected hernia repair, for a 
clean-contaminated field after first recurrence and in cases where more than one recurrence has 
occurred. However, 85% believe that synthetic mesh is the most cost-effective treatment due to the 
high cost of biological meshes. Overall, the surgeons thought the use of AlloDerm and other biologics 
was likely to increase over the coming years (no further explanation) but 70% said that would remain 
most important in terms of their product selection.  
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 Appendix 9: Search Strings for Chapter 6  
 
Search Date Database Term Yield 
1 Mar-07 Medline bone repair AND current treatment 715 
2 Mar-07 Medline bone repair AND current treatment AND autograft AND autogenous bone graft 2849 
3 Mar-07 Medline bone AND tissue engineering 4056 
4 Mar-07 Medline bone AND tissue engineering AND growth factors 859 
5 Mar-07 Medline bone AND tissue engineering AND growth factors AND BMP OR bone morphogenic proteins 859 
6 Mar-07 Medline bone AND tissue engineering AND cells 2662 
7 Mar-07 Medline bone AND tissue engineering AND stem cells 1172 
8 Mar-07 Medline bone AND tissue engineering AND cells AND MSCs 287 
9 Apr-07 Medline spinal fusion 13551 
10 Apr-07 Medline spinal fusion AND epidemiology 678 
11 Apr-07 Cochrane spinal fusion AND epidemiology 33 
12 Apr-07 Medline degenerative disc disease 847 
13 Apr-07 Cochrane degenerative disc disease 82 
14 Apr-07 Medline degenerative disc disease AND epidemiology 64 
15 Apr-07 Medline spinal fusion AND degenerative disc disease 297 
16 Apr-07 Medline spinal fusion AND degenerative disc disease AND 
epidemiology 21 
17 Apr-07 Medline spinal fusion AND tissue engineering 48 
18 Apr-07 Medline degenerative disc disease AND non-surgical OR disc 
replacement 937 
19 Apr-07 Medline degenerative disc disease AND total disc replacement 42 
20 Apr-07 Cochrane degenerative disc disease AND total disc replacement 8 
21 Apr-07 Medline degenerative disc disease AND nucleus pulposus 
replacement 13 
22 Apr-07 Medline Fracture nonunion AND nonunion of fractures 8925 
24 Apr-07 Cochrane Fracture nonunion AND nonunion of fractures 52 
25 Apr-07 Medline Fracture nonunion AND nonunion of fractures AND 
epidemiology 119 
26 Apr-07 Medline fracture nonunion AND segmental defects 72 
27 Apr-07 Medline segmental defects AND epidemiology 192 
28 May-07 Medline osteoporotic fractures 3975 
29 May-07 Cochrane osteoporotic fractures 418 
30 May-07 Medline osteoporosis AND spinal fractures 2780 
31 May-07 Cochrane osteoporosis AND spinal fractures 360 
32 May-07 Medline osteoporotic fractures AND epidemiology 966 
33 May-07 Medline osteoporotic fractures AND osteoporosis AND spinal fractures AND epidemiology 218 
34 May-07 Medline osteoporotic fractures AND current treatment 279 
35 May-07 Medline osteoporotic fractures AND kyphoplasty AND 
vertebroplasty 325 
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36 May-07 Cochrane osteoporotic fractures AND kyphoplasty AND 
vertebroplasty 4 
37 May-07 Medline osteoporotic fractures AND kyphoplasty AND 
vertebroplasty AND filler materials 2 
38 Jun-07 Medline bone cysts 973 
39 Jun-07 Cochrane bone cysts 44 
40 Jun-07 Medline bone cysts AND epidemiology 374 
41 Jun-07 Medline simple bone cysts 325 
42 Jun-07 Medline aneurysmal bone cysts 1271 
43 Jun-07 Medline bone cysts AND current treatment 66 
44 Jun-07 Medline bone cysts AND tissue engineering 6 
45 Nov-07 Medline autograft AND cost AND effectiveness 93 
46 Nov-07 Medline autograft AND BMP AND cost AND effectiveness 3 
47 Nov-07 Medline autograft AND spinal fusion AND cost-effectiveness 
analysis 6 
48 Nov-07 Medline autograft AND fractures AND cost-effectiveness 
analysis 2 
49 Nov-07 Medline harvesting iliac crest bone  
50 Nov-07 Medline Harvesting iliac crest bone and duration 10 
51 Nov-07 Medline 
QoL OR “Quality of Life” OR Utilit* OR disutilit* OR 
cost effective* OR cost-effective* OR contingent 
valuation OR willingness to pay OR willingness to 
accept OR WTP AND autogenous OR autologous 
AND “iliac crest bone graft” OR “bone graft” OR ICBG 
6076 
52 Nov-07 Medline 
QoL OR “Quality of Life” OR Utilit* OR disutilit* OR 
cost effective* OR cost-effective* AND autogenous 
OR autologous AND “iliac crest bone graft” OR “bone 
graft” OR ICBG 
6076 
53 Nov-07 Medline 
QoL OR “Quality of Life” OR Utilit* OR disutilit* OR 
“cost effective*” OR “cost-effective*” AND autogenous 
OR autologous AND “iliac crest bone graft” OR ICBG 
123 
54 Nov-07 Medline VAS AND health related QOL OR EuroQOL OR health 
valuations 968 
55 Nov-07 Medline VAS score AND QoL score OR "quality of life" score AND back pain 120 
56 Nov-07 Medline VAS OR Visual Analogue Scale AND QoL OR "quality 
of life" AND utilit* AND Back Pain 16 
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 Appendix 10: A Review of the Alternative to Spinal Fusion 
for the Treatment of Degenerative Disc Disease 
 
There is continued debate regarding the appropriateness and effectiveness of spinal fusion in the 
treatment of back pain and disc degeneration. A vast number of alternatives, both surgical and non-
surgical, are being developed at a rapid pace. Here I discuss evidence on the proposed alternatives to 
spinal fusion. 
 
Non-surgical Approaches 
Although spinal fusion has been the primary surgical treatment for DDD it does possess several 
limitations that would not be avoided by a RM method e.g. infection and pseudoarthrosis (Sakalkale et 
al., 2003). These would be a price worth paying if the surgery was effective, but the evidence from 
three published RCTs {Brox, 2003 164 /id;Fairbank, 2005 139 /id;Fritzell, 2001 166 /id} comparing 
spinal fusion to non-surgical interventions remains unclear.  
 
Of the three RCTs conducted to compare spinal fusion to non-surgical interventions, one trial (N=294) 
found fusion to be more effective than non-surgical treatments at reducing back and leg pain (p = 
0.0002 and p = 0.005, respectively) and disability (assessed using the Oswestry Disability Index (ODI), 
p = 0.015) {Fritzell, 2001 166 /id}, one trial (N=64) found that there was no significant (P = 0.33) 
difference between lumbar fusion and cognitive intervention plus exercise at the 1-year follow-up 
(assessed using the ODI) (Brox et al, 2003), and one trial (N=349) found that there was “no clear 
evidence” as the difference between lumbar fusion and intensive rehabilitation was marginal 
(measured using the ODI, p = 0.045), only just reaching the predefined clinical difference (Fairbank et 
al, 2005). For this reason, and because even large RCTs cannot exclude small benefits, it remains 
possible that the operation has some benefit, although any such benefit must be smaller than many 
previously thought and the results are also compatible with a small disbenefit.  
 
   
351 
A cost utility analysis was conducted by Rivero-Arias et al. (2005) based on a RCT comparing spinal 
fusion to intensive rehabilitation for the management of patients with chronic low back pain (Rivero-
Arias et al., 2005). At the two-year follow-up 38 patients (22%) randomised to the rehabilitation group 
underwent surgical fusion in addition to rehabilitation, 11 patients (6%) in the surgical group underwent 
re-operations and 7 patients (4%) in the surgical group received rehabilitation in addition to surgery. 
When the additional costs of unplanned surgery and patient care are taken into account the overall 
costs (after two years) associated with spinal fusion surgery and intensive rehabilitation were £7,830 
and £4,526, respectively, resulting in a cost difference of £3,304 (£2317 to £4291, P<0.001) in favour 
of intensive rehabilitation.  
 
No significant difference in utility was found between any of the follow-up points, except that for 
baseline. The mean QALY difference in favour of surgery was 0.068. The cost-effectiveness of 
surgery, expressed as an incremental cost per QALY, was estimated to be £48,588 (patient utility was 
estimated using the EuroQol questionnaire), and therefore at two years the chance that surgery will be 
cost-effective is less than 20%. However, the cost-effectiveness of surgery cannot be determined with 
certainty. Since it is possible that the number of patients receiving both interventions could increase 
beyond the two-year follow-up, and that this increase may disproportionately affect one arm of the trial 
more than the other, the cost-effectiveness of the surgery could be severely affected (this has been 
shown by sensitivity analysis) (Rivero-Arias et al, 2005). Therefore further follow-up of patients is 
required to determine the long-term effectiveness. 
 
Posterior Dynamic Stabilisation 
Posterior dynamic stabilisation is a surgical alternative, which like spinal fusion, is targeted at 
stabilisation of the spine, however it is designed to control rather than eliminate motion between 
vertebrae. This system uses autograft along with pedicle screws (e.g. Dynesys System) or an 
interspinous device to restabilise spinal segments and reduce intradiscal pressure (Schnake et al., 
2006). Adjacent vertebrae are connected with flexible rods allowing some restriction in motion and the 
disc between the two vertebral bodies is partially loaded. There evidence on the effectiveness of 
dynamic stabilisation remains unclear due to a lack of RCTs.  
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Intradiscal Electrothermal Therapy (IDET) 
IDET is a minimally invasive technique, which places a temperature controlled thermal resistive 
heating coil into the outer region of the disc (Freeman, 2006).  A systematic review (Andersson et al., 
2006) of studies comparing IDET with spinal fusion yielded similar results in improvement for two out 
of three outcomes evaluated: pain severity was reported as 51% and 50%, respectively and quality of 
life was determined as 43% and 46%, respectively. There was a difference observed for the back 
function outcome. The percentage improvement reported was 42% and 14% in favour of spinal fusion 
(p-value not given). However, the review identified just two RCTs for IDET treatment. IDET appears 
less expensive; Andersson and colleagues (Andersson et al, 2006) report that mean costs for fusion 
operations are $50,000, whereas IDET has been estimated to cost only $7,000 (these costs do not 
include management of any postoperative complications which may arise).  
 
Total Disc Replacement 
Total disc replacement involves the surgical insertion of a disc prosthesis anteriorly through an 
abdominal incision. There are numerous types currently being developed and under investigation 
(Table 1: Summary of artificial disc prosthesesTable 1) (Freeman et al., 2006).  Two RCTs comparing 
total disc replacement with spinal fusion are reported in literature; the first involving the Charité 
artificial disc and the second involving the Pro-Disc II total disc replacement (Freeman et al, 2006).  
 
The first RCT (n=304) compared spinal fusion (n=99) to total disc replacement using the Charité 
artificial disc (n=205). The findings reported an ODI and visual analogue score (VAS) for back pain 
improvement in favour of the Charité artificial disc at 24 months (ODI improvement of 24.8 points (from 
50.6 to 25.8) for Charité artificial disc and 22 points (from 52.1 to 30.1) for spinal fusion (no p-value 
given), and a Visual Analogue Score (VAS) for back pain improvement of 41.4 points (from 72 to 30.6) 
for Charité artificial disc and 35.5 points (71.8 to 36.3) for spinal fusion (no p-value given)) (Freeman 
et al, 2006). Furthermore, only 57% of patients with disc replacement and 46% of those with fusion 
met all four criteria for success (greater than 25% improvement in ODI at 24 months, no device failure, 
no major complications, and no neurological deterioration) (Freeman et al, 2006).  
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The Pro-Disc II clinical trial compared disc replacement to spinal fusion in both single and double 
DDD. The trial reported that there was no significant difference in the preoperative values of ODI or 
VAS scores between the two groups. At 6 weeks and 3 months the disc replacement patients showed 
significantly more improvement (in VAS score) compared to the fusion group (no p-value given).  By 6 
months both groups showed significant improvement in ODI and VAS compared to preoperative 
values (no p-value given) however, the difference between the two groups was not significant (no p-
value given) (Delamarter et al., 2005). However, it has been suggested total disc replacement using 
Pro-Disc II may only be beneficial for a highly selective group of patients (Siepe et al., 2006). 
 
Disc replacement is technically demanding as it is conducted in close proximity to the spinal cord, 
nerve roots and a complex network of large blood vessels. As yet no study has shown total disc 
replacement to be significantly superior to spinal fusion in terms of clinical outcome. Furthermore, the 
potential long-term benefits of total disc replacement in preventing adjacent level disc degeneration 
and any long-term complications also remain unknown (Freeman et al, 2006). However, postoperative 
recovery following disc replacement is reported to be more rapid than that following spinal fusion with 
commensurate reductions in hospital stay (Wilson-MacDonald et al., 2007). In my opinion it is too early 
to say whether, or in what circumstance disc replacement yields better outcomes than spinal fusion, 
and as discussed above, many think the jury is still out on the subject of spinal fusion itself. 
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Table 1: Summary of artificial disc prostheses 
Device Characteristics Studies Results References 
Charite 
Bi-convex ultra high molecular 
weight polyethylene spacer, 
which acts as a mobile core. 
Many single 
studies. 
Undergoing an 
FDA approved RCT 
Early clinical 
results equivalent 
to spinal fusion  
(Errico, 
2004;Freem
an et al, 
2006) 
ProDisc 
A metal on plastic device. The 
end plates are secured to 
vertebral end plates by a 
central keel, spikes and a 
porous coated surface 
Undergoing an 
FDA approved RCT 
Preliminary 
results promising. 
Some indications 
for patients 
(Errico, 
2004;Freem
an et al, 
2006;Siepe 
et al, 2006) 
Acroflex 
Elastomeric core sandwiched 
between two titanium 
endplates to optimize shock 
absorption qualities. 
One single study.                                                                                                 
RCT cancelled due 
to mechanical 
failure  
Disappointing. 
Implant failure 
lead to 
withdrawal from 
market 
(Freeman et 
al, 2006) 
MAVERICK 
3rd generation disc 
technology. A highly polished 
cobalt chrome ball and socket 
in a metal on metal design. 
Device provides a fixed 
posterior centre of rotation and 
resists both anterior and 
posterior shear forces. 
Approved for a 
clinical trial  
Errico, 
2004;Freem
an et al, 
2006) 
Flexicore 
A cobalt chrome molybdenum 
highly polished ball and socket, 
metal on metal prosthesis. 
Approved for 
clinical trials  
(Errico, 
2004) 
 
 
 
Whole Disc Transplantation 
Whole disc transplantation has been investigated following the success of organ transplantation. Disc 
transplantation has the theoretical advantage over artificial disc replacement and disc regeneration, of 
providing young, non-degenerated scaffold that could offer the best environment for the endogenous 
NP cells to survive or regenerate (Ruan et al., 2007). Animal models have shown that to preserve 
stability and mobility after discectomy is both technically and biologically feasible, and the restoration 
of mechanical function has been satisfactory (Ruan et al, 2007). Following the success of this method 
in primates, Ruan and colleagues proceeded with a preliminary study to examine the feasibility, safety, 
and long-term clinical results of disc transplantation in humans. 
 
Five patients received disc transplantation of fresh-frozen allografts. At 3 months good union of graft 
endplates was observed and no immunoreaction, migration or complications relating to surgical 
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procedure or wound healing were reported in any of the patients. At the five-year follow-up, 
neurological symptoms of all patients had improved compared to before surgery and mobility and 
stability of the disc was compatible with a satisfactory clinical outcome. Immediately following surgery 
mean disc height increased (5.32mm to 5.88mm) although was not maintained and soon after 
transplantation disc height was lost (4.33mm), but remained stabilised. In comparison artificial discs 
have shown to restore full disc height for the longer term. Three out of five patients had some 
evidence of pain at the five-year follow-up (although the level of discomfort was lower than that 
reported before surgery), whether this pain was a result of surgery or due to the natural history of 
degenerative disc disease at other levels in the spine is unclear (Ruan et al, 2007). 
 
Nucleus Pulposus Replacement 
Nucleus pulposus (NP) replacement is a recent alternative to total disc replacement. The NP lies at 
the centre of the disc (see figure 1), contains large amounts of water, and functions as a shock 
absorber. Degeneration of the disc results in the gradual loss of water from the NP (Di Martino et al., 
2005), therefore reducing the functional capacity of the disc. NP replacement exchanges just the inner 
part of the disc for prosthesis, leaving the remainder intact. It is a less invasive procedure, achieved 
via a posterior (e.g. PDN), lateral (e.g. Aquarelle), or anterior (e.g. Regain) approach, involving the 
splitting of the psoas muscle, removal of the existing nucleus and insertion of the prosthesis in the 
middle third of the disc. The prosthesis is inserted in its dehydrated state (its smallest size), which 
absorbs water once inserted, or in a liquid state, if curing polymers (table 6) were used to form the 
prosthesis, which harden after implantation (Di Martino et al, 2005). 
 
At present NP replacement is intended for use in lumbar disc degeneration (Di Martino et al, 2005), if 
the disc degeneration shows 10-50% loss of disc space height (Goins et al, 2005). It is thought this 
treatment could offer several advantages to other surgical treatments such as prevention of more 
serious injuries; avoidance of major blood vessels, thereby reducing risk to the patient; reduced 
scaring; avoidance of morbidities associated with fusion and total disc replacement; and be a 
minimally invasive procedure.  
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There are a number of NP prostheses currently under investigation and these are summarised in 
Table 2. To date the most widely studied nucleus replacement device has been the prosthetic disc 
nucleus (PDN) (Raymedica, Inc., Bloomington, MN), implanted in over 550 patients, a hydrogel pellet 
designed to absorb 80% of its weight in water allowing response to compressive forces and 
maintenance of disc height (Goins et al, 2005). Clinical results on 10 patients who received the PDN 
device for symptomatic lumbar DDD with a minimum 2-year follow up demonstrated “excellent results” 
with marked decreases in ODI scores (values not stated) in 8 patients, as well as restoration of disc 
space height and normal motion (Goins et al, 2005).  
 
Table 2 Summary of Nucleus Pulposus Prosthesis  
(Adapted from (Di Martino et al, 2005)) 
Device Technology Biomaterial Studies FDA approved 
Prosthetic Disc 
Nucleus 
intradiscal 
implant 
Hydrogel pellet 
encased in a 
polyethylene jacket 
Implanted in more than 
400 patients 
investigational 
use only 
Aquarelle intradiscal implant 
Semihydrated polyvinyl 
alcohol (PVA) hydrogel 
Animal experiments 
(baboon) plus 
cadaveric spine New 
Zealand rabbits 
 
Neudisc intradiscal implant 
Modified hydrolyzed 
polymer (Aquacryl) 
reinforced by a mesh 
New Zealand rabbits  
Newcleus intradiscal implant 
Polycarbonate 
urethane (PCU) 
elastomer curled into a 
preformed spiral 
Implanted in 5 patients  
Regain intradiscal implant  
implanted in few 
patients 
investigational 
device 
exemption to 
start 
IPD intradiscal implant 
Modular intervertebral 
prosthetic disc 
Tested in an animal 
experimental model in 
cow 
 
DASCOR Disc 
Arthroplasty 
device 
In Situ Curing 
polymer injectable polyurethane 
implanted in 16 
patients  
BioDisc In Situ Curing polymer protein hydrogel 
tested on animal 
models  
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Despite some early success with NP implants they are still considered experimental and require 
further research to answer questions surrounding reliability and maintenance of the viscoelastic 
properties of the native disc when subjected to multidirectional loads at differing rates (Goins et al, 
2005). As yet there have been no clinical trials comparing nucleus replacement to lumbar fusion 
(Sakalkale et al, 2003).  
 
Nucleus Pulposus Regeneration 
Biological disc replacement involves using growth factors or pluripotent cells to re-populate the NP 
with cells (Ruan et al, 2007). This form of disc regeneration uses gene therapy (GT) to repair 
damaged tissue and could be the ultimate cure for spinal cord injury (Zigler et al., 2003).  Although the 
precise pathophysiology of IVD degeneration has yet to be clearly defined, the progressive decline in 
aggrecan, the primary proteoglycan of the NP, appears to be a final common pathway (Sobajima et 
al., 2004), resulting in gradual dehydration of the ECM within the NP. It has been hypothesised that an 
imbalance in the synthesis and catabolism of certain critical ECM components can be alleviated by the 
transfer of genes to IVD cells encoding factors that modulate synthesis and catabolism of these 
components (Sobajima et al, 2004).  
 
The importance of growth factors in development and healing is already well established and several 
growth factors (TGF-1b, BMP-2, BMP-7 (described earlier)) have been shown to up-regulate ECM 
synthesis in vitro (Shimer et al., 2004). The effect of growth factors on IVD have shown positive 
results; demonstrating increased proteoglycan synthesis (Shimer et al, 2004); promotion of mRNA 
expression, ECM synthesis, and type II collagen; increased proliferation rate of the NP cells (Chen et 
al., 2006), and the ability to rescue IVD cells following inflammatory stress (Shimer et al, 2004).  
However, growth factors have a short biological half-life. Currently, GT is being investigated to 
overcome this through sustaining growth factor concentrations in animal models of degeneration 
(Shimer et al, 2004).  
 
Disc degeneration is accompanied by a decline in cellularity and successful GT requires the presence 
of an adequate number of responding cells. Cell numbers can be restored either by both stimulating 
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the division and inhibiting the death of endogenous cells or by introducing new cells into the disc. The 
latter strategy may be more successful, as the endogenous cells of a degenerating disc may be 
unresponsive or abnormal (Evans, 2006). MSC cells, isolated from bone marrow and other sources, 
have demonstrated an ability to restore pathologically altered disc tissue in animal models under the 
right environment (hypoxia, growth factor, three dimensional culture), and are seen as good 
candidates for transplantation and use in the repopulation of the NP (Risbud et al., 2004).  Although 
this work is in its infancy there is significant optimism in this technology. 
 
A recently published paper from the UK centre for Tissue Engineering has shown that the co- culture 
of human NP cells and MSCs, in the presence of cell-cell contact, causes MSC differentiation to a NP-
like phenotype. This could be a viable method for generating a large population of differentiated cells 
for use in cell-based TE therapies for regeneration of the degenerative IVD (Richardson et al., 2006).  
 
The major disadvantage to the treatments that target the NP is the degeneration of the physical 
structure of the annulus fibrosus, which could be too advanced for the disc to function normally, or it 
could continue to degrade and result in worsening of the condition (Ruan et al, 2007). 
 
Conclusion  
It is unlikely that spinal fusion will be superseded in the near future as many critics of alternatives point 
out; there is a real lack of evidence and controlled trials on some of these newer treatments. 
Furthermore, in the context of these studies which compare surgery and non-surgery interventions 
one must consider the patient population selected. Patient selection is fundamental to a successful 
outcome. However the ability to select appropriate patients for surgery can sometimes be a 
challenging one. Therefore, inconsistencies in the results which suggest excellent results for one 
patient and a lack of improvement for another are likely to be due to failures in patient selection rather 
than failures in the intervention. Better identification of the indications which determine a patient’s 
suitability for surgery is needed in order to achieve consistent symptomatic relief (Wilson-MacDonald 
et al, 2007). Advocates of fusion surgery believe that the spate of recent studies which brings into 
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question the effectiveness of spinal fusion may be underestimating the benefit due to poor patient 
selection and poor surgical technique.  
 
Further research in this area should aim to clarify the most effective technique for spinal fusion and 
determine the effectiveness of alternative treatment options via RCTs. Clear indications should be 
available stating when surgery is and is not appropriate. The frequency of each treatment option used 
would also be useful in determining the opinion of the field. There is currently no database of spinal 
surgery in the UK with adequate coverage and collation of long-term outcomes. There is an 
international database of back surgery to which some surgeons contribute but the difficulty has been 
in achieving high rates of follow-up. Likewise some members of the UK society for back pain research 
are collecting long-term outcomes and it may be that useful to establish a broad based database for 
spinal surgery in the UK and use tracker trials (Lilford et al., 2000) to determine the effectiveness of 
the new technologies. Sweden has already established a national register of lumbar spinal surgery 
and this is reviewed below. 
 
The Swedish National Spinal Register for Lumbar Surgery 
The Swedish national register for lumbar surgery aims to prospectively describe the outcome (focusing 
on pain relief and function) of disc surgery, decompressive surgery and fusion surgery of the lumbar 
spine, and to report the results annually (Fritzell et al., 2006). The National Board of Health and 
Welfare funds the register, at a cost of only £30,000 annually (which cover staff costs only with no 
payment to participating departments). The register is overseen by a management group lead by Bjorn 
Stromqvist and made up of orthopaedic surgeons (Jönsson, B; Fritzell, P; Hägg, O; Larsson, B-E; 
Lind, B.) from four hospitals around Sweden.  
 
Degenerative lumbar spine disorders are less well defined compared to hip and knee arthrosis and hip 
fracture, all of which have prospective registers (Johnsson et al., 2002). The Swedish register 
therefore records information that allows patients to be characterised in detail, and includes the results 
of imaging that are increasingly used in diagnosis and planning. Registers have the potential to 
provide information about the number and type of surgical interventions, by indication, and record 
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adverse events and outcomes such as patient satisfaction, quality of life and cost-effectiveness 
(Fritzell et al, 2006) for the different procedures according to indications.  
 
The Swedish national register was the first of its kind to evolve documenting multiple pre- as well as 
postoperative variables.  The latter includes the visual analogue scale (VAS) for back and leg pain, 
and the SF-36 questionnaire. Although established in 1993 it was not widely disseminated until 1998 
due in part to an economic recession and some initial problems centred on the surgeon-based 
protocol, insufficient IT knowledge, and registration fatigue. In 1999 improvements were made to the 
protocol; it became patient-based, a support function was created, and improved feedback was 
established. The register now includes more than 80% of (the estimated 5,000+) spinal operations for 
degenerative disorders, and the recent addition of a web-based version of the register is estimated to 
further increase registration (Johnsson et al, 2002). 
 
It is believed that there are four key factors which have contributed to the success of the Swedish 
endeavour: A national health service and existing unique patient identifiers make possible the 
identification and follow-up of ‘migrating’ patients who change the centre of treatment; an established 
culture for reporting procedures and outcomes; the data collection technology employed is easy to use 
and provides performance feedback to the surgeons; and the overall simplicity of the register (Roder 
et al., 2006). The register is being used more frequently with coverage expected to reach 85% in the 
coming year, and a protocol for the inclusion of Oswestry disability index (ODI) is being considered. 
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 Appendix 11: Search Strings for Chapter 7 
 
Search Date Database Term Results 
1 Jan-08 PubMed cartilage defect AND knee 527 
2 Jan-08 PubMed cartilage AND defect OR lesion AND knee 2327 
3 Jan-08 PubMed ACI  2788 
4 Jan-08 PubMed ACI AND cartilage AND Knee 62 
5 Jan-08 PubMed ACI AND cartilage AND Knee AND randomised 6 
6 Jan-08 PubMed microfracture 228 
7 Jan-08 PubMed microfracture AND cartilage AND Knee 87 
8 Jan-08 PubMed microfracture AND cartilage AND Knee AND 
randomised 2 
9 Jan-08 PubMed mosaicplasty 90 
10 Jan-08 PubMed mosaicplasty AND cartilage AND Knee 60 
11 Jan-08 PubMed mosaicplasty AND cartilage AND Knee AND randomised 4 
12 Jan-08 PubMed MACI 101 
13 Jan-08 PubMed MACI AND cartilage 16 
14 Jan-08 PubMed MACI AND cartilage AND Knee 13 
15 Jan-08 PubMed MACI AND cartilage AND Knee AND randomised 2 
16 Jan-08 PubMed osteoarthritis AND epidemiology 2706 
17 Jan-08 PubMed osteoarthritis AND Knee AND epidemiology 999 
18 Jan-08 PubMed osteoarthritis AND Knee AND epidemiology AND 
systematic Review 119 
19 Jul-08 PubMed quality of life OR QoL OR utilit* AND osteoarthritis of knee 474 
20 Jul-08 Cochrane quality of life OR QoL OR utilit* AND osteoarthritis of knee 16250 
21 Jul-08 PubMed quality of life OR QoL OR utilit* AND mild osteoarthritis 
of knee 23 
22 Jul-08 PubMed quality of life OR QoL OR utilit* AND severe 
osteoarthritis of knee 44 
23 Jul-08 PubMed quality of life OR QoL OR utilit* AND replacement of knee OR knee replacement OR total knee replacement 9747 
24 Jul-08 PubMed 
quality of life OR QoL OR utilit* AND first replacement of 
knee OR first knee replacement OR first total knee 
replacement 
969 
25 Jul-08 PubMed 
quality of life OR QoL OR utilit* AND second 
replacement of knee OR second knee replacement OR 
second total knee replacement 
358 
26 Jul-08 PubMed osteoarthritis AND knee AND knee replacement OR total knee replacement AND quality of life OR utilit* 68624 
27 Jul-08 Cochrane osteoarthritis AND knee AND knee replacement OR total knee replacement AND quality of life OR utilit* 3530 
28 Jul-08 PubMed osteoarthritis AND knee AND knee replacement OR total knee replacement AND quality of life  272 
29 Jul-08 Cochrane osteoarthritis AND knee AND knee replacement OR total knee replacement AND quality of life  218 
30 Jul-08 PubMed osteoarthritis AND knee AND knee replacement OR total knee replacement AND utilit* 51 
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 Appendix 12: Analysis of the TUFTS database 
 
As described in chapter 8, when I needed to find a source of utility values I thought the obvious place 
to start was the TUFTs database of utilities (Tufts Medical Centre, 2009). For my first task, I entered 
the information from the TUFTS dataset into an Excel spreadsheet so the data could be analysed. The 
TUFTS database consists of a large matrix containing 7874 utility values spanning across 1653 
studies and 68 disease classifications. The advantage of this database is that it enables the reader not 
only to find out what utility values have been described to various health states of different disease 
classifications but also in many instances to provide these results under different methods of 
elicitation. The measurement of the utility value could fall into one of 10 categories. This is illustrated 
in figure 1 below. It is, however, obvious from the graph that the categories with the largest number of 
utilities are in fact ‘unknown/NA’ and ‘other’ (I could not find an explanation of the term ‘other’). It is 
also clear though, that of the other defined measurement types, EQ-5D is dominant.  
 
Figure 1. Frequency of different measurements used to elicit utilities  
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Next, I examined the distribution of the utility values irrespective of measurement and then based on 
the method of elicitation. The results are illustrated below in figures 2 to 9 below. These graphs show 
the levelling effect of the utility values around the 1 decimal point values i.e. 05, 0.6, 0.7 etc.
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Figure 2: Distribution of all utility values reported on TUFTS 
database 
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Figure 3: Distribution of all utility values between 0 to 1.0 
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Figure 4: distribution of all utility values between 0.5 to 1.0 
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Figure 5: Distribution of all utility values between 0.9 and 1.0 
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Figure 6: Distribution of utility values based on measurement type 
between 0.5 and 1.0 
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Figure 7: Distribution of utility values between 0.5 and 1.0 for 
selected measures  
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Figure 8: Distribution of utility values based on measurement type 
between 0.9 and 1.0 
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Figure 9: Distribution of utility values between 0.5 and 1.0 for 
selected measures 
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There are also disadvantages to this database. The TUFTS database is a large matrix, which makes it 
difficult to select a limited number of values from a somewhat bewildering array of different values 
obtained from similar but not necessarily identical health states, elicited by one of 8 different utility 
measurements. I tried to address this issue by grouping the utilities by method of elicitation, however, 
a vast number of utilities remained, and this did not help with the issue that the descriptions of the 
health states were vague and often overlapping. My next approach was to try to tease out the health 
states, which had a utility value elicited by more than one measurement. I used two approaches to this 
problem, firstly by examining the studies, which had used several different utility measurements, and 
secondly by examining across studies within the same disease classification. 
 
For the first approach, I started with 1653 studies (which gave an average of 4.75 utilities per study). I 
selected only those studies, which reported using more than one type of utility measurement. This 
resulted in 161 studies (an average of 6.87 utilities per study). I then removed the measurement 
categories ‘other’ and ‘unknown/NA’ as these would not be helpful in any further analysis. This left 48 
studies (an average of 5.69 utilities per study). Selecting those utilities, which had a utility elicited 
using author judgement and at least one other form of utility measurement, I was left with 22 studies 
(an average of 6.0 utilities per study). I examined these 22 studies in more detail to ascertain whether 
any of the studies had reported the same health state measured using author judgement and any 
other measure (see table 1). I was unsuccessful in this endeavour.  
 
For the second approach I started with 68 disease classifications, as defined by the TUFTS database 
(see figure 10).  I selected the most common disease classifications (breast cancer, infectious 
disease, cardiovascular diseases and musculoskeletal and rheumatologic diseases). I tried to 
ascertain whether across all studies within a given disease classification the same health state had 
been reported using different methods of elicitation. This was not possible. It proved very difficult to 
define the health states so that ‘like’ could be compared with ‘like’.  
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Table 1. Studies with more than one utility value measured using author judgment and at least one other measurement 
Study Article ID Classification Health State Weight Measurement 
1 2002-01-01169 Hypertension 
Swedish general population age >80 0.60 Time trade off 
Swedish general population age 75-84 0.65 Time trade off 
Swedish general population age 65-74 0.81 Time trade off 
Patient at high risk of cardiovascular event (a baseline of 1) 0.90 Author Judgment 
2 2003-01-00484 Kidney Disease 
Glomerular filtration rate <15 (with or without proteinuria) 0.70 Time trade off 
Glomerular filtration rate =15-89 (with or without proteinuria) 0.95 Time trade off 
Glomerular filtration rate >=90 (proteinuria) 0.98 Author Judgment 
Glomerular filtration rate >=90 (without proteinuria) 0.99 Author Judgment 
3 2003-01-00683 
Musculoskeletal and 
Rheumatologic 
Diseases 
Complicated UGI event, surgical management 0.00 Author Judgment 
Non-fatal myocardial infarction 0.00 Author Judgment 
Complicated UGI event, medical management 0.31 Standard Gamble 
Symptomatic ulcer 0.38 Standard Gamble 
Dyspepsia 0.50 Standard Gamble 
Arthritis, no UGI 0.69 Standard Gamble 
Life after myocardial infarction 0.97 Standard Gamble 
4 2003-01-00839 Kidney Disease 
Patient receiving hemodialysis 0.43 Time trade off 
Patient receiving continuous ambulatory peritoneal dialysis 0.56 Time trade off 
Renal transplant recipient 0.84 Time trade off 
Donor 1.00 Author Judgment 
5 2003-01-00843 Kidney Disease 
Hospitalization associated with rejection episodes, complications, or the initial surgery. 0.00 Author Judgment 
Dialysis treatment 0.49 Time trade off 
Transplantation 0.78 Time trade off 
6 2004-01-00276 
Other Non-Infectious GI 
Diseases 
Short term disability from surgery for gastroesophageal reflux disease 0.50 Author Judgment 
Medical therapy for gastroesophageal reflux disease 0.62 SF36 
Surgical therapy with recurrent symptoms for gastroesophageal reflux disease 0.62 SF36 
Surgical therapy with no recurrent symptoms for gastroesophageal reflux disease 0.63 SF36 
7 2004-01-00375 
Program/ 
Organizational 
Interventions 
Hepatocellular cancer 0.10 Time trade off 
Liver biopsy for severe complications in HCV patients 0.20 Author Judgment 
Variceal bleeding 0.28 Time trade off 
Hepatic encephalopathy 0.30 Time trade off 
Ascites 0.35 Time trade off 
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Cirrhosis 0.44 Other 
Liver transplant in HCV patients during first year 0.50 Time trade off 
Side effects of HCV treatment 0.50 Unknown/NA 
Chronic hepatitis C 0.89 Other 
HCV Treatment without side effects 0.89 Other 
Liver transplant in HCV patients during second or subsequent years 0.90 Other 
Successful drug treatment for HCV 0.95 Other 
8 2005-01-01406 
Program/ 
Organizational 
Interventions 
Neurologic disability due to bacterial meningitis 0.06 HUI 
Multiple amputations due to bacterial meningitis 0.61 HUI 
Single amputation due to bacterial meningitis 0.71 HUI 
Hearing loss due to bacterial meningitis 0.72 HUI 
Skin scarring due to bacterial meningitis 1.00 Author Judgment 
9 2007-01-02969 Digestive Diseases 
Successful revision of dynamic graciloplasty (year 1) 0.45 Author Judgment 
Successful revision of primary artificial bowel sphincter (year 1) 0.58 Author Judgment 
Successful revision of dynamic graciloplasty (years 2-5) 0.65 Author Judgment 
Successful revision of primary artificial bowel sphincter (years 2-5) 0.66 Author Judgment 
End stoma for fecal incontinence 0.69 SF36 
Successful dynamic graciloplasty 0.84 SF36 
Successful primary artificial bowel sphincter 0.91 SF36 
10 2007-01-03447 Diabetes Mellitus 
Diabetes in the first year when the end stage renal failure occurs 0.64 QWB 
Diabetes in the first year when the heart failure occurs 0.69 QWB 
Diabetes in the first year when the stroke occurs 0.72 QWB 
Diabetes in the first year when the retinopathy occurs 0.75 QWB 
Diabetes in the first year when the myocardial infarction occurs 0.76 Author Judgment 
Diabetes in the first year when the lower extremity amputation occurs 0.80 QWB 
Diabetes in the event-free health states 0.80 Unknown/NA 
11 2007-01-03493 Colorectal Cancer 
Hospitalization (except neutropenia) -0.50 Author Judgment 
Neutropenia, hospitalization -0.45 Unknown/NA 
Diarrhea (no hospitalization) -0.36 Unknown/NA 
Neuropathy (no hospitalization), grade 2/3, disease-free -0.30 Unknown/NA 
Neuropathy (no hospitalization), grade 2/3, after relapse -0.23 Unknown/NA 
Neutropenia, no hospitalization -0.23 Unknown/NA 
Nausea, vomiting (no hospitalization) -0.19 Unknown/NA 
Survivor of colorectal cancer with recurrence 0.20 HUI 
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Survivor of colorectal cancer 0.85 HUI 
12 2008-01-03654 Ischemic Heart Disease 
Alive with HF and Stroke 0.22 Author Judgment 
Alive with major disabling stroke 0.36 Unknown/NA 
Alive with HF 0.62 Time trade off 
Good health post AMI 0.90 Unknown/NA 
13 2008-01-03657 
Program/ 
Organizational 
Interventions 
Infant neurologic 0.51 Time trade off 
Infant respiratory (hospitalization) 0.58 Time trade off 
Anaphylaxis 0.60 Author Judgment 
Severe cough illness 0.81 Time trade off 
Pneumonia 0.82 Time trade off 
Infant respiratory (outpatient) 0.85 Author Judgment 
Moderate caugh illness 0.85 Time trade off 
Mild caugh illness 0.90 Author Judgment 
Systemic reaction 0.93 Time trade off 
local reaction 0.95 Time trade off 
14 2008-01-03826 Diabetes Mellitus 
Complication: amputation 0.51 EQ5D 
Severe complications 0.52 Author Judgment 
Complication: renal failure 0.58 Author Judgment 
Complication: nonfatal stroke 0.62 EQ5D 
Complication: heart failure 0.68 EQ5D 
Complication: angina 0.70 EQ5D 
Complication: blind in one eye 0.71 EQ5D 
Complication: nonfatal myocardial infarction 0.73 EQ5D 
Weel: no long-term complication 0.79 EQ5D 
15 2008-01-03830 Digestive Diseases 
Active + fistula 0.40 Author Judgment 
Non-responding active 0.40 Author Judgment 
Post-surgery complications 0.50 Author Judgment 
Active 0.55 EQ5D 
Active + fistula closure 0.55 EQ5D 
Post-surgery remission 0.67 Unknown/NA 
Remission + fistula 0.68 Author Judgment 
Surgery 0.73 Unknown/NA 
Remission 0.83 EQ5D 
Remission + fistula closure 0.83 EQ5D 
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16 2008-01-04015 Digestive Diseases 
Untreatable adenocarcinoma 0.40 Standard Gamble 
Surgical complications 0.50 Author Judgment 
Surgical treatment 0.55 Author Judgment 
Symptomatic adenocarcinoma 0.68 Standard Gamble 
Well after regression from Barrett's oesophagus 0.80 EQ5D 
Barrett's oesophagus 0.81 Standard Gamble 
High-grade dysplasia(HGD) 0.81 Standard Gamble 
Low-grade dysplasia(LGD) 0.81 Standard Gamble 
Well after surgery 0.86 Standard Gamble 
Diagnosed with adenocarcinoma 0.88 Standard Gamble 
17 2008-01-04292 Malignant Neoplams 
Disease progression of unresectable gastrointestinal stroma tumors (GIST) 0.58 EQ5D 
During the 4 weeks with the treatment of each cycle of sunitinib 0.71 EQ5D 
During the 2 weeks without treatment of each cycle (rest weeks) of sunitinib 0.77 EQ5D 
Best supportive care (BSC) no progression 0.78 EQ5D 
Spanish patients with metastatic and/or unresectable gastrointestinal stroma tumors 
(GIST) after progression or intolerance with imatinib 0.79 Author Judgment 
18 2008-01-04297 
Ischaemic Heart 
Disease 
Systemic complications 0.72 Time trade off 
After failed cardiac rehabilitation 0.83 Author Judgment 
After non-fatal cardiac event 0.83 EQ5D 
Pre-rehabilitation 0.83 EQ5D 
After successful cardiac rehabilitation 0.98 EQ5D 
19 2008-01-04509 HIV/AIDS 
Pancreatitits 0.50 Author Judgment 
Lipoatrophy 0.87 Unknown/NA 
Neuropathy 0.94 EQ5D 
20 2008-01-04522 Digestive Diseases 
Ulcerative colitis in remission-difference between no maintenance 5 Aminosalycylic acid 
therapy vs. maintenance 0.01 Author Judgment 
In patient flare 0.61 Unknown/NA 
Post pouch excision/ileostomy 0.73 Unknown/NA 
Outpatient flare 0.77 Time trade off 
After colectomy with ileal pouch 0.84 Unknown/NA 
Ulcerative colitis in remission-no maintenance 5 Aminosalycylic acid therapy 0.92 Time trade off 
Ulcerative colitis in remission-maintenance 5 Aminosalycylic acid therapy 0.92 Time trade off 
21 2009-01-04903 Digestive Diseases 
Very severe 0.43 Standard Gamble 
Severe 0.69 Standard Gamble 
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Moderate 0.80 Standard Gamble 
Remission 0.86 Author Judgment 
22 2009-01-05169 Digestive Diseases 
Distal Cancer (Dukes D) 0.25 EQ5D 
Regionalized Cancer (Dukes C) 0.59 EQ5D 
Localized Cancer - Dukes (A/B) 0.74 EQ5D 
Between stage I and stage II of ileal pouch anal anastomosis 0.80 Author Judgment 
Long term after ileal pouch anal anastomosis 0.92 EQ5D 
Permanent ileostomy 0.92 EQ5D 
Ulcerative colitis in remission (before ileal pouch anal anastomosis) 0.94 Author Judgment 
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Figure 10. Frequency of the disease classification for all the health states on the TUFTS database 
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The biggest challenge with this approach was that the description of the health states were vague and 
often overlapping, such that it was difficult to summarise utilities across different diseases to ensure 
‘like’ was compared with ’like’. I tried to overcome this problem by referring back to the relevant 
publication in an attempt to define the health state more precisely, but this was not as straightforward 
as I had originally hoped it would be. It was incredibly time consuming and raised other issues around 
the quality of the utility values reported in the literature and subsequently reported in the database. 
Without being able to accurately define the health states, it was difficult to select which health states 
should be chosen for the hierarchy. In addition, the whole process was complicated by the shear 
volume of the database. I do not think that the size of the database is ultimately a bad thing. However, 
I do have concerns about the quality of the some of the values reported and the vague health states 
described. It is the size which means that it would take more time than I had available to accurately 
define the health states for the given utilities and to asses the quality of the reported values, to select a 
meaningful sample to produce such a hierarchy as I intend.  
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 Appendix 13: Analysis of NICE appraisals 
As discussed previously in chapter 8 and appendix 12, the TUFTs database did not provide an 
appropriate source of utilities and therefore an alternative source of utilities was required. I therefore 
considered other sources of utilities where I could borrow strengths from previous work and identified 
NICE appraisals as on e such source. The advantage of NICE appraisals was that i) the health states 
are reasonably tightly defined, and ii) NICE committees review the quality of the appraisals. Therefore, 
I decided it would be reasonable to assume that these utilities would offer the best estimates currently 
available in the literature, which allowed me to account for the variations in quality.  
 
I identified the NICE appraisals from the website - www.nice.org.uk/Guidance/TA/Published. At the 
time the search (June 2010) there were 191 published technology appraisals available. I entered this 
information (ref number, title, date issued, and review date) into an Excel spreadsheet for further 
analysis. Once in Excel my first task was to edit the list. Many of the appraisals were updates of an 
earlier appraisal so I removed any that had been superseded by a more recent review. My second 
task was to categorise the appraisals by assigning a disease topic to each of the appraisals. I ended 
up with 138 appraisals (table 1), which covered 78 disease topics (see figure 1). 
 
 
Next, I needed to start identifying the utility values. I surveyed the list to pick out conditions that on the 
face of it would cover a wide range of diseases/ sub-diseases, varying from psoriasis to motor 
neurone disease for example. Those selected are shown in bold in table 1 and illustrated in pink in 
figure 1. This was still a time consuming process as not all the NICE appraisals state the baseline 
utility score, often they state just the QALY gain between the comparative treatments/ interventions. In 
these cases, I sourced the corresponding NICE Evidence Review Group (ERG) report and/or the 
NICE Technology Assessment Report (TAR) to gather the required information. Both the ERG report 
and TAR can be found via the advanced search function under published HTA report 
(http://www.hta.ac.uk/project/htapubs.asp), from here, there is a link to the corresponding NICE report 
and access to the ERG report and TAR. Further details on the utility values identified are given in 
chapter 8, page 233. 
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Table 1. A list of the NICE technology appraisals used to form the basis of identifying utility values for given health states 
Ref Topic Title Date Issued 
TA167 Abdominal aortic aneurysm Abdominal aortic aneurysm - endovascular stent-grafts  Feb-09 
TA182 Acute coronary syndrome Acute coronary syndrome – prasugrel Oct-09 
TA47 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) Sep-02 
TA98 ADHD Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine  Mar-06 
TA111 Alzheimer’s disease Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine Sep-07 
TA142 Anaemia Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin May-08 
TA73 Angina and myocardial 
infarction 
Angina and myocardial infarction - myocardial perfusion scintigraphy Nov-03 
TA52 Myocardial infarction – thrombolysis Oct-02 
TA143 Ankylosing spondylitis Ankylosing spondylitis - adalimumab, etanercept and infliximab May-08 
TA95 Arrhythmia Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) Jan-06 
TA35 Arthritis Arthritis (juvenile idiopathic) – etanercept Mar-02 
TA138 
Asthma 
Asthma (in adults) - corticosteroids  Mar-08 
TA131 Asthma (in children) – corticosteroids  Nov-07 
TA133 Asthma (uncontrolled) – omalizumab Nov-07 
TA38 Asthma (older children) - inhaler devices Mar-02 
TA10 Asthma (children under 5) - inhaler devices Aug-00 
TA88 Bradycardia Bradycardia - dual chamber pacemakers Feb-05 
TA23 Brain cancer Brain cancer – temozolomide Apr-01 
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide Jun-07 
TA116 
Breast cancer 
Breast cancer - gemcitabine  Jan-07 
TA112 Breast cancer (early) - hormonal treatments Nov-06 
TA108 Breast cancer (early) – paclitaxel Sep-06 
TA109 Breast cancer (early) – docetaxel Sep-06 
TA107 Breast cancer (early) – trastuzumab Aug-06 
TA34 Breast cancer – trastuzumab Mar-02 
TA94 Cardiovascular disease Cardiovascular disease – statins Jan-06 
TA89 Cartilage Cartilage injury - autologous chondrocyte implantation (ACI) (review) May-05 
TA183 Cervical cancer Cervical cancer (recurrent) - topotecan  Oct-09 
TA69 Cervical cancer - cervical screening (review) Oct-03 
TA100 Colon cancer Colon cancer (adjuvant) - capecitabine and oxaliplatin Apr-06 
TA176 Colorectal cancer Colorectal cancer (first line) – cetuximab Aug-09 
TA118 Colorectal cancer (metastatic) - bevacizumab & cetuximab Jan-07 
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TA105 Colorectal cancer - laparoscopic surgery (review) Aug-06 
TA93 Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review) Aug-05 
TA61 Colorectal cancer - capecitabine and tegafur uracil May-03 
TA152 Coronary artery disease Coronary artery disease - drug-eluting stents Jul-08 
TA187 Crohn’s disease Crohn's disease - infliximab (review) and adalimumab (review of TA40) May-10 
TA40 Crohn's disease – infliximab Apr-02 
TA97 Depression & anxiety Depression and anxiety - computerised cognitive behavioural therapy (CCBT) Feb-06 
TA59 Electroconvulsive therapy (ECT) Apr-03 
TA151 
Diabetes 
Diabetes - insulin pump therapy  Jul-08 
TA113 Diabetes (type 1 and 2) - inhaled insulin Dec-06 
TA60 Diabetes (types 1 and 2) - patient education models Apr-03 
TA53 Diabetes (types 1 and 2) - long acting insulin analogues Dec-02 
TA114 Drug misuse Drug misuse - methadone and buprenorphine Jan-07 
TA115 Drug misuse – naltrexone Jan-07 
TA177 
Eczema 
Eczema (chronic) - alitretinoin  Aug-09 
TA81 Atopic dermatitis (eczema) - topical steroids Aug-04 
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus Aug-04 
TA79 Epilepsy Epilepsy (children) - newer drugs Apr-04 
TA76 Epilepsy (adults) - newer drugs Mar-04 
TA110 Follicular lymphoma Follicular lymphoma – rituximab Sep-06 
TA179 Gastrointestinal stromal 
tumour 
Gastrointestinal stromal tumours – sunitinib Sep-09 
TA86 Gastro-intestinal stromal tumours (GIST) - imatinib Oct-04 
TA188 Growth failure Human growth hormone (somatropin) for the treatment of growth failure in children (review) May-10 
TA64 Growth hormone deficiency (adults) - human growth hormone Aug-03 
TA128 Haemorrhoid Haemorrhoid - stapled haemorroidopexy Sep-07 
TA172 Head & neck cancer Head and neck cancer (squamous cell carcinoma) - cetuximab Jun-09 
TA145 Head and neck cancer – cetuximab  Jun-08 
TA166 Hearing Hearing impairment - cochlear implants Jan-09 
TA120 Heart failure Heart failure - cardiac resynchronisation May-07 
TA173 
Hepatitis b 
Hepatitis B - tenofovir disoproxil fumarate Jul-09 
TA154 Hepatitis B - telbivudine  Aug-08 
TA153 Hepatitis B - entecavir  Aug-08 
TA96 Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a Feb-06 
TA106 Hepatitis c Hepatitis C - peginterferon alfa and ribavirin Aug-06 
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TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon Jan-04 
TA189 Hepatocellular carcinoma Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) May-10 
TA83 Hernia Hernia - laparoscopic surgery (review) Sep-04 
TA44 Hip Hip disease - metal on metal hip resurfacing Jun-02 
TA2 Hip disease - replacement prostheses Apr-00 
TA132 Hypercholesterolaemia Hypercholesterolaemia – ezetimibe Nov-07 
TA117 Hyperparathyroidism Hyperparathyroidism – cinacalcet Jan-07 
TA164 Hyperuricaemia Hyperuricaemia - febuxostat  Dec-08 
TA168 Influenza Influenza - zanamivir, amantadine and oseltamivir (review) Feb-09 
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir Sep-08 
TA77 Insomnia Insomnia - newer hypnotic drugs Apr-04 
TA71 Ischaemic heart disease Ischaemic heart disease - coronary artery stents Oct-03 
TA122 Ischaemic stroke (acute) – alteplase Jun-07 
TA174 
Leukaemia 
Leukaemia (chronic lymphocytic, first line) - rituximab Jul-09 
TA119 Leukaemia (lymphocytic) – fludarabine Feb-07 
TA70 Leukaemia (chronic myeloid) – imatinib Oct-03 
TA29 Leukaemia (lymphocytic) – fludarabine Sep-01 
TA190 
Lung cancer 
Lung cancer (non-small-cell) - pemetrexed (maintenance) Jun-10 
TA162 Lung cancer (non-small-cell) - erlotinib  Nov-08 
TA124 Lung cancer (non-small-cell) - pemetrexed  Aug-07 
TA184 Lung cancer (small-cell) – topotecan Nov-09 
TA181 Lung cancer (non-small cell, first line treatment) - pemetrexed  Sep-09 
TA137 Lymphoma Lymphoma (follicular non-Hodgkin's) - rituximab Feb-08 
TA155 Macular degeneration 
 
Macular degeneration (age-related) - ranibizumab and pegaptanib Aug-08 
TA68 Macular degeneration (age-related) - photodynamic therapy Sep-03 
TA78 Menstrual bleeding Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation Apr-04 
TA135 Mesothelioma Mesothelioma - pemetrexed disodium Jan-08 
TA20 Motor neurone disease Motor neurone disease – riluzole Jan-01 
TA171 Multiple myeloma Multiple myeloma – lenalidomide Jun-09 
TA129 Multiple myeloma – bortezomib Oct-07 
TA127 Multiple sclerosis Multiple sclerosis – natalizumab Aug-07 
TA32 Multiple sclerosis - beta interferon and glatiramer acetate Jan-02 
TA65 Non-hodgkins lymphoma Non-Hodgkin's lymphoma – rituximab Sep-03 
TA165 Organ preservatin Organ preservation (renal) - machine perfusion and static storage Nov-08 
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TA160 Osteoporosis Osteoporosis - primary prevention Oct-08 
TA161 Osteoporosis - secondary prevention including strontium ranelate Oct-08 
TA102 Other Conduct disorder in children - parent-training/education programmes Jul-06 
TA49 Central venous catheters - ultrasound locating devices Sep-02 
TA91 Ovarian cancer Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) May-05 
TA55 Ovarian cancer - paclitaxel (review) Jan-03 
TA159 Pain Pain (chronic neuropathic or ischaemic) - spinal cord stimulation  Oct-08 
TA25 pancreatic cancer Pancreatic cancer – gemcitabine May-01 
TA156 Pregnancy Pregnancy (rhesus negative women) - routine anti-D (review) Aug-08 
TA101 prostate cancer Prostate cancer (hormone-refractory) - docetaxel Jun-06 
TA180 
Psoriasis 
Psoriasis - ustekinumab  Sep-09 
TA146 Psoriasis – adalimumab Jun-08 
TA134 Psoriasis – infliximab Jan-08 
TA125 Psoriatic arthritis (moderate to severe) - adalimumab  Aug-07 
TA103 Psoriasis - efalizumab and etanercept Jul-06 
TA104 Psoriatic arthritis - etanercept and infliximab Jul-06 
TA136 Psychosis Structural neuroimaging in first-episode psychosis Feb-08 
TA178 Renal cell carcinoma 
 
Renal cell carcinoma  Aug-09 
TA169 Renal cell carcinoma – sunitinib Mar-09 
TA48 Renal failure Renal failure - home versus hospital haemodialysis Sep-02 
TA99 Renal transplantation Renal transplantation – immunosuppressive regimens for children and adolescents Apr-06 
TA85 Renal transplantation - immuno-suppressive regimens (adults) Sep-04 
TA186 
Rheumatoid arthritis 
Rheumatoid arthritis - certolizumab pegol Feb-10 
TA141 Rheumatoid arthritis (refractory) - abatacept Apr-08 
TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab Oct-07 
TA126 Rheumatoid arthritis (refractory) - rituximab Aug-07 
TA84 Sepsis Sepsis (severe) – drotrecogin Sep-04 
TA139 sleep apnoea Sleep apnoea - continuous positive airway pressure (CPAP) Mar-08 
TA123 Smoking Smoking cessation - varenicline  Jul-07 
TA185 Soft tissue carcinoma Soft tissue sarcoma – trabectedin Feb-10 
TA92 Teeth Tooth decay – HealOzone Jul-05 
TA1 Wisdom teeth – removal Mar-00 
TA74 Trauma Trauma - fluid replacement therapy Jan-04 
TA163 Ulcerative colitis Ulcerative colitis (acute exacerbations) - infliximab  Dec-08 
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TA140 Ulcerative colitis (subacute manifestations) - infliximab  Apr-08 
TA90 Vascular disease Vascular disease - clopidogrel and dipyridamole May-05 
TA170 Venous thromboembolism Venous thromboembolism – rivaroxaban Apr-09 TA157 Venous thromboembolism - dabigatran  Sep-08 
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Figure 1. Distribution of disease topics across the 138 NICE appraisals 
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